### Abortion, Spontaneous (Early Pregnancy Loss)—Cats

#### BASICS

**DEFINITION**
- Spontaneous abortion—natural expulsion of fetus(es) prior to the point at which they can sustain life outside the uterus. • Early pregnancy loss—generalized term for any loss of conceptus including early embryonic death and resorption.

**PATHOPHYSIOLOGY**
- Infectious causes result in pregnancy loss directly by affecting the embryo, fetus, or fetal membranes, or indirectly by creating debilitating systemic disease in the queen.
- Non-infectious causes of pregnancy loss result from any factor other than infection that leads to the death or premature expulsion of the conceptus (e.g., uterine disease, inadequate maternal nutrition, endocrine dysfunction, toxicity, genetic defects).

**SYSTEMS AFFECTED**
- Endocrine • Reproductive • Other systems—any debilitating illness can result in pregnancy loss.

**GENETICS**
- Genetic defects are more prevalent in highly inbred individuals; heritability of susceptibility to FIPV thought to be very high.

#### INCIDENCE/PREVALENCE

Unknown—pregnancy frequently not confirmed, owners may not recognize late pregnancy loss if the queen is fastidious; early embryonic death is difficult to document.

**SIGN/MENT**

#### SPECIES
- Cat

**BREED PREDICTIONS**
- Purebred cats—higher incidence of non-infectious abortion; imprinting increases risk of genetic disease. Predisposition to developing FIP increased in some breeds including Bengal, Berman, and Himalayan.

**MEAN AGE AND RANGE**
- Infectious abortion seen in all ages; non-infectious abortion seen more commonly in young and aged queens.

**SIGNS**

**GENERAL COMMENTS**
- Early embryonic death and resorption frequently have no clinical symptoms; any combination of historical and physical examination findings may occur, with some queens displaying no symptoms.

**HISTORICAL FINDINGS**
- Failure to deliver litter at expected time, return to estrus sooner than expected, decrease in abdominal diameter and weight loss, discovery of fetal material, behavior change, anorexia, vomiting, diarrhea.

### Physical Examination Findings

- Purulent, mucoid, watery, or hemorrhagic vaginal discharge; dehydration, fever, abdominal straining, abdominal discomfort.

#### CAUSES

**INFECTIOUS**
- Bacterial—organisms implicated in causing abortion via ascending infection include Escherichia coli, Staphylococcus spp., Streptococcus spp., Chlamydia spp., Pasteurella spp., Klebsiella spp., Pseudomonas spp., Salmonella spp., Mycoplasma spp., and Ureaplasma spp. • Feline—Toxoplasma gondii • Viral—FHV-1, FIV, FeLV, FPLV

**NON-INFECTIOUS**
- Uterine—cystic endometrial hyperplasia, pyometra, chronic endometritis, anatomical abnormalities of the uterus, mechanical trauma to uterus or fetus. • Ovarian—early termination of corpora lutea function causes a decline in serum progesterone concentrations resulting in early parturition/abortion. Primary hypoluteoidism is rare but secondary hypoluteoidism may result from certain drugs, prolonged stress and uterine inflammation. • Fetal—chromosomal abnormalities resulting in abnormal or arrested development and embryonic or fetal death. • Systemic—malnutrition or nutritional disorders such as taurine deficiency, vitamin A deficiency or toxicity; severe non-reproductive illness; congenital drug administration; estrogen, glucocorticoids, PCP, and dopamine agonists (cabergoline, bromocriptine) will disrupt normal corpora lutea function; fenoterol or ter ugocrine drugs; chemotherapeutic agents, antifungal agents, some ionotropics (trimethoprim-sulfamethoxazole, tetracyclines, gemtanezol); modified live vaccines.

**RISK FACTORS**
- Previous history of pregnancy loss • Concurrent systemic disease • Recent trauma • Purebred cat with high degree of inbreeding • Very young or old queen • Previous use of progestins to suppress estrus • Malnourishment • Homemade and raw diets • Overcrowded or unsanitary environment

**DIAGNOSIS**

#### DIFFERENTIAL DIAGNOSIS
- Early pregnancy loss—failure to conceive, disorder of sexual development, anovulatory cycle • Vulvar discharge—pyometra, mucositis, uterine stump pyometra; vaginitis, metritis, cystitis; impending parturition or dystocia; neoplasia or trauma of urinary bladder, urethra, vagina, or uterus; estrus—very little discharge typically seen • Abdominal straining or discomfort—urethral obstruction; intermittent foreign body; peritonitis; trauma; impending parturition or dystocia

#### CBC/BIOCHEMISTRY/U'RINALYSIS
- May be normal. • Inflammatory leukogram or stress leukogram depending on systemic disease response. • Hemocrit/concentration and anemia with dehydration.

#### OTHER LABORATORY TESTS

- Cytology and bacterial culture of vaginal flora. • FeLV—test for antigens in queens using ELISA or IFA. • FHV-1—IFA or PCR from conjunctival or conjunctival swabs, viral isolation from conjunctival, nasal, or pharyngeal swabs. • FIP—submit fetal tissue for histopathology and immunohistochemistry. • FIV—ELISA, confirm positive results with Western blot. • FPLV—viral isolation from fures submitted for necropsy; document serumconversion in the queen.

#### NON-INFECTIOUS CAUSES
- To rule out anovulatory cycle, confirm progesterone > 1.5 ng/mL one week following mating. • Hypoluteoidism—serum progesterone level < 1.0 ng/mL prior to abortion indicates luteal failure but does not determine whether the luteal failure was primary or secondary. • Disorder of sexual development can be evaluated with description of external genitalia, karyotype, and histopathology of reproductive tract.

#### IMAGING
- Abdominal ultrasound in early gestation (21–25 days post-breeding) to confirm pregnancy and screen for evidence of resorption. Late pregnancy, evaluate health and viability of fetus(es) and associated fluid and membranes; abnormal uterine fluid accumulation and non-reproductive disease. • Radiography—evaluates relative size, number, and position of fetal skeletons; can also be used for fetal measurement, fetal malpresentation, and non-reproductive disease.

#### DIAGNOSTIC PROCEDURES
- Genetic defects—sterropgy aborted fetus(es); submit samples from aborted and stillborn fennas for karyotyping. • Nutrition—submit sample of diet for nutritional analysis: of particular importance when queen is fed a homemade and/or raw diet. • Fetus—submit sample for pathological analysis: of particular importance when queen is fed a homemade and/or raw diet. • Ultrasound analysis to evaluate inbreeding coefficient • Evaluate cattery for vaccination protocols, feeding regimen, general sanitation procedures, and quarantine procedures for pregnant queens and new arrivals. • Submit reproductive tract (uterus, ovaries, uterine tubes) and aborted, stillborn, mummified fetuses and fetal membranes (fresh, refrigerated, on wet ice) for evaluation of anatomic and pathologic changes, gross
treatment.}

**CONTRAINDICATIONS**
- Terbutaline—cardiac or respiratory disease, pyometra, infectious disease, CEH.

**PRECAUTIONS**
- Use of tocolytics to maintain pregnancy requires accurate documentation of breeding dates to know when treatment should be discontinued; tocolytics used most successfully in combination with tocodynamometry to establish desired dosing interval based on increased pretense uterine activity. Terbutaline can cause hypertension leading to increased hemorrhage from the placental sites during parturition or at the time of c-section.

**POSSIBLE INTERACTIONS**
- Progesterone administration during pregnancy is associated with masculinization of female fetuses; do not administer in the first half of pregnancy and use with informed consent thereafter. Use of tocolytics to maintain pregnancy is associated with increased risk of dystocia, failure of normal placental separation at parturition, lack of mammary gland development and milk production, and poor maternal behavior for the first few days postpartum.

**FOLLOW-UP**

**PATIENT MONITORING**
- Serial ultrasound evaluation q 5–7 days to evaluate fetal viability for queens receiving tocolytics.

**PREVENTION/AVOIDANCE**
- Institute infectious disease prevention, control, and surveillance plan. Replace infertile queens with more reproductively fit individuals. Avoid exposure to abortifacient, teratogenic, or fetotoxic drugs.

**POSSIBLE COMPLICATIONS**
- Depends on etiology. Metritis, endometritis, uterine rupture, sepsis, shock.
- Diabetes, CEH, masculinization of female fetuses with progesterone treatment.

**EXPECTED COURSE AND PROGNOSIS**
- Infectious disease—normal pregnancy, repeated abortion, or infertility possible with viral disease. Poor prognosis for normal pregnancy in queens with severe CEH. Fair prognosis for successful pregnancy with treatment for primary hypoluteoidism; significant monitoring required for good outcome. Pregnancy loss due to genetic abnormalities likely to recur if queen is bred to tom with similar pedigree.

**MISCELLANEOUS**

**AGE-RELATED FACTORS**
- Queens > 6 years old have higher incidence of infertility. Pregnancy loss seen most frequently in very young and old queens.

**ZOOONOTIC POTENTIAL**
- Toxoplasma gondii

**SEE ALSO**
- Breeding, Timing, Sexual Development Disorders

**ABBREVIATIONS**
- CEH = cystic endometrial hyperplasia
- ELISA = enzyme-linked immunosorbent assay
- FeLV = feline leukemia virus
- FHV-1 = feline herpesvirus 1
- FIPV = feline infectious peritonitis virus
- FIV = feline immunodeficiency virus
- IFIA = indirect fluorescent antibody
- OHE = ovariohysterectomy
- PGF2α = prostaglandin F2α

**INTERNET RESOURCES**
- www.theriojournal.com
- www.whelpwise.com

**Suggested Reading**

**Author** Milan Hess

**Consulting Editor** Sara K. Lyle
## Abortion, Spontaneous (Early Pregnancy Loss)—Dogs

### Basics

**Definition**
Loss of a fetus because of resorption in early stages or expulsion in later stages of pregnancy.

### Pathophysiology
- **Direct causes**—cortical abnormality, infectious disease, trauma. **Indirect causes**—infectious placentitis, abnormal ovarian function, abnormal uterine environment.

### Systems Affected
- Reproductive. Any dysfunction of a major body system can adversely affect pregnancy.

### Genetics
- No genetic basis for most causes of abortion. 

### Lympohipophysiody—Single-gene recessive trait in borzois.

### Incidence/Prevalence
- True incidence unknown. Resorption estimated between 11–13%, some estimates up to 30% of all one resorption.
- Incidence of stillbirth reported as 2.2–4.4% increases with dysplasia to 22.3%.

### Signalement
- **Species**: Dog.
- **Breed Predictions**: Familial lymphocytic hypothyroidism reported in borzois—prolonged estrous interval, poor conception rates, abortion midgestation, stillbirth. Many breeds considered at risk for familial hypothyroidism (see Hypothyroidism).
- **Mean Age and Range**: Usually 6 years old.
- **Predominant Sex**: Intact bitches.

### Historical Findings
- **Failure to weep on time**. Expansion of recognizable fetuses or placental tissues.
- **Disease in abdominal size**. **Weight loss**.
- **Anorexia**. Vomiting, diarrhea.
- **Behavioral changes**.

### Physical Examination Findings
- **Sanguineous or purulent vulvar discharge**.
- **Disappearance of vesicles or fetuses** previously documented by palpation, ultrasonography, or radiography.
- **Abdominal straining, discomfort**.
- **Depression**. **Dehydration**. Fever in some patients.

### Causes
- **Infectious**: *Tulipaana gendbi, Neoplasma caninum*.
- **Miscellaneous**: Ureaplasma, Neoplasma.
- **Miscellaneous bacteria**: *E. coli, Streptococcus, Campylobacter, Salivella.*
- **Miscellaneous viruses**: Distemper virus, parovirus, adenovirus.
- **Uterine**: Cystic endometrial hyperplasia and pyometra. **Trauma**—acute and chronic.
- **Neoplasia**. **Embryotoxic drugs**. **Chemotherapeutic agents**. **Estrogens**.
- **Glucocorticoids**—high dosages.
- **Antibiotics**—lysis of corpora lutea.

### Differential Diagnoses
- **Hypothyroidism**—newborn. **Hyperprolactinemia**—common endocrine disease and has been suggested as a cause for fetal wastage; role in pregnancy loss unclear; subnormal T4 concentrations indicate need for further testing (see Hypothyroidism).
- **Serum progesterone concentration** (when no infectious agents are identified)—hypothyroidism may cause fetal wastage; dogs depend on ovarian progesterone production throughout gestation (minimum of 2 mg/L required to maintain pregnancy); collect sample and determine as soon as possible after abortion; in subsequent pregnancies, start weekly monitoring at week 3, which may be before pregnancy can be documented with ultrasound; start biweekly sampling around the gestational age of previous loss. Pregnancy loss typically occurs during the seventh week of gestation (see Premature Labor).
- **Vaginal culture**—B. canis with positive serologic test; *Mycoplasma, Ureaplasma, other bacterial agents*; all except B. canis can be normal flora, therefore diagnosis difficult from vaginal cultures alone; *Salivella* associated with systemic illness in the bitch.

### Imaging
- **Radiography**—identifies fetal structures after 45 days of gestation; earlier, can determine uterine enlargement but cannot assess uterine contents.
- **Ultrasonography**—identifies uterine size and content and assesses fluid and its consistency; assesses fetal remains or fetal viability by noting heartbeats (normal, >200 bpm; stress, <150 or <280 bpm).

### Diagnostic Procedures
- **Vaginoscopy**—identifies ovarian follicles and early pregnancy stages or expulsion in later stages of pregnancy.
- **Cytologic examination** and bacterial cultures may reveal an inflammatory process (e.g., uterine infection); technique for culture: see a.
guarded swab culture instrument to ensure an intact sample (oral reproductive tract is normally heavily contaminated with bacteria), or collection of secretions via transcervical swab culture.

PATHOLOGIC FINDINGS
Histopathologic examination of culture of fetal and placental tissue—may reveal infectious organisms; tissue culture, particularly of stomach contents, to identify infectious bacterial organisms.

TREATMENT
APPROPRIATE HEALTH CARE
Most bitches should be confined and isolated pending diagnosis. • Hospitalization of infectious patients preferred. • B. canis—highly infective to dogs; shed in high numbers during abortion; suspected cases should be isolated. • Ovariohysterectomy (OHE)—preferred for stable patients with no breeding value; cystic endometrial hyperplasia is an irreversible change. No special dietary considerations for uncomplicated cases

CLIENT EDUCATION
• Critical for B. canis—confirmed, euthanasia recommended due to lack of successful treatment and to prevent spread of infection; may try OHE and long-term antibiotic; discuss surveillance program for kennel situations: monthly serology for all individuals, culling any positive animals, until kennel situation is negative; 
• Infertility or pregnancy loss—may recur in future bitches; mammary gland disease.

SURGICAL CONSIDERATIONS
OHE—preferred for stable patients with no breeding value.

MEDICATIONS
DRUG(S) OF CHOICE
• PGF₂α (Lutalyse, dinoprost tromethamine)—uterine evacuation after abortion; 0.05–0.1 mg/kg SC q8–24h; cloprostenol (Estrumate, cloprostenol)—1–5 µg/kg SC q24h; not approved for use in dogs, but adequate documentation legitimizes its use; use only if all living fetuses have been expelled.  
• Antibiotics—for bacterial disease; initially administer broad-spectrum agent; specific agent depends on culture and sensitivity testing of vaginal tissue or uterine biopsy.  
• Progesterone (Regu-Mate) at 0.088 mg/kg (1 mL/25 kg PO q24h); progesterone in oil at 2 mg/kg IM q48–72h; progesterone (Prometrium®), 10 mg/kg PO q24h, adjust daily dosage based on serum progesterone)—for documented hypoluteodism only to maintain pregnancy, must have accurate due date to know when to discontinue therapy—inaudiently prolonging gestation will result in fetal death.

CONTRAINDICATIONS
Progesterone supplementation—contraindicated in dogs with endometrial or mammary gland disease.

PRECAUTIONS
PGF₂α—metabolized in the lung; side effects are related to smooth muscle contraction, are dose-related, and diminish with each injection; paresthesia, urticaria, hypotension, and defecation constitute; dose critical (L23α, for domestic—5 mg/kg).

ALTERNATIVE DRUG(S)
Oxytocin—1 U/75 kg SC q6–24h for uterine evacuation; should only be considered in cases where uterine evacuation is desired solely through uterine contraction.  

FOLLOW-UP
PATIENT MONITORING
• Partial abortion—monitor viability of remaining fetuses with ultrasonography; monitor systemic health of the dam for complications of pregnancy.  
• Vulvar discharges—daily; for decreasing amount, odor, and inflammatory component; for consistency (increasing mucoid content is pathologically good).  
• PGF₂α—continued for 5 days or until most of the discharge ceases (range 3–15 days). • B. canis—monitor after neutering and antibiotic therapy; yearly serologic testing to identify recrudescence.  
• Hypothyroidism—treat appropriately; neutering recommended (hereditary nature); see Hypothyroidism.

PREVENTION/AVOIDANCE
• Brucellosis and other infectious agents—surveillance programs to prevent introduction to kennel. • OHE—for bitches with no breeding value. • Use of modified-live vaccines (e.g., some distemper, parvovirus, etc., vaccines).

POSSIBLE COMPLICATIONS
• Unruled pyometra—septicaemia, toxaemia, death. 
• Brucellosis—discoidritis, endophthalmitis, recurrent uveitis.

EXPECTED COURSE AND PROGNOSIS
• Pyometra—recovery rate during subsequent cycle is high (up to 70%) unless pregnancy is established. • CEH—recovery of fertility unlikely; pyometra common complication. • Hormonal dysfunction—often manageable; familial aspects should be considered. 
• Brucellosis—guarded; extremely difficult to successfully eliminate infection even if combined with neutering.

MISCELLANEOUS
AGE-RELATED FACTORS
Older bitches more likely to have CEH or Brucellosis—can be transmitted to humans, especially when handling the aborting bitch and expelled tissue; massive numbers of organisms expelled during abortion. People that are immunocompromised are at greatest risk for infection.

SEE ALSO
Brucellosis • Hypothyroidism • Infertility, Female—Dogs • Premature Labor

ABBREVIATIONS
• CEH = cystic endometrial hyperplasia  
• OHE = ovariohysterectomy  
• PGF₂α = progesterin F₂α

Suggested Reading
Author Julie T Cecere
Consulting Editor Sara K. Lyle
Acknowledgment The author and editors acknowledge the prior contribution of Beverly J. Passwell.
ABORTION, TERMINATION OF PREGNANCY

BASICS

DEFINITION
Termination of an unwanted pregnancy. May be accomplished by drugs that alter embryonic development or by surgical means. In the former, establishment of a pregnancy, and/or cause luteal regression, terminating an established pregnancy. Due to their possible side effects (CEH, aplastic anemia and bone marrow suppression), drugs that impair embryonic transit through the oviduct (estrogens) are not commonly used or recommended.

PATHOPHYSIOLOGY
After fertilization the embryo travels the oviduct in a timely manner before entering the uterus. Impaired embryo transport through the oviduct leads to embryonic degeneration and implantation abnormalities. In the dog and cat, pregnancy maintenance is dependent on progesterone production from the corpora lutea. In dogs and cats, maintenance of the corpora lutea during the second half of gestation is also supported by prolactin. Drugs that cause luteal regression, terminating an established pregnancy, and/or cause luteal regression, terminating an established pregnancy, are commonly used or recommended. Recommended as screening test prior to treatment in patients with suspected underlying disease.

SYSTEMS AFFECTED
• Cardiovascular • Digestive • Gastrointestinal
• Reproductive • Respiratory

GENETICS
N/A

INCIDENCE/PREVALENCE
N/A

GEOGRAPHIC DISTRIBUTION
N/A

SIGNALMENT
Species
Dog and cat

Breed Predilections
N/A

Mean Age and Range
Postpubertal bitch and queen

Predominant Sex
Pregnant bitch or queen

CAUSES
• Impaired oviductal transport • Luteal regression • Progesterone receptor antagonism

RISK FACTORS
N/A

DIAGNOSIS

• Confirm pregnancy first, less than 40% of misnamed bitches become pregnant:
  - Abdominal palpation (bitch: 31–33 days after LH surge; queen: 21–23 days after breeding): + Transabdominal ultrasound (bitch: >25 days after LH surge; queen: >16 days after breeding): + Abdominal radiographs (bitch: >45 days after LH surge; queen: >38 days after breeding): + Serum relaxin concentration in the bitch (>28 days after LH surge) (Witness Zoetis Corp., http://synbiotics.com/index.html; 800/733-5500). + Accurately that a breeding took place: a tie in the bitch and costal "after-rotation" in the queen.

DIFFERENTIAL DIAGNOSIS
• Hydroametra • Macropotametra • Hematometra • Pyometra • Pseudopregnancy

CBC/BIOCHEMISTRY/URINALYSIS

Within normal limits during first half of pregnancy in healthy patients. Decrease in PCV during second half of pregnancy in bitches and queens is normal. Recommended as screening test prior to treatment in patients with suspected underlying disease.

OTHER LABORATORY TESTS

• Vaginal cytology—determines stage of estrous cycle and presence of sperm (absence does not rule out a previous breeding). Methods to increase detection of sperm: infuse and recover 5–10 mL of saline from anterior vagina using standard AI pipette. • Cervical, examine pellet; collect routine cytology and allow swab to sit in 1–2 mL of saline, express fluid, centrifuge, examine pellet. • Serum progesterone concentration determines if the female is in diestrus and monitors luteal regression during treatment.

IMAGING
• Transabdominal ultrasound (method of choice): diagnose pregnancy and monitor uterine evacuation during treatment. • Abdominal radiographs.

PATHOLOGIC FINDINGS
N/A

TREATMENT

APPROPRIATE HEALTH CARE

• Physical examination before initiation of treatment. • Monitor 30–60 minutes after treatment for side effects (vomiting, defecation, defecation, hyperesthesia, paroxysmal, micturition, tachycardia). • Pregnancy status in early diestrus is unknown; ultrasonographic confirmation of pregnancy is possible until 4–6 weeks after breeding. • Treatment on day 6–12 of diestrus—may have reduced efficacy compared to midestrous but can be less distasteful to client (less discharge and recognizable fetuses are not passed). • PGF2α and bromocriptine given in combination—improved efficacy of either drug given alone.

NURSING CARE

N/A

ACTIVITY
Normal

DIET
Avoid feeding prior to each treatment and for 1–2 hours after treatments (reduces nausea and vomiting).

CLIENT EDUCATION

• Discuss patient’s reproductive future with owner. If no litters are desired, then OHE is the best option. + Discuss with the client the potential side effects of the treatment options; reach a mutual agreement on the treatment plan.

SURGICAL CONSIDERATIONS

OHE is recommended for patients with no reproductive value or when owners do not desire future litters.

MEDICATIONS

DRUG(S) OF CHOICE

• Confirmation of pregnancy before initiating any of the treatment protocols suggested below is recommended. Lengths of treatment suggested may vary; treatments should be continued until abortion is complete.

PGF2α: causes luteal regression with subsequent decline in progesterone concentration, cervical relaxation, and uterine contractions; bitches and cats low dose protocol: 10 mcg/kg SC, q12h for 7–10 days or until pregnancy terminated (in the bitch), then 25 mcg/kg q12h for 1–2 days; then 50 mcg/kg q12h for 3–4 days (the queen is more resistant to the luteolytic effects of PGF2α than bitches—often higher doses for longer periods are required); bitch standard dose protocol: 150 mcg/kg SC, q12h for 2 days, then 200 mcg/kg SC, q12h until pregnancy termination; queens: 0.5–1 mg/kg SC q12h every other day > day 40, or 2 mg/cat IM q24h for 5 days > day 53.

Cloprostenol (prostaglandin analogue): bitches: 2.5 mcg/kg SC q24h or q12h every 48 hours until pregnancy termination (>6 days after start of treatment).

Demeclocinchine: mode of action is unknown; bitches: 0.2–0.4 mg/kg PO q12h for 5 days, then decreasing from 0.16 to 0.02 mg/kg over the last five days; treatment failures not uncommon.

Cabergoline (PRL antagonist): causes luteal regression; bitches: 1.05 mcg/kg SC q24h for 5 days or 0.5 mcg/kg PO q24h for 5 days > day 40; queens: 1.65 mcg/kg SC for


5 days = 30 or 5 μg/kg PO q 24h for 5 days = > day 35.
• Bromocriptine (PRL antagonist): causes luteal regression; bitches: 50–100 μg/kg q24h IM or PO for 4–7 days = > day 35 (50% effective); vomiting common side effect, reduce dose and give with meal.
• Cabergoline and cabergoline combination: bitches: cabergoline 5 μg/kg PO q24h for 10 days plus clomprostenol 2.5 μg SC at start of treatment or 1 μg/kg SC at start of treatment and at day 5 of treatment; treatment should be initiated 28 days post-LH surge; queen: cabergoline 5 μg/kg PO q24h plus clomprostenol 5 μg/kg SC q48h (> 30 days after breeding) until abortion is complete (> 9 days).
• Cloprostenol and bromocortisone combination: bitches: bromocortisone 30 μg/kg q6h PO for 10 days plus clomprostenol 2.5 μg/kg SC or 1 μg/kg SC at start of treatment and at day 5 of treatment; treatment should be initiated 28 days post-LH surge.

CONTRAINDICATIONS
• PGF2α and analogues: animals with respiratory disease (bronchoconstriction); do not administer intravenously.
• Cabergoline and bromocortisone: avoid administration in animals hypersensitive to ergot alkaloids; use with caution in patients with significantly impaired liver function. * Estrogens may cause cystic endometrial hyperplasia, polymyelitis, and bone marrow suppression leading to pancytopenia.

PRECAUTIONS
• PGF2α and analogues: side effects are dose-dependent and include vomiting, defecation, dysphoria, tachycardia, salivation, restless, and anxiety; side effects subside within 60 minutes; the severity of effects can be ameliorated with premedication (> 15 minutes) with a combination of atropine (0.025 mg/kg, use extreme caution in dogs and cats with preexisting cardiopulmonary, liver, and renal diseases. * Dexamethasone: polyuria, polydipsia, and polyphagia are reported side effects. Long-term administration has been associated with hyperadrenocorticism. * Cabergoline and bromocortisone: should be administered with caution in patients with impaired liver function. Side effects may include vomiting and anorexia; prolonged use (> 2 weeks) may cause coat color changes.

POSSIBLE INTERACTIONS
• PGF2α and analogues: effect may be reduced by concomitant administration of prostegins; use may enhance effects of oxytocin. * Cabergoline and bromocortisone: cabergoline effects may be reduced with concomitant treatment with dopamine (D2) antagonists; avoid concomitant treatment with hypotensive drugs.

ALTERNATIVE DRUG(S)
• The following drugs are recommended for use in bitches but not available in the United States: * Mifepristone (RU486; progestin and glucocorticoid receptor antagonist): 2.5–5 μg/kg PO q24h for 4–5 days > day 32 of pregnancy (dog); no side effects have been reported. * Aglepiristine (progestin and glucocorticoid receptor antagonist): 10 μg/kg SC q24h for 2 days > day 32 days post-LH surge (dog); pregnancy is terminated in 4–7 days; mild reaction at injection site have been reported; mild vaginal discharge may be observed. * Aglepiristine and cloprostenol combination: aglepiristine (10 mg/kg SC) combined with cloprostenol (1 μg/kg SC) q24h for 2 days > 25 days pregnancy; pregnancy is terminated within 6 days. Side effects after treatment include vomiting and diarrhea. Vaginal discharge may be observed. * Aglepiristine (10 mg/kg SC, q24h for 2 days) with intrauterine misoprostol (200–600 μg, depending on body size) daily until abortion complete; abortion complete within 7 days. Vomiting, diarrhea, polydipsia, anorexia not observed with this regimen.

Author Jose A. Len
Consulting Editor Sara K. Lyle
Client Education Handout available online

EXPECTED COURSE AND PROGNOSIS
• The interinterval in bitches treated with prostaglandins and PRL inhibitors may be shortened (< 1 month). Queens may resume estrous behavior 7–10 days after pregnancy termination. * Subsequent estrus fertility is not affected.

MISCELLANEOUS

ASSOCIATED CONDITIONS
N/A

AGE-RELATED FACTORS
N/A

ZOONOIC POTENTIAL
N/A

PREGNANCY/FERTILITY/BREEDING

SYNONYMS
Induced abortion

SEE ALSO
Breeding, Timing.

ABBREVIATIONS
• CEH = cystic endometrial hyperplasia
• GnRH = gonadotropin-releasing hormone
• LH = luteinizing hormone
• OHE = ovariohysterectomy
• PCV = packed cell volume
• PGF2α = prostaglandin F2α
• PRL = prolactin

Suggested Reading
Blackwell’s Five-Minute Veterinary Consult

**Abcessation**

**Basics**

**Definition**
An abscess is a localized collection of purulent exudate contained within a cavity.

**Pathophysiology**
- Bacteria are often inoculated under the skin via a puncture wound; the wound surface then seals.
- When bacteria and/or foreign objects persist in the tissue, purulent exudate forms and collects.
- Accumulation of purulent exudate—if not quickly resolved or discharged to an external surface, stimulates formation of a fibrous capsule; may eventually lead to abscess rupture.
- Prolonged delay of evacuation—formation of a fibrous abscess wall; to heal, the cavity must be filled with granulation tissue from which the causative agent may not be totally eliminated; may lead to chronic or intermittent discharge of exudate from a draining sinus tract.

**Systems Affected**
- Skin/Exocrine—percutaneous (dogs > cats), anal sac (cats > dogs); mammary gland (male)
- Ophthalmic—periorbital tissues
- Gastrointestinal—pancreas (dogs > cats)

**Genetics**
N/A

**Incidence/Prevalence**
N/A

**Geographic Distribution**
N/A

**Signalement**
Species Cat and dog

**Breed Predilections**
N/A

**Mean Age and Range**
N/A

**Predominant Sex**
Mammary glands (female); prostate gland (male)

**Signs**

**General Comments**
- Determined by organ system and/or tissue affected.
- Associated with a combination of inflammation (pain, swelling, redness, heat, and loss of function), tissue destruction, and/or organ system dysfunction caused by accumulation of exudates.

**Historical Findings**
- Often presented for nonspecific signs such as lethargy and anorexia.
- History of traumatic insult or previous infection.
- A rapidly appearing painful swelling with or without discharge; if affected area is visible.
- Physical Examination Findings
- Determined by the organ system or tissue affected.
- Classic signs of inflammation (heat, pain, swelling, and loss of function) are associated with specific anatomic location of the abscess.
- Inflammation and discharge from a fistulous tract may be visible if the abscess is superficial and has ruptured to an external surface.
- A variably sized, painful mass of fluctuant to firm consistency attached to surrounding tissues may be palpable.
- Fever if abscess is not ruptured and draining.
- Sepsis occasionally, especially if abscess ruptures internally.

**Causes**
- Foreign objects.
- Prostatic bacteria—*Staphylococcus* spp.; *Escherichia coli*, β-hemolytic *Streptococcus* spp.; *Peptostreptococcus*; *Mycoplasma* and *Mycoplasma*-like organisms (β-forms); *Pasteurella multocida*, *Corynebacterium*; *Actinomycosis* spp.; *Nocardia*, *Brucella*.
- Obligate anaerobes—*Bacteroides* spp.; *Clostridium* spp.; *Prevotella*; *Fusobacterium*.

**Risk Factors**
- Anal sac—impaction; anal saculitis.
- Brain—otitis interna; sinusitis oral infection.
- Esophagus—intragastric, intrathoracic, foreign objects; *E. coli*, *Fusobacterium*; *Pseudomonas*; *Mycoplasma*; *Bacteroides*.
- Lung—foreign object aspiration bacterial pneumonia.
- Liver—*M. haemolytica*; *S. aureus*, *S. epidermidis*, *S. aureus* strains, *S. epidermidis*.
- Gastrointestinal—pancreatitis; *E. coli*, *P. aeruginosa*, *S. maltophilia*.
- Liver—*M. haemolytica*; *S. aureus*, *S. epidermidis*, *S. aureus* strains, *S. epidermidis*.

**Diagnosis**

**Differential Diagnosis**

**Mass Lesions**
- Cyst—less or only transtuminal painful; slower growing.
- Fibrous scar tissue—firm; non-painful.
- Granuloma—less painful; slower growing; generally forms without obvious sinus tract.
- Hematoma/seroma—variable pain (depends on cause); non-encapsulated; rapid initial growth but slow increase once full size is attained; unattached to surrounding tissues; fluctuant and fluid filled initially but more firm with organization.

**Draining Tracts**
- Mycobacterial disease.
- *Mycetoma*—*B. dermatitidis* and *G. globosa*.
- Neoplasia—variable growth; consistent; painful.

**Imaging**
- Radiography—soft tissue density mass in affected area; may reveal foreign body.
- Ultrasonography—determine if mass is fluid filled or solid; determine organ system affected; reveal fluctuant-appearing fluid characteristic of pus; may reveal foreign object.
- Echocardiography—helpful for diagnosis of pericardial abscess.
- CT or MRI—helpful for diagnosis of brain abscess.

**Diagnostic Procedures**

**Aspiration**
- Reveals a red, white, yellow, or green liquid.
- Protein content ≥ 2.5–3.0 g/dL.
- Nucleated cell count—5,000–100,000 (or more) cells/µL, primarily degenerative neutrophils with lesser numbers of macrophages and lymphocytes.
- Probiotic bacteria—may be seen in cells and free within the fluid.
- If the causative agent is not readily identified with a Romanovsky-type stain, specimens should be stained with an acid-fast stain to detect mycobacteria or *Nocardia* and PAS stain to detect fungus.

**Biopsy**
- Sample should contain both normal and abnormal tissue in the same specimen.
- Impression smears—stained and examined.
- Tissue submit for histopathologic examination and culture.
A

ABSCESSTION

SURGICAL CONSIDERATIONS

- Appropriate debridement and drainage—may need to leave the wound open to an external surface; may need to place surgical drains.
- Early drainage—to prevent further tissue damage and formation of abscess wall.
- Remove any foreign object(s), necrotic tissue, or nidus of infection.

MEDICATIONS

**DRUG(S) OF CHOICE**

- Antimicrobial drugs—effective against the infectious agent; gain access to site of infection.
- Broad-spectrum agent—bactericidal and with both aerobic and anaerobic activity; until results of culture and sensitivity are known.
- Dogs and cats: amoxicillin (11–22 mg/kg PO q8–12h); amoxicillin/clavulanic acid (12.5–25 mg/kg PO q12h); clindamycin (5 mg/kg PO q6h); and minocycline/ sulfadiazine (15 mg/kg PO IM q24h). Cats with Mycoplasma and F-forms doxycycline (5 mg/kg PO q24h).
- Aggressive antimicrobial therapy—sepsis or septicemic conditions.

**CONTRAINDICATIONS**

N/A

**PRECAUTIONS**

N/A

**POSSIBLE INTERACTIONS**

N/A

**ALTERNATIVE DRUG(S)**

N/A

FOLLOW-UP

PATIENT MONITORING

Monitor for progressive decrease in drainage, resolution of inflammation, and improvement of clinical signs.

PREVENTION/AVOIDANCE

- Pericervical abscesses—prevent fighting.
- Anal sac abscesses—prevent impaction; consider anal saculotomy for recurrent cases.
- Prostatic abscesses—castration possibly helpful.
- Mastitis—prevent lactation (spaying).
- Periorbital abscesses—do not allow chewing on foreign object(s).

POSSIBLE COMPLICATIONS

- Sepsis.
- Peritonitis/pleuritis if intra-abdominal or intrathoracic abscess rupture.
- Compromise of organ function. Delayed evacuation may lead to chronically draining fistulous tracts.

EXPECTED COURSE AND PROGNOSIS

Duration of hospitalization depends on infection involved and amount of tissue destruction.

MISCELLANEOUS

**ASSOCIATED CONDITIONS**

- FeLV or FIV infection
- Immunosuppression

**AGE-RELATED FACTORS**

N/A

ZOONOTIC POTENTIAL

- Minimal for pyogenic bacteria.
- Mycobacterial and systemic fungal infections carry some potential.

PREGNANCY/FERTILITY/BREEDING

Teratogenic agents—avoid use in pregnant animals.

SEE ALSO

- Actinomycosis
- Anaerobic Infections
- Collarenclosis
- Mycoplasmosis
- Nocardiosis
- Sepsis and Bacteremia

ABBREVIATIONS

- CSF = cerebrospinal fluid
- CT = computed tomography
- FeLV = feline leukemia virus
- FIV = feline immunodeficiency virus
- MRI = magnetic resonance imaging
- PAS = periodic acid-Schiff

Suggested Reading


**Acetaminophen (apap) Toxicosis**

**BASICS**

**DEFINITION**
Results from accidental animal ingestion or owner administration of over-the-counter acetaminophen-containing analgesic and antipyretic medications.

**PATHOPHYSIOLOGY**
When the normal biotransformation mechanisms for detoxification (glucuronidation and sulfation) are saturated, cytochrome P450-mediated oxidation produces a toxic metabofate (N-acetyl-p-benzoquinone imine) that is electrophilic, conjugates with glutathione, and binds to sulfhydryl groups leading to hepatic necrosis.

**Dogs**
- Liver is most susceptible to toxicity.
- Signs commonly observed at exposures >100 mg/kg.
- Methemoglobinemia may develop at doses >200 mg/kg.

**Cats**
- Cannot effectively glucuronidate; more limited capacity for acetaminophen elimination than dogs.
- Saturate glucuronidation and sulfation biotransformation routes.
- RBCs are most susceptible to oxidative injury following glutathione depletion.
- Develop toxic cytochrome P450 metabolite at much lower doses than dogs.
- Poisoned by as little as 50–60 mg/kg (often as little as one-half tablet); deacetylation of acetaminophen to p-aminophenol (PAP) causes oxidative damage to RBCs, rapidly producing methemoglobinemia by binding to sulfhydryl groups on hemoglobin.
- Slower-developing hepatotoxicosis may not be fully expressed before development of fatal methemoglobinemia.

**SYSTEMS AFFECTED**
- Hematologic/Immune—RBCs are damaged by glutathione depletion, allowing oxidation of hemoglobin to methemoglobin.
- Hepatobiliary—liver necrosis (more common in dogs).
- Cardiovascular (primarily cats)—edema of the face, paws, and (to a lesser degree) forelimbs through an undefined mechanism.

**GENETICS**
Cats—genetic deficiency in the glucuronide conjugation pathway makes them vulnerable.

**INCIDENCE/PREVALENCE**
Common drug toxicity in cats; less frequent in dogs.

**GEOGRAPHIC DISTRIBUTION**
N/A

**SIGNMENT**
Species
- Cats more often than dogs

**SIGNS**
General Comments
- Relatively common—owing to widespread human use.

**Historical Findings**
- Depression
- Hyperventilation
- Darkened mucous membranes
- Signs may develop 1–4 hours after dosing

**Physical Examination Findings**
- Progressive depression
- Salivation
- Vomiting
- Abdominal pain
- Tachypnea and cyanosis or muddied mucous membranes—reflect methemoglobinemia
- Edema—face, paws, and possibly forelimbs; after several hours
- Chocolate-colored urine—hematuria and methemoglobinuria; especially in cats
- Icterus
- Hypothermia
- Shock
- Death

**CAUSES**
Acetaminophen toxicosis

**RISK FACTORS**
- Nutritional deficiencies of glucose and/or sulfate
- Simultaneous administration of other glutathione-depressing drugs

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
Other causes of liver injury
- Hepatotoxic mushrooms
- Blue-green algae
- Alcaloïdes
- Iron, copper, zinc
- Sulfanilamide
- NSAIDs

**OTHER CAUSES OF METHEMOGLOBINEMIA**
- Onion/garlic
- Naphthalene
- Chlorates
- Nitrates
- Sulfites
- Phenol
- Benzocaine
- Propylene glycol (cats)

**CBC/BIOCHEMISTRY/URINALYSIS**
- Methemoglobinemia and progressively rising serum concentrations of liver enzymes (ALT, AST)—characteristic.
- As hepatic function becomes impaired—decreased BUN, cholesterol, and albumin, and increased serum bilirubin.
- Heinz bodies (cats)—prominent in RBCs within 72 hours.
- Anemia, hemoglobinemia, and hemoglobinuria or hematuria.

**OTHER LABORATORY TESTS**
Acetaminophen plasma, serum, or urine concentrations

**IMAGING**
N/A

**DIAGNOSTIC PROCEDURES**
N/A

**PATHOLOGIC FINDINGS**
- Methemoglobinemia
- Pulmonary edema.
- Centrilobular necrosis and congestion of the liver.
- Renal tubular edema and degeneration with proteinaceous tubular casts.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- With methemoglobinemia—must evaluate promptly.
- With dark or bloody colored urine or stools—imminent.

**NURSING CARE**
- Gentle handling—imperative for clinically affected patients.
- Induced emesis and gastric lavage—useful within 4–6 hours of ingestion.
- Anemia, hematuria, or hemoglobinuria—may require whole blood transfusion.
- Fluid therapy—maintain hydration and electrolyte balance.
- Oxygen therapy may be needed.
- Drinking water—available at all times.
- Food—offered 24 hours after initiation of treatment.
Acetaminophen (APAP) Toxicosis

**ACTIVITY**
Restricted

**DIET**
N/A

**CLIENT EDUCATION**
- Warn client that treatment in clinically affected patients may be prolonged and expensive.
- Inform client that patients with liver injury may require prolonged and costly management.

**SURGICAL CONSIDERATIONS**
N/A

**MEDICATIONS**

**DRUG(S) OF CHOICE**
- Activated charcoal 2 g/kg PO, immediately after completion of emesis or gastric lavage.
- N-acetylcysteine (Mucomyst) 140 mg/kg diluted in D5W as loading dose PO, IV; then 70 mg/kg diluted in D5W PO, IV, q4h for 5–7 additional treatments.
- S-adenosylmethionine (SAMe) as a glutathione donor; 40 mg/kg PO × 1 dose, then 20 mg/kg PO × 7 days.
- Added benefit of using methylene blue, cimetidine, and/or ascorbic acid is controversial.

**CONTRAINDICATIONS**
Drugs that contribute to methemoglobinemia or hepatotoxicity.

**PRECAUTIONS**
Drugs requiring extensive liver metabolism or biotransformation—use with caution; expect their half-lives to be extended.

**POSSIBLE INTERACTIONS**
Drugs requiring activation or metabolism by the liver have reduced effectiveness.

**FOLLOW-UP**

**PATIENT MONITORING**
- Continual clinical monitoring of methemoglobinemia—vital for effective management; laboratory determination of methemoglobin percentage every 2–3 hours.
- Serum liver enzyme activities (ALT, ALP) every 12 hours; monitor liver damage.

**PREVENTION/AVOIDANCE**
- Never give acetaminophen to cats.
- Give careful attention to the acetaminophen dose in dogs.

**POSSIBLE COMPLICATIONS**
Liver necrosis and resulting fibrosis—may compromise long-term liver function in recovered patients.

**EXPECTED COURSE AND PROGNOSIS**
- Rapidly progressive methemoglobinemia—serious sign.
- Methemoglobin concentrations ≥ 50%—grave prognosis.
- Progressively rising serum liver enzyme levels 12–24 hours after ingestion—serious concern.
- Expect clinical signs to persist 12–48 hours; death owing to methemoglobinemia possible at any time.
- Dogs and cats receiving prompt treatment that reverses methemoglobinemia and prevents excessive liver necrosis—may recover fully.

**SYNONYMS**
- Paracetamol
- Tylenol

**SEE ALSO**
Poisoning (Intoxication) Therapy

**ABBREVIATIONS**
- PAP = p-aminophenol
- ALT = alanine aminotransferase
- AST = aspartate transaminase
- RBC = red blood cell
- D5W = 5% dextrose injection

**INTERNET RESOURCES**
http://www.aspca.org/pet-care/poison-control/

**Suggested Reading**

**Author**
Lisa A. Murphy

**Consulting Editor**
Lynn R. Hovda

**Client Education Handout available online**
Acidosis, Metabolic (Traditional Approach)

**DEFINITION**
A process in the body that leads to a decrease in pH below the reference interval for that species. A decline in blood pH is specifically termed acidemia. Associated with a decrease in plasma bicarbonate concentration (HCO₃⁻) (dogs, > 18 mEq/L; cats, > 16 mEq/L) and base excess (BE) (< –4 mmol/L) with a compensatory increase in carbon dioxide tension (PCO₂).

**PATHOPHYSIOLOGY**
- Metabolic acidosis may develop either as a loss of HCO₃⁻ (hyperchloremic acidosis) or a gain in acid (high anion gap acidosis). It is usually secondary to an accumulation of metabolically produced weak cations (strong ion gap or high anion gap acidosis), accumulation of weak acids (hyperchloremia, corrected), hyperkalemia (hyperchloremic acidosis), or as a compensatory mechanism for respiratory alkalosis.
- **High anion gap acidosis**: Increase in the concentration of other strong acids through addition (e.g., ethylene glycol toxicity), excessive production (e.g., lactate produced by prolonged anerobic metabolism), or renal failure (e.g., renal failure) of strong acids other than chloride causes metabolic acidosis without increasing chloride concentration (so-called normochloremic or high AG metabolic acidosis).
- **Hyperchloremic acidosis**: Increase in plasma weak acids (e.g., inorganic phosphate) is associated with metabolic acidosis and increased anion gap. As pH of 7.4, a 1 mg/dL increase in phosphate concentration is associated with a 0.58 mEq/L increase in AG. Hyperchloremia commonly develops with decrease renal phosphate excretion (e.g., renal failure, hypophosphatemia, etc.), cellular lysis (e.g., hypoxia—lactic acidosis), acute circulatory shock (hemorrhagic), exposure to toxins (e.g., ethylene glycol, salicylate, and paraldehyde), diarrhea, administration of carbonic anhydrase inhibitors (e.g., acetazolamide and diphtheria).
- **Hyperchloremic Metabolic Acidosis**
  - Associated with Hyperchloremia
  - Associated with Normochloremia (High Anion Gap Metabolic Acidosis)
  - Associated with Hyperkalemia
  - Associated with Respiratory Acidosis

**CAUSES**
- **Congenital**—a fall in pH results in an increase in sympathetic discharge but simultaneously causes a decrease in the responsiveness of the cardiac myocytes and vascular smooth muscle to the effects of catecholamines. In mildly acidic conditions (pH > 7.2), the effects of increased sympathetic stimulation predominate and result in a mild increase in heart rate and cardiac output. More severe acidemia (pH < 7.1), especially if acute, may decrease cardiac contractility and predispose the heart to ventricular arrhythmias and ventricular dilation. Respiratory—increased [H⁺] stimulates peripheral and central chemoreceptors to increase alveolar ventilation; hyperventilation decreases PCO₂, which counteracts the effects of low plasma HCO₃⁻ on pH. In dogs, a decrease of approximately 0.7 mmHg in PCO₂ is expected for each 1 mEq/L decrease in plasma HCO₃⁻. Little is known about compensation in cats, but it appears to be almost nonexistent. Renal/Urologic—the kidneys increase net acid excretion, primarily by increasing excretion of NH₃ and chloride. This compensatory mechanism is not very effective in cats.

**SIGNALMENT**
Any breed, age, or sex of dog and cat

**HISTORICAL FINDINGS**
- Chronic disease processes that lead to metabolic acidosis (e.g., renal failure, diabetes mellitus, and hypoparathyroidism), acute circulatory shock (hemorrhagic), exposure to toxins (e.g., ethylene glycol, salicylate, and paraldehyde), diarrhea, administration of carbonic anhydrase inhibitors (e.g., acetazolamide and diphtheria).
- Hyperchloremic acidosis may be caused by chloride retention (e.g., renal failure, renal tubular acidosis) that typically occurs in response to HCO₃⁻ loss. Chloride and HCO₃⁻ are reciprocally related; a loss of HCO₃⁻ generally results in retention of chloride. Other mechanisms for hyperchloremic acidosis include: excessive loss of sodium relative to chloride (e.g., diuresis, Addison’s) and administration of substances containing more chloride than sodium as compared with normal extracellular fluid composition (e.g., administration of KCL 0.9%NaCl). Acidemia is usually not seen in patients with hyperchloremic acidosis.

**SYSTEMS AFFECTED**
- Cardiovascular—falls in pH result in an increase in sympathetic discharge but simultaneously causes a decrease in the responsiveness of the cardiac myocytes and vascular smooth muscle to the effects of catecholamines. In mildly acidic conditions (pH > 7.2), the effects of increased sympathetic stimulation predominate and result in a mild increase in heart rate and cardiac output. More severe acidemia (pH < 7.1), especially if acute, may decrease cardiac contractility and predispose the heart to ventricular arrhythmias and ventricular dilation.
- Respiratory—increased [H⁺] stimulates peripheral and central chemoreceptors to increase alveolar ventilation; hyperventilation increases PCO₂, which counteracts the effects of low plasma HCO₃⁻ on pH. In dogs, a decrease of approximately 0.7 mmHg in PCO₂ is expected for each 1 mEq/L decrease in plasma HCO₃⁻. Little is known about compensation in cats, but it appears to be almost nonexistent. Renal/Urologic—the kidneys increase net acid excretion, primarily by increasing excretion of NH₃ and chloride. This compensatory mechanism is not very effective in cats.

**DIAGNOSIS**
- Low plasma HCO₃⁻ and hyperchloremia may also be compensatory in animals with chronic respiratory alkalosis, in which PCO₂ is low and pH is high or near normal, despite decreased HCO₃⁻ and increase in chloride concentration. Blood gas determination is required to differentiate.

**LABORATORY FINDINGS**
- Drugs That May Alter Laboratory Results: Potassium bromide is measured as chloride in most analyzers, so potassium bromide administration artificially decreases the anion gap.
- Disorders That May Alter Laboratory Results: Too much heparin (> 10% of the sample) decreases HCO₃⁻. Blood samples stored at room temperature for > 15 minutes have low pH because of increased PCO₂. Hypocalcemia lowers AG; negative charges of albumin are the main component of the anion gap.

**Valid if Run in Human Laboratory?** Yes

**CBC/BIOCHEMISTRY/URINALYSIS**
- Low total CO₂—total CO₂ in serum samples handled aerobically closely approximates the serum HCO₃⁻ concentration; unfortunately, patients with chronic respiratory alkalosis also have low total CO₂, and the distinction cannot be made without blood gas analysis.
- Metabolic acidosis are traditionally divided into hyperchloremic and high anion gap by means of the anion gap. Anion gap, the difference between the measured cations and the
measured anions, is calculated as $AG = ([Na^+] - [HCO_3^-] + [Cl^-]) - ([Ca^{2+}] + [K^+] - [HCO_3^-] + [Cl^-])$, depending on the preference of the clinician or laboratory. Normal values with potassium included in the calculation are usually 12–24 mmol/L in dogs and 13–27 mmol/L in cats. The negative charges of albumin are the major contributors to the normal anion gap; this should be taken into account when evaluating anion gap in patients with hypalbuminemia. At pH 7.4 in dogs, a decrease of 1 g/dL in albumin is associated with a decrease of 1 mmol/L in the anion gap. • Normal anion gap (i.e., noninfectious metabolic acidosis) • High anion gap (i.e., normochloric metabolic acidosis). • Hyperpyrexia—see Hyperpyrexia. • Anemia—see Anemia. • Hyperphosphatemia—see Hyperphosphatemia. • High lactate concentration—see Lactic Acidosis. • Hyperkalemia—see Hyperkalemia. (continued)

**TREATMENT**

- Acid-base disturbances are secondary phenomena; successful resolution depends on controlling the underlying disease process. • Restore blood volume and perfusion deficits before considering NaHCO_3. • Avoid NaHCO_3 in patients with respiratory acidosis cannot adequately change the pH. • Avoid NaHCO_3, in acute (<10 minutes) cardiac arrest as it may impair tissue oxygen unloading.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

- NaHCO_3 may help patients with hyperchloremic, hyperphosphatemic, or uremic acidosis, but not patients with lactic acidosis or diabetic ketoacidosis.

**CONTRAINDICATIONS**

- Avoid NaHCO_3 in patients with respiratory acidosis because it generates CO_2. • Patients with respiratory acidosis cannot adequately excrete CO_2, and increased PCO_2 will further decrease the pH. • Avoid diuretics that act on the distal nephron (e.g., spironolactone). • Avoid carbonic anhydrase inhibitors (e.g., acetazolamide, dichlorphenamide). • Avoid NaHCO_3 in acute (>10 minutes) cardiac arrest, as it may impair tissue oxygen unloading.

**PRECAUTIONS**

Use NaHCO_3 cautiously in patients with congestive heart failure because the sodium load may cause decompensation of the heart failure.

**POSSIBLE INTERACTIONS**

- None

**ALTERNATIVE DRUG(S)**

- None

**FOLLOW-UP**

- Patient monitoring

Recheck acid-base status frequently dictated by the underlying disease and patient response to treatment.

**POSSIBLE COMPLICATIONS**

- Hyperkalemia in acute hyperchloremic acidosis • Myocardial depression and ventricular arrhythmias

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**

- Hyperkalemia • Hyperchloremia

**AGE-RELATED FACTORS**

- Pregnancy/Fertility/Breeding

**SYNONYMS**

- Diabetic ketoacidosis—metabolic acidosis resulting from increased free water in plasma. • Hyperchloremic acidosis—normal anion gap acidosis. • Hyperphosphatemic acidosis—metabolic acidosis resulting from high phosphate concentration. • Non-respiratory acidosis. • Normochloric acidosis—high anion gap acidosis. • Organic acidosis—metabolic acidosis resulting from accumulation of organic anions (e.g., ketoadipic, uremic acidosis, and lactic acidosis).

**SEE ALSO**

- Anemia • Diabetes Mellitus with Ketoacidosis • Hyperchloremia • Hyperkalemia • Hyperphosphatemia • Lactic Acidosis

**ABBREVIATIONS**

- AG = anion gap • BE = base excess • CNS = central nervous system • H^+ = hydrogen ion • HCO_3^- = bicarbonate • NaHCO_3 = sodium bicarbonate • O_2 = oxygen • PCO_2 = carbon dioxide tension

**Suggested Reading**


**Authors**

- Helio S. Auran de Morais and Neil E. Palmer

**Consulting Editor**

- Carl A. Osborne

**Canine and Feline, Sixth Edition**

- Acidosis, Metabolic (Traditional Approach)

**ACKNOWLEDGMENTS**

- Helio S. Auran de Morais and Neil E. Palmer

- Consulting Editor Carl A. Osborne
Acne—Cats

**Basics**

**Overview**
- Inflammatory dermatitis affecting the chin and lips
- Symptons may be recurrent or persistent
- Precise etiology unknown

**Signalement**
- Cats
- Prevalence for sex, age, or breed not reported

**Signs**
- Cats may have a single episode, a life-long recurrent problem, or a continual disease
- Frequency and severity of each occurrence varies with the individual
- Comedones, mild erythematous papules, serous crusts, and dark keratin debris develop on the chin and less commonly on the lips
- Swelling of the chin
- Severe cases—nodules, hemorrhagic crusts, pustules, cysts, fistulae, severe erythema, alopecia, and pain
- Pain often associated with bacterial folliculitis

**Causes & Risk Factors**
- Precise etiology unknown; may be a disorder of keratinization, poor grooming, abnormal sebum production, immunosuppression, viral infection, or stress

**Diagnosis**

**Differential Diagnosis**
- Bacterial folliculitis
- Demodicosis
- Malassezia infection
- Dermatophytosis
- Neoplasia of sebaceous or apocrine glands
- Eosinophilic granuloma
- Contact hypersensitivity

**CBC/Biochemistry/Urine Analysis**
N/A

**Other Laboratory Tests**
N/A

**Imaging**
N/A

**Diagnostic Procedures**
- Skin scrapings—demodicosis
- Fungal culture—dermatophylosis
- Cytology—bacteria, Malassezia
- Biopsy—rarely needed; necessary in selected cases to characterize changes such as cystic follicles, to differentiate acne from other diseases such as demodicosis, infections (bacterial, yeast, or dermatophytes), or to diagnose neoplasia

**Pathologic Findings**
- Mild disease—follicular distention with keratin (comedo), hyperkeratosis, and follicular plugging
- Severe disease—mild to severe folliculitis and perifolliculitis with follicular pustule formation leading to furunculosis and progranulomatous dermatitis
- Bacteria and Malassezia in these lesions are considered secondary invaders and not causative agents
- Demodex mites can be primary agents of this disease

**Treatment**
- Initial treatment—gentle clipping and soakings to soften crusts
- Continue one or a combination of the therapies listed below until all lesions have resolved
- Discontinue treatment by tapering medication over a 2- to 3-week period
- Recurrent episodes—once the recurrence rate is determined, an appropriate maintenance protocol can be designed for each individual
- Continual episodes—life-long maintenance therapy necessary

**Medications**

**Drug(S)**
- **Topical**
  - Shampoo—once or twice weekly with antiseborrheic (sulfur-salicylic acid, benzoyl peroxide, or ethyl lactate)
  - Cleansing agents—benzoyl peroxide, salicylic acid, chlorhexidine-phospholipid
  - Wet wipes—Dosoo Chlorhexidine pads®, Malaseb® wipes, MalAcetic® wipes, GlycoZoo® wipes
  - Antibiotic ointment—mupirocin 2%
  - Other topicalsv—clindamycin or erythromycin solution or ointment
  - Combination topicalsv—benzoyl peroxide-antibiotic gels (e.g., Benzamycin)
  - Topical retinoids—Tretinoin (Retin-A 0.05% gel)
- In severe inflammatory periods 10–14 days of oral prednisolone (1–2 mg/kg q24h) may help to reduce scar tissue formation

**Systemic**
- Antibiotics—amoxicillin with clavulante, cephalosporin, or fluoroquinolone
- Severe cases may warrant treatment with isotretinoin (Accutane) or cyclosporine, modified (Atopica)
- Demodex—oral ivermectin 400 μg/kg daily until mites are cleared

**Contraindications/Possible Interactions**
- Benzoyl peroxide and salicylic acids—can be irritating
- Some wipes contain alcohols that can be irritating
- Systemic isotretinoin—use with caution, if animal will not allow application of topical medications; potential deleterious side effects in human beings (drug interactions and teratogenicity); container should be labeled for animal use only and kept separate from human medications to avoid accidental use; currently difficult to obtain for animal patients

**Follow-Up**
- Monitor for relapses
- Maintenance cleansing programs can be used to reduce relapses
- Affected cats are likely to have variable numbers of comedones life-long, often are just cosmetic and treatment is not necessary

**Miscellaneous**

**Pregnancy/Fertility/Breeding**
- Systemic isotretinoin should not be used on breeding animals

**Suggested Reading**

**Author**
- Alexander H. Werner

**Consulting Editor**
- Alexander H. Werner
Recognized almost exclusively in Isotretinoin (Accutane)—1–2 mg/kg/day. Repeat bacterial culture/sensitivity if lesions may be painful on palpation; most lesions may not respond to systemic antibiotics.

**BASICS**

**OVERVIEW**
- Also called muzzle folliculitis and furunculosis.
- Chronic inflammatory disorder of the chin and lips of young animals.
- Characterized by folliculitis and furunculosis; rarely comedogenic as seen in ‘true acneform’ lesions of human beings.
- Recognized almost exclusively in short-coated breeds.
- Genetic predisposition and local trauma may play a more important role than hormonal effects.

**SIGNALMENT**
- Dogs
- Predisposed short-coated breeds—boxer, Doberman pinscher, English bulldog, Great Dane, Weimaraner, mastiff, rottweiler, German short-haired pointer, pit bull terrier.

**SIGNS**
- Ventral chin and lip margins may be minimally to markedly swollen with numerous erythematous papules and pusules.
- Initial lesions are sterile; bacteria may not be isolated and lesions may not respond to antibiotics.
- Advanced stages—lesions may be exudative, indicating secondary deep bacterial folliculitis-furunculosis.
- Lesions may be painful on palpation; most are non-painful and non-pruritic.
- Chronic resolved lesions may be scarred and lichenified.

**CAUSES & RISK FACTORS**
Some short-coated breeds appear to be genetically predisposed to follicular keratosis and secondary bacterial infection.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Dermatitis
- Demodectis
- Foreign body
- Contact dermatitis

**CBC/BIOCHEMISTRY/URINALYSIS**
N/A

**OTHER LABORATORY TESTS**
N/A

**IMAGING**
N/A

**DIAGNOSTIC PROCEDURES**
- Bacterial culture and sensitivity testing—in patients with suppurative folliculitis and furunculosis that are non-responsive to initial antibiotic selection.
- Biopsy—histologic confirmation in cases in which diagnosis is in question.
- Skin scrape—demodicosis.
- Dermatophyte culture—dermatophytosis.

**PATHOLOGIC FINDINGS**
- Clinical signs and histopathologic findings are diagnostic.
- Initial lesions—hairless follicular papules characterized histopathologically by marked follicular keratosis, plugging, dilatation, and perifolliculitis.
- Bacteria—not present and cannot be isolated from lesions in early stages.
- As disease progresses, papules enlarge and rupture, promoting a suppurative folliculitis and furunculosis.

**MEDICATIONS**

**DRUG(S)**
- **Topical**
  - Benzoyl peroxide shampoo or gel (antibacterial).
  - Mupirocin 2% ointment (antibacterial-staphylococcus).
- **Systemic**
  - Antibiotics appropriate for deep bacterial infection—when indicated (e.g., cephalaxin, 22 mg/kg PO q8–12h for 6–8 weeks).
  - May need to perform bacterial culture and sensitivity test.
  - Isotretinoin (Accutane)—1–2 mg/kg/day.
  - Oral corticosteroids: tapering dosages of prednisolone (initial 0.5 mg/kg/day) to reduce significant inflammation; not for continued use.

**TREATMENT**
- Depends on the severity and chronicity of the disease.
- Reduce behavioral trauma to the chin (e.g., rubbing on the carpet, chewing bones that increase salivation).
- Frequent cleansing with benzoyl peroxide shampoo or gel.
- Mupirocin 2% ointment to reduce the bacterial numbers on the surface of the skin.
- Instruct owners to avoid expressing the lesions, which may cause internal rupture of the papule and massive inflammation.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**
- Benzoyl peroxide—may bleach carpets and fabrics; may be irritating.
- Mupirocin ointments—greasy; may be irritating.
- Topical steroids—may cause adrenal suppression and thinning of skin with repeated use.
- Isotretinoin—may cause keratoconjunctivitis sicca, hyperactivity, ear pruritus, erythema of maculopapular junctions, lethargy with vomiting; abdominal distension, anorexia with lethargy, collapse, and swollen tongue; CBC and chemistry screen abnormalities include high platelet count, hyperglycemia, hyperlipidemia, and high alanine transaminase.

**FOLLOW-UP**

**PATIENT MONITORING**
- Continue antibiotics until lesions have healed.
- Repeat bacterial culture/sensitivity if lesions worsen.
- Discontinue topical corticosteroids when possible.

**EXPECTED COURSE AND PROGNOSIS**
- Long-term topical treatment may be required.
- Chronic scarring may be prevented by early and aggressive therapy.

**MISCELLANEOUS**

**PREGNANCY/FERTILITY/BREEDING**
Synthetic retinoids—teratogenic; do not use in pregnant animals, animals intended for reproduction, or intact female animals; should not be handled by women of childbearing age.

**Suggested Reading**
- Author Karen Helton Rhodes Consulting Editor Alexander H. Werner
**Acral Lick Dermatitis**

### BASICS

**OVERVIEW**
- Chronic lesions directly caused by self-trauma.
- A cycle of licking, pruritus, and secondary infection develops.

**SYSTEMS AFFECTED**
- Skin/Fur/scale

**SIGNALMENT**
- Dogs.
- Most common in large breeds—especially Doberman pinschers, Labrador retrievers, Great Danes, Irish and English setters, golden retrievers, Akita, Dalmatians, boxers, Shar-Pei, and Weimaraners.
- Age: onset—varies (especially with cause).
- No sex predilection.

**CAUSES & RISK FACTORS**
- Focal trauma to the area initiating a lick-itch cycle.
- Anything causing a local irritation or lesion may initiate response.
- Associated diseases—staphylococcal furunculosis, hypersensitivity, endocrinopathy, demodicosis, dermatophytosis, foreign body reaction, neoplasia, underlying joint disease or arthritis, trauma, neuropathy, psychogenic, or sensory nerve dysfunction.

### DIAGNOSIS

**DIFFERENTIAL DIAGNOSIS**
- Neoplasia
- Bacterial furunculosis
- Focal dermatophytosis

**CBC/BIOCHEMISTRY/URINALYSIS**
Normal except in cases of endocrinopathy.

**OTHER LABORATORY TESTS**
Endoscopy—free T4/TSH, ACTH stimulation test or LDDST.

**IMAGING**
Radiology—neoplasia; local trauma; radiopaque foreign bodies; bony proliferation may be seen secondary to the chronic irritation; evidence of underlying arthritis if over a joint.

**DIAGNOSTIC PROCEDURES**
- Skin scrapings—demodicosis.
- Dermatophyte culture—fungal infection.
- Epidermal cytology—bacterial infection.
- Bacterial culture and sensitivity—tissue cultures may differ from surface culture.
- Food elimination diet—determine food allergy.
- Intradermal allergy testing—atopy.
- Biopsy—to rule out neoplasia, other infections.
- Behavioral history.
- Neurologic and orthopedic evaluation.

**PATHOLOGIC FINDINGS**
- Histopathology—epidermal hyperplasia, plasmacytic dermal inflammation, folliculitis, furunculosis, perifollicular, hidradenitis, and vertical streaking fibrosis.

### TREATMENT

**Behavioral therapy:** attempt to identify psychological causes and remediate.
- Physical restraints—Elizabethan collar and bandaging permit healing.
- Therapeutic laser—one controlled study did not demonstrate efficacy.
- Diet—no modification unless food hypersensitivity is suspected.
- Surgery (laser or standard)—may cause increased licking and attention to a larger affected area, if underlying causes are not addressed, recurrence is likely.

**FOLLOW-UP**
- Monitor level of licking and chewing closely.
- Treat underlying disease to prevent recurrence.
- If no underlying disease is detected, suspect psychogenic causes (compulsive or self-mutilation disorder); prognosis is guarded.

### MEDICATIONS

**DRUG(S)**
- **Antihistamines—e.g., hydroxyzine (1–2 mg/kg PO q12h); chlorpheniramine (4–8 mg/dog PO q12–24h).**
- **NSAIDs—e.g., carprofen (2.2 mg/kg PO q12–24h); rimoxifene (0.5–1 mg/kg PO q24h); meloxicam (0.3–0.5 mg/kg PO q24h).**
- **Dopamine antagonists:** e.g., prochlorperazine (0.5–2 mg/kg PO q12h), metoclopramide (0.35 mg/kg PO q12h).
- **SSRIs:** clomipramine (4–8 mg/dog PO q12h; maximum of 30 mg q24h).
- **TCA:** e.g., amitriptyline (1–2.2 mg/kg PO q12–24h; doxepin (5–10 mg/kg PO q12h); imipramine (1–2 mg/kg PO q12–24h).
- **Combination and/or withdraw administration of these medications carefully.**

**TOPICAL**
- Fluocinolone, triamcinolone, betamethasone, desonide, or fluocinonide may be applied to affected areas for 10–15 minutes.
- Animals should be kept from licking the area for 10–15 minutes.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**
- Doxepin—caution using with monoamine oxidase inhibitors, clozapine, antidepressants, oral anticoagulants, steroid hormones, antiarrhythmics, or aspirin.
- Neuroleptics—may cause sedation.
- Psychotropic medications should be combined and/or withdrawn carefully.
- Cardiotoxicity and hepatotoxicity—rare cases in animals on TCAs. Routine monitoring recommended.

**MISCELLANEOUS**

**AGE-RELATED FACTORS**
- Dogs <5 years old—strongly consider allergy.

**ZOONOTIC POTENTIAL**
- Can be transmitted to humans only if dermatophilosis is the underlying cause; exceedingly rare.
- Methicillin-resistant *Staphylococcus aureus* may have zoonotic implications.

**ABBREVIATIONS**
- LDDST = low-dose dexamethasone suppression test
- SSRI = selective serotonin reuptake inhibitor
- TCA = tricyclic antidepressant
- TSH = thyroid stimulating hormone
- ACTH = adrenocorticotropic hormone

**Suggested Reading**

**Author**
Alexander H. Werner

**Consulting Editor**
Alexis H. Werner

**Acknowledgments**
The author and editors acknowledge the prior contribution of Jean S. Greek.
Organomegaly—most commonly bilateral IGF1—diabetic cats receiving insulin can Pituitary-dependent hyperadrenocorticism

In the long run, cats need to be Acromegaly and PDH can occur Cat
GH hypersecretion. The only currently available means of Many patients gain weight and have Clinical signs are due to growth hormone's Median age—11 years (range of 6–17 years) Broadening of facial features, prognathia Elevated IGF1 activity induces excessive soft Myocardial hypertrophy occurs in many, but heart failure is uncommon. The catabolic actions of GH result from insulin antagonism leading eventually to pancreatic β cell exhaustion and DM. Between 25 and 33% of diabetic cats may have acromegaly. Like most diabetic cats the potential for remission remains if the excessive GH production can be normalized, likelihood of remission is inversely related to the duration of DM.

IMAGING
CBC/BIOCHEMISTRY/URINALYSIS
CAUSES & RISK FACTORS
• Syndrome resulting from growth hormone (somatotropin) hypersecretion by tumorous or hyperplastic somatotrophs in the anterior pituitary.
• Clinical signs are due to growth hormone's direct cardiotoxic/diabetogenic effects and its indirect anabolic effects mediated through insulin-like growth factor 1, which is secreted by the liver in response to growth hormone stimulation.
• Elevated IGF1 activity induces excessive soft tissue growth, viscer al organomegaly, bone remodeling and thickening (especially in bones formed from membranous ossification) resulting in arthropathy, broad facial features, and enlarged "dubbed" paws.
• Myocardial hypertrophy occurs in many cats, but heart failure is uncommon.
• The catabolic actions of GH result from insulin antagonism leading eventually to pancreatic β cell exhaustion and DM. Between 25 and 33% of diabetic cats may have acromegaly.
• Like most diabetic cats the potential for remission remains if the excessive GH production can be normalized, likelihood of remission is inversely related to the duration of DM.

SIGNALMENT
• Cat
• Median age—11 years (range of 6–17 years) Approximately 80% are males

SIGNS
• Initial signs relate to unrelated DM with the vast majority of cases presenting with polyuria, polydipsia, and often profound polyphagia accompanied with concurrent weight gain (weight loss has also been reported).
• Many patients gain weight and have increased body size due to increased bone and soft tissue mass, not from increased adipose tissue. Weight gain in an unregulated diabetic cat strongly suggests acromegaly.
• Broadening of facial features, prognathia inferior, and increased paw size reflect long-standing or severe disease.
• Organomegaly—most commonly bilateral renalomegaly and hepatomegaly.
• Muur and/or gallop rhythm occasionally present; signs of heart failure uncommon.
• Lumeness may develop.
• Neurologic sign refractive to intracranial disease through an expanding pituitary mass lesion possible.
• Recent reports suggest the majority of acromegalic cats are indistinguishable phenotypically from non-acromegalic diabetic cats.

CAUSES & RISK FACTORS
• GH hypersecretion.
• Progestins do not cause GH secretion and acromegaly in cats as they do in dogs.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Uncomplicated DM or DM secondary to hyperadrenocorticism. Pituitary-dependent hyperadrenocorticism and acromegaly can both produce insulin-resistant DM with an associated pituitary mass lesion. Differentiation may require use of a low-dose dexa methasone suppression test to rule out PDH.
• Acromegaly and PDH can occur concurrently.
• Other disorders causing weight loss with increased body size due to increased bone and tissue growth, visceral organomegaly, bone remodeling and thickening (especially in bones formed from membranous ossification) resulting in arthropathy, broad facial features, and enlarged “dubbed” paws.
• Myocardial hypertrophy occurs in many cats, but heart failure is uncommon. The catabolic actions of GH result from insulin antagonism leading eventually to pancreatic β cell exhaustion and DM. Between 25 and 33% of diabetic cats may have acromegaly. Like most diabetic cats the potential for remission remains if the excessive GH production can be normalized, likelihood of remission is inversely related to the duration of DM.

OTHER LABORATORY TESTS
• IGF1—diabetic cats receiving insulin can have higher IGF1 levels than normal; hence there is significant potential for overlap between acromegalic and non-acromegalic diabetic cats; however, dramatically elevated IGF1 levels (e.g., >1,000 ng/ml) are strongly suggestive of the acromegaly.
• IGF1 is well preserved across the species, so valid assays are commonly available.
• GH—elevated basal serum levels are diagnostic. However, as GH is not well preserved across the species, a validated GH assay has limited availability.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Uncomplicated DM or DM secondary to hyperadrenocorticism. Pituitary-dependent hyperadrenocorticism and acromegaly can both produce insulin-resistant DM with an associated pituitary mass lesion. Differentiation may require use of a low-dose dexamethasone suppression test to rule out PDH.
• Acromegaly and PDH can occur concurrently.
• Other disorders causing weight loss with increased body size due to increased bone and tissue growth, visceral organomegaly, bone remodeling and thickening (especially in bones formed from membranous ossification) resulting in arthropathy, broad facial features, and enlarged “dubbed” paws.
• Myocardial hypertrophy occurs in many cats, but heart failure is uncommon. The catabolic actions of GH result from insulin antagonism leading eventually to pancreatic β cell exhaustion and DM. Between 25 and 33% of diabetic cats may have acromegaly. Like most diabetic cats the potential for remission remains if the excessive GH production can be normalized, likelihood of remission is inversely related to the duration of DM.

MEDICATIONS
Somatostatin analogs and dopamine agonists have been used to try to inhibit GH secretion by the pituitary, mostly without success. Recently, a novel somatostatin analog, pasireotide (Novartis, Basel, Switzerland) has been shown to be effective at achieving this, although further research is required to evaluate the use of this drug, including dosing regimes, in the long run.

SURGERY
• Hypophysectomy is considered the treatment of choice in human hypopituitarism. It has also been proven to be the only consistently effective and reliable method to cure HS in cats.
• An experienced neurosurgeon and appropriate pre-, peri- and postoperative care are essential for success. A transphenoidal approach is currently preferred (incising the soft palate).
• In the long run, cats need to be supplemented with thyroid hormone and a glucocorticoid; synthetic ADH (DDAVP) supplementation can often be ceased 6–8 weeks postoperatively. When performed early in the disease process, diabetic remission is a realistic outcome and often occurs within 2 months after the procedure.

OF CANINE AND FELINE, SIXTH EDITION
PALLIATIVE TREATMENT

- When definitive treatment is not possible, the focus should lie on gaining more control of the diabetes mellitus and treating possible comorbidities.
- Eventually most cats tend to need high dosages of insulin and/or combinations of short-acting and long-acting insulin types to ensure an adequate quality of life for both pet and owner.
- Nevertheless, a minority achieve an adequate quality of life.
- Regular veterinary assessment is recommended.
- Iatrogenic hypoglycemia is a major concern given the pulsatile nature of GH secretion (and therefore associated insulin resistance).

FOLLOW-UP

- Clinical signs that might be attributed to poor diabetic control (e.g., profound polyphagia) will not improve with improved diabetic control; thus levels of glycated proteins or blood glucose levels are better indicators of diabetic control than clinical signs.
- Serum IGF1 levels are not suitable for monitoring therapy as they do not change during or after radiotherapy.
- Reported survival times vary enormously—from a few months to many years, and dying from causes unlikely to be related to acromegaly.

MISCELLANEOUS

Suggested Reading


Authors Deborah S. Greco and David Church

Consulting Editor Deborah S. Greco
Actinomycosis

OVERVIEW
An infectious disease caused by Gram-positive, branching, pleomorphic, rod-shaped bacteria of the genus Actinomyces. A. viscosus and A. bovis—most commonly identified isolates (though most isolates are not identified to the species level); survivers in microaerophilic or anaerobic conditions. Rarely found as the single bacterial agent in a lesion, more commonly, it is a component of a polymicrobial infection.

SIGNS
Infections—usually localized; may be draining tracts and pleural or peritoneal effusions must be addressed.

CBC/BIOCHEMISTRY/URINALYSIS
Non specific changes. Leukostasis with a left shift and mononcytosis—reported. Nonregenerative anemia—may develop. Hypoglycemia and hyperglycobilinemia—reported.

IMAGING
Radiographs of infected bone—periosteal is variable. Rarely found as the single bacterial agent in a lesion, more commonly, it is a component of a polymicrobial infection.

TREATMENT
Enitoxic liquid (thorax, abdomen, or a swollen extremity may develop.

DIFFERENTIAL DIAGNOSIS
Nocardiosis—primary differential diagnosis; Actinomyces not reliably distinguished from Nocardia spp by Gram staining, cytology, or clinical signs. Other causes of chronic

CONTRAINdications/POSSIBLE INTERACTIONS
Meniralcondro—avoid use; actinomycosis unlikely to respond. Aminoglycosides—do not use; ineffective against anaerobic infections. A. bovis—one cell—wall deficient variant (3-phage); does not usually respond well to penicillin; consider clindamycin, erythromycin, and chloramphenicol.

DRUG(S)
Aminoglycosides—do not stain acid-fast; stains may enhance visualization of tissue sections should be submitted; special granules can be difficult to find so multiple

MISCELLANEOUS
Age-related factors
Young outdoor dogs.

Zoonotic Potential
There are no reported cases of actinomycosis being transmitted from animals to man; transmission by bite wound may be possible so appropriate attention should be given to bite wounds.

Suggested Reading

Author: Sharon Foodrice Grace
Consulting Editor: Stephen C. Barr

Canine and Feline, Sixth Edition
BASICS

DEFINITION
An emergency condition characterized by historical and physical examination findings of a tense, painful abdomen. May represent a life-threatening condition.

PATHOPHYSIOLOGY
- A patient with an acute abdomen has pain associated with either distention of an organ, inflammation, traction on the mesentery or peritoneum, or ischemia.
- The abdominal viscera are sparsely innervated, and diffuse involvement is often necessary to elicit pain; nerve endings also exist in the submucosa-musculature of the bowel wall.
- Any process that causes fluid or gaseous distension (i.e., intestinal obstruction, gastric dilatation-volvulus, ileus) may produce pain.
- Inflammation produces abdominal pain by releasing vasoactive substances that directly stimulate nerve endings.
- Many nerves in the peritoneum are sensitive to a diffuse inflammatory response.

SYSTEMS AFFECTED
- Behavioral—trembling, inappetence, vocalizing, lethargy, and abnormal postural changes such as the praying position to achieve comfort.
- Cardiovascular—severe inflammation, ischemia, and sepsis may lead to acute circulatory collapse (shock). May be associated with SIRS and septic shock.
- Gastrointestinal—vomiting, diarrhea, inappetence, generalized functional ileus; pancreatic inflammation, necrosis, and abscesses may lead to cranial abdominal pain, vomiting, and ileus.
- Hepatic—jaundice associated with extrahepatic cholestasis from biliary obstruction (including pancreatitis) and bile peritonitis. Hyperbilirubinemia may occur secondary to sepsis.
- Renal/Urologic—azotemia can be due to prerenal causes (dehydration, hypovolemia, and shock), renal causes (acute pyelonephritis and acute renal failure), and post-renal causes (ureteral obstruction, urethral obstruction and ureteronephroureteral reflux). Respiratory—increased respiratory rate due to pain or metabolic/acid-base disturbances.

SIGNALMENT
- Dogs and cats.
- Dogs more commonly.
- Younger animals tend to have a higher incidence of trauma-related problems, intussusceptions, and acquired diet- and infection-related diseases; older animals have a greater frequency of malignancies.
- Male cats and dogs are at higher risk for urethral obstruction.

CAUSES
- Male Dalmatians in particular have a higher risk of urethral obstruction because of the high incidence of urate urinary calculi.
- German shepherds with pancreatic atrophy have a higher risk of mesenteric volvulus.
- Patients treated with corticosteroids and non-steroidal anti-inflammatory drugs are at higher risk for gastrointestinal ulceration and perforation.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS
- Renal-associated pain, retroperitoneal pain, spinal or paraspinal pain, and disorders causing diffuse muscle pain may mimic abdominal pain; careful history and physical examination is essential.
Antagonists
Anemia may be seen with blood loss
Pancreatitis patients may have an abdominal
Keep patient NPO if vomiting, until a
Perform abdominocentesis on all patients
Hyperbilirubinemia and elevated hepatic
Use caution when evaluating postoperative
Intravenous fluid therapy is usually required
Characterize ileus as functional (due to
Diagnostic peritoneal lavage can be
Azotemia is associated with prerenal, renal,
Evaluate hydration and electrolytes (with
Loss of contrast or radiographic detail in the
Urine specific gravity (before fluid therapy)
Creatinine concentration higher in
Similarly, higher bilirubin concentration in
Many causes of acute abdominal pain
FAST ultrasound is a published technique
Pain medication may be indicated for
If severe circulatory compromise (shock)
Very sensitive diagnostic tool that may be
This can prevent both potentially
Free abdominal gas is consistent with a
Upper GI barium contrast radiographs are
Use caution when interpreting radiographs
Canine and feline pancreatic lipase
Inflammation or infection may be
Inpatient management with supportive care
Ranitidine 2 mg/kg IV q12h
Aggressive therapy and prompt
Famotidine 0.5–1.0 mg/kg IV, SC or IM

Other Laboratory Tests
Venous blood gas analysis including lactate concentration may indicate acid-base abnormalities, and increased lactate may be associated with hypoperfusion.
Canine and feline pancreatic lipase immunoactivity can be useful in evaluating pancreatitis.

Imaging
Abdominal Radiography
May see abdominal masses or changes in shape or shifting of abdominal organs.
Loss of abdominal detail with abdominal fluid accumulation is an indication for abdominocentesis.
Free abdominal gas is consistent with a ruptured GI viscus or infection with gas-producing bacteria and is an indication for emergency surgery.
Use caution when interpreting radiographs following abdominocentesis with an open needle. Free gas may be introduced with this technique.
Use caution when evaluating postoperative radiographs; free gas is a normal postoperative finding.
Ileus is a consistent finding with peritonitis.
Characterize ileus as functional (due to metabolic or inflammatory causes) or mechanical (due to obstruction).
Foreign bodies may be radiopaque.
Upper GI barium contrast radiographs are useful in evaluating the GI tract, particularly for detection of GI obstruction.
Loss of contrast or radiographic detail in the area of the pancreas can be observed with pancreatic inflammation.

Abdominal Ultrasound
A sensitive diagnostic tool for the detection of abdominal masses, abdominal fluid, abscesses, cysts, lymphadenopathy, and biliary gas-producing bacteria and is an indication for abdominocentesis.
FAST ultrasound is a published technique measuring focused Assessment with Sonography in Trauma.
Abdominal CT
Very sensitive diagnostic tool that may be used especially when surgery requires additional information.

Diagnostic Procedures
Abdominocentesis/Abdominal Fluid Analysis
Perform abdominocentesis on all patients presenting with acute abdomen.
Four-quadrant approach may improve yield. Fluid can often be obtained for diagnostic evaluation even when only a small amount of free abdominal fluid exists, well before detectable radiographic sensitivity.
Ultrasound is much more sensitive than radiography for the detection of fluid and can be used to direct abdominocentesis. Blind abdominocentesis can be performed safely without ultrasound guidance. Abdominal fluid analysis with elevated WBC count, degenerate neutrophils, and intracellular bacteria is consistent with septic peritonitis and is an indication for immediate surgery.
Diagnostic peritoneal lavage can be performed by introducing sterile saline (10–20 ml/kg) and performing abdominocentesis with or without ultrasound guidance.
Measurement of glucose concentration in abdominal effusion in comparison with peripheral blood may aid in the diagnosis of septic abdomen. A blood-to-abdominal fluid glucose difference of > 20 mg/dl is consistent with septic effusion.
Peritoneal patients may have an abdominal effusion characterized as a non-septic (sterile) peritonitis.
Creatinine concentration higher in abdominal fluid than in serum indicates urinary tract leakage.
Similarly, higher bilirubin concentration in abdominal fluid than in serum indicates bile peritonitis.

Sedation and Abdominal Palpation
Because of abdominal splinting associated with pain, thorough abdominal palpation is often not possible without sedation; this is particularly useful for detecting intermittent foreign bodies that do not appear on survey radiographs.

Exploratory Laparotomy
Surgery may be helpful diagnostically (as well as therapeutically) when ultrasonography (or other advanced imaging) is not available or when no definitive cause of the acute abdomen has been established with appropriate diagnostics.

Treatment
Appropriate health care
Inpatient management with supportive care until decision about whether the problem is to be treated medically or surgically. Early intervention with surgery is important when indicated.
Aggressive therapy and prompt identification of the underlying cause is very important.
Many causes of acute abdominal pain require emergency surgical intervention.
Keep patient NPO if vomiting, until a definitive cause is determined and addressed.
Intensive fluid therapy is usually required because of the large fluid loss associated with an acute abdomen; the goal is to restore the normal circulating blood volume.
If severe circulatory compromise (shock) exists, supplement initially with isotonic crystalloid fluids (90 ml/kg, dogs, 70 ml/kg, cats) over 1–2 hours; hypertonic fluids or colloid may also be beneficial if refractory to isotonic crystalloids or hypoproteinemic.
Evaluate hydration and electrolytes (with appropriate treatment adjustments) frequently after commencement of treatment.

Diet
Early nutritional support important, especially in order to maintain GI mucosal barrier. Nutritional support can be enteral (oral, nasoesophageal, esophageal tube, gastroscope tube, enterostomy tube) or parenteral.

Surgical Considerations
Many different causes of an acute abdomen (with both medical and surgical treatments) exist; make a definitive diagnosis whenever possible prior to surgical intervention.
This can prevent both potentially unnecessary and expensive surgical procedures and associated morbidity and mortality.
It will also allow the surgeon to prepare for the task and to educate the owner on the prognosis and financial investment.

Medications
Drug(s)
Analgesics
Pain medication may be indicated for control of abdominal discomfort.
Opioids, such as hydrodromorphone or fentanyl, are often good choices.
Histamine H2 Antagonists
Reduce gastric acid production.
Famotidine 0.5–1.0 mg/kg IV, SC, or IM q12h.
Ranitidine 2 mg/kg IV q12h.
**Acute Abdomen (Continued)**

**Proton Pump Inhibitor**
Pantoprazole 1–1.5 mg/kg IV as a CRI over 24 hours.

**Protectants**
Sucralfate 0.35–1 g PO q8h.

**Antiemetics**
- Metoclopramide 0.2–0.4 mg/kg IV q6–8h (or 24-hour continuous rate infusion (1–2 mg/kg/24h).
- Maropitant: dogs, 1–2 mg/kg SC; cats, 1 mg/kg SC.
- Ondansetron 0.5–1 mg/kg IV slowly q6–12h.
- Dolasetron 1 mg/kg IV q24h.

**Antibiotics**
- Antibiotics may be indicated if signs of infection (fever, elevated white blood cell count, positive culture) are seen or hemorrhagic diarrhea is present.
- Broad spectrum for Gram-positive, Gram-negative, and anaerobic bacteria.
- Gram stain and cultures prior to treatment if possible, but do not delay intervention pending results.

**CONTRAINDICATIONS**
Do not use metoclopramide if GI obstruction is suspected. Do not use barium if gastrointestinal perforation is suspected. Use iodinated contrast agent instead.

**PRECAUTIONS**
Gentamicin and most NSAIDs can be nephrotoxic and should be used with caution in hypovolemic patients and those with renal impairment. Opiates are preferred to NSAIDs for pain management as NSAIDs may cause GI complications.

**FOLLOW-UP**

**PATIENT MONITORING**
Patients usually require intensive medical care and frequent evaluation of vital signs and laboratory parameters.

**MISCELLANEOUS**

**SYNONYM**
Colic

**SEE ALSO**
- Gastric Dilatation and Volvulus Syndrome
- Gastroduodenal Ulceration/Erosion (GUE)
- Gastrointestinal Obstruction
- Intussusception
- Pancreatitis
- Pyelonephritis
- Prostatitis and Prostatic Abscess
- Urinary Tract Obstruction

**ABBREVIATIONS**
- GI = gastrointestinal
- NSAID = nonsteroidal anti-inflammatory drug

**Suggested Reading**

**Author** Steven L. Marks

**Consulting Editor** Stanley L. Marks
Acute Respiratory Distress Syndrome

**BASICS**

**DEFINITION**
- Acute respiratory distress syndrome (ARDS) is a syndrome of acute onset of respiratory failure typified by diffuse bilateral pulmonary infiltrates on a chest roentgenogram with no evidence of left atrial hypertension or volume overload.
- ARDS results from an overwhelming inflammatory reaction in the alveolar-capillary membrane in response to a systemic or pulmonary inflammatory insult. The end result is increased vascular permeability leading to edema. The 2012 Berlin Definition of ARDS defines three categories of severity based on PaO₂/FiO₂ ratio and level of PEEP employed during ventilation, with mild ARDS defined by a PEEP ratio of 200–300 mmHg with PEEP ≥ 5 mmHg, moderate ARDS as a PEEP ratio of 100–200 mmHg with PEEP ≥ 5 mmHg, and severe ARDS as a PEEP ratio < 100 mmHg with PEEP ≥ 5 mmHg.

**PATHOPHYSIOLOGY**
- ARDS is due to a diffuse inflammatory insult that causes widespread damage to alveolar endothelial and epithelial cells resulting in thickening of the membrane and impaired gas exchange. This inflammatory insult can be triggered by primary pulmonary disease or it can be of non-pulmonary origin, and leads to exudative, proliferative, and fibrotic changes within the lung. First, excessive accumulation and activation of neutrophils, monocytes, and plasmeges in the pulmonary microvasculature leads to increased alveolar endothelial permeability. This causes protein-rich edema fluid and interstitial edema to fill up the alveolar interstitium and alveolar spaces. Alveolar epithelial injury results from release of cytokines and other inflammatory mediators from leukocytes and platelets. Epithelial injury involves both type I and II alveolar epithelial cells, and results in alveolar flooding and surfactant dysfunction. This causes collapse and consolidation of alveoli with development of severe hypoxemia, and hyaline membrane formation in the alveolar spaces. Microthrombi in the pulmonary vasculature, hypoxic pulmonary vasoconstriction, and release of endogenous vasodilators lead to pulmonary arterial hypertension, which can lead to right-sided heart failure. Pulmonary venous hypertension results from pulmonary edema. Pulmonary capillary wedge pressure (PCWP) is used to rule out cardiogenic cause for edema; PCWP ≥ 18 mmHg is evidence of pulmonary hypertension.

**CAUSES**

**Primary Pulmonary Causes**
- Aspiration pneumonia
- Pneumonia
- Pulmonary contusion
- Near drowning
- Smoke inhalation
- An idiopathic form of ARDS associated with acute interstitial pneumonia or idiopathic pulmonary fibrosis has been reported in humans and dogs.

**Non-pulmonary Causes**
- SIRS
- Septic
- Neutropenia
- Pancreatitis
- Severe trauma and shock
- Severe bee sting envenomation

**RISK FACTORS**
- SIRS
- Septic
- Severity of illness
- Multiple transfusions

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Left-sided congestive heart failure
- Fluid overload
- Diffuse pneumonia
- Pulmonary hemorrhage

**CBC/BIOCHEMISTRY/URINALYSIS**
- Leukocytosis or leukopenia
- Other changes dependent on the underlying disease process

**OTHER LABORATORY TESTS**
- Arterial blood gases—low PaO₂/FiO₂ ratio (A-a gradient PaO₂ is measured in mmHg and FiO₂ is 0.21–1.0). Normal PaO₂/FiO₂ ratio = 500; comparison of this ratio allows evaluation of severity of lung disease and allows direct comparison of blood gases taken at different FiO₂. PaCO₂ is often low; hypercapnia tends to be a late (prolonged) development.
- Total protein of airway edema fluid compared with serum total protein—ratio of edema fluid to serum total protein < 0.5 is suggestive of low-protein hydrostatic pressure pulmonary edema (e.g., heart failure, fluid overload); edema fluid/serum total protein ratio > 0.7 suggests a high-protein, increased permeability pulmonary edema such as ARDS and pneumonia. Coagulation panel may reveal hypofibrinogenemia supportive of DIC or cause of pulmonary hemorrhage.

**IMAGING**

**Thoracic Radiographs**
- Bilateral/diffuse pulmonary infiltrates
- Severity of radiographic signs can lag behind clinical disease by 12–24 hours
- Can be difficult to distinguish from cardiogenic edema. Cardiac silhouette and pulmonary vascular size is usually normal in ARDS.

**Echocardiography**
- Attempt to rule out cardiogenic cause for pulmonary edema. May be able to estimate degree of pulmonary hypertension.

**DIASTOLIC PROCEDURES**
- Pulmonary artery catheter to measure pulmonary artery occlusion pressure can be used to rule out cardiogenic cause for edema. In humans and dogs, PAOP > 18 mmHg.

**PATHOLOGIC FINDINGS**

**Gross Pathology**
- Lungs are dark, heavy, and have fluid when cut

**Histopathology**
- Acute phase—pulmonary vascular congestion with edema fluid and inflammatory cell accumulation in the interstitium and alveoli; epithelial cell damage, hyaline membrane formation, microthrombi, microatelectasis.
- Proliferative phase—hyperlplasia of type 2 pneumocytes, interstitial monomacrophage infiltration, organization of hyaline membranes, and fibroproliferation.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- There is no specific therapy. General aims are to maintain tissue oxygenation and to maximize intrathoracic lung injury while treating the underlying disease. Oxygen therapy—no more than is required to maintain PaO₂ > 60–80 mmHg to minimize oxygen toxicity. Positive-pressure ventilation is essential in ARDS and ARDS-like patients. It is indicated in patients that are hypoxemic despite oxygen therapy. Patients requiring high levels of inspired oxygen for
Blood pressure monitoring, as systemic inflammatory response syndrome (SIRS) is common in ARDS, and positive-pressure ventilation with moderate to high PEEP often results in increased tidal volumes and permissive hypercapnia which is recommended to minimize ventilator-induced lung injury. Tidal volumes of 6 mL/kg have been found to increase survival significantly in human ARDS patients compared to tidal volumes of 12 mL/kg. Recruitment maneuvers and higher levels of PEEP can both cause significant hemodynamic compromise and patients should have constant direct arterial blood pressure monitoring.

NURSING CARE

• Monitor temperature closely, especially in recumbent patients. 
• Ventilator patients require frequent position changes and physical therapy; regular oral care with a dilute fluoride solution is important to reduce dental caries and to maintain normovolemia while avoiding fluid overload, as this will negatively affect lung function.

ACTIVITY

If not anesthetized for ventilation, strict cage confinement is indicated. 

DIET

Nutritional support is important but challenging. Enteral feeding is desired over parenteral nutrition, but must consider high risk of regurgitation and aspiration in a recumbent patient.

CLIENT EDUCATION

Clients need to be aware of the guarded prognosis and high costs of therapy.

SURGICAL CONSIDERATIONS

The underlying disease may require surgery.

MEDICATIONS

DRUG(S) OF CHOICE

• No specific drug therapy

• Antibiotics for the underlying disease where indicated.

• Vasoactive drugs to maintain blood pressure.

• Anesthetic drugs to allow positive-pressure ventilation.

• Analgesia as appropriate.

• Low-dose corticosteroids—use remains controversial with conflicting reports of efficacy for low-dose steroids in early or late ARDS.

ALTERNATIVE DRUG(S)

Furosemide may produce pulmonary venous dilation and improve lung function, as an intermittent bolus of 1 mg/kg IV q6–12h or as a CRI of 0.2 mg/kg/h IV. Beware dehydration and effects on organ function.

FOLLOW-UP

PATIENT MONITORING

Arterial blood gases, pulse oximetry, end-tidal carbon dioxide, thoracic radiographs, arterial blood pressure, ECG, temperature, urine output, CRP, coagulation profiles, serum chemistry, blood cultures, monitoring for other organ dysfunction.

PREVENTION/AVOIDANCE

• Aggressive therapy of primary disease processes to reduce the inflammatory insult to the lung. • Intensive cardiovascular monitoring and support of critically ill animals to ensure adequate tissue perfusion. • Careful management of recumbent animals to reduce the chance of aspiration, especially if patient has neurologic disease or upper airway disorders that reduce the ability to protect the airway. • Judicious use of blood products in patients with inflammatory or severe systemic disease.

POSSIBLE COMPLICATIONS

• Multiple organ dysfunction syndrome—acute kidney dysfunction, DIC, and gastrointestinal disease are the more common forms of organ dysfunction seen. 
• Barotrauma—can result in pneumothorax. Incidence is thought to be less with lower tidal volume ventilation strategies. 
• Ventilator-associated pneumonia—patients on PPV have increased risk of pneumonia that may be difficult to differentiate from worsening of the initial lung injury. Airway cultures should be considered in deteriorating patients. 
• Oxygen toxicity may be unavoidable due to severity of hypoxemia in spite of PPV. Oxygen toxicity is indistinguishable from ARDS on histopathology making the incidence of this problem impossible to determine.

EXPECTED COURSE AND PROGNOSIS

• Mortality in human patients remains at 40–60%. • Mortality in veterinary patients likely approaches 100%.

MISCELLANEOUS

ASSOCIATED CONDITIONS

Systemic inflammatory response syndrome, multiple organ dysfunction syndrome, sepsis.

SYNONYMS

• Acute hypoxic respiratory failure 
• Acute interstitial pneumonia • Adult respiratory distress syndrome • High-protein pulmonary edema • Shock lung

SEE ALSO

• Deepens and Respiratory Distress • Pneumonia and Tachypnea • Pulmonary Edema, Noncardiogenic • Sepsis and Bacteremia

ABBREVIATIONS

• ARDS = acute respiratory distress syndrome
• PEEP = positive end-expiratory pressure
• PaO2/FiO2 ratio = PTP = positive-pressure ventilation
• SIRS = systemic inflammatory response syndrome

INTERNET RESOURCES

http://www.ardsnet.org

Suggested Reading


Authors Casey J, Kohen and Kate Hopper

Consulting Editor Lynelle R. Johnson
Adenocarcinoma, Anal Sac

**BASICS**

**OVERVIEW**
- Malignant neoplasm derived from apocrine glands of the anal sac.
- Locally invasive.
- High metastatic rate, often to sublumbar lymph nodes.
- Frequently associated with hyperparathyroidism.
- Secondary to parathyroid hormone–related peptide secretion.
- Prognosis guarded to fair.

**SIGNALMENT**
- Older dogs; extremely rare in cats.
- Females overrepresented in some studies.
- English cocker spaniels significantly overrepresented; Springer and Cavalier King Charles spaniels also overrepresented.

**SIGNS**

**Historical Findings**
Signs may be due to physical obstructive nature of primary tumor (rectal mass, tenesmus) or enlarged local lymph node metastasis (tenesmus, constipation, stranguria), or systemic manifestations due to hypercalcemia (anorexia, polyuria/polydipsia, lethargy).

**Physical Examination Findings**
- Mass associated with anal sac may be quite small despite massive metastatic disease.
- Sublumbar lymphadenopathy—on rectal or abdominal palpation.

**CAUSES & RISK FACTORS**
None definitively identified.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Anal sac abscess
- Perianal adenoma/adenocarcinoma
- Mast cell tumor
- Lymphoma
- Squamous cell carcinoma
- Pruritic dermatitis

**CBC/BIOCHEMISTRY/URINALYSIS**
- Hypercalcemia—25–30% of cases.
- Secondary renal failure may develop.

**OTHER LABORATORY TESTS**
If hypercalcemia is present, and tumor cannot be identified, parathyroid hormone and PTHrP levels can be assessed—high PTHrP supports neoplasia as the cause of hypercalcemia.

**IMAGING**
- Abdominal radiography—to evaluate sublumbar lymph nodes and lumbar and pelvic bone.
- Thoracic radiography—to evaluate for pulmonary metastasis.
- Abdominal ultrasonography—may identify mildly enlarged sublumbar lymph node not visible radiographically, also nodules in liver/spleen.
- MRI—recently shown to identify lymphadenopathy with greater sensitivity than ultrasonography.

**DIAGNOSTIC PROCEDURES**
- Fine-needle aspiration of anal sac mass to rule out conditions other than adenocarcinoma; while differentiation of benign versus malignant neoplasm of perianal masses is difficult, apocrine gland adenocarcinomas of the anal sac will have a neuroendocrine appearance and can be differentiated from perianal gland tumors.
- Fine-needle aspiration of enlarged lymph nodes, liver, or splenic nodules to confirm metastasis.
- Incisional biopsy for histology required for definitive diagnosis, although excisional biopsy may be appropriate if location of mass and cytology are supportive of anal gland neoplasia.

**TREATMENT**
- Surgical resection—treatment of choice.
- Resection of primary tumor and enlarged local lymph nodes may prolong survival.
- If mass is large and regionally invasive at diagnosis, surgery often palliative, not curative.
- Debulking all disease present may control growth of sublumbar metastases.
- Toceranib phosphate reported to have some support neoplasia as the cause of hypercalcemia.

**MEDICATIONS**

**DRUG(S)**
- Limited reports of partial responses to platinum compounds in dogs—cisplatin (70 mg/m² IV with 6-hour saline diuresis—18.3 mg/kg/h), carboplatin (100 mg/m² IV as a slow bolus) every 3 weeks.
- Mitoxantrone (5 mg/m² IV every 3 weeks for five treatments) in combination with radiation therapy used in one small case series.
- Possible role for melphalan after debulking surgery (7 mg/m² PO q3q4hs for 5 days every 3 weeks).
- Toceranib phosphate reported to have some benefit (partial response or stable disease) in 28 dogs with metastable tumors.

**CONTRAINDICATIONS/Possible Interactions**
- Avoid platinum chemotherapeutic agents in dogs with renal insufficiency.
- Do not use cisplatin in cats.

**FOLLOW-UP**

**PATIENT MONITORING**
- Complete resection—physical examination, thoracic radiography, abdominal ultrasonography, and serum biochemistry at 1, 3, 6, 9, and 12 months postoperatively.
- Then every 6 months thereafter.
- Incomplete resection—monitor tumor size and blood calcium and renal values.

**EXPECTED COURSE AND PROGNOSIS**
- Guarded prognosis with both local progression and metastasis occurring.
- Cures may occur if tumor is found early and treated aggressively.
- Growth of the tumor may be slow and debulking lymph node metastatic disease may significantly prolong survival.
- Hypercalcemia is variably associated with a poor prognosis.
- Four papers involving 200 dogs showed median survival times of 6 to 20 months, depending on stage and treatment.
- A recent report on 16 dogs without metastasis showed a median survival time not met with a follow-up of 33 months.
- Dogs with lymph node metastasis lived significantly longer if the nodes were resected.
- Ultimately, dogs that cannot have their tumors excised completely succumb to hypercalcemia-related complications or mass effect from primary tumor or sublumbar nodal metastases.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
Hypercalcemia as a paraneoplastic syndrome

**ABBREVIATION**
PTHrP = parathyroid hormone-related peptide

**Suggested Reading**
Author: Laura D. Garrett
Consulting Editor: Timothy M. Fan

Client Education Handout available online
**Adenocarcinoma, Lung**

### BASICS

**OVERVIEW**
- Comprised 75% of primary pulmonary tumors in dogs and cats.
- Strongest predictors of outcome are tumor grade, node involvement, and clinical signs.
- May metastasize.
- May be associated with hyperadrenocorticism.

**SIGNALMENT**
- Dogs:
  - 1% of all tumors
  - Mean age of affected animals: 10 years
  - No sex predilection
- Medium to large breeds overrepresented

**Cats**
- Rare in dogs
- Mean age of affected animals: 11 years
- No breed predilection

**HISTORICAL FINDINGS**
- Related to presence of a lung mass:
  - Nonproductive cough (>50% of dogs)
  - Dyspnea (may be related to pneumothorax)
  - Tachypnea
  - Hemoptysis
- Other pulmonary signs:
  - Lameness—bone metastasis or hyperadrenocorticism from ectopic production of ACTH
  - Fever

**PHYSICAL EXAMINATION FINDINGS**
- May be asymptomatic or lack respiratory signs
- Tachypnea and dyspnea
- Limb swelling
- Auscultation
- Diuresis

### CAUSES & RISK FACTORS

Some evidence correlates risk to urban environment; controversial.

### DIAGNOSIS

- Fine-needle aspirate cytology
- Tissue biopsy or definitive resection

### DIFFERENTIAL DIAGNOSIS

- Granulomatous lesion (fungal, foreign body, parasitic)
- Pulmonary abscess
- Other primary lung tumors: Squamous cell carcinoma, Sarcoma (osteosarcoma, chondrosarcoma, liposarcoma), Metastatic lung tumor
- Lymphoma
- Pneumonia
- Adrenocortical tumors
- Congenital cyst
- Lung torsion or hernia

### CBC/BIOCHEMISTRY/URINALYSIS

No specific abnormalities

### OTHER LABORATORY TESTS

- Coagulation tests
- Thoracic radiography

### IMAGING

- Thoracic radiography—usually demonstrates a focal, solitary, well-circumscribed mass; must be performed in cats presenting with multiple digit tumors.
- CT—most accurate assessment of surgical feasibility, lymphadenopathy (93% accuracy), metastatic disease.
- Dogs—most common in right caudal lung lobe and accessory lobe; cats—most common in left caudal lung lobe.

### DIAGNOSTIC PROCEDURES

- Thoracoscopy with cytologic examination (for pleural effusion)
- Cytology—transthoracic fine-needle aspiration (83% agreement with histopathology)
- Bronchoalveolar lavage
- Open lung biopsy—specimen via thoracotomy, or minimally invasive thoracoscopy

### PATHOLOGIC FINDINGS

- Adenocarcinoma—classified according to location (bronchial, bronchiolar, bronchiolo-alveolar, or alveolar) and degree of differentiation
- Thyroid transcription factor-1 positivity may distinguish primary from metastatic carcinoma
- Cats tend to have less differentiated tumors, corresponding to a more aggressive behavior

### EXPECTED COURSE AND PROGNOSIS

- Postoperative survival in dogs (∼1 year) and with metastasis, 60 days. More common (75%) in cats.
- Postoperative survival in dogs (<1 yr) is better than in cats (∼4 mo), but around 2 years in either species if positive prognostic factors are present. Other patients, tumor, and treatment factors influencing prognosis—complete surgical excision, size of the primary tumor (<5 cm better); metastasis (better if none); degree of cell differentiation (histologic score, better if well differentiated); lack of clinical signs prior to surgery.

### TREATMENT

- Surgery—mainstay of treatment: partial or complete lobectomy with tracheobronchial anastomosis
- Chemotherapy can be used to treat malignant pleural effusion
- Radiation therapy—administered with surgical treatment

### MEDICATIONS

**DRUG(S)**
- Chemotherapy—vindesine is a rational choice for palliation
- Doxorubicin, cisplatin, carboplatin, mitoxantrone, vinorelbine, and/or vinorelbine—rational choices for palliation
- Platinum based or gemcitabine chemotherapy may be superior
- Toceranib Phosphate (Famprid) has shown some anecdotal success

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**

- Doxorubicin—monitor patients with underlying cardiac disease carefully; consider pretreatment with oral cyclosporine and serial echocardiograms and ECGs.
- Cisplatin—do not give to cats (feline); do not use in dogs with pre-existing renal disease; never use without appropriate and concurrent diuresis.

### FOLLOW-UP

**PATIENT MONITORING**

- Serial thoracic radiographs—consider every 3 months; administer a minimum of two cycles of chemotherapy before evaluating response to treatment.
- Perform CBC (with any chemotherapy), biochemical analysis (creatinine, and urinalysis (creatinine) before each chemotherapy treatment.

**POSSIBLE COMPLICATIONS**

- Following diagnostic procedures or thoracoscopy: pneumothorax or hemothorax
- Resulting from chemotherapy: myelosuppression, fever, sepsis, nausea

### MISCELLANEOUS

**PREGNANCY/FERTILITY/BREEDING**

Chemotherapy is not advised in pregnant animals.

**ABBREVIATIONS**

- ACTH = adrenocorticotropic hormone

**Suggested Reading**


**Author** Kim A. Selting

**Consulting Editor** Timothy M. Fan

**Acknowledgments** The author and editors acknowledge the prior contribution of Renee Al-Saraff.
**Adenocarcinoma, Nasal**

### Causes
- Doliococephalic morphology, p53 mutations, and COX-2 overexpression may all play a role.

### Risk Factors
- Urban environment and second-hand smoke may be risk factors.

### Diagnosis

#### Differential Diagnosis
- Other sinonasal tumors (e.g., squamous cell carcinoma, lymphoma, sarcoma, olfactory neuroblastoma)
- Intranasal neoplasia
- Viral infection—cats
- Fungal infections including aspergillosis (dogs) and cryptococcosis (cats)
- Bacterial sinusitis
- Parasites (e.g., nasal mites)
- Foreign body
- Trauma
- Tooth root abscess and oronasal fistula
- Cogulopathies
- Ehrlichiosis, leishmaniasis
- Systemic hypertension

#### CBC/Biochemistry/Urinalysis
- Usually normal
- Occasional blood loss anemia

#### Other Laboratory Tests
- Cytologic examination: occasionally helpful
- Cytologic evaluation of regional lymph nodes to assess regional metastatic disease.

#### Imaging
- CT or MRI best imaging method for local staging and observing integrity of cribriform plate or orbital invasion, and also used for definitive therapeutic planning.
- Effect; may see fluid density in the frontal sinuses secondary to outflow obstruction.
- Thoracic radiography: evaluate for lung metastasis (uncommon).
- CT or MRI best imaging method for local staging and observing integrity of cribriform plate or orbital invasion, and also used for therapeutic planning.

#### Diagnostic Procedures
- Blood pressure
- Oral exam under anesthesia
- Rhinoscopy may permit visual observation of the mass and aid biopsy.
- Tissue biopsy necessary for definitive diagnosis. Biopsies may be performed blind, following advanced imaging, using pinch biopsy instrument including retractable rhinoscopic biopsy of nasopharynx, cannula (closed suction), or hydrodissection techniques.
- Cytologic evaluation of regional lymph nodes to assess regional metastatic disease.

#### Pathologic Findings
- Bilateral involvement and osteolytic common.
- Regional lymph node metastasis <10% at time of diagnosis but up to 45% at recurrence.

### Treatment

#### Appropriate Healthcare
- Radiation therapy is the standard of care.
- Radiation therapy can be administered with curative intent (definitive) or for palliation of clinical signs.

#### Definitive radiation involves multiple fractions for a high total dose.
- Palliative radiation uses a low total dose to minimize toxicity while improving the quality of life through reduction of tumor size.
- Novel radiation techniques including IMRT and stereotactic radiation therapy may decrease risk of late toxicity while improving tumor control.

#### Combining radiation therapy with novel drug therapy (tumor-directed therapies, others) appears safe and well tolerated.

#### Radiation therapy followed by surgery to debulk residual mass may improve local control time but results in higher risk of late toxicity.

#### Surgery alone considered ineffective with most tumors relapsing within 6 months.

#### Nursing Care
- During radiation therapy, supportive care for radiation related mucositis may involve softening food, rinsing mouth with saline, dilute black tea, and administration of medications to control discomfort.

#### Activity
- Limit activity to minimize risk of epistaxis and dyspnea.
- Using a harness instead of a collar during walks may help minimize epistaxis.

#### Diet
- Soften food if needed during radiation therapy.
- Avoid extremes of temperatures and salty foods with radiation therapy-related mucositis.

#### Client Education
- Nasal adenocarcinoma may be painful even though the pet is not showing visible signs of pain.
- Consider the use of medications for discomfort and congestion.
- Radiation therapy is the most effective option and is well-tolerated using modern radiotransmission techniques.
- Radiation side effects may impact the patient’s quality of life during treatment, but most pets enjoy a relatively normal quality of life following treatment.
**ADENOCARCINOMA, NASAL** (Continued)

- Intermittent congestion and sneezing may occur post therapy due to increased sensitivity from the tumors’ destruction of the nasal turbinates.

**SURGICAL/ANESTHETIC CONSIDERATIONS**

Anesthetic recovery—ensure airway is maintained until animal is sternal to prevent apnea in patients with bilateral nasal obstruction.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

- Chemotherapeutics have gastrointestinal, hematologic, and other potential side effects and should be administered and monitored by an oncologist.

**CONTRAINDICATIONS**

- Piroxicam can cause gastric ulceration so use with caution in animals on nonsteroidal anti-inflammatory drugs (NSAIDs).

**POSSIBLE INTERACTIONS**

- Concurrent radiation therapy and chemotherapy will increase the risk of side effects but have not shown to significantly improve tumor control.

**ALTERNATIVE DRUGS**

- Pallada, a tyrosine kinase inhibitor, may have antitumor activity in some carcinomas including nasal adenocarcinomas. It is currently being investigated as the labeled dose alone and in combination with radiation therapy.

**FOLLOW-UP**

**PATIENT MONITORING**

- CT or MRI are needed to assess response to therapy and are recommended 2–3 months post radiation treatment.

- Other staging tests including thoracic radiography or CT and lymph node evaluation are generally recommended in 3-month intervals during/after therapy.

- Routine staging with CT/MRI and monitoring of recurrent clinical signs can direct early recurrence.

**POSSIBLE COMPLICATIONS**

- Lymphoma, nasal
- Palladia, a tyrosine kinase inhibitor, may improve tumor control.

**EXPECTED COURSE AND PROGNOSIS**

- Median survival around 2–6 months.

- Radiation therapy—median survival times around 12–18 months in dogs and 12–20 months in cats. 1-year survival rate 20–57% (dogs and cats); 2-year survival rate 20–48% (dogs and cats).

- Presence of infraorbital nerve, brain involvement or metastatic disease (advanced stage) are poor prognostic indicators.

- Incidence and severity of ophthalmic toxicity are decreasing with advanced radiation therapy techniques now commonly used.

- Chronic rhinitis is possible following radiation therapy for sinonasal tumors and may require periodic symptomatic therapy.

**MISCELLANEOUS**

**AGE-RELATED FACTORS**

None

**PREGNANCY/FERTILITY/BREEDING**

Chemotherapeutic drugs and general anesthesia are a risk to the fetus and would not be recommended in pregnant animals.

**SYNONYMS**

- Nasal carcinoma
- Nasal tumor

**SEE ALSO**

- Squamous cell carcinoma, nasal
- Chondrosarcoma, nasal
- Lymphoma, nasal

**ABBREVIATIONS**

- CT = computed tomography
- MRI = magnetic resonance imaging

**INTERNET RESOURCES**

- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643460/
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643460/
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643460/
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643460/

**Suggested Reading**


**ACKNOWLEDGMENT**

The author and editors acknowledge the prior contribution of Louis-Philippe de Lorimier.
Adenocarcinoma, Pancreas

Basics

Overview
- Malignant tumor of ductal or acinar origin arising from the exocrine pancreas.
- Usually metastasize by the time of diagnosis, affecting regional lymph nodes and visceral abdominal organs (liver) and associated peritoneal cavity.

Signalment
- Rate in dogs—0.5–1.8% of all tumors
- Rate in cats—2.8% of all tumors
- Older female dogs and Airedale terriers at higher risk than others
- Median age (dogs)—9.2 years
- Mean age (cats)—11.6 years

Signs
- Nonspecific—fever; vomiting; weakness; anorexia; icterus; malabsorption syndrome; weight loss.
- Abdominal pain—variable.
- Abdominal effusion—malignant.
- Metastasis to bone and soft tissue common.
- Pathologic fractures secondary to metastasis reported.
- Palpable abdominal mass (cats).
- Pancreatic pseudocysts—encephalopathic
- Pancreatic thickening, echogenicity, large pancreas, hyperechoic masses or concurrent pancreatitis (mixed echogenicity, large pancreas, hyperechoic peripancreatic fat).
- Pancreatic, thickening, abdominal effusion, and single to multiple nodules of varying size may be identified. Sonographic findings may be impossible to distinguish from pancreatic nodular hyperplasia. Rarely the ultrasound of the pancreas may appear normal except for dilation of the pancreatic duct.

Diagnostic Procedures
- Surgical biopsy—definitive.
- Fine-needle aspirate cytology—supportive. In many cases, where the tumor is not resectable, the fine-needle aspirates may provide strong enough evidence to start medical treatment.

Diagnosis

Differential Diagnosis
- Primary pancreatitis; may be concurrent and delay early diagnosis
- Pancreatic pseudocyst
- Pancreatic nodular hyperplasia
- Hepatic neoplasia
- Other causes of vomiting and icterus
- Peritoneal carcinomatosis
- Other causes of abdominal effusion in cats

CBC/Biochemistry/Urinalysis
- Usually nonspecific changes (e.g., mild anemia and neutrophilia).
- Hyperglycemia less reliable than hyperlipasemia.
- Lipase concentrations are often markedly elevated and may serve as a non-invasive biochemical marker of neoplasia in dogs.

Other Laboratory Tests
- Rarely there may be significant metabolic alterations that affect glucagon, insulin, and amino acid concentrations.

Imaging
- Abdominal radiographs may reveal a mass or loss of serosal detail associated with concurrent pancreatitis or peritoneal effusion.
- Ultrasonography may reveal one or more masses or concurrent pancreatitis (mixed echogenicity, large pancreas, hyperechoic peripancreatic fat). Pancreatic thickening, abdominal effusion, and single to multiple nodules of varying size may be identified. Sonographic findings may be impossible to distinguish from pancreatic nodular hyperplasia. Rarely the ultrasound of the pancreas may appear normal except for dilation of the pancreatic duct.

Surgery
- Partial or total pancreatectomy may prolong survival.
- The absence of systemic metastasis, may have resectable, the fine-needle aspirates may provide strong enough evidence to start medical treatment.

Treatment
- None reported curative.
- Palliation of pain with aggressive analgesic combinations is necessary.
- Surgical intervention to alleviate intestinal and biliary obstruction, if necessary.
- Surgery is typically not a good option in many cases, due to the extent of the disease at the time of diagnosis.
- If surgery is an option, partial or total pancreatectomy may prolong survival.
- Treat concurrent pancreatitis.
- Antiemetics and supportive care (hydration and caloric requirements).

Medications
- Gemcitabine is used in humans for the treatment of pancreatic carcinoma, and used in dogs with cancer, it has not been established as the standard of care for dogs with pancreatic adenocarcinoma.
- Always consult a veterinary oncologist for updates in treating this rare neoplasm.

Contraindications/Possible Interactions
- N/A

Follow-up

Possible Complications
- Intestinal obstruction
- Biliary obstruction
- Pancreatic abscess
- Peritonitis
- Metastasis

Expected Course and Prognosis
- Progression to death is often rapid given that there is no successful curative treatment available. Despite the grave prognosis, individual patients treated with complete resection of their tumor and chemotherapy, in the absence of systemic metastasis, may have prolonged survival.

Miscellaneous

Associated Conditions
- Gastrin-secreting pancreatic carcinoma (gastrinoma) has been reported in dogs and cats. Clinical signs are associated with hypergastrinemia, which results in inappropriate hydrochloric acid secretion by the stomach, leading to gastroduodenitis.

Suggested Reading
- Author: Nick Dervisis
- Consulting Editor: Timothy M. Fan
- Acknowledgment: The author and editors acknowledge the prior contribution of Wallace B. Morrison.
Adenocarcinoma, Prostate

Basics

Overview
Prostatic adenocarcinoma is a malignant tumor that occurs in both neutered and intact male dogs.

- Although this neoplasm represents <1% of all canine malignancies, it is the most common prostatic disorder in neutered male dogs.
- Metastases to regional lymph nodes, lungs, and the lumbosacral skeleton are common. Skeletal metastases can adopt an osteoblastic appearance.

Signs
Dog and rarely cat
- Medium- to large-bred intact or neutered male dogs
- Median age of 9–10 years

Signalment
- Caudal abdominal mass, cachexia, pyrexia, rear limb lameness or neurologic weakness

Differential Diagnosis
- Neutered males are at increased risk for prostatic neoplasia
- Other primary neoplasia (i.e., squamous cell carcinoma, transitional cell carcinoma).
- Metastatic or locally invasive neoplasia (i.e., transitional cell carcinoma).
- Acute or chronic prostatitis, benign prostatic hypertrophy, prostatic abscess, and prostatic cysts are possible differentials in intact male dogs but are highly unlikely in neutered dogs.

Diagnosis

- Prostatic adenocarcinoma is a malignant tumor that occurs in both neutered and intact male dogs.
- Although this neoplasm represents <1% of all canine malignancies, it is the most common prostatic disorder in neutered male dogs.
- Metastases to regional lymph nodes, lungs, and the lumbosacral skeleton are common. Skeletal metastases can adopt an osteoblastic appearance.

Signs
- Caudal abdominal mass, cachexia, pyrexia, rear limb lameness or neurologic weakness

Differential Diagnosis
- Neutered males are at increased risk for prostatic neoplasia
- Other primary neoplasia (i.e., squamous cell carcinoma, transitional cell carcinoma).
- Metastatic or locally invasive neoplasia (i.e., transitional cell carcinoma).
- Acute or chronic prostatitis, benign prostatic hypertrophy, prostatic abscess, and prostatic cysts are possible differentials in intact male dogs but are highly unlikely in neutered dogs.

CBC/Biochemistry/Urinalysis
- Inflammatory leukogram possible.
- Alkaline phosphatase may be high if skeletal metastases exist.
- Post-renal azotemia may be present if urethral obstruction exists.
- It is prudent to evaluate urine samples via cystocentesis and free-catch techniques, as hematuria, pyuria, and malignant epithelial cells may be observed in free-catch samples but are unusual in samples obtained by cystocentesis.

Other Laboratory Tests
- Serum and seminal plasma markers such as acid phosphatase, prostate specific antigen, and canine prostate specific rease are not elevated in dogs with PAC.

Imaging
- Thoracic radiography—metastases may appear as pulmonary nodules or increased interstitial markings.
- Abdominal radiography—sublumbar lymphadenopathy, mineralization of the prostate, lytic lesions to the lumbar vertebrae or pelvis as a consequence of direct tumor extension from regionally infiltrated lumbar lymph nodes may be seen.
- Abdominal ultrasonography—focal to multifocal hyperechogenicity with asymmetry and irregular prostatic outline, if prostatic mineralization.
- Contrast cystography may help differentiate prostatic from urinary bladder disease.

Diagnostic Procedures
- Prostatic aspirate (percutaneous or transrectal).
- Prostatic wash.
- Prostatic biopsy performed percutaneously or surgically.
- Percutaneous biopsy has been associated with tumor seeding along the biopsy tract.

Treatment
- Prostatectomy if local disease (success of this procedure depends on the skill of the surgeon and extent of disease).
- Radiation therapy may palliate signs and prolong survival.
- Prostatic urethral stenting can alleviate urethral obstruction.
- Neutering—however, most tumors are not androgen responsive.

Medications
- Chemotherapy—carboplatin, mitomycin, or doxorubicin; may offer short-term benefit.
- Amiobisphosphonates for the relief of painful skeletal metastases.
- Stool softeners to relieve tenesmus.

Follow-up

- Ability to urinate and defecate, pain secondary to skeletal metastases, quality of life.

Prevention/Avoidance
- Keeping dogs sexually intact may decrease risk.

Possible Complications
- Urinary obstruction.
- Metastasis to regional lymph nodes, skeleton, and lungs.

Expected Course and Prognosis
- Guarded to poor, survival of 2–6 months depending upon presenting clinical symptoms. Treatment early in the course of disease with curative-intent radiation and systemic chemotherapy can extend survival times to 12 months.

Miscellaneous

- None
- No age-related factors

Suggested Reading

Author Ruthanne Chun
Consulting Editor Timothy M. Fan
Adenocarcinoma, Renal

**BASICS**

**OVERVIEW**
- Accounts for < 1% of all reported neoplasms in dogs.
- Renal tumors tend to be highly metastatic via hematogenous dissemination, locally invasive, and often bilateral.
- Renal cystadenocarcinoma, a rare heritable syndrome with a less aggressive behavior and better long-term prognosis than renal adenocarcinoma, has been described in German shepherd dogs.

**SIGNS**
- Adenocarcinoma—older (8–9 years) dogs, 1.6:1 male-to-female ratio, no breed predilection.
- Cystadenocarcinoma—German shepherd dogs, often female.

**CAUSES & RISK FACTORS**
- Adenocarcinoma—unknown.
- Cystadenocarcinoma—heritable in German shepherd dogs.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Other primary neoplasia (i.e., lymphoma, nephroblastoma)
- Metastatic neoplasia (i.e., hemangiosarcoma)
- Renal adenoma or cyst
- Pyelonephritis

**CBC/BIOCHEMISTRY/URINALYSIS**
- CBC may show leukocytosis or anemia.
- Urinalysis may show hematuria, proteinuria, bacteriuria, or casts.

**IMAGING**
- Thoracic radiographs—metastatic disease reported in up to 10% of patients.
- Abdominal radiographs—mass visualized in 81% of patients.
- Abdominal ultrasonography, CT, or contrast radiography—useful in identifying and staging the disease. Advanced imaging can guide decisions regarding surgical resectability.

**DIAGNOSTIC PROCEDURES**
- Renal biopsy (ultrasound-guided or surgical) for definitive diagnosis.
- Percutaneous fine-needle aspirate can be used for supportive diagnosis.

**TREATMENT**
- Aggressive surgical excision is the treatment of choice for unilateral disease.
- Successful chemotherapeutic management of either disease has not been described.
- Supportive management for patients in renal failure may be necessary.

**MEDICATIONS**
- None

**FOLLOW-UP**
- Renal failure—measure serum urea nitrogen and creatinine, urinalysis.
- Quality of life if bilateral or otherwise non-surgical disease.

**PREVENTION/AVOIDANCE**
- N/A

**POSSIBLE COMPLICATIONS**
- Renal failure
- Metastatic disease
- Invasion of local vital structures (vena cava, aorta)

**EXPECTED COURSE AND PROGNOSIS**
- Adenocarcinoma—median reported survival of 49 dogs was 16 months (range 0–59 months).
- Cystadenocarcinoma—few large studies of this rare disease, reported median survival of 12± months with no definitive therapy.

**SUGGESTED READING**

**ABBREVIATION**
- CT = computed tomography

**ASSOCIATED CONDITIONS**
- The paraneoplastic syndromes of hypertrophic osteopathy, polycythemia, and a neutrophilic leukocytosis have been reported in isolated cases.
- Renal failure.
- Nodular dermofibrosis and uterine leiomyomas are commonly associated with cystadenocarcinoma.

**MISCELLANEOUS**
### Adenocarcinoma, Salivary Gland

#### Overview
- Tumor arising from major (e.g., parotid, mandibular, sublingual, or zygomatic) or minor salivary glands.
- Mandibular or parotid glands constitute 80% of cases.
- Mandibular gland most frequently affected in dogs.
- Mandibular gland most frequently affected in cats.
- Locally invasive and regionally metastatic.
- Cats typically have more advanced disease than dogs at time of diagnosis.
- Metastasis—regional lymph node involvement in 39% of cats and 17% of dogs at diagnosis; distant metastasis reported in 16% of cats and 8% of dogs at diagnosis but may be slow to develop.
- Other salivary gland neoplasms—carcinoma; squamous cell carcinoma; mixed neoplasia.
- Epithelial malignancies—constitute roughly 85% of salivary gland tumors.
- Fibrosarcomas, lipomas, mast cell tumors, and lymphomas have involved the salivary glands by direct extension and invasion. A concurrent malignant fibrous histiocytoma (giant cell type) and malignant mixed tumor (likely of ductal origin) within the salivary gland has also been described.
- Adenomas comprise only 5% of salivary tumors.

#### Signalment
- Dog and cat.
- Mean age, 10–12 years.
- Siamese cats—may be at relatively higher risk.
- Male cats affected twice as often as female cats.
- No other breed or sex predilection has been determined.

#### Signs
- Unilateral, firm, painless swelling of the upper neck (mandibular and sublingual), ear base, and maxilla (zygomatic), or mucous membrane of lip (accessory or minor salivary tissue).
- Other signs may include halitosis, weight loss, anorexia, dysphagia, dysphonia, Horner's syndrome, sneezing, and dysphonia.

#### Causes & Risk Factors
Unknown

#### Diagnosis
- Differential Diagnosis
  - Squamous cell carcinoma
  - Mucocele
  - Abscess
  - Soft tissue sarcoma, e.g., fibrosarcoma
  - Lymphoma
  - Salivadenoma

#### CBC/Biochemistry/Urine Analysis
Results often normal

#### Imaging
- Regional radiographs usually are normal; may see periosteal reaction on adjacent bones or displacement of surrounding structures.
- MRI or CT imaging allows superior discrimination of tumor for surgery and/or radiation treatment planning.
- Thoracic radiographs indicated to check for lung metastases.

#### Diagnostic Procedures
- Cytologic examination of aspirate may differentiate salivary adenocarcinoma from mucocele and abscess.
- Needle core or wedge biopsy for histopathology—definitive diagnosis.

#### Treatment
- Aggressive surgical resection—when possible; most are invasive and difficult to excise completely.
- Radiotherapy—good local control and prolonged survival in three reported cases.
- Aggressive local resection (usually histologically incomplete) followed by adjuvant radiation can achieve local control and long-term survival, but further studies are needed to determine the most effective treatment, including the possible role for chemotherapy.

#### Medications
- Chemotherapy (mitoxantrone or carboplatin) efficacy is largely unreported; however, may be indicated for treatment/palliation of metastatic disease.

#### Follow-Up
- Patient Monitoring
  - Evaluations—physical examination and thoracic radiographs every 3 months are reasonable if aggressive surgery and/or radiation therapy employed.
  - Expected course and prognosis
    - Improved survival time in dogs without evidence of nodal or distant metastasis at diagnostic, clinical stage not prognostic for cats.
    - Median survival 550 days for dogs and 516 days for cats in retrospective study.
  - Local control obtained through radiation and/or surgery remains critical.

#### Miscellaneous
- Abbreviations
  - CT = computed tomography
  - MRI = magnetic resonance imaging

Suggested Reading

Author Anthony J. Mutsaers
Consulting Editor Timothy M. Fan
Adenocarcinoma, Skin (Sweat Gland, Sebaceous)

**Overview**
Malignant growth originating from sebaceous or apocrine sweat glands of the skin.

**Signalment**
- Apocrine sweat gland—rare in dogs, uncommon in cats.
- Sebaceous gland—rare in both dogs and cats.
- Middle-aged to older pets.
- Female dogs overrepresented for apocrine adenocarcinoma in one study.

**Signs**
- May appear as solid, firm, raised, superficial skin lesions.
- May be ulcerated and bleeding and accompanied by inflammation of the surrounding tissue.
- Apocrine sweat gland—often poorly circumscribed, ulcerated, very invasive into underlying tissue; may occur anywhere on the body, frequently affecting the trunk in dogs.
- Sebaceous gland—often ulcerated and inflamed, moderate risk of lymph node involvement.
- Dermal and lymphatic tracking can be observed early in disease course.

**Causes & Risk Factors**
Unknown

**Diagnosis**
**Differential Diagnosis**
- Other more frequent skin tumors
- Cutaneous histiocytic diseases
- Immune-mediated skin diseases
- Bacterial/fungal infections

**CBC/Biochemistry/Urine Analysis**
Normal

**Other Laboratory Tests**
N/A

**Imaging**
Thoracic radiographs recommended at the time of diagnosis to assess for distant metastases.

**Diagnostic Procedures**
- Biopsy for histopathology and definitive diagnosis
- Cytologic examination or biopsy of draining lymph nodes

**Pathologic Findings**
- Apocrine gland adenocarcinomas are typically invasive into the underlying stroma and blood vessels, and often show poorly demarcated borders and a high mitotic index.
- Sebaceous gland adenocarcinomas often reveal lymphatic vessel invasion.

**Treatment**
- Aggressive en bloc surgical excision, including resection of draining lymph node, recommended for both types. Histopathologic analysis of lymph nodes assists with determining prognosis and establishing adjuvant treatment plan.
- Margins of entire tissue specimen must be evaluated histologically to assess completeness of resection.
- Radiation therapy may be recommended for treatment of draining lymph nodes after resection to prevent recurrence and development of regional metastases; radiation therapy of primary tumor site recommended when wide and complete resection not possible.
- Margins of entire tissue specimen must be evaluated histologically to assess completeness of resection.

**Medications**
**Drug(s)**
- Chemotherapy has been used anecdotally for the treatment of both tumor types, in both species.
- Contact a veterinary oncologist for any updated treatments that may be available.
- Nonsteroidal anti-inflammatory drugs and other analgesics are recommended, as indicated, for pain control.

**Follow-up**
- Sebaceous gland adenocarcinoma—little is known about the metastatic potential of this malignancy, but it may be rapidly metastatic to regional lymph nodes in some patients; long-term prognosis is anecdotally good with multimodal therapy combining aggressive surgery, chemotherapy, and radiation therapy.
- Apocrine gland adenocarcinoma—fair to good long-term prognosis; the histologic finding of vascular invasion is a negative prognostic factor predicting systemic metastases; aggressive surgical resection (local and regional tumor control) followed by adjuvant chemotherapy is recommended to improve survival. A study reported a post-enucleation median survival time of 30 months in dogs.

**Miscellaneous**
Suggested Reading
Author Louis-Philippe de Lorimier Consulting Editor Timothy M. Fan
ADENOCARCINOMA, STOMACH, SMALL AND LARGE INTESTINE, RECTAL

OVERVIEW

- Uncommon tumor arising from the epithelial lining of the gastrointestinal tract.
- Prognosis guarded to poor.

SIGNMENT

- Dog more commonly affected than cat.
- Middle-aged to older (3-16 years) animals; age range 3-13 years.
- No breed predisposition.
- Median survival gastric—2 months.

SIGNS

HISTORICAL FINDINGS

- Stomach—vomiting, anorexia, weight loss, hematomasis, and melena.
- Small intestine—vomiting, weight loss, borborygmus, flatulence, and melena.
- Large intestine and rectum—mucus and blood-tinged feces and tenesmus.

PHYSICAL EXAMINATION FINDINGS

- Stomach—nonspecific.
- Small intestine—may feel mid-abdominal mass, distended, painful loops of small bowel; melena on rectal exam.
- Large intestine and rectum—pulpsable mass per rectum, may form annular ring, or multiple nodular lesions protruding into the colon; bright red blood on feces.

REASON & RISK FACTORS

- Unknown.
- Nitrofurantoin—reported as causative agent in experimental literature.
- Possible genetic cause—gastric adenocarcinoma in related Belgian shepherds and Dutch Tervuren shepherds.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS

- Foreign body
- Inflammatory bowel disease
- Lymphoma
- Parasites
- Leukemia
- Leiomyosarcoma
- Pancreatitis

CBC/BIOCHEMISTRY/URINALYSIS

- Stomach and small intestine—may see microcytic, hypochromic anemia (iron-deficiency anemia). Mild and persistent elevations in blood urea nitrogen in the face of normal creatinine can support intestinal blood loss.
- Large intestine and rectum—no characteristic changes.

OTHER LABORATORY TESTS

Fecal occult blood may be positive; diet may affect results—can recheck to confirm after feeding non-meat diet for 3 days.

IMAGING

- Ultrasound—may reveal a thickened stomach or bowel wall; may see mass in the gastrointestinal tract, enlarged lymph nodes.
- Positive contrast radiography—filling defect (stomach); intraluminal space-occupying or annular constriction (small bowel); gastric neoplasm must often found in distal two-thirds of stomach.
- Double contrast radiography—large intestine and rectum; polypoid or annular space-occupying mass.
- Advanced imaging with contrast CT or MRI can provide highest quality images of gastrointestinal tract.

DIAGNOSTIC PROCEDURES

- Ultrasound-guided fine-needle aspirate of mass; distended, painful loops of small bowel; melena on rectal exam.
- Advanced imaging with contrast CT or MRI can provide highest quality images of gastrointestinal tract.

TREATMENT

- Surgical excision—treatment of choice; seldom curative.
- Gastric—usually non-resectable.
- Small intestine—remove by resection and anastomosis; metastasis to regional lymph nodes and the liver common.
- Large intestine and rectal—may occasionally be treated by a pull-through surgical procedure; metastasis common; transcolonic debulking may provide palliation of obstruction.

MEDICATIONS

- Piroxicam 0.3 mg/kg PO q24h can provide palliation for large intestinal and rectal tumors.
- Aggressive combination analgesics should be instituted.

CONTRADICTION/POSSIBLE INTERACTIONS

Seek advice before initiating treatment with cystostatic drugs.
BASICS

DEFINITION
A malignant tumor arising from the follicular or parafollicular cells (medullary/C-cells) of the thyroid gland.

PATHOPHYSIOLOGY
- About 60% of patients are euthyroid, 30% hyperthyroid, and 10% hypothyroid.
- Typically very invasive tumors with high rate of metastasis (lungs, retropharyngeal lymph nodes, fovea), with up to 30–40% of dogs having metastasis at the time of diagnosis.
- Animals with bilateral tumors have a sixteen times greater risk of developing metastatic disease than animals with unilateral tumors.

SYSTEMS AFFECTED
- Cardiovascular—hyperthyroid dogs are usually tachycardic and may have systemic hypertension; may see arrhythmias and DIC in advanced disease.
- Endocrine/Metabolic—affected dogs may be hypothyroid, euthyroid or hyperthyroid; rarely may see hypercalcemia; isosthenuria; DIC.
- Respiratory—dogs may be dyspneic owing to a space-occupying mass adjacent to the trachea; metastasis to the lungs common.
- Gastrointestinal—affected dogs may see weight loss, polyuria, polydypsia, polyphagia, weight gain, diarrhea, vomiting.
- Neurologic—may see episodes of collapse.

GENETICS
Unknown

INCIDENCE/PREVALENCE
Accounts for 1.2–3.8% of all canine tumors and represents 10–15% of all primary head and neck tumors.

GEOGRAPHIC DISTRIBUTION
May be more common in iodine-deficient areas.

SIGNALMENT
Species
Dog

Breed Predilections
Rottweilers, golden retrievers, Siberian huskies, and beagles at increased risk but seen in any breed.

Mean Age and Range
Older dogs (median 9–15 years; range 4–18 years)

Predominant Sex
No gender predilection.

SIGNS
General Comments
- Usually not diagnosed until a large mass is palpable.
- Approximately 65% are unilateral, 35% are bilateral.

Historical Findings
- Palpable mass/swelling in cervical neck, coughing, dyspnea, dysphagia, dysphonia, facial edema, neck pain.
- If functional thyroid tumor—may see polyuria, polydypisia, polyphagia, weight loss, restless behavior, diaphoresis.
- If hyperthyroid—may see poor hair coat, weight gain, lethargy.

Physical Examination Findings
- Freely movable or fixed cervical mass, unilateral or bilateral.
- May be more common in iodine-deficient areas.
- Respiratory—dogs may be dyspneic owing to a space-occupying mass adjacent to the trachea; metastasis to the lungs common.
- Large compressive masses can result in caval syndrome manifested as facial edema.

OTHER LABORATORY TESTS
- CBC/BIOCHEMISTRY/URINALYSIS
- Usually normal.
- May see non-regenerative normocytic normochromic anemia of chronic disease, leukocytosis.
- Rare—hypercalcemia; isosthenuria; DIC.
- OTHER LABORATORY TESTS
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.
- Imaging
- Thoracic radiography (3 views)—evaluation of lungs and other thoracic structures for metastasis.
- Cervical ultrasonography, computed tomography, and magnetic resonance imaging—evaluation of tumor size, mobility, cervical lymph nodes.
- Technetium-99m sestamibi imaging to evaluate for ectopic thyroid tissue or metastatic lesions.

DIFFERENTIAL DIAGNOSIS
- Other primary neoplasms—lymphoma; soft tissue sarcoma; salivary gland adenocarcinoma; parathyroid carcinoma; castral body tumor.
- Secondary tumors—metastatic oral squamous cell carcinoma; oral melanoma.
- Inflammatory—abscess or granuloma.
- Parathyroid—parathyroid hyperplasia or parathyroid adenocarcinoma.

CAUSES
Unknown

RISK FACTORS
- Unilateral or bilateral.
- Hyperthyroid—cardiac arrhythmias or murmurs.
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.

OTHER TREATMENT OPTIONS
- Toceranib phosphate (Palladia) can exert cytoreductive activity.
- Other palliative radiation and/or chemotherapy recommended for tumors that are metastatic at presentation.
- Radioiodine studies—may provide information about the tumor’s ability to produce thyroid hormone.

DIAGNOSTIC PROCEDURES
Biopsy
Tru-Cut not recommended owing to high risk of severe hemorrhage; open biopsy usually required and allows for controlled hemostasis in the event of bleeding.

Cytology
- Examination of fine-needle aspirates from tumor and palpable regional lymph nodes.
- Specimen almost always heavily contaminated with blood owing to highly vascular nature of tumor.
- Homogenous population of epithelial cells, sometimes with colloid and/or erythrocytes.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS
- Other primary neoplasms—lymphoma; soft tissue sarcoma; salivary gland adenocarcinoma; parathyroid carcinoma; castral body tumor.
- Secondary tumors—metastatic oral squamous cell carcinoma; oral melanoma.
- Inflammatory—abscess or granuloma.
- Parathyroid—parathyroid hyperplasia or parathyroid adenocarcinoma.

CAUSES
Unknown

RISK FACTORS
- Unilateral or bilateral.
- Hyperthyroid—cardiac arrhythmias or murmurs.
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.

OTHER TREATMENT OPTIONS
- Toceranib phosphate (Palladia) can exert cytoreductive activity.
- Other palliative radiation and/or chemotherapy recommended for tumors that are metastatic at presentation.
- Radioiodine studies—may provide information about the tumor’s ability to produce thyroid hormone.

DIAGNOSTIC PROCEDURES
Biopsy
Tru-Cut not recommended owing to high risk of severe hemorrhage; open biopsy usually required and allows for controlled hemostasis in the event of bleeding.

Cytology
- Examination of fine-needle aspirates from tumor and palpable regional lymph nodes.
- Specimen almost always heavily contaminated with blood owing to highly vascular nature of tumor.
- Homogenous population of epithelial cells, sometimes with colloid and/or erythrocytes.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS
- Other primary neoplasms—lymphoma; soft tissue sarcoma; salivary gland adenocarcinoma; parathyroid carcinoma; castral body tumor.
- Secondary tumors—metastatic oral squamous cell carcinoma; oral melanoma.
- Inflammatory—abscess or granuloma.
- Parathyroid—parathyroid hyperplasia or parathyroid adenocarcinoma.

CAUSES
Unknown

RISK FACTORS
- Unilateral or bilateral.
- Hyperthyroid—cardiac arrhythmias or murmurs.
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.

OTHER TREATMENT OPTIONS
- Toceranib phosphate (Palladia) can exert cytoreductive activity.
- Other palliative radiation and/or chemotherapy recommended for tumors that are metastatic at presentation.
- Radioiodine studies—may provide information about the tumor’s ability to produce thyroid hormone.

DIAGNOSTIC PROCEDURES
Biopsy
Tru-Cut not recommended owing to high risk of severe hemorrhage; open biopsy usually required and allows for controlled hemostasis in the event of bleeding.

Cytology
- Examination of fine-needle aspirates from tumor and palpable regional lymph nodes.
- Specimen almost always heavily contaminated with blood owing to highly vascular nature of tumor.
- Homogenous population of epithelial cells, sometimes with colloid and/or erythrocytes.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS
- Other primary neoplasms—lymphoma; soft tissue sarcoma; salivary gland adenocarcinoma; parathyroid carcinoma; castral body tumor.
- Secondary tumors—metastatic oral squamous cell carcinoma; oral melanoma.
- Inflammatory—abscess or granuloma.
- Parathyroid—parathyroid hyperplasia or parathyroid adenocarcinoma.

CAUSES
Unknown

RISK FACTORS
- Unilateral or bilateral.
- Hyperthyroid—cardiac arrhythmias or murmurs.
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.

OTHER TREATMENT OPTIONS
- Toceranib phosphate (Palladia) can exert cytoreductive activity.
- Other palliative radiation and/or chemotherapy recommended for tumors that are metastatic at presentation.
- Radioiodine studies—may provide information about the tumor’s ability to produce thyroid hormone.

DIAGNOSTIC PROCEDURES
Biopsy
Tru-Cut not recommended owing to high risk of severe hemorrhage; open biopsy usually required and allows for controlled hemostasis in the event of bleeding.

Cytology
- Examination of fine-needle aspirates from tumor and palpable regional lymph nodes.
- Specimen almost always heavily contaminated with blood owing to highly vascular nature of tumor.
- Homogenous population of epithelial cells, sometimes with colloid and/or erythrocytes.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS
- Other primary neoplasms—lymphoma; soft tissue sarcoma; salivary gland adenocarcinoma; parathyroid carcinoma; castral body tumor.
- Secondary tumors—metastatic oral squamous cell carcinoma; oral melanoma.
- Inflammatory—abscess or granuloma.
- Parathyroid—parathyroid hyperplasia or parathyroid adenocarcinoma.

CAUSES
Unknown

RISK FACTORS
- Unilateral or bilateral.
- Hyperthyroid—cardiac arrhythmias or murmurs.
- Thyroid hormone (T4 and/or T3) levels and endogenous TSH levels.

OTHER TREATMENT OPTIONS
- Toceranib phosphate (Palladia) can exert cytoreductive activity.
- Other palliative radiation and/or chemotherapy recommended for tumors that are metastatic at presentation.
- Radioiodine studies—may provide information about the tumor’s ability to produce thyroid hormone.

DIAGNOSTIC PROCEDURES
Biopsy
Tru-Cut not recommended owing to high risk of severe hemorrhage; open biopsy usually required and allows for controlled hemostasis in the event of bleeding.

Cytology
- Examination of fine-needle aspirates from tumor and palpable regional lymph nodes.
- Specimen almost always heavily contaminated with blood owing to highly vascular nature of tumor.
- Homogenous population of epithelial cells, sometimes with colloid and/or erythrocytes.
ADENOCARCINOMA, THYROID—DOGS (CONTINUED)

- Warn owners of possible postoperative laryngeal paralysis and intraoperative hemorrhage.
- Warn owners of acute radiation therapy toxicities—moist desquamation, laryngitis, tracheitis, esophagitis.

**SURGICAL CONSIDERATIONS**
See “Appropriate Health Care”

**Risks**
- Marked hemorrhage—tumors highly vascular and invasive into surrounding structures including vasculature; may need blood transfusion and intensive postoperative care.
- Laryngeal paralysis—owing to trauma to recurrent laryngeal nerve.
- Damage parathyroid glands—may occur during surgery.

**MEDICATIONS**

**DRUG(S) OF CHOICE**
- Chemotherapeutic agents:
  - Chemotherapy is recommended as a sole therapy, or possibly in combination with surgery and/or radiation therapy.
  - Cisplatin (60 mg/m² every 3 weeks), carboplatin (500 mg/m² every 3 weeks), or doxorubicin (30 mg/m² every 3 weeks)—reported to effect partial remission in approximately 50% of cases.
- Toceranib (2.5–3 mg/kg 3 times a week)—had biologic activity in 80% of cases (20% partial remission, 53% stable disease).
- Cisplatin—neurotoxic; may use with saline diuresis (18.3 mL/kg/hour IV over 6 hours; give cisplatin after 4 hours).
- Antimetics for cisplatin therapy:
  - Maropitant 1 mg/kg SC before cisplatin, or
  - Dolasetron 0.6–1 mg/kg IV or PO q24h, or
  - Butorphanol 0.4 mg/kg IM before and after cisplatin.
- Thyroid management:
  - Thyroidectomy:—may potentiate doxorubicin-induced cardiotoxicity

**ALTERNATIVE DRUG(S)**
N/A

**FOLLOW-UP**

**PATIENT MONITORING**
- Serum calcium concentration—if bilateral thyrotoxicosis was performed, signs of hypercalcemia (agitation, panting, muscle tremors, tremor, and seizures) may be observed.
- Treat with 10% calcium gluconate (1–1.5 mL/kg IV over 10–20 minutes).
- Maintain serum calcium with dihydrotachysterol (vitamin D) orally.
- Thyroid hormone—supplementation with thyroxine may be necessary after bilateral thyrotoxicosis.
- TSH concentration—a goal of thyroxin therapy in affected dogs not determined.
- Site of primary tumor—physical examination and cervical ultrasound; thoracic radiographs every 3 months to detect pulmonary metastasis.

**PREVENTION/AVOIDANCE**
Unknown

**POSSIBLE COMPLICATIONS**
- Tumor—adenocarcinoma, thyroid carcinoma, DDC, respiratory distress.
- Chemotherapy—dilated cardiomyopathy; renal failure; pancreatitis; septic gastrointestinal upset.
- Surgery—hemorrhage, hypothyroidism; hypoparathyroidism leading to hypercalcemia, laryngeal paralysis.
- Radiotherapy—acute side effects—moist desquamation, pharyngeal mucositis; esophagitis; tracheitis; late side effects—alopecia, and skin or coat color change (at radiation site).

**EXPECTED COURSE AND PROGNOSIS**
- Prognosis—related to stage of disease (tumor size, mobility and evidence of metastatic disease) with small, non-attached unilateral, non-metastatic tumors having best prognosis.
- MST after surgical removal of unilateral thyroid tumors is 1462 days vs. 365 days for patients undergoing bilateral thyroidecromy.
- For animals treated with full course external beam radiation therapy—progression-free survival at 1 year—89%, and 72% at 3 years in one study and in another study MST 24.5 months.
- Palliative radiation therapy in 13 dogs—MST 24 months.
- 131I therapy in combination with surgery—MST 34 months, or 131I alone MST 30 months.
- Animals treated with cisplatin alone (13 dogs)—overall response rate was 53%, median progression-free interval for responders was 202 days and overall MST was 98 days.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
- Non-thyroidal malignancies common
- Multiple endocrine neoplasia reported

**AGE-RELATED FACTORS**
None

**PREGNANCY/FERTILITY/BREEDING**
It is not recommended to breed animals with cancer. Chemotherapy is teratogenic—do not give to pregnant animals.

**SYNONYMS**
Thyroid carcinoma

**ABBREVIATIONS**
- DTC = disseminated intravascular coagulation
- MST = median survival time
- TSH = thyroid stimulating hormone

**Suggested Reading**
- Author: Rebecca G. Newman
- Consulting Editor: Timothy M. Fan
- Acknowledgments: The author and editors acknowledge the prior contribution of Linda S. Fineman.
Generalized anxiety disorder may be confident, possessiveness. Aggression is directed toward a person or dog that does not live in the household. Regular visitors may also be targets. May be within the range of normal behavior, but may be compounded by fearfulness.

**SYSTEMS AFFECTED**
- Behavioral
- Sympathetic stimulation (e.g., tachycardia, tachypnea)

**INCIDENCE/PREVALENCE**
Stranger-directed aggression represents 32.5% of canine behavioral referral caseload.

**SIGNALMENT**
- Can occur at any age. Signs may begin to emerge as primary socialization wanes (approximately 12–16 weeks of age) or may arise or intensify at social maturity (approximately 18–36 months). Genetic concerns and poor prognosis if signs arise before 12 weeks.
- Territorial aggression more common in intact males—initial signs usually present by 1 year. Aggression toward unfamiliar people and dogs overrepresented in males. Breed prediction for inter-dog aggression in “fighting breeds” (e.g., pit bull terriers) and terriers.

**SIGNS**
- Aggression (barking, growling, lip-lifting, snarling, snapping, lunging, biting) toward unfamiliar people and dogs. May be accompanied by fearful or submissive body postures/facial expressions (head down, crouching, backing away, ears back, tail tucked, looking away, lip licking) or confident body postures (standing straight up, approach with tail up, ears forward). Territorial aggression arises in familiar locations or spaces (e.g., home, yard, car). May be confident, fearful or conflict. Fear aggression more likely when dog is cornered or cannot escape.
- May be more frequent or severe on- or off-leash.

**CAUSES & RISK FACTORS**
- May be a normal canine behavior.
- Strongly influenced by previous experience (e.g., early socialization, painful conditions, rough handling, inappropriate punishment, previous fear-eliciting experience with unfamiliar people or dogs).
- Underlying medical conditions, especially pain.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Fear aggression
- Territorial aggression
- Possessive aggression
- Conflict aggression
- Generalized anxiety disorder

**CBC/BIOCHEMISTRY/URINALYSIS**
Usually unremarkable. Abnormalities suggest an underlying medical condition.

**OTHER LABORATORY TESTS**
Usually unremarkable.

**IMAGING**
MRI if CNS disease suspected. Other imaging as needed to rule out underlying medical conditions.

**TREATMENT**

**CLIENT EDUCATION**
Treatment is aimed at controlling the problem, not at achieving a “cure.” Successful treatment, resulting in a decrease in aggressive incidents, depends on owner understanding of basic canine social behavior, risks involved, how to follow safety and management recommendations, correct identification of the aggression-eliciting stimuli, and effective implementation of reward-based behavior modification.

**Safety Recommendations**
- Owners’ main responsibility is safety by avoiding situations that may evoke a fearful or aggressive reaction. Avoidance is also necessary to insure the pet’s welfare and prevents further learning of aggressive behaviors. Owners should be advised that dog owners may be liable for bites and could face civil/criminal prosecutions if a person be injured. Successful treatment is more likely if a period of preventing exposure to aggression-provoking stimuli is instituted prior to behavior modification.
- Confining dog away from potential victims, avoid walks or parks where stimulus exposure might occur or have dog under direct physical control of a responsible adult whenever an aggression-provoking situation could arise (e.g., public location, when visitors are at the house).
- Confining territorial dogs to where they cannot see/hear visitors approaching territory before they become aggressively agitated.
- Introduce a head halter (e.g., Gentle Leader) and basket muzzle for easier and safer control.
- Owners should be advised that punishment/dominance-based training can lead to increased aggression, fear, agitation, and/or injuries and should be avoided. If safety cannot be insured, dogs should be removed from the household.

**Behavior Therapy**
- Structured interactions (also known as learn to earn or say please by sitting) where the dog is consistently taught to sit for anything it values (before feeding, petting, play, going for a walk) gives the dog control of its resources by sitting calmly, provides structure and predictability in all interactions, teaches impulse control and trains the dog that good things happen by sitting calmly.
- Commands: teach the dog to focus on the owner for guidance using eye contact and hand target (e.g., dog touch nose to owner’s hand). Teach the dog to sit and relax on verbal cue in neutral situations using food reward to teach to go to mat, heel or crate to settle; teach to walk on loose leash. Train with head halter or muzzle if needed to insure safety. Private session with a force-free trainer should be considered to achieve basics before any exposure.

**Behavior Modification: Systematic Desensitization and Counter-conditioning (DS/CC)**
- When owner can effectively control and calm in the absence of stimuli, begin exposure by determining the limit (distance, location, person, dog) at which the dog will orient but not react. Have the dog focus on the owner or continue walking calmly (heel) and give favored (highest value) rewards to make positive associations with each stimulus exposure. Gradually (baby steps) increase stimulus intensity, staying below the threshold that would result in fear and/or aggression by decreasing distance, increasing distractions, or moving to more challenging environments.
- Progress is slow (typically months). Carefully monitor body language to avoid setbacks. If the dog is not calm, show aggression orPinterest to aggression (e.g., fixating on the stimulus) reduce the level of stimulation by moving further away or taking the dog out of the situation. Future sessions should be at greater distances, or in locations or with stimuli where success can be achieved.
- Example: if the dog is calm when unfamiliar people pass on a walk, but when strangers pass the house the dog barks, revert to practicing DS/CC with the dog on walks and work up more slowly to practicing around the house. Owners must always be vigilant for the approach of stimuli that might incite fear or aggression.

**SURGICAL CONSIDERATIONS**
- Castration reduced aggression by at least 50% toward unfamiliar dogs in < 20% of
dogs studied and toward human territorial intruders in <10% of dogs studied. Castration reduced inter-male aggression in 62% of dogs. • Military working German shepherds spayed at 5–10 months of age were more reactive 4–5 months post-surgery to approach by an unfamiliar person walking with an unfamiliar dog than intact dogs.

**MEDICATIONS**

**SUPPLEMENTS**

- Consider for mild fear or as an adjunct to drug therapy.
- Supplements are not a substitute for and should only be used to facilitate behavior modification.

L-theanine (Anxiteam®)
- 2.5–3 mg/kg q12h.
- Active ingredient in green tea purported to increase serotonin, dopamine and GABA. Side effects: none reported.

Alpha-casozepine (Zykone®)
- 15 mg/kg PO q24h (canine). Discontinue if no effect after 10 days.
- Purposed to increase GABA.
- Side effects: sedation, anorexia, ataxia, GIT effects, cardiac conduction disturbances, and increased aggression.

**DRUGS**

- There are no medications licensed for treatment of canine aggression. Owners must be made aware that the use of medications is off-label. Note in the patient's record that owners were informed of potential risks and side effects. A signed informed consent form is advisable. NEVER use medications without concurrent behavior modification. Before prescribing medication, be sure that owners understand the risks and liability in owning an aggressive dog, will follow safety procedures, and do not expect medications to insure safety. In fact, medication may not be appropriate in all situations (e.g., households with small children, or individuals that have difficulty). There is a strong placebo effect when using drugs for behavior therapy in dogs. Studies have not shown a robust effect of drug treatment on aggression.

Selective Serotonin Reuptake Inhibitors
- Fluoxetine 0.5–2 mg/kg PO q24h.
- Paroxetine 0.5–1 mg/kg PO q24h.
- Sertraline 1–3 mg/kg PO q24h.
- Side effects: sedation, irritability, GIT effects, increased aggression; anorexia is common and usually transient.

Tricyclic Antidepressants
- Clomipramine 1–3 mg/kg q12h (labeled restricted for aggression).
- Side effects: sedation. GIT effects, anticholinergic effects, cardiac conduction disturbances if predisposed, and increased aggression.

Alpha-2 agonists
- Clonidine 0.01–0.05 mg/kg PO PRN
- 1.5–2 hours before eliciting trigger, up to q12h.
- Side effects: transient hyperglycemia, hypotension, collapse, and bradycardia (responsive to atropine), and increased aggression.

Serotonin 2a antagonist/reuptake inhibitors
- Trazodone 2–5 mg/kg PRN prior to eliciting trigger up to q8h. Titrated to 8–10 mg/kg if no adverse effects.
- Side effects: sedation, anorexia, ataxia, GIT effects, cardiac conduction disturbances, and increased aggression.

PRECAUTIONS

- Use caution as any psychotropic medication may disinhibit, resulting in an increase rather than decrease in aggression. • Do not combine SSRIs, SARIs, TCAs, MAO inhibitors (e.g., amitraz, selegiline), opioids (e.g., tramadol) or other medications that increase serotonin—can result in potentially fatal serotonin syndrome.

**FOLLOW-UP**

PATIENT MONITORING

- Clients need ongoing assistance and should receive at least one follow-up call within the first 1–4 weeks after consultation. Provisions for further follow-up should be made.
- Ongoing communication improves client compliance.

PREVENTION/AVOIDANCE

- Treatment recommendations are life-long—aggression may recur with treatment lapses and continued exposure to fear- and aggression-producing stimuli. Owners must always be vigilant and in control of the dog's behavior. • Appropriate early socialization and habituation may help prevent fear-based behaviors later in life. Puppies that are not socialized during the first three months of life are more likely to be fearful, defensive, and possibly aggressive later in life. Socialization may include attending well-structured, positive reinforcement puppy classes starting during the sensitive period for socialization from 7–12 weeks (perhaps up to 14–16 weeks). One study found that vaccinated puppies that attended puppy socialization classes were at no increased risk of parvovirus.

**POSSIBLE COMPLICATIONS**

Human injuries; euthanasia or relinquishment of patient

EXPECTED COURSE AND PROGNOSIS

- There is no cure. Prognosis is more favorable if aggression is motivated by fear, at a low intensity, and occurs only in a few predictable situations. Prognosis is highly dependent on owner compliance.

**MISCELLANEOUS**

ASSOCIATED CONDITIONS

- Other fear- or anxiety-based conditions (e.g., noise phobias, separation anxiety) Aggression to other stimuli

ZOONOTIC POTENTIAL

Human injury from bite wounds

PREGNANCY/FERTILITY/BREEDING

Do not breed dogs with extremely fearful behavior or fear/aggression.

SEE ALSO

- Aggression toward Familiar People—Dogs
- Aggression, Food and Resource Guarding—Dogs
- Aggression—Between Dogs in the Household
- Fear and Aggression in Veterinary Visits

ABBREVIATIONS

- CNS = central nervous system • DSSCO = de-sanitization and counter-conditioning
- GABA = gamma-aminobutyric acid • GIT = gastrointestinal tract • MAO = monoamine oxidase • MRI = magnetic resonance imaging • SARI = selective serotonin reuptake inhibitor • SAR = Serotonin 2a antagonist/reuptake inhibitor • TCA = tricyclic antidepressant

Suggested Reading


Acknowledgment

The author and editors acknowledge the prior contribution of Laurie Bergman.
**AGGRESSION TOWARD CHILDREN—DOGS**

**OVERVIEW**
Children are the most frequent victims of reported dog bites and tend to be injured more severely than adults.

**SIGNALMENT**
Any breed, age, gender, and neuter status.

**Breed**
- Breeds reports vary with demographics.
- Breed identification may be unreliable.
- Breeds most commonly presenting to a behavior referral service that had bitten a child include English Springer spaniel, German shepherd, Labrador retriever, golden retriever, and American cocker spaniel.
- Most fatal attacks (uncommon) are attributed to rottweilers, pit bulls, and their mixes.
- Larger breeds and mixed breeds may be more likely to inflict severe injury.
- Smaller breeds can also be dangerous.

**Sex**
- More frequent in males than females.
- Neutering will not significantly reduce the risk.

**Age**
- Any age, but more frequent in socially mature dogs (2+ years old). Risk may increase in geriatric dogs because of pain, sensory impairment, or irritability.

**CAUSES & RISK FACTORS**
Clinical Categories/Motivation for Aggression
- Fear-related
- Pain-related
- Play-related
- Conflict-related
- Prevalent
- Territorial
- Resource (food/toy/ball) guarding

Dog-Associated Risk Factors
- Disease and associated irritability
- Pain-related aggression and resource guarding
- The most common reasons for bites to familiar children 6–8 years old: Generalized anxiety.
- Fearful behavior.
- Dog being down, particularly under or on furniture.
- Parent/littermate aggression.

Environmental/Social Risk Factors
- Younger children most likely bitten by the family pet or other familiar dogs.
- Presence of infants (risk of predatory attacks).
- Punishment-based training.
- Inadequate supervision by parents/caregivers.
- History of growling, snarling, biting.
- Hugging, kissing, bending over anxious, fearful, or conflict-aggressive dog.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
See “Clinical Categories/Motivations for Aggression.”

**CBC/BIOCHEMISTRY/URINALYSIS**
Baseline profile to rule out medical contributing factors.

**OTHER LABORATORY TESTS**
- Anecdotal evidence (only) correlates canine hypothyroidism with increased aggression; however, no data-based evidence.
- Urinary supplementation with thyroid hormone may predispose to agitation or aggression.

**DIAGNOSTIC PROCEDURES**
- Thorough physical examination. A detailed history of the bite event and the behavior of both dog and child to determine motivation.

**TREATMENT**

**SAFETY WITH FAMILIAR DOGS**
- Never leave infant or young children unsupervised with dogs. Securely separate infants from dogs when alone, if both asleep.
- If one adult is present, separate dog from young children.
- If more than one adult is present, assign responsibility for one adult to young children.
- Do not allow child to approach or interact with dog when dog is lying down.
- Do not allow child to remove any object from dog.
- Do not allow child to bug, kiss, bend over, or lie down beside dog.
- Separate dog when eating or chewing valued items.

**SAFETY WITH UNFAMILIAR DOGS**
- Do not tether unsupervised.
- Do not allow child to remove any object from dog.
- Do not allow child to bug, kiss, bend over, or lie down beside dog.
- Separate dog when eating or chewing valued items.

**BEHAVIOR MODIFICATION THROUGH LEARNING/TRAINING**
- Redirect dog’s attention. Teach “look” or “touch” cues.
- Establish secure, separate “safe haven” for dog.
- Restrict fearful or reactive dog on lead and offer food at safe distance from children, to turn a negative situation into a positive one.
- Do not rely on training alone; safe practices require prevention.

**MEDICATIONS**

**DRUGS**
- Anxiolytic drug may be indicated for dogs with generalized or situational anxiety or fearful behavior.
- Selective Serotonin Reuptake Inhibitors
  - Fluoxetine 0.5–2.0 mg/kg q24h
  - Sertraline 0.5–3 mg/kg q24h
- Tryptic Antidepressants
  - Clomipramine 1–3 mg/kg q12h

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**
- Psychotropic medication can increase agitation and anxiety or disinhibit aggression. Use with caution in dogs with a history of bites.
- Avoid the following combinations:
  - SSRI + TCA
  - SSRI + TCA + trazodol
  - SSRI or TCA + MAOI including amitriptyline + SSRI + NSAID (caution, due to increased risk of GI or other hemorhagia).

**FOLLOW-UP**

**PREVENTION/AVOIDANCE**
- Do not rely on training alone to eliminate aggression.
- Preventive measures are most important in management of canine aggression to children.
- Even well-trained, socialized dogs may bite.

**POSSIBLE COMPLICATIONS**
- Family may not acknowledge risks.
- Disease may aggravate aggression.
- Family may not be compliant.
- Psychotropic drug may be unacceptably relied upon or ineffective.
- Young children may be impulsive and difficult to control.

**EXPECTED COURSE AND PROGNOSIS**
Aggressive behavior can often be reduced and controlled. However, lifetime compliance is needed. Prognosis is poor if social/physical environment cannot be controlled.

In some cases it may be necessary to remove or euthanize dog, while in others the dog’s behavior may improve as the child grows older.

**MISCELLANEOUS**

**ABBREVIATIONS**
- GI = gastrointestinal
- MAOI = monoamine oxidase inhibitor
- NSAID = nonsteroidal anti-inflammatory drug
- SSRI = selective serotonin reuptake inhibitor
- TCA = tricyclic antidepressant

**Suggested Reading**

**Author** Ilana R. Reisner
**Consulting Editor** Gary M. Landsberg
AGGRESSION TOWARD FAMILIAR PEOPLE—DOGS

DEFINITION
Aggression, directed toward household members or people with an established relationship with the dog, often in situations involving access to resources. May be status-related/dominance, conflict, impulsive, competitive or possessive aggression.

PATHOPHYSIOLOGY
Three dogs may show anxiety or be impulsive and unpredictable. When the aggression is guarding of resources, or in response to fear eliciting stimuli (e.g., threats, punishment, possibly handling) might be normal.

SYSTEMS AFFECTED
Behavioral

GENETICS
Pedigree analyses have shown increased occurrence in related dogs. May be genetic factors associated with impulse dyscontrol in English springer spaniel and English cocker spaniel. May be more common in show than field lines.

INCIDENCE/PREVALENCE
20–44% of behavioral referral caseloads.

GEOGRAPHIC DISTRIBUTION
Regional breed differences exist.

SIGNAMENT
Species
Dog

Breed Predilections
Spanish (English springer and cocker), terriers, but may be exhibited by any breed.

Mean Age and Range
Usually manifested by social maturity (12–36 months of age). May be seen in younger dogs.

Predominant Sex
Male (castrated and intact).

SIGNALMENT
Species
Dog

Breed Predilections

Mean Age and Range

Predominant Sex
Male (castrated and intact).

SIGNS
General Comments
Detailed history-taking is needed to make a diagnosis, assess risks, and devise a safe and realistic treatment plan. Mild signs of aggression (e.g., snarling, growling, baring teeth) often precede bites. Details of early aggressive episodes are vital to establish the diagnosis and prognosis. Often anxiety or fear based but may be motivated by desire to control, e.g., personal space, resources.

Historical Findings

Aggression (barking, growling, lip-lifting, snarling, snapping, lunging, biting) directed toward family members. Aggression may occur around resources such as resting areas, food, or toys, handling (e.g., petting and reaching toward), or favored possessions (including resting with one family member when another approaches). Aggression may be seen in other contexts, e.g., denied access to items or activities, when resting, when confronted or punished, or during uncomfortable or fear-evoking interactions (e.g., ear cleaning, grooming, bathing). History-taking should attempt to establish triggers and frequency/severity of aggressive episodes. Aggression may not be directed uniformly toward each household member.

Confident/dominant body postures (offfencing, staring, standing straight up, ears forward, tail up, and/or approaching/direct contact with the person) may be associated with aggressive behavior, or the motivation may be fear (tensing, head down, crouching, backing away, ears back, tail tucked, looking away, lip-licking). Owners may report a combination of confident and submissive postures representing uncertainty (conflict). Owners may describe dogs as “moody” and may be able to predict when aggression is likely to occur. Early on the dog may show fear (e.g., eye aversion, tail tucked, avoidance) that may diminish and the dog may give less warning as it becomes more confident that aggression will be effective (negative reinforcement). Anxiety may be noted in pet-owner interactions and other situations.

Physical Examination Findings

Usually unremarkable. Medical conditions, especially pain, may contribute to the expression of aggression.

CAUSES
May be part of normal canine social behavioral repertoire, but its expression is influenced by environment, learning, and genetics. Display of aggression may be influenced by underlying medical conditions (especially pain), early experiences that learning that aggression is effective to control situations), and inconsistent or lack of clear rules and routines in the household and in human-pet interactions.

RISK FACTORS
Incidental or inappropriate physical punishment and punishment owner interactions.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
Fear-based aggression • Conflict aggression • Anxiety conditions • Disease conditions associated with aggression (e.g., painful conditions, endocrinopathies)

CBC/BIOCHEMISTRY/URINALYSIS
Usually unremarkable. Abnormalities may indicate an underlying or contributing medical condition.

OTHER LABORATORY TESTS
As indicated to rule out underlying diseases. Rule out hyperthyroidism.

IMAGING
MRI if CNS disease is suspected; other imaging may be needed to rule out other medical conditions.

TREATMENT
ACTIVITY
Ensure behavioral needs are being met.

DIET
Low-protein/tryptophan-supplemented diets may help reduce aggression.

CLIENT EDUCATION
General Comments
• Treatment is aimed at controlling the problem, not achieving a “cure.” • Successful treatment, resulting in a decrease in aggressive incidents, depends on owner understanding of basic canine social behavior and communication, risks involved in living with an aggressive dog, and how to implement safety and management recommendations. • Owners must be aware that the only certain way to prevent future injuries is euthanasia. • Owners must be educated about the risks of using physical punishment and training techniques that rely on “dominating” their dogs. Improper and inappropriate use of physical punishment/dominance techniques such as alpha rolls, corrections with choke chains or prong collars, or even yelling “no” can lead to human injury, increased aggression and anxiety, and disruption of the human-animal bond.

Safety Recommendations
• If owners elect not to euthanize, they must be aware that their main responsibility is preventing human injury by diligently avoiding all situations that might evoke an aggressive response including situations that excite fear even if not aggression. • Treatment must begin with prevention of exposure to all aggression-provoking stimuli prior to any behavior modification. • Use patient history to identify each situation or trigger for owners to avoid. This may include not allowing on furniture or beds where aggression might arise, not giving valuable treats or toys (e.g., rawhide) except when confined away from family members, and limiting physical contact with the dog including petting in any place or situation where the dog might resist or bite. Instead provide the dog with opportunities (control) to avoid undesirable interactions (e.g., safe haven, crate). Reward the dog for entering the safe haven and for leaving (coming out). Do not physically punish or reprimand the dog. • Introducing a head halter (e.g., Gentle Leader) with a lightweight 8–16-foot leash attached or a basket muzzle whenever in contact with people or in any situation where problems might arise, makes controlling potentially dangerous situations
Aggression Toward Familiar People—Dogs

Easier and safer • Use the long leash to safely remove the dog from situations that may elicit aggression; do not reach for the dog directly.

Behavioral Therapy • Behavior modification—use non-confrontational methods and reward-based training to achieve desirable outcomes and teach the dog behaviors without experiencing fear or becoming aggressive. * Structured interactions (also known as “learn to earn or say please by sitting”) where the dog is consistently taught to sit for anything it values (before feeding, petting, play, going for a walk) gives the dog control of its resources by sitting calmly, provides structure and predictability in all interactions, teaches impulse control and trains the dog that good things happen by sitting calmly. Owners must ignore the dog until it sits or train “sit,” whenever soliciting attention. • Use positive reinforcement (e.g., food, toys, play, petting) for response (or counter commanding) to teach behaviors that are incompatible with those that have resulted in aggression.

Desensitization and Counter-Conditioning • Decreasing reactivity to situations that have resulted in aggression by making positive associations with each interaction. Do not begin until owner can insure success with reward-based training and sit for all interactions. • Teach the dog strategies to relax (sit, down, go to your bed) on verbal cue in neutral situations using food rewards. • Expose the dog to a sufficiently reduced stimulus where no fearful or aggressive reaction is elicited (e.g., owner, passing by resting dog at sufficient distance): • Reward calm, non-fearful/aggressive behavior (e.g., verbal praise, tossing favored treats). • Gradually increase the level of stimulation, staying below the threshold that would result in fear and/or aggression. • Progress is slow (typically months) and careful monitoring is essential to understand and respect the dog’s limits. • Train on cues those behaviors needed to manage specific problems, e.g., go to your bed (for dogs that are protective of resting areas) or “drop it” (for resource guarding).

SURGICAL CONSIDERATIONS • Castration reduced aggression by at least 50% toward family members in approximately 30% of dogs studied. • Females that start to show dominance aggression at less than 6 months of age may be less aggressive if spaying delayed until 9 months.

MEDICATIONS

DRUG(S) • There are no medications licensed for treatment of canine aggression. Owners must be aware that the use of medications is off-label. Note in the patient’s record that owners were informed of potential risks and side effects. A signed informed consent form is advisable. NEVER use medications without concurrent behavior modification. Before prescribing medication, be sure that owners understand the risks and liability in owning an aggressive dog, will follow safety procedures, and do not expect medications to insure safety. In fact, medication may not be appropriate in all situations (e.g., households with small children or individuals with disabilities).

• There is a strong placebo effect when using drugs for behavior therapy in dogs. Studies have not shown a robust effect of drug treatment on aggression.

Selective Serotonin Reuptake Inhibitors • Fluoxetine 0.3–2 mg/kg PO q24 h. • Paroxetine 0.5–2 mg/kg PO q24 h. • Sertraline 1–3 mg/kg PO q24 h. • Side effects: sedation, irritability, GIT effects, increased aggression; anorexia is common and usually transient.

Tricyclic Antidepressants • Clomipramine 1–3 mg/kg q12 h in dogs (labeled restriction for aggression) • Side effects: sedation, GIT effects, anticholinergic effects, cardiac conduction disturbances if predisposed, and increased anticholinergic effects, cardiac conduction disturbances if predisposed, and increased anticholinergic effects. • Use caution as any psychotropic medication in dogs may reduce fear-based inhibition resulting in an increase rather than decrease in aggression.

PRECAUTIONS Use caution as any psychotropic medication may reduce fear-based inhibition resulting in an increase rather than decrease in aggression.

CONTRAINDICATIONS Use caution as any psychotropic medication may reduce fear-based inhibition resulting in an increase rather than decrease in aggression.

ABREVIATIONS • CNS = central nervous system • GIT = gastrointestinal tract • MAO = monoamine oxidase • MRI = magnetic resonance imaging • SRRI = selective serotonin reuptake inhibitor • TCA = tricyclic antidepressant

POSSIBLE INTERACTIONS Do not combine SSRIs, TCAs, MAO inhibitors (e.g., amitraz, selegiline), opioids (e.g., tramadol), and other medications that increase serotonin—can result in potentially fatal serotonin syndrome.

FOLLOW-UP

PATIENT MONITORING Clients need ongoing assistance and should receive first follow-up call within the first 1–4 weeks after consultation. Provisions for further follow-up (by phone or in person) should then be made.

PREVENTION/AVOIDANCE Treatment, including safety recommendations, are life-long—aggression may recur if preventive strategies not maintained.

POSSIBLE COMPLICATIONS • Human injuries; euthanasia or relinquishment of patient.

EXPECTED COURSE AND PROGNOSIS There is no cure. Prognosis is more favorable if aggression is at a low intensity and occurs in relatively few predictable situations. Prognosis is highly dependent on owner compliance.

MISCELLANEOUS

ASSOCIATED CONDITIONS Other forms of aggression, including interdog aggression, resource guarding, and aggression to unfamiliar people or dogs. Aggressive dogs often have underlying anxiety.

ZOONOTIC POTENTIAL • Human injury.

PREGNANCY/FERTILITY/BREEDING Do not breed aggressive dogs.

SYNONYMS • Competitive aggression • Conflict aggression • Dominance-related aggression • Rage syndrome • Status-related aggression

ABBREVIATIONS • CNS = central nervous system • GIT = gastrointestinal tract • MAO = monoamine oxidase • MEI = magnetic resonance imaging • SRRI = selective serotonin reuptake inhibitor • TCA = tricyclic antidepressant

SEE ALSO • Aggression Toward Unfamiliar People and Unfamiliar Dogs—Dogs • Aggression, Food and Resource Guarding—Do • Aggression—Between Dogs in the Household


AUTHOR Meredith E. Stepita

CONSULTING EDITOR Gary M. Landshog

ACKNOWLEDGMENT The author and editors acknowledge the prior contribution of Laurie Bergman.

Client Education Handout available online
Aggression Toward Humans—Cats

**DEFINITION**
Human-directed aggression in cats

**PATHOPHYSIOLOGY**
The more common causes for human-directed aggression in cats include play, fear/pain-related, redirected, maternal, and petting intolerance. Content is going to contribute greatly when making the correct diagnosis. For example, play aggression is likely to be seen in a young, solitary cat, while pain-related/fear aggression is a common behavior seen in the clinic setting.

**SYSTEMS AFFECTED**
- Behavioral
- Gastrointestinal—decreased appetite if fear and/or pain-related
- Hematologic/Lymphatic/Immune—chronic stress effects on immune function
- Ophthalmic—dilated pupils in response to autonomic nervous system stimulation
- Skin/Exocrine—may show displacement behaviors such as overgrooming

**GENETICS**
There is no known genetic basis for human-directed aggression in cats.

**INCIDENCE/PREVALENCE**
Aggression is second only to inappropriate elimination for feline cases seen by veterinary behavior specialists.

**GEOGRAPHIC DISTRIBUTION**
None

**SIGNALMENT**
Cats of any age, gender/ neuter status, breed can be affected. Play-motivated aggression more likely in juvenile, solitary cat.

**SIGNS**
- Play-motivated: cat approaches its “victim,” crouches in wait, stalks and chases; tail is twitching and ears are forward. Typically will attack moving target.
- Fear/Pain-related: ears back, body and tail lowered, piloerection, pupils dilated; may hiss and growl. Avoidance of person(s) who elicit the aggression. Attacks possible if approached and/or cornered. Extreme cases: expression of aggression is second only to inappropriate elimination for feline cases seen by veterinary behavior specialists.
- Redirected: occurs during interference in, or interruption of, situations that have caused the cat to become aggressively aroused—such as a cat fight (between familiar household cats), the presence of a cat outside or noise.
- Maternal: recent birth of litter
- Fear: poor socialization with humans and/or feral living, an aversive event associated with a person, or people in general.
- Pain-related: obvious medical/physical condition.
- Redirected: occurs during interference in, or interruption of, situations that have caused the cat to become aggressively aroused—such as a cat fight (between familiar household cats), the presence of a cat outside or noise.
- Maternal: recent birth of litter
- Fear: poor socialization with humans and/or feral living, an aversive event associated with a person, or people in general.
- Pain-related: obvious medical/physical condition.

**CAUSES & RISK FACTORS**
- Play-motivated: lacking in opportunities for normal play—no other cats, insufficient and/or inappropriate toys; history of owner using hands/feet to play with kitten and/or playing roughly with the kitten.
- Fear: poor socialization with humans and/or feral living, an aversive event associated with a person, or people in general.
- Pain-related: obvious medical/physical condition.
- Redirected: occurs during interference in, or interruption of, situations that have caused the cat to become aggressively aroused—such as a cat fight (between familiar household cats), the presence of a cat outside or noise.
- Maternal: recent birth of litter
- Fear: poor socialization with humans and/or feral living, an aversive event associated with a person, or people in general.
- Pain-related: obvious medical/physical condition.
- Redirected: occurs during interference in, or interruption of, situations that have caused the cat to become aggressively aroused—such as a cat fight (between familiar household cats), the presence of a cat outside or noise.
- Maternal: recent birth of litter
- Fear: poor socialization with humans and/or feral living, an aversive event associated with a person, or people in general.
- Pain-related: obvious medical/physical condition.

**DIAGNOSIS**
Differential diagnosis: see causes above.

**CBC/BIOCHEMISTRY/URINALYSIS**
Rule out contributing medical conditions based on presentation.

**OTHER LABORATORY TESTS**
- Senior cats: a complete thyroid panel.
- Urinalysis if inappropriate elimination and/or urine marking is presented as part of the aggression.

**IMAGING**
Based on clinical examination and/or suspected pain component

**DIAGNOSTIC PROCEDURES**
Thorough behavioral history including a description of the cat’s postures during aggression and injuries inflicted; context, presence of outside cats, early historical information, litter box use, food consumption, and hiding behaviors.

**PATHOLOGIC FINDINGS**
N/A

**TREATMENT**

**APPROPRIATE HEALTH CARE**
Applicable only if health/medical issue diagnosed.

**NURSING CARE**
Applicable only if health/medical issue diagnosed.

**ACTIVITY**
- Play-motivated: cat should be provided with increased opportunity for appropriate play—either in the form of toys, human interaction, or additional housemate.
- Redirected: cat should be denied access to windows where outside cats can be seen.

**DIET**
- Hill’s Science Diet c/d Multicare Feline Urinary Stress.
- Royal Canin Feline Calm

**CLIENT EDUCATION**
- Play-motivated: normal play behavior and the importance for opportunities for appropriate play.
- Fear: avoidance of fear-inducing situations—ongoing exposure may worsen signs, cause severe stress, and compromise animal welfare.
- Redirected: importance in addressing primary stimuli—such as outside cats.
- Maternal: normal maternal and kitten-protective behavior—same as for fear-motivated aggression.
- Petting intolerance: normal feline grooming patterns; observation of cat’s warnings so that behavior does not escalate.

**Behavior Modification Exercises**
- Desensitization and Counter-Conditioning (DS & CC)
- Desensitization: exposing cat to the fear-inducing stimulus (scary person) at a low level so the cat does NOT react fearfully or aggressively. Over time, the intensity of the stimulus is increased (i.e., the distance between the cat and stimulus is decreased) without causing fearful responses.
- Counter-conditioning: rewarding the cat with a special treat, toy, grooming, petting, for relaxation.

**Classical Conditioning (CC)**
Classical conditioning: pairing the stimulus (person threatening to the cat) with a tasty treat, toy, petting. Example: scary person = tuna fish.

**MEDICATIONS**
The short-term use of medication may be necessary to decrease overall levels of anxiety and reactivity in more severe cases.

**DRUG(S) OF CHOICE**

**Azaipirones**
Buspirone 0.5–1.0 mg/kg PO q12h. Most useful for fearful and withdrawn cats. Decreases anxiety and may increase “self-confidence.” Anecdotal reports of “increase in affection,” therefore might be useful in severe cases of petting intolerance. Response noted in 1–2 weeks.
Selective Serotonin Reuptake Inhibitors (SSRIs)
- Fluoxetine, paroxetine, sertraline 0.5–1.5 mg/kg PO q48h.
- SSRIs must be given daily. May take 4–8 weeks to reach peak effects.

Tricyclic Antidepressants (TCAs)
- Amitriptyline 0.5–2.0 mg/kg PO q12–24h.
- Clomipramine 0.25–1.5 mg/kg PO q48h.
- TCAs must be given daily. May take 4–8 weeks to reach peak effects.

Benzodiazepines
- Alprazolam 0.125–0.25 mg/cat PO q8–24h.
- Fluoxetine, paroxetine, sertraline (rarely used due to potential hepatopathies).
- Can be given “as needed” for specific encounters with people inducing the fear response and during desensitization, counter-conditioning and classical conditioning sessions.
- Can be used in conjunction with azapirones, SSRIs, and TCAs.

CONTRAINDICATIONS/ PRECAUTIONS/POSSIBLE INTERACTIONS
- None of the drugs listed are approved for use in cats.
- All of the medications are to be administered orally; as they have not been shown to be effective through transdermal dosing.
- Atapirones: side effects are uncommon but occasional excitement is noted. Should not be given in combination with an MAOI. Avoid use in the aggressor cat; may increase any “bully” behavior.
- Neither SSRIs nor TCAs should be given with each other, nor in combination with MAOIs.
- SSRIs: side effects include mild sedation and decreased appetite, constipation, and urinary retention. Competitive inhibition of cytochrome P450 liver enzymes; when administered concurrently with medication utilizing the P450 enzymes, elevated plasma levels of the medications may increase, causing toxic levels.
- TCAs: side effects include sedation, constipation, diaphoresis, urinary retention, appetite changes, ataxia, decreased tear production, mydriasis, cardiac arrhythmias, tachycardia, and changes in blood pressure.
- Benzodiazepines: side effects include sedation, ataxia, muscle relaxation, increased appetite, paradoxical excitation, and increased friendliness. Idiopathic hepatic necrosis has been reported in cats.

FOLLOW-UP
PATIENT MONITORING
Weekly follow-up is recommended in the early stages of treatment, especially when on medication(s). Monthly follow-up once stable. For cats on medication, follow-up blood testing recommended every 6–12 months.

PREVENTION/AVOIDANCE
- Fear: avoidance of the fear-inciting stimuli if at all possible. Early socialization to people and events may help prevent some occurrences of fear-related responses to people.
- Pain: treat underlying condition(s).
- Redirected: address possible aversive stimuli—indoors and outdoors.
- Maternal: as for fear.
- Petting intolerance: limit amount of time petting the cat; desensitization and counter-conditioning to increase petting time.

POSSIBLE COMPLICATIONS
Potential human injury in all of the above cases, especially if the cat is approached or cornered and/or when highly aroused.

EXPECTED COURSE AND PROGNOSIS
Progress occurs slowly. Relining is a process and each case is individual. If medications are indicated, begin at a low dose and work up as necessary. To discontinue medication, wait until the new behavior is stable (8–12 weeks) and wean off slowly, usually over weeks. If aggressive behavior recurs, return to the last dose that controlled the anxiety/reactivity and continue treatment.

MISCELLANEOUS
ASSOCIATED CONDITIONS
- N/A

AGE-RELATED FACTORS
- Play-motivated: typically seen in young, solitary cat in household.

ZOONOtic POTENTIAL
People injured during an aggressive attack should seek prompt medical attention. Infection by Bartonella henselae can result from a cat scratch or bite.

PREGNANCY/FERTILITY/BREEDING
- Avoid medications in breeding/nursing cats.

SYNONYMS
- N/A

SEE ALSO
- Aggression Overview—Cats
- Fears, Phobias, and Anxieties—Cats

ABBREVIATIONS
- CC = classical conditioning
- DS & CC = desensitization and counter-conditioning
- MAOI = monoamine oxidase inhibitor
- SSRI = selective serotonin reuptake inhibitor
- TCA = tricyclic antidepressant

Suggested Reading


Author Terry Marie Curtis
Consulting Editor Gary M. Landsberg
# Aggression, Food and Resource Guarding—Dogs

## Overview
- Aggressively guarding food (e.g., in food bowls, rawhide, bones, stolen/found items) or objects (e.g., toys, stolen objects).
- Usually within the range of normal behavior; genetics, learning or early experience may contribute to excessive expression of aggression.

## Systems Affected
- Behavioral

## Signalement
- No breed or sex predilections.

## Signs
- Aggression (barking, growling, lip-lifting, snarling, snapping, lunging, biting) toward people, other animals or objects (e.g., toys, stolen/found items) or resources, make the dog more responsive to others that lead to aggression including a calm sit and watch before giving any food, chews or toys, and drop it to release toys for valuable rewards.
- Prevent access to items that might be stolen or guarded by supervising with leash if necessary.
- Dogs and people contact aversive substances such as hot sauce.
- Systematic desensitization and counter-conditioning to specific aggression-provoking stimuli if safety and owner compliance can be insured.
- Find the threshold (distance, location) at which the dog shows no anxiety or aggression when in possession of food or chews and make positive associations by tossing small valued rewards.
- Give food and any other objects that the dog might guard in a confinement/safe haven away from people and other animals; removing from the home.

## Causes & Risk Factors
- May be part of normal canine behavior.
- Strongly influenced by previous experiences of successfully defending food, or objects through aggression and by resource availability/novelty.
- Underlying medical conditions or medications; especially those causing polyphagia, or calorie-restricted diets may increase level of food aggression.
- Fear aggression
- Social status/dominance or conflict aggression
- Underlying medical conditions and medications; especially those causing polyphagia, or calorie-restricted diets may increase level of food aggression.
- MRI if CNS disease suspected. Other imaging as needed to rule out underlying medical conditions.

## Diagnosis
- CBC/Biochemistry/Urinalysis
- Usually unremarkable. Abnormalities suggest an underlying or contributing medical condition.

## Other Laboratory Tests
- Usually unremarkable.

## Imaging
- MRI if CNS disease suspected. Other imaging as needed to rule out underlying medical conditions.

## Differential Diagnosis
- Fear aggression
- Social status/dominance or conflict aggression

## Client Education
- Treatment is aimed at control, not achieving a "cure." Successful treatment resulting in a decrease in aggressive incidents, depends on owner understanding of basic canine social behavior, risks involved in living with an aggressive dog, and ability to follow safety and management recommendations.
- If safety cannot be insured, pet should be removed from the home.

## Safety Recommendations
- The owner's main focus must be on preventing injury by diligently avoiding situations that may evoke an aggressive reaction.
- Owners may be more compliant with avoidance recommendations if they understand both the risk and the potential liability if the dog causes injury.
- Successful treatment is more likely if a period of preventing exposure to aggression-provoking stimuli is initiated prior to behavior modification.
- Always confine the dog away from potential victims or the dog must be under the direct physical control of a responsible adult whenever an aggression-provoking situation could arise.
- Give food and any other objects that the dog might guard in a confinement/safe haven away from people and other animals; removing from the home.

## Treatment
- Command-response-reward program (say please by sitting); to increase owners' control of resources, make the dog more responsive to the owner, and create structure and predictability in the dog's life.
- Use positive reinforcement (e.g., food, toys, play) to teach behaviors that are incompatible to those that lead to aggression including a calm sit and watch before giving any food, chews or toys, and drop it to release toys for valuable rewards.

## Possible Complications
- Human injuries; euthanasia or relinishment of patient.

## Medications
- Medications are generally not indicated in the treatment of resource guarding.

## Follow-Up
- Clients usually need ongoing assistance with at least one follow-up call within the first 1–3 weeks after the consultation. Provisions for further follow-up should be determined at that time.
EXPECTED COURSE AND PROGNOSIS
There is no cure. Prognosis for improvement is more favorable if aggression is at a low intensity, occurs in only a few predictable situations, and can be effectively and practically prevented.

MISCELLANEOUS ASSOCIATED CONDITIONS
Fear and dominance/conflict aggression

ZOONOTIC POTENTIAL
Human injury and bite wounds

PREGNANCY/FERTILITY/BREEDING
Do not breed dogs with extreme aggression.

SEE ALSO
• Aggression Toward Unfamiliar People and Unfamiliar Dogs—Dogs
• Aggression Toward Familiar People—Dogs
• Aggression Between Dogs in the Household—Dogs

ABBREVIATIONS
• CNS = central nervous system
• MRI = magnetic resonance imaging

Suggested Reading


Author Meredith E. Stepita

Consulting Editor Gary M. Landsberg

Acknowledgment The author and editors acknowledge the prior contribution of Laurie Bergman.
A

AGGRESSION, INTERCAT AGGRESSION

BASICS

DEFINITION

Intercat aggression—offensive or defensive aggression between cats consisting of staring, displacing, vocalizing (growling, yawning, shrieking), spitting, hissing, swatting, lunging, chasing/stalking, and/or biting other cats.

PATHOPHYSIOLOGY

• May be normal behavior or abnormal.
• May be caused by underlying medical disease (e.g., CNS) or the indirect result of concurrent medical disease lowering the threshold for irritable responses (e.g., pain, hyperthyroid).
• May be multiple motivations including predation, play, disputes over territory, sexual, fear, anxiety, and redirected.

SYSTEMS AFFECTED

• Behavioral. Skin/Fascia—secondary to traumatic injury. Immune—chronic stress may alter the immune response.
• Secondary infection (cat bite abscesses) are not uncommon. Nervous.

GENETICS

No specific genetic basis, although some evidence to suggest that friendliness is more genetic and related to paternal effects.

INCIDENCE/PREVALENCE

Unknown

GEOGRAPHIC DISTRIBUTION

None

SIGNALMENT

Breed Predilections

None

Mean Age and Range

• Can occur at any age when due to changes in social environment (e.g., addition of a new cat, return of a cat from the veterinarian or redirected. • Previously stable cat relationships can deteriorate as cats reach social maturity (2–4 years of age).

Predominant Sex

• Intact males more likely to initiate intercat aggression (related to territory, and/or proximity to females). • Females will defend their young from unfamiliar individuals.
• Male kittens are more likely to initiate intercat aggression related to the predatory components of play.

SIGNS

Historical Findings

• May arise spontaneously and vary in frequency and intensity. • Owners most likely to seek behavioral intervention if there are physical injuries, the welfare of the aggressor and/or victim is compromised, or fighting becomes sufficiently distressing. • Human intervention in an attempt to interrupt fighting may result in human-directed aggression/injury.

Risk Factors

• Singletons and/or bottle-raised kittens.
• Lack of social exposure and experience with specifics during the socialization period (2–7 weeks) and beyond.
• Male in multi-cat households.
• Postpartum females with kittens in multi-cat households.
• Separating and returning housemates (e.g., following veterinary visit, grooming).
• Changes in social group such as the addition of a "new" cat to a home of resident cats.
• Scratching and biting during the first introduction raise future intercat aggression.
• Access to the outdoors and/or intrusion of unfamiliar cats onto the territory.
• Crowding or lack of adequate social space and access to resources (food, water, litter boxes, and resting stations).
For Cases that have a Low Frequency of Intense, Injurious Aggressive Outbursts
• Separate the cats when they cannot be supervised (create “safe zones”). • Either keep them separate in the same areas each day in an effort to form separate core territories for each cat, or “time share” the space between cats.
• Confine the newly introduced cat or the aggressor to the smaller, less familiar area.
• For multiple cats, separate by stability of relationship between cats. Any despotic/bully cats should be confined alone. • Consider “artificial background marking” to form a communal scent between the cats that that fighting; a towel (facelock) may be rubbed (cephalocaudally) to obtain the scent of one cat and then rubbed onto the other cat and vice versa. • Treat each cat separately with operant counterconditioning and controlled reintroduction. This is especially valuable for the aggressor. • Set up desensitization and counter-conditioning, sessions daily, initially utilize physical and visual barriers. • Introduce the cats (in their kennels or on leashes and harness) at a distance from each other that prevents overt/covert aggression.
Feed the cats or engage in play for classical counterconditioning. • Over many sessions gradually reduce the distance between the cats, being careful to stay far enough apart during each session that no overt or covert behavioral signs of aggression and/or fear are seen. Start and end all sessions on a successful note. • Teach the cats a “come and/or go to place” cue using operant counterconditioning and positive reinforcement. Practice these cues several times daily so each cat learns to respond reliably. Behavioral cues are best taught when animals are not stressed. • When ready to allow the cats more freedom with each other, follow the instructions for less severe intercat aggression (above).

SURGICAL CONSIDERATIONS
Neutering intact males is approximately 90% effective in reducing roaming, intercat aggression, and urine spraying. Neutering females is effective in reducing mounting/sexual behavior.

MEDICATIONS
DRUG(S) OF CHOICE
As all medications are extra-label, insure that the client is informed, and review target desirable outcomes and potential adverse effects.

For the Aggressor and/or Victim
Selective serotonin reuptake inhibitors (SSRI)
• Fluoxetine or paroxetine 0.5–1 mg/kg PO q24h
• Drugs of choice for aggression, anxiety, and/or urine marking, may decrease impulsivity.
• Side effects may include gastrointestinal upset, decreased appetite, sedation, urinary
Recent and mild side effects include gastrointestinal upset, fear/anxiety, and ataxia, and may be more common in young active and playful cats. These medications should be used cautiously or avoided unless the potential benefits are significant. A negative initial encounter is often associated with future intercat aggression. Related and familiar cats are less likely to have intense intercat aggression. Intercat aggression may be more common when cats are housed indoors with more sedentary or aged individuals.

For the Victim

**Axapiron**
Busipron 0.5–1 mg/kg PO q8–24 h (feline dose): reserved for victims to increase social confidence.

**Benzodiazepines**
- Lorazepam 0.125–0.25 mg/cat PO up to q12–24 h or oxazepam 0.2–0.5 mg/kg PO q12–24 h for anxious or fearfully aggressive cats and as an appetite stimulant helping to facilitate passive counter conditioning. May be used as needed with peak effects seen within 1 hour.
- Side effects may include increased appetite, anxiety, inhibited learning, and disinhibition of aggression.
- Note: controlled substance; dependence can develop. Medication should be gradually tapered if user used consistently for longer than 2 weeks.

**CONTRAINDICATIONS**
- Benzodiazepines should be used cautiously or avoided in cats with hepatoopathies.
- Benzodiazepines and TCAs should be used with caution in patients with histories of cardiac arrhythmias or intercat aggression. Benzodiazepines and TCAs should be used with caution in patients with histories of cardiac arrhythmias.

**PRECAUTIONS**
- Any behavioral drug has the potential to produce paradoxical reactions, including fear, anxiety, hyperactivity, and/or aggression.
- Medications that alter serotonin levels have the potential to produce serotonin syndrome.

**POSSIBLE INTERACTIONS**
- Avoid concurrent use of SSRIs and TCAs or MAO inhibitors such as selegiline and use cautiously or avoid with busipron, trazodol, and tryptophan due to possible serotonin syndrome. Caution with concurrent medications considered substrates of P450.

**ALTERNATIVE DRUGS**
- Clomipramine (TCA) 0.5–1 mg/kg PO q12–24 h for anxious cats especially if comorbid recurrent FIC/FLUTD; not selective for serotonin reuptake inhibition and likely less effective for the aggressor. Dietary supplementation with alpha-casozepine (Zylkene: Vetoquinol), ROYAL CANIN Veterinary Diet CALM (contains alpha-casozepine, L-tryptophan, and nicotinamide) or Hill’s Prescription Diet Multicare Feline Urinary Stress (contains L-tryptophan and milk protein hydrolysate).

**FOLLOW-UP**

**PATIENT MONITORING**
- Clients should monitor patients 2 weeks after treatment initiation and monthly for the first few months by phone or email; a follow-up visit should be scheduled 4–8 weeks into treatment if drugs dispensed to assess response and adjust dose if necessary.
- Behavioral therapy and/or medications may be rechecked immediately if any adverse events, including anorexia. Medication should be used for at least 4–6 weeks after resolution of signs, then gradually weaned by reducing the dosage no faster than 25% per day on a weekly basis. Some patients require long-term medication; recheck laboratory work every 6 months to 1 year depending on health and age.

**PREVENTION/AVOIDANCE**
- Proper socialization 2–7 weeks and ongoing. Gradual introduction more closely resembles the natural process through which new cats enter an existing group at the prophyphylly and may be accepted over time. Intercat aggression may be more common when unfamiliar cats are suddenly placed together. A negative initial encounter is often associated with future intercat aggression. Related and familiar cats are less likely to have intense intercat aggression. In stable multi-cat households, avoid adding additional cats.

**POSSIBLE COMPLICATIONS**
- Abrupt withdrawal of behavioral medications may result in aggression and rebound anxiety.

**EXPECTED COURSE AND PROGNOSIS**
- The prognosis for most cases is fair; it is complicated by prolonged duration, high intensity, underlying medical conditions, and incomplete owner compliance. In one study 62%/58%/48% were considered cured and 37%/17%/48% not cured (cat given away, euthanized or permanently separated). Recent and mild (low-intensity, low-frequency) cases may have better long-term outcomes.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
- Urine marking/graying • House soiling
- Excessive grooming • Fearful/anxiety-related behavior • Human-directed or interspecies aggression

**AGE-RELATED FACTORS**
Most behavioral medications are contraindicated in breeding animals.

**SYNONYM**
Feline intraspecies aggression

**ABBREVIATION**
- FEL = feline leukemia virus
- FIC/FLUTD = feline idiopathic cystitis/lower urinary tract disease
- FIV = feline immunodeficiency virus
- MAO = monoamine oxidase inhibitor
- SSR = selective serotonin reuptake inhibitor
- TCA = tricyclic antidepressant

**SEE ALSO**
- Aggression, Overview—Cats • Pediatric Behavior Problems—Cats

**INTERNET RESOURCES**
http://indoorpet.osu.edu/cats/

**Suggested Reading**

**Authors**
E. Lise Christensen Bell and Kenneth M. Martin

**Consulting Editor**
Gary M. Landsberg
Aggression is a behavioral strategy used to manage aversive situations. • May be normal and adaptive in certain situations. • May be abnormal with serious deleterious effects on the cat’s physical and emotional well-being. • Aggressiveness describes both mood and temperament traits relating to the propensity to show aggression when environmental circumstances dictate it might be used.

OVERVIEW OF TYPES

Play Aggression (Toward People)
• Typically refers to a cat who scratches and bites the owners during play. • Not true aggression but overzealous play without proper impulse control due to lack of training or proper intraspecific social feedback. • The cat’s intent is not to harm the person. • Behavior encouraged and rewarded by owners through rough play with a kitten; when larger and stronger, becomes perceived as aggression rather than overzealous play.

Predatory Aggression (Toward People or Other Animals)
• Cats have an innate drive to “hunt” or show predation behavior, which includes stalk, hide, and pounce. • Predation is not a direct function of hunger. • Typically stimulated by fast movements and can progress to the cat hiding and waiting for an animal or person to walk by. • Play is a common way for young cats to perfect predation skills; play aggression and predatory aggression may overlap.

Redirected Aggression (Toward People or Other Animals)
• Cats who see, hear, or smell a trigger and predatory aggression may overlap.

Fear/Defensive Aggression (Toward People or Other Animals)
• Cats who are in pain may show aggression (fear, defensive aggression) after introducing a new cat to the home. • Cats may be particularly sensitive to being handled, stroked along the dorsum, the common method used by owners.

Contact-Induced/Petting Aggression (Toward People)
• Cats who show early signs of aversion when people stroke their cats, with their cats going back and tail swishing. • If physical contact continues, they typically bite. • Owners often miss the early warning signs. • When cats grooms one another, they typically limit the grooming to the head region. • Some cats appear to be particularly sensitive to being stroked along the dorsum, the common method used by owners.

Intercat Aggression Within a Home
• Fifty percent of cat owners report fighting (scratching and biting) after introducing a new cat to the home. • The number of cats, gender, and age are not significant factors in predicting which cats will show aggression. • Any of the above categories of aggression are all possibilities for fights between or among cats. • Fear/anxiety is the most common cause of intraspecific aggression.

CONTRIBUTING FACTORS TO THE PATHOPHYSIOLOGY

Behavior problems are typically multifactorial in cause, and Figure 1 is a diagram illustrating some of the more common components that need to be evaluated to accurately diagnose and treat aggression.

SYSTEMS AFFECTED

• Behavioral—vary with type of aggression, occur alone or in combination: tail washing/switching, cats turned sideways or flattened, stiffening of shoulders/legs, crouching, dilation of pupils, hissing, spitting, growling, piloerection, staring, chasing, stalking, pawing, ranging. • Cardiovascular—signs associated with psychogenic activation and HPA activation. • Endocrine and Metabolic—long-term changes associated with fear/stress/anxiety, symptoms associated with long-term activation of the HPA system. • Gastrointestinal—with chronic HPA stimulation may see a cat more prone to anorexia and GI distress. With acute fear aggression: evacuation of the bowel and possible diarrhoea. IBD possible in chronic stress. • Hematopoietic—decreased immune response with chronic HPA stimulation; stress leukogram. • Musculoskeletal—an outcome of the aggression may result in damage to the muscles from damage by the tails and teeth. • Both the victim and the aggressor may suffer injuries. With chronic activation of the HPA, may see muscle wasting. • Nervous—increased reactivity for up to 72 hours following an aggressive outburst. May see an increase in aggression with decreased provocation as the synapses in the amygdala become sensitized. Some animals may have decreased serotonin, causing aggressive outbursts. Depending on the type of aggression, may see stimulated motor patterns, sharking, or trembling. • Ophthalmic—decreased immune response with chronic HPA activation.

SIGNALMENT

• May appear at social maturity (2-4 years of age) except for play-related and should occur in specific social contexts/interactions. If occurring in an older cat, medical causes should be ruled out first. • General comments: most owners are able to detect overt signs of aggression (hissing, biting, growling) but may
miss more subtle signs of aggression that typically occur between cats (staring) and the resulting anxious behaviors that can result in aggression (meatloaf position, averting gaze, etc.). Videotapes of interest interactions allow the clinician to assess the behavior.

CAUSES
- Underlying medical issues can cause aggression. • Temperament/behavior is influenced by genetics, rearing, socialization, environment in which the cat lives, and types of interactions the cat has with people.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
- CNS disease (e.g., infections, toxins, tumors, partial seizures, focal seizures)
- Hyperthyroid • Hepatic encephalopathy
- Any condition causing pain (e.g., arthritis, pancreatitis, dental disease, and sacculitis)
- Lead poisoning • Diabetic neuropathy (pain-induced aggression when paws touched)

CBC/CHEMISTRY/URINALYSIS
Physical examination, baseline blood and urine screening followed by additional diagnostics as indicated based on history, examination and laboratory results.

OTHER LABORATORY TESTS
- Discuss thiamine testing in any cat that bites or scratches people. • Thyroid levels.
- Urinalysis g culture if house soiling is part of the aggression issue. • Feline serumology (FCV, FeLV, FIV).

TREATMENT
- Never use physical correction/punishment may escalate the aggression. • Never try to physically handle or manipulate a cat in an aggressive state. • Avoid known triggers.
- Identify triggers and desensitize and counter-condition the cat to the triggers. • Implement safety measures (rail caps, wearing long pants/long sleeves, keep flattened cardboard boxes around home to place between yourself and your cat, redirect the behavior in early arousal phase).
- Behavior modifications to redirect the cat and reduce arousal (specific plans are dependent upon the specifics of each case). • Teach your cat to commands such as “sit,” “go to place,” etc. • Implement environmental enrichment. • Teach owners to identify early signs of arousal so the cat can be redirected or so they can avoid the cat. • After a very aggressive outburst, keep aggressor isolated in a room for at least 24 hours (as long as the cat remains aroused after an attack). • Phenytoin. • Medications.

MEDICATIONS

DRUGS OF CHOICE
- SSRI's: Fluoxetine or paroxetine 0.5 mg/kg PO q24h
- TCA's: clomipramine 0.5 mg/kg PO q24h.
- Buspirone 0.5–1.0 mg/kg q8–24h or benzodiazepines such as oxazepam at 0.2–0.5 mg/kg q12–24h might reduce fear and build confidence in the fearful cat that does not retaliate or fight back.

CONTRAINDICATIONS
- Any medication the cat is on, the practitioner should look up which liver enzyme system is utilized in metabolism to maximize safety in combining medications.

ALTERNATIVE DRUGS
- Amitriptyline 0.5–1.0 mg/kg PO q12–24h
- SAMe
- Multicat diffuser l-theanine 25 mg PO q24h

FOLLOW-UP

PATIENT MONITORING
- Call owners once every 1–2 weeks for the first 2 months after a treatment plan has been recommended. • Determine implementation of safety recommendations and the behavioral plan. • If medications are involved, the medication dose should be reevaluated every 3–4 weeks. • Frequency of follow-up will be dictated by the severity of the case and owner compliance. • CBC, chemistry, T4 prior to medication. Recheck liver and kidney values 2–3 weeks after starting medication. Recheck bloodwork annually in young healthy patients, semiannually in older patients.

MISCELLANEOUS

AGE-RELATED FACTORS
- Older cats—cognitive decline, CNS disease, arthritis, meningioma, other medical conditions. • Age 2–4—social maturity, when cats may start to show certain kinds of aggression.

ABBREVIATIONS
- CNS = central nervous system • FCV = feline calicivirus • FeLV = feline leukemia virus • FIV = feline immunodeficiency virus • FLUTD = feline lower urinary tract disease • GI = gastrointestinal • HPA = hypothalamic-pituitary-adrenal • IBD = inflammatory bowel disease • SAMe = S-adenosylmethionine-tyrosine disulfate • SSRI = selective serotonin reuptake inhibitor • TCA = tricyclic antidepressant

SEE ALSO
- Aggression—Interact Aggression
- Aggression Toward Humans—Cats

Suggested Reading

Author: Emily D. Levine

Consulting Editor: Gary M. Landsberg
Acknowledgment: Karen L. Overall

Client Education Handout available online
In the majority of cases, people are bitten by dogs. Numerous functional types have been posited. Here, aggression is classified on the basis of (1) affective aggression, (2) predatory aggression, and (3) play-related aggression. Affective (emotional) aggression is the focus of this chapter. Affective states, such as fear and arousal, and motivational factors, such as hunger and sexual drive, influence the probability of overt aggression, such as biting. Affective aggression may be human-directed or dog-directed. Within these contexts, there may be additional specificity, such as human-directed aggression toward unfamiliar persons, or human-directed aggression directed toward familiar persons. Often dogs display aggression in a single context.

- Human-directed aggression toward familiar persons in response to controlling gestures is historically called dominance aggression, although newer terminology, such as conflict aggression, may be used to avoid often-errosneous semantic assumptions inherent in the term “dominance.”
- Human-directed aggression toward unfamiliar persons specific to home location is called territorial aggression.
- Predatory aggression refers to behaviors associated with chasing and hunting prey. It is often considered nonaffective and may be socially facilitated by other dogs. Predatory behavior may be triggered by movement or high-pitched sounds and may be misdirected to humans or objects.
- Play-related aggression involves aggressive gestures, such as growling and biting, in the context of play and is commonly displayed toward other dogs or humans. It is often initiated by signs of play, such as the play bow.
- In all cases, medical factors that might contribute to aggression (including pain) must be evaluated.

### PATHOPHYSIOLOGY
- Affective aggression involves arousal of the sympathetic nervous system. Some pathologic conditions are associated with an increase in aggression because of CNS effects such as pain or irritability.
- Abnormalities in the CNS serotonin neurotransmitter system have been implicated in one type of impulsive human-directed aggression, colloquially called “rags,” directed toward familiar persons over controlling gestures.
- Aggression often has a learned component whereby dogs learn to use aggression to manage distance from fearful stimuli or control resources.

### SYSTEMS AFFECTED
- **Behavior.** Other, if there is an underlying medical etiology.
- **Affective (emotional) aggression** may be human-directed or dog-directed.
- **Predatory aggression** refers to behaviors associated with chasing and hunting prey. It is often considered nonaffective and may be socially facilitated by other dogs. Predatory behavior may be triggered by movement or high-pitched sounds and may be misdirected to humans or objects.
- **Play-related aggression** involves aggressive gestures, such as growling and biting, in the context of play and is commonly displayed toward other dogs or humans. It is often initiated by signs of play, such as the play bow.
- In all cases, medical factors that might contribute to aggression (including pain) must be evaluated.

### BASICS

**DEFINITION**
- Action by one dog directed against another organism with the result of, limiting, depriving, or harming that organism.
- Aggression refers to any behavior along an aggression continuum, from a stare, to immobility (freeze), growl, snarl, lunge, air snap, single bite, multiple bite, multiple attacks, and chase and attack.
- Numerous functional types have been posited. Here, aggression is classified on the basis of (1) affective aggression, (2) predatory aggression, and (3) play-related aggression.
- Affective (emotional) aggression is the focus of this chapter. Affective states, such as fear and arousal, and motivational factors, such as hunger and sexual drive, influence the probability of overt aggression, such as biting. Affective aggression may be human-directed or dog-directed. Within these contexts, there may be additional specificity, such as human-directed aggression toward unfamiliar persons, or human-directed aggression directed toward familiar persons. Often dogs display aggression in a single context.
- Human-directed aggression toward familiar persons in response to controlling gestures is historically called dominance aggression, although newer terminology, such as conflict aggression, may be used to avoid often-errosneous semantic assumptions inherent in the term “dominance.”
- Human-directed aggression toward unfamiliar persons specific to home location is called territorial aggression.
- Predatory aggression refers to behaviors associated with chasing and hunting prey. It is often considered nonaffective and may be socially facilitated by other dogs. Predatory behavior may be triggered by movement or high-pitched sounds and may be misdirected to humans or objects.
- Play-related aggression involves aggressive gestures, such as growling and biting, in the context of play and is commonly displayed toward other dogs or humans. It is often initiated by signs of play, such as the play bow.
- In all cases, medical factors that might contribute to aggression (including pain) must be evaluated.

### GENERAL COMMENTS
- Any age
- Mean Age and Range
- Breed Predispositions
- Any breed
- Predominant Sex
- Any sex
- Males—intact or castrated are more aggressive than those with parti coat color.
- Females—spayed are less likely than males to display human-directed “dominance” aggression.
- Intact males are overrepresented in dog-bite fatalities.
- Females—spayed are more commonly implicated in aggression to other female dogs in the home. In some studies, spayed females are less likely than males to display human-directed aggression.

### SIGNS

**General Comments**
- Any dog can display aggression. Many factors, including individual dog, temperament and experience, influence the propensity to bite.
- Dogs may display warning signs—including immobility, growls, snarls, or air snaps that may provide time to avoid overt aggression.
- These signs should not be punished, as this might decrease the probability of warning signs without affecting the underlying risk, or may further intensify the aggressive (defensive) response. Instead, the animal should be safely removed from the situation and the underlying triggers for the affective state should be addressed.

### INCIDENCE/PREVALENCE
- Canine aggression is the most common diagnostic category seen by board-certified veterinary behaviorists in North America.
- According to the Centers for Disease Control and Prevention (2009), about 4.7 million people are bitten by dogs each year in the US, although this number is considered an underestimate as the majority of dog bites are not reported.
- In the US, it is estimated that one in five of those who are bitten require medical attention for dog bite–related injuries.
- Among children and adults, males are more likely than females to be bitten.
- Based on emergency room data in the US, the rate of dog bite–related injuries is highest for children aged 5–9 years.

### INTRODUCTION

In some breeding programs, aggressive tendencies and bite styles have been selected for (or against). One study in the United States linked English springer spaniels that display human-directed dominance aggression to one breeding sire, implicating a heritable component. One study of human-directed dominance aggression among English cocker spaniels reported that males were more aggressive than females, and dogs with solid coat color were more aggressive than those with parti coat color.

### GENETICS
- Aggression is the most common diagnostic category seen by board-certified veterinary behaviorists in North America.
- According to the Centers for Disease Control and Prevention (2009), about 4.7 million people are bitten by dogs each year in the US, although this number is considered an underestimate as the majority of dog bites are not reported.
- In the US, it is estimated that one in five of those who are bitten require medical attention for dog bite–related injuries.
- Among children and adults, males are more likely than females to be bitten.
- Based on emergency room data in the US, the rate of dog bite–related injuries is highest for children aged 5–9 years.

### SIGNALMENT

**Species**
- Dog

**Breed Predispositions**
- Any breed or mixed breed
- Pit bull, German shepherd dog, and rottweiler are the most common breeds implicated in fatal dog bites in the US.
- In the US, English springer spaniels appear to be at risk for human-directed “dominance” aggression.

### GEOGRAPHIC DISTRIBUTION
- Worldwide

**Species**
- Dog

**Breed Predispositions**
- Any breed or mixed breed
- Pit bull, German shepherd dog, and rottweiler are the most common breeds implicated in fatal dog bites in the US.
- In the US, English springer spaniels appear to be at risk for human-directed “dominance” aggression.

**Mean Age and Range**
- Any age

**Predominant Sex**
- Any sex
- Males—intact or castrated are more aggressive than those with parti coat color.
- Females—spayed are less likely than males to display human-directed aggression.

### SIGNS

**General Comments**
- Any dog can display aggression. Many factors, including individual dog, temperament and experience, influence the propensity to bite.
- Dogs may display warning signs—including immobility, growls, snarls, or air snaps that may provide time to avoid overt aggression.
- These signs should not be punished, as this might decrease the probability of warning signs without affecting the underlying risk, or may further intensify the aggressive (defensive) response. Instead, the animal should be safely removed from the situation and the underlying triggers for the affective state should be addressed.

### INCIDENCE/PREVALENCE
- Canine aggression is the most common diagnostic category seen by board-certified veterinary behaviorists in North America.
- According to the Centers for Disease Control and Prevention (2009), about 4.7 million people are bitten by dogs each year in the US, although this number is considered an underestimate as the majority of dog bites are not reported.
- In the US, it is estimated that one in five of those who are bitten require medical attention for dog bite–related injuries.
- Among children and adults, males are more likely than females to be bitten.
- Based on emergency room data in the US, the rate of dog bite–related injuries is highest for children aged 5–9 years.
AGGRESSION, OVERVIEW—DOGS

**Historical Findings**
- Variable.
- Basis for risk analysis and details of treatment program. Important questions: Who is the target? Who was present to manage the dog? How severe were the resulting injuries? What are the circumstances (including location, time) in which aggression occurred? Are there any reliable triggers for the aggressive behavior? Abnormalities in mentation or awareness might indicate a medical cause.

**Physical Examination Findings**
- Usually unremarkable.
- Use extreme care when handling aggressive dogs.
- A comfortable, well-fitting basket muzzle is recommended prior to examination of any dog with a history of human-directed aggression. Basket-style muzzles allow dogs to pant.
- Abnormalities on the neurologic examination may suggest an organic disease process (e.g., rabies, pain, blindness). Dogs can display aggressive prefrontal, postural or ictal period.

**CAUSES**
- Part of the normal range of behavior; strongly influenced by individual temperament, experience, early socialization (before 12 weeks), and other variables.
- Variable handling and confrontational responses can escalate aggression and should be avoided.
- May be a manifestation of an organic condition, such as hepatic encephalopathy or pain.
- In all cases, evaluate medical causes of aggression.

**RISK FACTORS**
- Inadequate socialization during the canine critical period (3–12 weeks).
- Traumatic/fearful/negative experience(s).
- Predisposing environmental conditions—lack of training, inadequate restraint, harsh handling.
- Inability of owner to safely confine or manage the dog in order to prevent future incidents. Helpful devices include a barrier fence, a muzzle, a collar or head halter, a leash.
- Previous aggression/bite history (number of incidents, number of bites per incident, target, severity of injury); legal situation for biting.
- Unpredictability of aggressive behaviors, lack of warning signals.
- Presence of children, elderly people, or other humans or animals at high risk living in or visiting household.

**Diagnosis**

**Differential Diagnosis**
- A thorough medical evaluation should be conducted on all cases of aggression.
- Identify pathologic conditions associated with aggression before making a purely behavioral diagnosis.
- Rule out developmental abnormalities (hydrocephalus; lissencephaly; hepatic shunts), metabolic disorders (hyperglycemia, hepatic encephalopathy, diabetes), neuroendocrinopathies (hypothyroidism, hyperadrenocorticism), dermatopathy, neurologic conditions (intracranial neoplasm, seizures), toxins, inflammatory diseases (encephalitis, rabies), cognitive dysfunction, acute or chronic pain, and iatrogenic causes, such as glucocorticoid administration.

**Diagnostic Procedures**
- Collection of thorough behavioral history and evaluation of medical concerns.
- Postmortem fluorescent antibody test is indicated for any aggressive dog for which rabies is a differential diagnosis, including any dog not quarantined for 10 days after a bite injury to a human or other animal.

**Treatment**

**Appropriate Health Care**
- Manage any underlying medical conditions.
- Manage success—combination of multiple modalities: safe environmental control, behavior modification to teach animals appropriate behavior, and pharmacotherapy.
- Consult a veterinarian with experience and training in aggression management.
- Euthanasia should be discussed or recommended when the risk of injury is high. Note recommendation in medical record.
- Rehoming aggressive dogs may put those involved at liability risk.

**Nursing Care**
A boarding facility able to safely manage the dog might be used until a safe management plan can be implemented, or until an outcome decision can be made.

**Activity**
Since frustration and arousal may increase the incidence of aggression, an appropriate and safe exercise regime should be incorporated into the treatment program.

**Diet**
There is modest evidence that a low-protein diet may reduce territorial aggression in dogs, an effect that might be enhanced with tryptophan supplementation.

**Client Education**
- Safe practices should dictate all decisions.
- These practices include safe confinement, physical barriers, head halters, leash control, muzzle use, and supervision by a competent adult.
- Situations that have led to aggression in the past should be listed and a specific plan developed to avoid these situations and associated locations in the future, and a long-term management plan developed.
- The dog should calmly be removed from aggression-provoking situations.
- Safe, non-confrontational techniques that manage resources and use positive reinforcement to teach the dog appropriate responses should be employed.
Aggression, Overview—Dogs

- Confrontational management techniques, such as roll-overs, increase the probability of a defensive aggressive response, may lead to human injury, and should be strictly avoided.
- Management (“dominance”) techniques including punishment are associated with defensive fear responses by the dog and an increased risk of human-directed aggression. These should be avoided and replaced with positive management techniques.
- The client should be advised to consider personal and legal liability risks of keeping the dog. Human injury, bite-related lawsuits, and homeowner’s insurance claims can result from canine aggression. Such risk assessment may help the client objectively evaluate the situation.
- Euthanasia should be considered if safe management cannot be employed, or when the risk of injury is high.

SURGICAL CONSIDERATIONS
Castration of males may reduce the incidence of inter-male aggression.

MEDICATIONS

**DRUG(S) OF CHOICE**
- None approved by the FDA for the treatment of aggression.
- No drug will eliminate the probability of aggression.
- Use drugs only when a safe management plan has been implemented.
- Inform the client of the extra-label nature of medication and risk involved; document in the medical record, obtain signed informed consent.
- Drugs that increase serotonin may be helpful to reduce anxiety, arousal, and impulsivity.
- Treatment duration: minimum 4 months, maximum: lifetime.
- See Table 1 for drugs used to facilitate management of aggression in combination with a safe management plan.

**CONTRAINDICATIONS**
- Fluoxetine is generally contraindicated in cases of seizures.
- Clomipramine is contraindicated in cases of cardiac conduction disturbances or seizures; in one open trial, clomipramine was no more effective than control in cases of human-directed aggression.

**PRECAUTIONS**
Avoid the use of benzodiazepines (e.g., diazepam) in aggressive dogs because of the risk of behavioral disinhibition. Aggression may increase when dogs lose their fear of the repercussions of biting.

**POSSIBLE INTERACTIONS**
Do not use SSRIs or TCAs with monoamine oxidase inhibitors, including amitraz and selegiline, or with each other because of the risk of serotonin syndrome.

**ALTERNATIVE DRUG(S)**
- L-Tryptophan (10 mg/kg PO q12h).
- Trazodone (4–8 mg/kg PO q12h or PRN) may be used with the agents listed in Table 1 to reduce anxiety and arousal.
- Clonidine (0.01–0.05 mg/kg PO q12h or PRN), may be used with the agents listed in Table 1 to reduce anxiety and arousal.

**FOLLOW-UP**

**PATIENT MONITORING**
Weekly to biweekly contact recommended in the initial phases to guide clients with behavior modification plans and medication management.

**PREVENTION/AVOIDANCE**
- To prevent aggressive incidents, avoid all situations that have led to aggression in the past, using safe confinement, gates, halters, collars, leashes, muzzles.
- Reduce the risk of aggression in young dogs (3–12 weeks) with a positive socialization program; avoid intimidation techniques and negative, fear-inducing situations.

**POSSIBLE COMPLICATIONS**
- Injury to humans or animals.
- Liability to client, veterinarian.
- In cases of dog-directed aggression, although not the intended target, humans who interfere are often seriously injured either by accident or by redirected aggression; owners should not reach for fighting dogs; pull apart with leashes.
- Aggressive dogs are at risk for relinquishment or euthanasia.

**EXPECTED COURSE AND PROGNOSIS**
- Aggressive dogs weighing over 18.5 kg are at increased risk for behavioral euthanasia.
- Aggressive dogs may be successfully managed, but should not be considered “cured.”
- Prognosis is case-dependent due to risk factors and management features of each situation.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
N/A

**AGE-RELATED FACTORS**
Onset of aggression in mature dogs suggests a medical cause; carefully evaluate sensory acuity, sources of pain, endocrinopathy, cognitive function.

### Table 1

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Class</th>
<th>Oral Dosage in Dogs</th>
<th>Frequency</th>
<th>Side Effects—usually transient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>SSRI</td>
<td>1.0–2.0 mg/kg</td>
<td>q24 h</td>
<td>Decreased appetite, sleepiness</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>SSRI</td>
<td>1.0–2.0 mg/kg</td>
<td>q48 h</td>
<td>Constipation</td>
</tr>
<tr>
<td>Sertraline</td>
<td>SSRI</td>
<td>2.0–4.0 mg/kg</td>
<td>q48 h</td>
<td>Sleepiness</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>TCA</td>
<td>1.0–3.0 mg/kg</td>
<td>q12 h</td>
<td>Sleepiness, vomiting</td>
</tr>
</tbody>
</table>
A

AGGRESSION, OVERVIEW—DOGS

ZOONOTIC POTENTIAL
• Dog bites are a significant public health risk.
• Rabies is a potential cause of aggression.

PREGNANCY/FERTILITY/BREEDING
Tricyclic antidepressants are contraindicated in breeding males and pregnant females.

SYNONYM
Biting

SEE ALSO
• Aggression—Between Dogs in the Household
• Aggression, Food and Resource Guarding—Dogs
• Aggression to Unfamiliar People and Unfamiliar Dogs
• Aggression Toward Children—Dogs
• Aggression Toward Familiar People—Dogs

ABBREVIATIONS
• CNS = central nervous system
• CT = computed tomography
• FDA = US Food and Drug Administration
• MRI = magnetic resonance imaging
• SSRI = selective serotonin reuptake inhibitor
• TCA = tricyclic antidepressant

INTERNET RESOURCES
• American Veterinary Medical Association Dog Bite Prevention: https://www.avma.org/public/Pages/Dog-Bite-Prevention.aspx
• Centers for Disease Control and Prevention Dog Bites: http://www.cdc.gov/HomeandRecreationalSafety/Dog-Bites/
• ASPCA Aggression in Dogs http://www.aspca.org/pet-care/virtual-pet-behaviorist/dog-behavior/aggression-dogs

Suggested Reading


Authors
Barbara L. Sherman and Margaret E. Gruen

Consulting Editor
Gary M. Landsberg

Client Education Handout available online
with other dogs, inappropriate punishment). Breed predispositions due to selective breeding for interdog aggression. *Aggression is likely to be more severe toward dogs of the same sex, especially two females. *Instigators are usually newer to the household and younger than recipients. *In cases of aggression within a household, there may be history of owners interfering in normal canine communication, especially when one dog appears to be denying another dog access to something that the owners think they should “share.” This shift may actually support one dog in what would be considered inappropriate “canine” behavior and results in escalation of the interdog aggression. For example, an owner calling dog “A” into a room when the other dog “B” has blocked its access even though “A” was willing to remain outside of the room or the owner punishing dog “B” for blocking dog “A”’s access. Both of these situations undermine dog “B” in its hierarchical position while it was safely asserting control to which dog “A” was willing to defer. *Underlying medical conditions, especially pain, may increase the level of aggression. *If the aggressor initiates or continues its attack despite deference from the other dogs, or if the deferent dog is overly fearful or defensive, then these may indicate abnormal responses that might have a poor prognosis (unable to socially communicate) or require drug therapy to manage the abnormal behavior.

### DIFFERENTIAL DIAGNOSIS

- **Play behavior/existed non-aggressive arousal**
- **Possessive aggression**
- **Fear aggression**
- **Others depending on circumstances**

### CBC/BIOCHEMISTRY/URINALYSIS

Usually unremarkable. Rule out underlying medical conditions with blood, urine and thyroid screening.

### OTHER LABORATORY TESTS

As needed to rule out underlying medical conditions.

### IMAGING

MRI if CNS disease suspected; as needed to rule out underlying medical conditions.

### DIAGNOSTIC PROCEDURES

N/A

### TREATMENT

#### CLIENT EDUCATION

**General Comments**

- Treatment is aimed at controlling the problem, not achieving a “cure.” Successful treatment, as measured by a decrease in aggressive incidents, depends upon owner understanding of basic canine social behavior and communication; risks involved in living with an aggressive dog(s), and willingness and ability to follow safety and management recommendations. * Owners must be aware that the only way to absolutely prevent future injuries is to continually separate the dogs or remove one from the home.

**Safety Recommendations**

- The owner’s primary responsibility is to ensure safety by identifying and avoiding all situations that may evoke an aggressive reaction. Dogs within a household may initially need to be kept in separate housing areas to prevent fighting. * Owners should be advised that they may be liable if their dog bites and could face civil/criminal prosecutions should a person be injured. * If needed, owners must be instructed in methods of safely breaking up dog fights.

- Treatment is most likely to be successful if aggression-provoking stimuli can be effectively prevented prior to behavior modification. * The dogs must be confined away from each other or under the direct physical control of a responsible adult whenever an aggression-evoking situation could arise (e.g., around food/valued resources). * Teaching the dogs to be comfortable wearing a head halter (e.g., Gentle Leader) with a lightweight 8- to 10-foot leash attached or a basket muzzle makes controlling potentially dangerous situations easier and safer. * If needed, use the long leash both for prevention and to safely remove the dog from situations that may elicit aggression; do not reach for the dog directly.

- The more dominant dog typically asserts control of resources (e.g., staring, growling) with confident body postures directed toward the more subordinate dog who relinquishes the resource by moving or looking away.

- When there is competition over resources, allow priority access to the more controlling/dominant individual and encourage and reinforce deference in the other dog(s).

- Priority access may vary between resources (individual motivation), and contexts (location, who accesses first)—separate (time out) any dog displaying an inappropriate response. * For some dogs problems may be resolved if additional resources and sufficient distribution are provided to reduce competition. * Alternately, dogs may need to be separated when given resources that are a source of repeated conflict.

**Behavior Therapy**

- Depending on the situation, supporting and reinforcing the hierarchical positions of the dogs will result in rapid (e.g., 1–2 weeks) resolution of the problem and a dramatic decrease in aggressive incidents between dogs. Fighting is likely to recur if support of the hierarchy by humans is not continued. * Separately, teach each dog those behaviors that will serve as a foundation for
management and control when together including sit and relax, down-sit-crawl and teaching to go to mat, bed or crate to settle. • NEVER allow dogs to “fight it out” as serious injuries may occur. • During times together, use verbal cues or leave leads attached to train desirable and prevent or interrupt undesirable behavior. • Structured interactions (also known as learn to earn or say please by sitting) where each dog is consistently taught to sit for anything it values (before feeding, petting, play, going for a walk) provides structure and predictability in all interactions, teaches impulse control and gives the dog control of its resources by sitting calmly. • Systematic desensitization and counter-conditioning to fear-provoking stimuli.

### MEDICATIONS

**DRUG(S)**
- There are no medications licensed for the treatment of canine aggression. Owners must be aware that the use of medication is off-label. • A signed informed consent form is advisable listing potential risks and side effects. • NEVER use medications without concurrent behavior modification. • Before prescribing medication, be sure that owners understand the risks in owning an aggressive dog, will follow safety procedures, and that they understand that medication will not eliminate aggression. • Medications may not be appropriate in all situations (e.g., households with small children, individuals that are immunocompromised or have disabilities). • Studies have not shown a robust effect of drug treatment on aggression. Placebo effect may be strong. • Medications are most likely to be helpful in situations where there is a strong fear/anxiety component, or where one or both dogs are behaviorally abnormal (e.g., reactivity, impulsivity, intensity) as opposed to situations where closely ranked dogs use aggression to establish resource control.

**Selective Serotonin Reuptake Inhibitors**
- Fluoxetine 0.5–2 mg/kg PO q24h.
- Paroxetine 0.5–1 mg/kg PO q24h.
- Sertraline 1–3 mg/kg PO q24h. • Side effects: sedation, irritability, GIT effects, increased aggression; anorexia is common and usually transient.

**Tricyclic Antidepressants**
- Clomipramine 1–3 mg/kg PO q12h (caution: label restriction for aggression).
- Side effects: sedation, GIT effects, anticholinergic effects, cardiac conduction disturbances if predisposed, and increased aggression.
- **Alpha-2 agonists**
  - Clonidine 0.01–0.05 mg/kg PO PRN 1.5–2 hours before eliciting trigger, up to q12h. • Side effects: transient hypotension, anticholinergic, hypertension, collapse, and bradycardia (responsive to atropine), and increased aggression.
  - Serotonin 2a antagonist/reuptake inhibitors
  - Tramadol 2–5 mg/kg PO PRN prior to eliciting trigger, up to q48—may titrate up to 8–10 mg/kg if no adverse effects. • Side effects: sedation, anorexia, ataxia, GIT effects, cardiac conduction disturbances, increased aggression.

**CONTRAINDICATIONS**
- Use caution as any psychotropic medication may reduce fear-based inhibition resulting in an increase rather than decrease in aggression.

**PRECAUTIONS**
- Any psychotropic medication may increase irritability and aggression. Corticosteroids are contraindicated in food-aggressive dogs; polyphagia can lead to increased frequency/intensity of aggression.

**POSSIBLE INTERACTIONS**
- Do not combine SSRIs, TCAs, MAO inhibitors (e.g., amitraz, selegiline), opioids (e.g., tramadol), and other medications that increase serotonin—can result in potentially fatal serotonin syndrome.

**FOLLOW-UP**

**PATIENT MONITORING**
- Clients usually need ongoing assistance and should receive at least one follow-up call within the first 1–3 weeks after the consultation. Provisions for further follow-up should be made at that time.

**PREVENTION/AVOIDANCE**
- Treatment recommendations are life-long.

**POSSIBLE COMPLICATIONS**
- Injuries to dogs and humans; euthanasia or relinquishment of patient.

**EXPECTED COURSE AND PROGNOSIS**
- There is no cure. Prognosis for improvement is more favorable if aggression is at a fairly low intensity and occurs in only a few predictable situations. Prognosis is highly dependent on owner compliance. Relationship issues may recur with changes in housing, health or age.

### MISCELLANEOUS

**ASSOCIATED CONDITIONS**
- Other fear- or anxiety-based conditions; territorial aggression

**ABBREVIATIONS**
- CNS = central nervous system • GIT = gastrointestinal tract • MAO = monoamine oxidase • MRI = magnetic resonance imaging • SSR1 = selective serotonin reuptake inhibitor • SARI = Serotonin 2a antagonist/reuptake inhibitor • TCA = tricyclic antidepressant

Suggested Reading


Author Meredith E. Serpita

Consulting Editor Gary M. Landsberg

Acknowledgment The author and editors acknowledge the prior contribution of Laurie Bergman.
BASICS
DEFINITION
A process in the body that leads to an elevation in pH above the reference interval for that species. An elevation in blood pH is specifically termed Alkalosis. Associated with an increase in plasma bicarbonate concentration ([HCO₃⁻]) in dogs, > 24 mEq/L; cats, > 22 mEq/L) and base excess (BE) (> +4 mmol/L) due to an obligatory increase in carbon dioxide tension (PCO₂).

PATHOPHYSIOLOGY
- Metabolic alkalosis may develop from either a gain in bicarbonate or a loss in acid.
- Bicarbonate gain subsequent to:
  - Contraction alkalosis due to free water deficit; iatrogenic administration of alkalinizing therapy (e.g., NaHCO₃); metabolism of organic ions (lactate, citrate, acetate, and ketones); hypokalemia; and renal ammoniagenesis.
- Acid loss subsequent to:
  - Gastric or renal acid loss (loop or thiazide diuretics); mineralocorticoid excess; presence of non-natratable anions; decreased weak acids (hyperchloremic metabolic alkalosis).
- Renal HCO₃⁻ excretion is often very efficient in eliminating an excess HCO₃⁻ load, but is hindered by decreased effective circulating volume; hypokalemia, hypophosphatemia, and hypokalemia; and renal ammoniagenesis.
- Metabolic alkalosis persists only if renal excretion of HCO₃⁻ is impaired. This primarily occurs from continued high rate of alkali administration, or some stimulus for the kidneys to retain sodium in the presence of a relative chloride deficit.
- Hypokalemic (corrected) metabolic alkalosis results from loss of fluid rich in chloride and H⁺ primarily from the alimentary tract or kidneys. Loss of chloride and H⁺ is associated with an increase in plasma HCO₃⁻ concentration. With chloride loss and volume depletion, the kidneys reabsorb sodium with HCO₃⁻ instead of chloride, perpetuating the metabolic alkalosis.
- Hypochloremic metabolic alkalosis is divided into chloride-responsive and chloride-resistant.
- Chloride-responsive results primarily from the loss of chloride rich fluid and is characterized by decreased extracellular fluid volume, hypokalemia, and low urinary chloride levels. This type of alkalosis responds to administration of chloride salts.
- Chloride-resistant is characterized by excessive mineralocorticoid leading to increased effective circulating volume and is not responsive to chloride salt.
- Hypokalemia may contribute to metabolic alkalosis by shifting H⁺ intracellularly; stimulating apical H⁺/K⁺ ATPase in the collecting duct; stimulating renal ammoniagenesis; impairing chloride ion reabsorption in the distal nephron; and reducing glomerular filtration rate (GFR) which decreases the filtered load of HCO₃⁻ and in the presence of volume depletion, impairs renal excretion of the excess HCO₃⁻. Hypochloremic alkalosis is due to a decrease in the level of plasma albumin. Plasma albumin is a weak acid.
- Compensatory metabolic alkalosis occurs in response to respiratory acidosis. This is associated with a low pH and elevated PCO₂.

SYSTEMS AFFECTED
- Nervous—muscle twitching and seizures occur rarely in dogs. Metabolic alkalosis and associated hypokalemia may precipitate hepatic encephalopathy in patients with liver failure.
- Urinary—the kidneys rapidly and effectively excrete excessive alkali. In patients with chloride deficiency (and less importantly, volume depletion), the kidneys cannot excrete the excess alkali. Therefore, metabolic alkalosis is maintained. In these patients, chloride administration is required for renal compensation to occur. Volume expansion will hasten compensation. Patients with mineralocorticoid excess have excessive chloride loss. Therefore, chloride administration does not lead to hyperchloremia and correction of metabolic alkalosis (so-called chloride-resistant metabolic alkalosis).
- Respiratory—low [H⁺] (elevated pH) reduces alveolar ventilation. Hypoventilation increases PCO₂ and helps offset the effects of high plasma HCO₃⁻ on pH. In dogs, for each 1 mEq/L increase in plasma HCO₃⁻, there is an expected increase of approximately 0.7 mmHg in PCO₂. Limited data is available for cats, but the degree of respiratory compensation appears to be similar.

SIGNALMENT
Any breed, age, or sex of dog and cats

SIGNS
Historical Findings
- Administration of loop diuretics (e.g., furosemide) or thiazide. Vomiting

Physical Examination Findings
- Signs related to the underlying disease or accompanying potassium depletion (e.g., weakness, cardiac arrhythmias, ileus, etc.).

CAUSES
- Chloride-responsive—pulmonary interstitial losses (e.g., gastric vomiting, nasogastric tube suctioning); renal losses (diuretic therapy); and rapid correction of chronic hypercapnia (respiratory alkalosis).
- Chloride-resistant—hyperaldosteronism and primary hyperaldosteronism.
- Oral administration of alkalinizing agents—sodium bicarbonate or other organic anions with sodium (e.g., lactate, acerate, glucuronate); administration of cation-exchange resin with non-absorbable alkali (e.g., phosphorus binders).
- Hypocalcemia—liver disease; protein losing nephropathy or enteropathy, nephrotic syndrome. For severe alkalosis, consider giving oral or intravenous insulin; water deprivation; post-obstructive diuresis; polyuric renal failure.
- Hypokalemia—see Hypokalemia.

RISK FACTORS
- Administration of loop or thiazide diuretics.
- Vomiting. Stomach drainage. Disease associated with hypocalcemia (e.g., nephrotic syndrome, liver failure).
- Diuretics.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
High plasma HCO₃⁻ and hypochloremia may also occur in animals compensating for chronic respiratory acidosis, in which PCO₂ is high and pH is low despite high HCO₃⁻ and low chloride concentration; blood gas determination required to differentiate.

LABORATORY FINDINGS
Drugs That May Alter Laboratory Results

None

Disorders That May Alter Laboratory Results

- Two or more hours (> 10% of the sample) decreases Pco₂, Pco₂, and HCO₃⁻. Blood samples stored at room temperature for more than 15 minutes lose pH because of increased PCO₂. Exposure to room air decreases Pco₂. Venous samples may have pH 0.0–1 unit lower and Pco₂ 0.4–10 mmHg higher than an arterial sample.

Valid If Run in Human Laboratory? Yes

CBC/BIOCHEMISTRY/URINALYSIS
- High total CO₂, total CO₂ in samples handled aerobically closely approximates HCO₃⁻. Low blood ionized calcium concentration. Serum electrolyte abnormalities vary with underlying cause.
- Hypochloremia—consider hypochloremic metabolic alkalosis, the most common reason for metabolic alkalosis in dogs and cats, which usually results from diuretic administration or vomiting of stomach contents. High sodium but normal chloride concentration—consider chloride-resistant metabolic alkalosis (e.g., hyperaldosteronism or primary hyperaldosteronism) or administration of alkali. Hypophosphatemia—consider hyperphosphatemic metabolic alkalosis (e.g., liver failure, protein-losing enteropathy, and protein-losing nephropathy). In vitro, a 1 g/dL decrease in albumin concentration is associated with an increase in pH of 0.093 in cats and 0.047 in dogs. Hypokalemia—
hypokalemia likely results from intracellular potassium shifting due to metabolic alkalosis or the underlying problem (e.g., vomiting of stomach contents or loop diuretic administration). Urine chloride levels—chloride-responsive metabolic alkalosis has urine chloride levels < 10 mEq/L, while chloride-resistant metabolic alkalosis involves urine chloride levels of > 20 mEq/L.

OTHER LABORATORY TESTS
Blood gas analysis reveals high HCO$_3^-$, PCO$_2$, pH and base excess (BE). Unlike HCO$_3^-$, BE is independent of changes in and is considered a more reliable measure of metabolic acid-base changes.

IMAGING
None

DIAGNOSTIC PROCEDURES
Blood pressure—the combination of hypertension, hypotension, and hypokalemia with metabolic alkalosis may indicate the presence of hyperaldosteronism.

• Diagnostic testing for hyperaldosteronism or primary hyperaldosteronism (e.g., plasma renin and aldosterone levels).

TREATMENT
• Acid-base disturbances are secondary phenomena. Diagnosis and treatment of the underlying disease process is integral to the successful resolution of acid-base disorders.
• Severe alkalosis is uncommon, but may be life-threatening. Patients with chronic respiratory disease and respiratory alkalosis are at risk of developing severe alkalosis if they start vomiting or receive diuretics.
• Discontinue drugs that may cause metabolic alkalosis. A chloride-responsive alkalosis should be directed at the underlying cause and the decreased colloid osmotic pressure.
• Foster enteral nutrition to increase endogenous albumin production.
• Consider species-specific plasma or albumin (canine albumin) therapy.

CONTRAINDICATIONS
• Avoid chloride-free fluids—they may correct volume depletion but will not correct alkalosis that results from volume contraction, but now known to be caused by chloride depletion. Volume depletion is a common but not essential feature.

Possible INTERACTIONS
None

ALTERNATIVE DRUG(S)
None

FOLLOW-UP

PATIENT MONITORING
Acid-base status—frequency dictated by the underlying disease and patient response to treatment.

POSSIBLE COMPLICATIONS
• Hypokalemia • Neurologic signs

MISCELLANEOUS

ASSOCIATED CONDITIONS
• Hypokalemia • Hypochloremia

AGE-RELATED FACTORS
None

PREGNANCY/FERTILITY/BREEDING
N/A

SYNONYMS
• Non-respiratory alkalosis
• Chloride-responsive metabolic alkalosis—metabolic alkalosis that responds to chloride administration
• Chloride-resistant alkalosis—metabolic alkalosis secondary to increased mineralocorticoid activity that does not respond to chloride administration.

• Hypochloremic alkalosis caused by low chloride concentration.
• Hypochloremic alkalosis—metabolic alkalosis caused by low chloride concentration.
• Hypochloremic alkalosis—metabolic alkalosis formerly attributed to volume contraction, but now known to be caused by chloride depletion. Volume depletion is a common but not essential feature.

SEE ALSO
• Hypokalemia • Hypochloremia

ABBREVIATIONS
• BE = base excess • H$^+$ = hydrogen ion • HCO$_3^-$ = bicarbonate • PCO$_2$ = carbon dioxide tension

Suggested Reading

Suggested Reading

Suggested Reading

Suggested Reading

Suggested Reading

Authors: Heloí S, Aurau de Morais, Stephen P DiBartola, and Lee E. Palmer
Consulting Editor: Carl A. Osborne
**BASICS**

**DEFINITION**
- Common problem • Pattern of hair loss—varied or symmetrical • Causes—multifactorial

**PATHOPHYSIOLOGY**
- Specific and unique for each cause
- Endocrine/Genetic • Inherited—alopecia universalis, hypotrichosis, lymphocytic mural folliculitis, pseudopelade.
- Peripheral—alopecia areata, alopecia areata-like, lymphocytic mural folliculitis, pseudopelade.

**SIGNALMENT**
- No specific age, breed, or sex predilection.
- Neoplastic and paraneoplastic associated alopecia—generally recognized in older cats.

**SIGNS**
- Depends on specific diagnosis

**CAUSES**
- Neoplastic/Behavioral—compulsive disorder • Endocrine—sex hormone alopecia, hyperthyroidism, hyperadrenocorticism, diabetes mellitus • Immunologic—allergic dermatis, alopecia areata, alopecia universalis, lymphocytic mural folliculitis, pseudopelade.
- Parasitic—demodicism, cheyletiellosis.
- Infections—dermatophytosis.
- Physiologic/metabolic—sebaceous adenitis.
- Neoplastic—paraneoplastic dermatitis, squamous cell carcinoma in situ, epitheliotropic lymphoma, thymoma with exfoliative dermatis. • Idiopathic/inherited—alopecia universalis, hypotrichosis, spontaneous pinnal alopecia, anagen and telogen deflation. • Injection site reaction.
- Medication effect—corticosteroids.
- Viral—FeLV and FIV—associated disease (giant cell dermatitis).

**RISK FACTORS**
- FeLV/FIV—reported risk for demodicosis (not all cases associated with viral infection).

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

**Endocrine Alopecia/Sex Hormone**
- Non-inflammatory alopecias are rarely hormonal in etiology; search for other causes before exploring endocrine etiology.
- Hormonal causes—primarily castrated males; alopecia along the caudal aspect of the hind limbs, which may extend along the perineum. • Excessive corticosteroid administration; may also cause curling of pinnal tips. • Megestrol acetate—may produce lesions similar to/associated with diabetes mellitus or hyperadrenocorticism.

**Compulsive Disorder**
- Uncommon as sole source of symptoms.
- Often misdiagnosed in cases of allergic alopecia—cats.

**Immunologic mechanisms**
- Possible dermatis in species. • Accumulation of lymphocytes in the eyelid margins. • Questionable association with systemic disease or stressful event (e.g., inflammatory syndrome, lupus erythematosus).

**Allergic Dermatitis**
- Often associated with papilloma virus; Bovine in site carcinoma. • Slightly elevated, often pigmented, plaque-like or papillary lesions with scaling and partially alopecic surfaces. • Often misdiagnosed as sebodermas before distinct lesions develop.
- About 25% may convert to squamous cell carcinoma or dp lesions along the borders (biologically).

**Epitheliodic Lymphoma**
- Early stages—varying degrees of alopecia associated with swelling and erythema. • Later stages—plaques and nodules. • Old cat.

**Alopecia Areata/Pseudopelade/ Lymphocytic Mural Folliculitis (Lymphocytic Invasion of the Hair Follicle)**
- Often associated with an immunologic inciting cause; may occasionally be pre-neoplastic. • Alopecia areata—rare; complete alopecia in a patchy distribution with no inflammation; head, neck, ears; histologic lymphocytic accumulation around the hair bulb. • Lymphocytic mucinous folliculitis—diffuse alopecia of the face, eyelids, muzzle; skin has a thick wax feel; histologic lymphocytic invasion of the follicular outer root sheath and epidermis. • Pseudopelade—well-circumscribed non-inflammatory patch/lesion on the face, nails may slough, lymphocytic invasion of the antral region of the hair follicle. • Feline Cutaneous Lymphocytosis (Pseudolymphoma)
- Characterized by dermal lymphocytic infiltration rather than follicular or epidermal.
- Older cat; often solitary lesions of partial alopecia with scaling g erythema and pruritus.

**Alopecia Universalis (Sphynx Cat)**
- Hereditary • Complete absence of primary hairs; decreased secondary hairs. • Thickened epidermis; normal dermis. • Sebaceous and apocrine ducts open directly onto the skin surface; oily feel to skin. • Wrinkled forehead; gold eyes; no whiskers; downy fur on paws, tip of tail, and scrotum.
- Comedones with or without secondary folliculitis.

**Feline Hypotrichosis**
- Siamese and Devon Rex cats (autosomal recessive alopecia). • Poorly developed primary telogen hair follicles. • Born with a normal coat; becomes thin and sparse as young adult.
ALOPECIA—CATS (CONTINUED)

Spontaneous Pinnal Alopecia
• Same as cats predisposed. • May represent a form of alopecia areata or pattern baldness.

Anagen and Telogen Defluxion
• Acute loss of hair due to interference with the growth cycle. • Causes—stress, infection, endocrine disorder, metabolic disorder, fever, surgery, anesthetics, pregnancy, drug therapy.

Demodicosis
• Rare. • Partial to complete multifocal alopecia of the eyelid, periorbital region, head, and neck; can generalize. • Variable pruritus with erythema, scale, and crust, and ceruminous otitis externa. • Demodex cati (elongated shape) often associated with metabolic disorder (e.g., FIV, systemic lupus erythematosus, diabetes mellitus). • Short/blunted Stage 3 stage mite is rarely a marker for metabolic disease; this form may be transferable from cat to cat and has been associated with pruritus most often affecting the lateral thorax and abdomen.

Cheyletiellosis
• Variable pruritus with scaling. • Not all animals in the household may be affected.

Dermatophytosis
Numerous clinical manifestations; always associated with alopecia.

CBC/BIOCHEMISTRY/URINALYSIS
Abnormalities may be noted with diabetes mellitus, hyperadrenocorticism, and hyperthyroidism.

OTHER LABORATORY TESTS
• FIV and FeLV titers for demodicosis. • Thyroid hormones—document hyperthyroidism. • ANA titer—look for systemic lupus erythematosus. • ACTH-response test, LDDST, and HDDST—diagnose hyperadrenocorticism.

IMAGING
• Abdominal ultrasound—assess adrenals in hyperadrenocorticism and look for neoplasia tumors in animals with hyperadrenocorticism.

DIAGNOSTIC PROCEDURES
• Skin biopsy. • Skin scrapes. • Dermatophyte culture. • Shirts/collar to prove self-trauma. • Food elimination trials. • Intradermal allergy test.

TREATMENT
• Therapy is specific for many of these disorders. • Behavioral modification or protecting hair coat with a shirt may prevent self-barbering. • Removal of an offending dietary item may alleviate the symptoms of food allergy. • If the pet is compliant, shampoo and topical therapy may relieve secondary problems, such as hyperkeratosis in sebaceous adenitis, crusting in demodicosis, secondary bacterial infection, and malodor for greasy dermatoses.

MEDICATIONS

DRUG(S)
• Compulsive disorders—antipruritic (10 mg/cat/day) as well as other behavior-modifying medications, such as gabapentin (5–10 mg/kg PO q12h).
• Endocrine alopecia (males)—testosterone supplementation.
• Allergic dermatitis—antihistamines, restricted-ingredient diet, corticosteroids, cyclosporine (7.3 mg/kg/day initially), allergen-specific immunotherapy, ectopicaine control.
• Hyperthyroidism—methimazole (iopanoic acid) or radioactive iodine therapy.
• Diabetes mellitus—regulation of glucose levels (insulin).
• Hyperadrenocorticism—surgery; no known effective medical therapy.
• Paraneoplastic alopecia—no therapy or surgical excision of neoplasia; often fatal.
• Epitheliotropic lymphoma—retinoids (isotreinoin), corticosteroids, interferon, cyclosporine, lomustine.
• Sebaceous adenitis—retinoids, corticosteroids, cyclosporine.
• Squamous cell carcinoma in situ—surgical excision, retinoids (topical and oral), topical imiquimod cream.
• Alopecia areata—no therapy; possibly counterirritants.
• Demodicosis—lime sulfur dips at weekly intervals for four to six dips.
• Cheyletiellosis—topical parasiticides and environmental control.
• Dermatophytosis—griseofulvin (see Dermatophytosis). • Toxicity with griseofulvin and itraconazole (idiosyncratic toxicity), terbinafine.

POSSIBLE INTERACTIONS
N/A

ALTERNATIVE DRUG(S)
N/A

FOLLOW-UP

PATIENT MONITORING
Determined by specific diagnosis

PREVENTION/AVOIDANCE
Determined by specific diagnosis

POSSIBLE COMPLICATIONS
Determined by specific diagnosis

EXPECTED COURSE AND PROGNOSIS
Determined by specific diagnosis

MISCELLANEOUS

ZOONOTIC POTENTIAL
• Dermatophytes—can cause skin lesions in humans. • Cheyletiellosis—can cause irritation in humans.

PREGNANCY/FERTILITY/BREEDING
Retinoids and griseofulvin should not be administered to pregnant animals.

SEE ALSO
• Cheyletiellosis • Demodicosis • Dermatophytosis • Diabetes Mellitus

ABBREVIATIONS
• ACTH = adrenocorticotropic hormone
• ANA = antinuclear antibody
• CT = computed tomography
• FIV = feline immunodeficiency virus
• FIV = feline immunodeficiency virus
• HDDST = high-dose dexamethasone-suppression test
• LDDST = low-dose dexamethasone-suppression test

Suggested Reading


### Alopecia—Dogs

#### BASICS

**DEFINITION**
- Common disorder.
- Characterized by a complete or partial loss of hair in areas where it is normally present.
- May be associated with multiple causes, be the primary problem, or be secondary to an underlying cause.

#### PATHOPHYSIOLOGY
- Multiple causes.
- Represents removal of hair or disruption in the growth of the hair from hypervirulence, infection, trauma, immunologic attack, mechanical ‘plugging,’ endocrine abnormalities, neoplasia, drug reaction, and/or blockage of the receptor sites for stimulation of the hair growth cycle.

#### SYSTEMS AFFECTED
- Endocrine/Metabolic
  - Hemat/Lymphatic/Immune
  - Skin/Exocrine

#### SIGNALMENT
- Breed predisposition listed below

#### SIGNS
- May be acute in onset or slowly progressive.
- Folliculitis of the body, including the head and extremities.
- Hyperpigmentation; alopecia often starts along the collar area of the neck; Pomeranian, chow chow, Akita, Samoyed, Keeshonden, Alaskan malamute, and Siberian husky.

#### CAUSES

<table>
<thead>
<tr>
<th>Multifocal</th>
<th>Localized demodicosis—partial to complete alopecia with erythema comedones, and mild scaling; lesions may become inflamed and crusted.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dermatophytosis—partial to complete alopecia with scaling; with or without erythema; not always ring-like.</td>
</tr>
<tr>
<td></td>
<td>Sphymocytic folliculitis—circular patterns of alopecia with epidermal collarettes, erythema, crusting, and hyperpigmented macules.</td>
</tr>
<tr>
<td></td>
<td>Injection reactions—inflammation with alopecia and/or cutaneous atrophy from scarring.</td>
</tr>
<tr>
<td></td>
<td>Rabies vaccine vasculitis—well-demarcated patch of alopecia observed 2–3 months post-vaccination.</td>
</tr>
<tr>
<td></td>
<td>Localized telodermatitis—well-demarcated, shiny, smooth, alopecic, thickened plaque; extremely rare; still considered a controversial disorder.</td>
</tr>
<tr>
<td></td>
<td>Alopecia areas—non-inflammatory areas of complete alopecia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symmetrical</th>
<th>Sebaceous adenitis of short-coated breeds (now termed “dysplastic perianal glandular dermatitis”)—annular to polycyclic areas of alopecia and scaling.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hyperadrenocorticism—truncal alopecia associated with atrophied skin, comedones, and telogen effluvium.</td>
</tr>
<tr>
<td></td>
<td>Hypothyroidism—thinning of truncal haircoat; generalized alopecia is an uncommon presentation; alopecia “rat” tail.</td>
</tr>
<tr>
<td></td>
<td>Non-inflammatory alopecia (alopecia X)—symmetrical truncal alopecia associated with hyperpigmentation; alopecia often starts along the collar area of the neck.</td>
</tr>
<tr>
<td></td>
<td>Hyperadrenocorticism—truncal alopecia.</td>
</tr>
<tr>
<td></td>
<td>Hyperthyroidism—thinning of truncal haircoat; generalized alopecia is an uncommon presentation; alopecia “rat” tail.</td>
</tr>
<tr>
<td></td>
<td>Hair folliculitis—black hair follicular dysplasia of the haircoat; generalized truncal alopecia with scaling and intense erythema, later nodules and plaque formation.</td>
</tr>
</tbody>
</table>

#### Specific Locations
- Pinnal alopecia/pattern baldness—miniarization of hairs and progressive alopecia; dachshund, greyhound, American water spaniel, Portuguese water spaniel, Boston terrier, Manchester terrier, whippet, Italian greyhound, Chihuahua.
- Symmetrical truncal alopecia—hair loss on the top and lateral aspect of the cranium secondary to having barrettes or rubber bands applied to the hair.
- Post-clipping alopecia—failure to regrow after clipping, may be associated with hair growth cycle disruption.
- Melanodermatosis (alopecia of Yorkshire terriers)—symmetrical alopecia of the pinnas, bridge of the nose, tail, and feet.
- Seborrheic alopecia—alopecia of the black-haired areas only.
- Dermatolymphositis—alopecia of the face, tip of ears, tail, and digits; associated with scale crusting and scaling.

#### Breed-Related Alopecia
- **Symmetrical**: Airedale terrier.
- **Patchy to Diffuse**
  - Demodicosis—often associated with erythema, folliculitis, and hyperpigmentation.
  - Bacterial folliculitis—polycyclic areas of circular alopecia to coalescing large patches of hair loss; epidemic comedones.
  - Dermatophytosis—often accompanied by scale, erythema, and hyperpigmentation.
  - Sebaceous adenitis—alopecia with a thick adherent scale, predominantly on the dorsum of the body, including the head and extremities.
  - Color mutation/dilution alopecia—sullen or coarse hair, thinning of the blue or fawn colored hair coat, and secondary folliculitis.
  - Follicular dysplasia—progressive alopecia.
  - Anagen defluxion and telogen defluxion—acute onset of alopecia.
  - Hypothyroidism—dilute thinning of the hair coat.
  - Hyperadrenocorticism—truncal alopecia with thin skin and formation of comedones.
  - Epidermotropic lymphoma—diffuse, generalized truncal alopecia with scaling and intense erythema, later nodules and plaque formation.
  - Pemphigus foliaceus—hair loss associated with scale and crust formation.
  - Keratinization disorders—alopecia associated with excessive scale and greasy surface texture.

#### Congenital Hypotrichosis
- Cocker spaniel, Inca hairless, Peruvian Inca Orchid, American hairless terrier (often associated with comedones, folliculitis, and furunculosis).
- Congenital hypotrichosis: cocker spaniel, Belgian shepherd, poodle, whippet, beagle, French bulldog, Yorkshire terrier, Labrador retriever, bichon frise, Ixua apu, basenji.
- Color dilution alopecia: blue or fawn Dohnerman pincher, silver Labrador, cream show Chow, blond Irish setter, blue pit bull terrier, other breeds with dilute coat colors.
- Melanodermatosis with alopecia in Yorkshire terrier.
- Seborrheic alopecia—alopecia of the scalp.
- Pinnal alopecia/pattern baldness—miniarization of hairs and progressive alopecia; dachshund, greyhound, American water spaniel, Portuguese water spaniel, Boston terrier, Manchester terrier, whippet, Italian greyhound, Chihuahua.
- Non-inflammatory alopecia (alopecia X)—symmetrical truncal alopecia associated with hyperpigmentation; alopecia often starts along the collar area of the neck. Pomeranian, chow chow, Akita, Samoyed, Keeshonden, Alaskan malamute, and Siberian husky.
### Alopecia—Dogs (Continued)

#### Risk Factors

N/A

#### Diagnosis

**Differential Diagnosis**
- Pattern and degree—important features for formulating a differential diagnosis.
- Inflammation, scale, crust, and epidermal collarettes—important for determining diagnosis.

**CBC/Biochemistry/Urine Analysis**
- Rule out metabolic causes such as hyperadrenocorticism.

**Other Laboratory Tests**
- Thyroid testing—diagnose hypothyroidism.
- ACTH-response test, HDDST, and LDDST—evaluate for hyperadrenocorticism.
- Sex hormone profiles (questionable validity).

**Imaging**
- Ultrasonography—evaluate adrenal glands for evidence of hyperadrenocorticism.

**Diagnostic Procedures**
- Response to therapy as a trial
- Fungal culture
- Cytology
- Skin biopsy—very useful to evaluate status of follicle/hair growth as well as epidermal changes associated with specific conditions.

#### Treatment

- **Demodicosis**—amitraz, ivermectin, milbemycin.
- **Dermatophytosis**—griseofulvin, ketoconazole, itraconazole, lime sulfur dips, terbinafine.
- **Seborrhea**—salicylic acid, salicylic acid shampoos, sulfur shampoos, ketoconazole, tricosanate, lime sulfur dips.
- **Sebaceous Adenitis**—keratolytic shampoos, avulsions, corticosteroids, cyclosporine.

#### Medications

**Drug(s) of Choice**
- Varies with specific cause; see "Treatment."

**Contraindications**
- N/A

**Precautions**
- Toxicity with griseofulvin, retinoids, ivermectin, milbemycin.

**Possible Interactions**
- N/A

**Alternative Drug(s)**
- N/A

#### Follow-Up

**Patient Monitoring**
- Determined by cause

**Possible Complications**
- N/A

#### Miscellaneous

**Associated Conditions**
- N/A

**Age-Related Factors**
- N/A

**Zoonotic Potential**
- N/A

**Pregnancy/Fertility/Breeding**
- Avoid retinoids and griseofulvin in pregnant animals.

**Suggested Reading**

**Abbreviations**
- **ACTH** = adrenocorticotropic hormone
- **HDDST** = high-dose dexamethasone-suppression test
- **LDDST** = low-dose dexamethasone-suppression test

**Client Education Handout**
- Available online
**BASICS**

**DEFINITION**
- Uncommon alopecic disorders that are associated with abnormal hair follicle cycling.
- Both endocrine and non-endocrine diseases can be associated with alopecia.
- Deleterious diagnosis often requires ruling out the more common endocrine alopecias.
- Alopecia X has also been called growth hormone-receptor alopecia, castration-responsive alopecia, adrenal hyperplasia-like syndrome, among others.

**PATHOPHYSIOLOGY**
- There are many factors that affect the hair cycle; both hormonal and non-hormonal.
- Increased sex hormones can affect the hair cycle. Estrogen is a known inhibitor of anagen, the growth phase of the hair follicle.
- The mechanism by which alopecia X influences the hair cycle is not known.
- Exposure to human exogenous hormone replacement therapy.

**SYSTEMS AFFECTED**
- Behavioral
- Endocrine/Metabolic
- Hemat/Lymphatic/Immune
- Skin/Exocrine

**GENETICS**
Breed predispositions exist for alopecia X; however, the mode of inheritance is unknown.

**INCIDENCE/PREVALENCE**
- Hypertriglyceridemia and hyperandrogenism are uncommon to rare causes of alopecia.
- Alopecia X is relatively common in predisposed breeds.

**GEOGRAPHIC DISTRIBUTION**
None

**SIGNALMENT**
Species: Dogs

**Breed Predispositions**
- Hypertriglyceridemia and hyperandrogenism—no breed predispositions.
- Alopecia X—miniature poodle and shih-tzu-coated breeds such as Pomeranian, chow chow, Akita, Samoyed, Keeshonden, Alaskan malamute, and Siberian husky.

**Mean Age and Range**
- Hypertriglyceridemia and hyperandrogenism—middle-aged to old intact dogs.
- Alopecia X—1–5 years of age; however, older dogs may develop the condition.

**Predominate Sex**
- Hypertriglyceridemia, primarily intact males.
- Hyperandrogenism, primarily intact females or males.
- Alopecia X, neutered or intact dogs of either sex.

**SIGNS**
**Historical Findings**
- Overall change in the hair coat—dry or bleached because the hairs are not being replaced; lack of normal shedding.
- Males with hyperestrogenism may attract other male dogs.

**Physical Examination Findings**
- Alopecia—usually diffuse and bilaterally symmetrical truncal alopecia sparing the head and distal extremities. Uncommon with hyperandrogenism.
- Hair coat—may be dry or bleached.
- Secondary seborrhea, pruritus, pyoderma, comedones, ceruminous otitis externa, and hyperpigmentation—variable.
- Enlargement of nipples, mammary glands, vulva, prepuce—may be associated with hyperandrogenism.
- Macular melanosomes and linear preputial dermatitis—may be associated with hyperestrogenism.
- Abnormal-sized or different-sized testicles—may be associated with hypertriglyceridemia or hyperandrogenism.
- Testicles may also appear normal in size.
- Tail gland hyperplasia and perianal gland hyperplasia—usually associated with hyperandrogenism.
- Systemic signs (PU/PD/polyphagia) are usually NOT present.

**CAUSES**
- **Hyperestrogenism—Females**
  - Estrogen excess associated with cystic ovaries, ovarian tumors (rare), or exogenous estrogen supplementation.
  - Animals with normal serum estrogen concentrations may have increased numbers of estrogen receptors in the skin (androgenom).

- **Hyperandrogenism—Males**
  - Androgen-producing testicular tumors (especially interstitial cell tumors).

- **Alopecia X**
  - Hair falls to cycle but an underlying endocrine cause has not been identified.

**RISK FACTORS**
- Intact male and female dogs are at increased risk for developing testicular tumors and ovarian cysts/tumors, respectively.
- Cryptorchid males are at increased risk for developing testicular tumors.
- Exogenous estrogen supplementation.
- Exposure to human exogenous hormone replacement therapy.
- There are no known risk factors for alopecia X other than breed predisposition.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Inflammatory causes of alopecia (psoriasis, demodicosis, and dermatophytes)—should be ruled out; these diseases usually cause a patchy rather than diffuse pattern of alopecia.
- Seborrhea—important is inflammatory cause of alopecia that may affect specific breeds (Samoyed, Akita).
- Hyperthyroidism and hyperadrenocorticism—critical to rule out as these disease may cause a very similar pattern of diffuse alopecia associated with lack of hair follicle cycling.
- Follicular dysplasia including color-dilution alopecia and black hair follicular dysplasia—alopecia should be color-restricted.
- Patterned alopecia of various breeds (dachshund, Boston terrier, greyhound, water spaniel, and others)—breed-specific alopecias of unknown cause.
- Seasonal/cyclic/canine flank alopecia—alopecia of the flank and dorsum, often serpiginous patterns with hyperpigmentation, more often in short-coated breeds (boston, English bulldog, Airedale) and may recur seasonally.
- Post-clipping alopecia—hair fails to regrow following clipping; however, hair regrowth occurs within a year.
- Telogen effluvium—alopecia occurs 1–2 months following an illness or severe stressful episode and is usually more sudden in onset with relative ease of epilation.

**CBC/BIOCHEMISTRY/URINALYSIS**
- Usually unremarkable.
- Anemia and/or bone marrow hypoplasia or aplasia can be associated with hyperestrogenism.

**OTHER LABORATORY TESTS**
- Serum sex hormone concentrations—often normal, treat according to suspected diagnosis based on clinical signs and ruling out other disorders.
- Serum estradiol concentrations—sometimes elevated in male dogs with testicular tumors or female dogs with cystic ovaries; however, normal fluctuation of estradiol occurs throughout the day, making interpretation of estradiol concentrations difficult.

**IMAGING**
- Radiography, ultrasonography, and laparoscopy—identify cystic ovaries, ovarian tumors, testicular tumors (testicular/abdominal), adrenal tumors, sublumbar lymphadenopathy, and possible thymic metastases of malignant tumors.

**DIAGNOSTIC PROCEDURES**
- Preputial cytology—may demonstrate contamination of cells in males with hyperestrogenism (similar to a bitch in estrus).
- Skin biopsy.
**Alopecia, Non-Inflammatory—Dogs**

This treatment works in approximately 80% of cases. Because this treatment is the most benign, it is considered the treatment of choice following neutering. Once hair regrowth has occurred, discontinue treatment.

- **Medroxyprogesterone acetate**—5–10 mg/kg SC of weeks for 4 treatments. Hair regrowth can take up to 6 months. This treatment works in approximately 40–50% of cases.

### POSSIBLE INTERACTIONS

None

### ALTERNATIVE DRUG(S)

- **Trilostane**—dosages as described for ACTH stimulation testing regularly. Therefore, these drugs are not recommended.

### FOLLOW-UP

**PATIENT MONITORING**
- Medroxyprogesterone acetate—complete physical examination and chemistry panel regularly.
- Mitotane—electrolytes and cortisol with ACTH stimulation testing regularly.

**PREVENTION/AVOIDANCE**

None
**Amebiasis**

**BASICS**

**OVERVIEW**

- Facultative parasitic amoeba that infects people and non-human primates, including dogs and cats.
- Found primarily in tropical areas throughout the world, including North America.

**SIGNALMENT**

- Dog and cat: Mainly young and/or immunosuppressed animals are infected.

**SIGNS**

- *Entamoeba histolytica* infections are usually asymptomatic. 
  - Severe infections—result in ulcerative colitis to cause dysentery (may be fatal).
  - Hematogenous spread—results in failure states of the organs (invariably fatal).
  - Granulomatous amebic meningoencephalitis (caused by *Acanthamoeba spp.*)—causes signs similar to distemper (anorexia, fever, lethargy, salivary discharge, respiratory distress, and diffuse neurologic abnormalities).
- Syndrome of inappropriate secretion of antidiuretic hormone has been reported in a young dog with acanthamoebiasis causing granulomatous meningoencephalitis with invasion of the hypothalamus.

**Cats**

- Colitis—causing chronic intractable diarrhea (as per dogs).
- Systemic amebiasis or *Acanthamoeba*—not reported in cats.

**CAUSES & RISK FACTORS**

- *Entamoeba histolytica*—infection occurs by ingesting cysts from human feces.
- Encystment of trophozoites seldom occurs in dogs or cats so they are not a source of infection.
- *Acanthamoeba*—inhabit the colonic lumen as commensals or invade the colonic wall but rarely from pets to man.
- Trophozoites (the pathogenic stage)—inhabit the colonic lumen as commensals or invade the colonic wall but can disseminate to other organs (rare).
- Pathogenesis—implies invasion and spread of the organism to involve death of the host.
- *Acanthamoeba*—free-living species found in freshwater, saltwater, soil, and sewage; can infect dogs.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

**Dogs**

- Causes of bloody diarrhea or tenesmus, including: 
  - Intestinal inflammation (allergic, parasitic, viral, bacterial).
  - Intestinal ulceration results when *E. histolytica* invades the colonic wall.
  - Systemic forms—involve the systemic circulation.
- Hematogenous spread—results in failure states of the organs (invariably fatal).
- Other causes of diffuse neurologic disease in young animals, including infectious disease; parasitism (giardiasis, parasites such as hookworms, roundworms, tritrichomonas); infectious (panleukopenia, FIV, FeLV); neoplasia; pancreatitis; and major organ disease (Addison’s disease); toxic (lead, fungal, or plant); occasionally major organ dysfunction.

**Cats**

- Other causes of diarrhea, including: 
  - Intestinal inflammation (allergic, parasitic, viral, bacterial).
  - Intestinal ulceration results when *E. histolytica* invades the colonic wall.
  - Systemic forms—involve the systemic circulation.
- Hematogenous spread—results in failure states of the organs (invariably fatal).

**IMAGING**

- MRI—shows brain granulomas.

**DIAGNOSTIC PROCEDURES**

- Brain biopsy—required to definitively diagnose neurologic forms antemortem.

**TREATMENT**

- Cats (caused by *E. histolytica*)—responds to metronidazole, although dogs continue to shed organisms. 
- Systemic forms (particularly neurologic disease)—invariably fatal despite treatment.

**MEDICATIONS**

- Tinidazole (44 mg/kg PO q24h for 6 days) in dogs—found to be more effective than metronidazole in treating amebiasis in humans.
- Metronidazole (20 mg/kg PO q12h for 7 days).

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**

- High doses of metronidazole (usually > 30 mg/kg) for extended periods may cause neurologic signs in dogs.

**FOLLOW-UP**

- Pets usually acquire infections from the same source as their owners; veterinarians must warn owners of possible risk.

**MISCELLANEOUS**

**ABBREVIATIONS**

- CSF = cerebrospinal fluid
- FeLV = feline leukemia virus
- FIV = feline immunodeficiency virus
- *GME* = granulomatous meningencephalitis
- *H&E* = hematoxylin & eosin
- *HGE* = hemorraghic gastroenteritis
- MRI = magnetic resonance imaging
- *WBC* = white blood cell

**Suggested Reading**

- Author Stephen C. Barr
- Consulting Editor Stephen C. Barr

**CONSULTING EDITOR**

**AUTHOR**
**Ameloblastoma**

**OVERVIEW**
- Common oral tumor of odontogenic (tooth structure) ectoderm origin.
- Biologically these tumors are benign histologically but possess locally invasive properties.
- Tumors may arise anywhere within the dental arcade.
- Several histologic subtypes exist with similar invasive behavior.

**SIGNALMENT**
- Middle-aged and old dogs
- Rare in cats

**SIGNS**
- Dogs may present with a smooth, firm, gingival mass that is usually non-ulcerated.
- It may be incidental finding during dental prophylaxis/procedures. If involving rostral dental arcade, incisor teeth can be displaced and enveloped by proliferative tissue.

**CAUSES & RISK FACTORS**
N/A

**DIFFERENTIAL DIAGNOSIS**
- Epulis
- Gingival hyperplasia
- Squamous cell carcinoma
- Amelanotic melanoma
- Plasma cell tumor

**TREATMENT**
- Surgical excision such as hemi- or total mandibulectomy or maxillectomy with >1–2 cm margins is recommended as a curative treatment option. Always submit resected tissue for histopathology, in order to confirm the original diagnosis, and evaluate soft tissue and bone margins.
- Radiation therapy may provide long-term control in large tumors, or when the owners decline surgery.
- Intraluminal chemotherapy with bleomycin has been reported, but results are generally inferior to those of surgery or radiation.

**DIAGNOSIS**
- CBC/BIOCHEMISTRY/URINALYSIS
- Other laboratory tests
- Imaging
  - Skull or dental radiographs may show bone lysis deep to the superficial mass. Not particularly useful for diagnostic or treatment planning.
  - Regional and distant metastasis has not been described.
  - Computed tomography is helpful for planning surgery or radiation therapy, especially in large or caudal tumors.
- Diagnostic procedures
  - Deep tissue biopsies are necessary and recommended for definitive diagnosis.
  - Squamous cell carcinoma may be misdiagnosed as ameloblastoma.

**MEDICATIONS**
- Drug(s)
- Contraindications/possible interactions
- N/A

**FOLLOW-UP**
- Careful oral examination at 1, 3, 6, 9, and 12 months after definitive treatment is recommended to monitor for local recurrence.

**MISCELLANEOUS**
- Suggested Reading
- Author
  - Nick Dervisis
- Consulting Editor
  - Timothy M. Fan
- Acknowledgment
  - The author and editors acknowledge the prior contribution of Wallace B. Morrison.
**BASICS**

**OVERVIEW**
- Amitraz—formamidine acaricide; applied topically to control ticks, mites, and lice.
- Amitraz-containing products (for dogs)—formulated as a 19.9% emulsifiable concentrate in 10.6 mL horde for dilution and sponging; as a 9% impregnated 25-in. collar and an 18-in. 18.5-g collar, as a 14.3% component of a 0.023 fl. oz., 0.045 fl. oz., 0.113 fl. oz., 0.180 fl. oz., or 0.225 fl. oz. spot-on (discontinued); and as a 7.6% component of a 0.036 fl. oz., 0.072 fl. oz., or 0.145 fl. oz. spot-on
- Systems affected—nervous; cardiovascular; gastrointestinal
- Clinical signs—most associated with α₂- adrenergic receptor agonist.
- After high-dose oral administration (d-gal)—peak plasma concentration reached at approximately 6 hours; elimination half-life as long as 24 hours; metabolites excreted in the urine.
- Ingestion of sustained-release impregnated collar—constant release and continued systemic exposure until collar segments have passed in the stool.
- Toxicosis—generally occurs when pieces of impregnated collar are ingested, when concentrated or improperly diluted solutions are applied topically, or when solutions are ingested or applied to the wrong size animal.
- Idiosyncratic reactions may occur.

**SIGNALMENT**
- Thorough history—usually identifies topical or collar use; topically missing collar or pieces seen in dog’s environment or in the stool.
- Dogs—common, owing to more common use.
- Cats—more sensitive than dogs although cats are less likely involved.
- Predilection for old and toy-breed animals.

**SIGNS**

**Historical Findings**
Develop acutely after exposure (topical or oral)

**Physical Examination Findings**
- Minor to severe depression/fatigue
- Weakness
- Ataxia
- Bradycardia
- Vomiting (pieces of collar)
- Hyperthermia/hypothermia
- Hyperglycemia; diabetic patients can show significant hyperglycemia following exposure
- Hypothermia
- Polyuria
- Gastrointestinal stasis

**CAUSES & RISK FACTORS**
- Ingestion of impregnated collar or pieces of collar
- Inappropriate direct dermal application.
- Ingestion of undiluted product.
- After application of properly diluted and applied solutions—less common.
- Elderly, sick, toy-breed, or debilitated animals—may be predisposed.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Recreational and prescription drugs—marijuana; opioids; barbiturates; benzodiazepines; phenothiazines; antihypertensive medications; skeletal muscle relaxants; antidepressants (tricyclic, SSRIs), and other depressant drugs or chemicals.
- Yohimben (Yobiner) 0.11–0.2 mg/kg IV, 0.225 fl. oz. spot-on (discontinued); and as a 7.6% component of a 0.036 fl. oz., 0.072 fl. oz., or 0.145 fl. oz. spot-on
- Systems affected—nervous; cardiovascular; endocrine/metabolic (β cells of the pancreas); gastrointestinal
- Clinical signs—most associated with α₂-adrenergic receptor agonist.
- After high-dose oral administration (d-gal)—peak plasma concentration reached at approximately 6 hours; elimination half-life as long as 24 hours; metabolites excreted in the urine.
- Ingestion of sustained-release impregnated collar—constant release and continued systemic exposure until collar segments have passed in the stool.
- Toxicosis—generally occurs when pieces of impregnated collar are ingested, when concentrated or improperly diluted solutions are applied topically, or when solutions are ingested or applied to the wrong size animal.
- Idiosyncratic reactions may occur.

**SIGNS**

**Historical Findings**
Develop acutely after exposure (topical or oral)

**Physical Examination Findings**
- Minor to severe depression/fatigue
- Weakness
- Ataxia
- Bradycardia
- Vomiting (pieces of collar)
- Hyperthermia/hypothermia
- Hyperglycemia; diabetic patients can show significant hyperglycemia following exposure
- Hypothermia
- Polyuria
- Gastrointestinal stasis

**CAUSES & RISK FACTORS**
- Ingestion of impregnated collar or pieces of collar
- Inappropriate direct dermal application.
- Ingestion of undiluted product.
- After application of properly diluted and applied solutions—less common.
- Elderly, sick, toy-breed, or debilitated animals—may be predisposed.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Recreational and prescription drugs—marijuana; opioids; barbiturates; benzodiazepines; phenothiazines; antihypertensive medications; skeletal muscle relaxants; antidepressants (tricyclic, SSRIs), and other depressant drugs or chemicals.
- Yohimben (Yobiner) 0.11–0.2 mg/kg IV, 0.225 fl. oz. spot-on (discontinued); and as a 7.6% component of a 0.036 fl. oz., 0.072 fl. oz., or 0.145 fl. oz. spot-on
- Systems affected—nervous; cardiovascular; endocrine/metabolic (β cells of the pancreas); gastrointestinal
- Clinical signs—most associated with α₂-adrenergic receptor agonist.
- After high-dose oral administration (d-gal)—peak plasma concentration reached at approximately 6 hours; elimination half-life as long as 24 hours; metabolites excreted in the urine.
- Ingestion of sustained-release impregnated collar—constant release and continued systemic exposure until collar segments have passed in the stool.
- Toxicosis—generally occurs when pieces of impregnated collar are ingested, when concentrated or improperly diluted solutions are applied topically, or when solutions are ingested or applied to the wrong size animal.
- Idiosyncratic reactions may occur.

**MEDICATIONS**

**TREATMENT**
- Inpatient—severely affected patients.
- Mild sedation after correctly applied sponging-on solutions—often transient; may require no treatment.
- Mild signs after topical application—wearing gloves, scrub with a hard dishwashing detergent; rinse with copious amounts of warm water; institute non-specific supportive therapy (e.g., intravenous fluids, maintenance of blood pressure and normal body temperature, nutritional support); monitor 1–2 days until improvement is noted.
- Ingestion of collar possible—endoscopic retrieval of the collar—removal of large segments from the stomach may be beneficial; usually numerous small pieces are located throughout the gastrointestinal tract, making removal unrealistic.

**CAUSES & RISK FACTORS**
- Ingestion of impregnated collar or pieces of collar
- Inappropriate direct dermal application.
- Ingestion of undiluted product.
- After application of properly diluted and applied solutions—less common.
- Elderly, sick, toy-breed, or debilitated animals—may be predisposed.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Recreational and prescription drugs—marijuana; opioids; barbiturates; benzodiazepines; phenothiazines; antihypertensive medications; skeletal muscle relaxants; antidepressants (tricyclic, SSRIs), and other depressant drugs or chemicals.
- Yohimben (Yobiner) 0.11–0.2 mg/kg IV, 0.225 fl. oz. spot-on (discontinued); and as a 7.6% component of a 0.036 fl. oz., 0.072 fl. oz., or 0.145 fl. oz. spot-on
- Systems affected—nervous; cardiovascular; endocrine/metabolic (β cells of the pancreas); gastrointestinal
- Clinical signs—most associated with α₂-adrenergic receptor agonist.
- After high-dose oral administration (d-gal)—peak plasma concentration reached at approximately 6 hours; elimination half-life as long as 24 hours; metabolites excreted in the urine.
- Ingestion of sustained-release impregnated collar—constant release and continued systemic exposure until collar segments have passed in the stool.
- Toxicosis—generally occurs when pieces of impregnated collar are ingested, when concentrated or improperly diluted solutions are applied topically, or when solutions are ingested or applied to the wrong size animal.
- Idiosyncratic reactions may occur.

**MEDICATIONS**

**TREATMENT**
- Inpatient—severely affected patients.
- Mild sedation after correctly applied sponging-on solutions—often transient; may require no treatment.
- Mild signs after topical application—wearing gloves, scrub with a hard dishwashing detergent; rinse with copious amounts of warm water; institute non-specific supportive therapy (e.g., intravenous fluids, maintenance of blood pressure and normal body temperature, nutritional support); monitor 1–2 days until improvement is noted.
- Ingestion of collar possible—endoscopic retrieval of the collar—removal of large segments from the stomach may be beneficial; usually numerous small pieces are located throughout the gastrointestinal tract, making removal unrealistic.
Blackwell’s Five-Minute Veterinary Consult

Amitraz Toxicosis

(Continued)

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**

Yohimbine and atipamezole—excessive administration may result in apprehension, CNS stimulation, and rarely seizures.

**FOLLOW-UP**

- Body temperature, blood pressure, serum glucose, and heart rate—important parameters.
- Close observation for recurrence of clinical signs—required for 24–72 hours.
- Yohimbine and atipamezole—requires readministration in severe cases, because reversal effects subside before collar segments have passed or before amitraz has been eliminated from the body.
- No long-term adverse effects expected.

**MISCELLANEOUS**

**AGE-RELATED FACTORS**

- Elderly, sick, or debilitated animals may take longer to fully recover.

**ABBREVIATIONS**

- CNS = central nervous system
- GI = gastrointestinal
- SSRI = selective serotonin reuptake inhibitor

**Suggested Reading**


Authors: Steven R. Hansen and Safdar A. Khan

Consulting Editor: Lynn R. Hovda
**AMPHETAMINE AND ADD/ADHD MEDICATION TOXICOSIS**

**BASICS**

**DEFINITION**

Acute gastrointestinal, neurologic, neuromuscular, and cardiac toxiosis as the result of excessive consumption of amphetamine or a derivative. May be due to ingestion of prescription medications or illegal drugs.

**PATHOPHYSIOLOGY**

- Amphetamine and its derivatives belong to the CNS stimulant class phenylethylamines. Various substitutions of the basic phenylethylamine structure account for many pharmaceutical and illicit compounds found today.
- Amphetamine is a sympathomimetic that is structurally related to norepinephrine.
- Central action—stimulates cortical centers including cerebral cortex, medullary respiratory center, and reticular activating systems.
- Peripheral action—directly stimulates alpha and beta receptors and stimulates the release of norepinephrine from stores in adrenergic nerve terminals.
- Amphetamine may slow catecholamine oxidase.
- Several different product formulations including immediate and extended release and topical patch.
- Amphetamines are well absorbed orally; peak plasma levels are generally reached in 1–3 hours; this may be delayed with extended release formulations.
- Metabolism is minimal.
- The half-life, which varies from 7–34 hours, and rate of excretion of unchanged amphetamine in the urine are both dependent upon urine pH, with shorter half-lives associated with more acidic urine.
- Clinical signs may be seen at doses below 1 mg/kg.
- Oral lethal dose in dogs for most amphetamines ranges from 10 mg/kg to 23 mg/kg and for methamphetamine sulfate is 9–11 mg/kg. Oral lethal dose for amphetamine sulfate is 20–27 mg/kg.
- Amphetamine and its derivatives are used in humans to treat ADD/ADHD, narcolepsy, hyperactivity, obesity.
- Illicit use of amphetamines in humans is today.

**SYSTEMS AFFECTED**

- Cardiovascular—stimulation most common: tachycardia and hypertension.
- Nervous—stimulation most common, depression uncommon.
- Neuromuscular—stimulation: muscle tremors and seizures.
- Respiratory—stimulation, tachypnea.
- Ophthalmic—mydriasis.
- Gastrointestinal—anorexia, vomiting, diarrhea.

**INCIDENCE/PREVALENCE**

N/A

**SPECIES**

Dogs and cats, although more prevalent in dogs.

**BREED PREDICTIONS**

N/A

**MEAN AGE AND RANGE**

N/A

**PRODOMINANT SEX**

N/A

**SIGNS**

**HISTORICAL FINDINGS**

- Abnormal behavior—usually hyperactivity, anxiety or pacing, anorexia, fast heart rate, panting, observed or evidence of exposure by owner/careraker.

**PHYSICAL EXAMINATION FINDINGS**

- Nervous—hypersensitivity, agitation, restlessness, head bobbing, pacing, circling, vocalization, disorientation, hyperesthesia, ataxia, lethargy or depression (less common).
- Cardiovascular—tachycardia or bradycardia (less common, may be reflexive), hypertension.
- Neuromuscular—muscle fasciculation or tremors, seizures.
- Respiratory—tachypnea.
- Ophthalmic—mydriasis with possibly poor pupillary light response.
- Other—hyperthermia.

**CAUSES**

Acute ingestion or administration, malicious poisoning.

**RISK FACTORS**

Households with children or adults currently taking prescription or illicit amphetamine or derivative.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

- Sydromine
- Organophosphate insecticides
- Methylxanthines
- 4-aminoypyridine
- Metaldehyde
- Phenylpropanolamine
- Albuterol
- Nicotine
- Tremorgenic myotoxins
- Hypernatremia
- Pseudophedrine, phenylephrine
- 5-fluorouracil
- Ma huang, guarana, or ephedra
- CBC/biochemistry/urinalysis
- CBC—dissociated intravascular coagulopathy secondary to severe hyperthermia (rare).
- Chemistry—
- Anemia—prerenal—secondary to dehydration; renal—secondary to shock, oliguria, and myoglobinuria (rare).
- Elevated liver enzymes—secondary to seizures and/or hyperthermia (rare).
- Hypoglycemia.
- Urinalysis—evidence of myoglobinuria, urine specific gravity (high—prerenal azotemia, isotonicity—renal failure).

**OTHER LABORATORY TESTS**

- Electrolytes—imbalance secondary to GI effects.
- Acid-base status—acidosis occurs.
- Over-the-counter urine drug screens—watch for false positive or negative. Consult user handbook for further information.
- Amphetamines are present in blood, urine, and saliva; consult local veterinary diagnostic lab or human hospital for availability and proper sample submission.

**IMAGING**

N/A

**DIAGNOSTIC PROCEDURES**

- EEG for presence of any tachyarrhythmia or less commonly Bradycardia.
- Blood pressure—identification of hypertension.

**PATHOLOGIC FINDINGS**

On necropsy presence of amphetamines may be found in the gastric contents, urine, plasma, liver, kidney, or muscle.

**TREATMENT**

**APPROPRIATE HEALTH CARE**

Majority of cases require emergency inpatient intensive care management.

**NURSING CARE**

- Intravenous fluid therapy to correct dehydration and electrolyte imbalances as well as support renal function and promote excretion of amphetamines. Use blood pressure to help guide fluid rate.
- Cool intravenous fluids, fans, cool water baths for hyperthermia.

**ACTIVITY**

Minimize activity and stimuli.

**DIET**

Withhold food if moderately to severely affected. Blood diet for a few days post-exposure if significant gastrointestinal signs were noted.
Amphetamine and ADD/ADHD Medication Toxicosis

CLIENT EDUCATION
In case of an exposure, owner should contact local veterinarian or veterinary poison center immediately.

SURGICAL CONSIDERATIONS
N/A

MEDICATIONS

DRUG(S) OF CHOICE
Decontamination

Induce emesis—If a recent exposure and pet is not already symptomatic.

Ascorbic acid or ammonium chloride—for urinary acidification to promote elimination; however, only use if can measure acid-base status.

Contraindications

While diazepam has been successfully used to treat amphetamine exposures, there is evidence that benzodiazepines may intensify neurologic signs.

Urinary acidification if unable to monitor acid-base status or if myoglobinuria is present.

Inducing emesis in a symptomatic patient.

PRECAUTIONS
N/A

POSSIBLE INTERACTIONS

Amphetamines inhibit the metabolism of adrenergic blockers (dorzoxin, phenoxybenzamine, prazosin, terazosin), phenothalib, and phenytoin.

Amphetamines potentiate the metabolism of coumarin anticoagulants, monoamine oxidase inhibitors, opioid analgesics, and tricyclic antidepressants.

ALTERNATIVE DRUG(S)
Phenothalib, pentobarbital, and propofol for CNS stimulatory signs.

FOLLOW-UP

PATIENT MONITORING

Monitor in hospital until resolution of clinical signs.

If severely affected, monitor liver and kidney values every 24 hours for 72 hours or until resolution.

PREVENTION/AVOIDANCE

All medications and illicit drugs should be kept out of pets’ reach at all times.

POSSIBLE COMPLICATIONS

Acute renal failure secondary to myoglobinuria or DIC (rare).

INFORMATION RESOURCES

http://www.petpoisonhelpline.com/animal-poison-control-center-articles.php

SUGGESTED READING


ABBREVIATIONS

ADD = attention deficit disorder
ADHD = attention deficit/hyperactivity disorder
DIC = disseminated intravascular coagulation
ECG = electrocardiogram
GCS = Glasgow coma scale
N/B = not between
N/A = not applicable
POSSIBLE INTERACTIONS

Amphetamines inhibit the metabolism of adrenergic blockers (dorzoxin, phenoxybenzamine, prazosin, terazosin), phenothalib, and phenytoin.

Amphetamines potentiate the metabolism of coumarin anticoagulants, monoamine oxidase inhibitors, opioid analgesics, and tricyclic antidepressants.

ALTERNATIVE DRUG(S)
Phenothalib, pentobarbital, and propofol for CNS stimulatory signs.

FOLLOW-UP

PATIENT MONITORING

Monitor in hospital until resolution of clinical signs.

If severely affected, monitor liver and kidney values every 24 hours for 72 hours or until resolution.

PREVENTION/AVOIDANCE

All medications and illicit drugs should be kept out of pets’ reach at all times.

POSSIBLE COMPLICATIONS

Acute renal failure secondary to myoglobinuria or DIC (rare).

INFORMATION RESOURCES

http://www.petpoisonhelpline.com/animal-poison-control-center-articles.php

SUGGESTED READING


ABBREVIATIONS

ADD = attention deficit disorder
ADHD = attention deficit/hyperactivity disorder
DIC = disseminated intravascular coagulation
ECG = electrocardiogram
GCS = Glasgow coma scale
N/B = not between
N/A = not applicable
POSSIBLE INTERACTIONS

Amphetamines inhibit the metabolism of adrenergic blockers (dorzoxin, phenoxybenzamine, prazosin, terazosin), phenothalib, and phenytoin.

Amphetamines potentiate the metabolism of coumarin anticoagulants, monoamine oxidase inhibitors, opioid analgesics, and tricyclic antidepressants.

ALTERNATIVE DRUG(S)
Phenothalib, pentobarbital, and propofol for CNS stimulatory signs.

FOLLOW-UP

PATIENT MONITORING

Monitor in hospital until resolution of clinical signs.

If severely affected, monitor liver and kidney values every 24 hours for 72 hours or until resolution.

PREVENTION/AVOIDANCE

All medications and illicit drugs should be kept out of pets’ reach at all times.

POSSIBLE COMPLICATIONS

Acute renal failure secondary to myoglobinuria or DIC (rare).

INFORMATION RESOURCES

http://www.petpoisonhelpline.com/animal-poison-control-center-articles.php

SUGGESTED READING


ABBREVIATIONS

ADD = attention deficit disorder
ADHD = attention deficit/hyperactivity disorder
DIC = disseminated intravascular coagulation
ECG = electrocardiogram
GCS = Glasgow coma scale
N/B = not between
N/A = not applicable
POSSIBLE INTERACTIONS

Amphetamines inhibit the metabolism of adrenergic blockers (dorzoxin, phenoxybenzamine, prazosin, terazosin), phenothalib, and phenytoin.

Amphetamines potentiate the metabolism of coumarin anticoagulants, monoamine oxidase inhibitors, opioid analgesics, and tricyclic antidepressants.

ALTERNATIVE DRUG(S)
Phenothalib, pentobarbital, and propofol for CNS stimulatory signs.

FOLLOW-UP

PATIENT MONITORING

Monitor in hospital until resolution of clinical signs.

If severely affected, monitor liver and kidney values every 24 hours for 72 hours or until resolution.

PREVENTION/AVOIDANCE

All medications and illicit drugs should be kept out of pets’ reach at all times.

POSSIBLE COMPLICATIONS

Acute renal failure secondary to myoglobinuria or DIC (rare).

INFORMATION RESOURCES

http://www.petpoisonhelpline.com/animal-poison-control-center-articles.php

SUGGESTED READING


## Amyloidosis

**Species**
- Dog and cat

**Breed Predilections**
- **Dog:** Chinese shar-pei, beagle, collie, pointer, English foxhound, and walker hound.
- **Cat:** German shepherd dog and mixed breeds are at lower risk.
- **Cat:** Abyssinian, Oriental shorthair, and Siamese.

### Mean Age and Range
- **Cat:** Mean age at diagnosis 7 years; range 1–17 years.
- **Dog:** Mean age at diagnosis is 9 years; range 1–15 years.

**Siamese cats—median age at diagnosis is 5 years; range 3.6–17 years.**

### Prevails increases
- **Abyssinian cats—range:** <1–1.7 years.
- **Chinese shar-pei dogs—** usually <6 years of age when signs of renal failure develop. Siamese cats with familial amyloidosis of the liver and thyroid gland usually develop signs of liver disease when 1–4 years old.

### Predominant Sex
- Dogs and Abyssinian cats—females at a slightly higher risk (2:1). Female-to-male ratio is higher in Chinese shar-pei dogs (2:3.1).

### Signs

**General Comments**
- **Depend on the organs affected:** amount of amyloid, and the reaction of the affected organs to amyloid deposits.
- **Usually caused by kidney involvement:** occasionally, hepatic involvement may cause signs in Chinese shar-pei dogs and Oriental shorthair and Siamese cats.

### Historical Findings

- **No clear history of a predisposing disorder in most (75%) cases.**
- **Anemia, heparin, polycythemia, weight loss, vomiting.**
- Acute and peripheral edema in animals with nephrotic syndrome.
- Chinese shar-pei dogs may have a history of previous episodic joint swelling and high fever that resolves spontaneously within a few days.
- **Beagle dogs with juvenile polyarteritis may have a history of fever and seek pain that persists for 3–7 days.**
- **Oriental shorthair and Siamese cats may present with spontaneous hepatic hemorrhage leading to acute collapse and hemosudomine.

### Physical Examination Findings

**Related to renal failure:** renal ascension, emaciation, vomiting, and dehydration; kidney usually small, firm, and irregular in affected cats; they may be small, normal-sized, or slightly enlarged in affected dogs.

**Signs of nephritic syndrome:** acute and chronic glomerulonephritis.

**Related to the primary inflammatory or neoplastic disease process:** Thromboembolic phenomena—may occur in up to 40% of affected dogs; signs vary with the location of the thrombus; patients may develop pulmonary thromboembolism (e.g., dogana) or iliac or femoral artery thromboembolism (e.g., caudal paresis).

**Chinese shar-pei dogs** and Oriental shorthair and Siamese cats may have signs of hepatic disease (e.g., jaundice, cachexia, and spontaneous hepatic rupture with intra-abdominal bleeding).

### Causes
- Neoplasia and chronic infectious and non-infectious inflammatory conditions can be found in 30–50% of dogs with reactive amyloidosis.
- **Chronic inflammation—** systemic myositis (e.g., blasticomycosis, coccidiodomycosis), chronic bacterial infections (e.g., osteomyelitis, broncho-pneumonia, pleuritis, sepsis, pyometra, pyelonephritis, chronic suppurative dermatitis, chronic suppurative arthritis, chronic peritonitis, necrosis, chronic stomatitis), parasitic infections (e.g., dirofilariasis, leishmaniasis, hepatitis, and immune-mediated diseases (e.g., systemic lupus erythematosus).
- Amyloid deposits may be found in up to 35% of FIV-positive cats.
- **Neoplasia (e.g., lymphoma, plasmacytoma, multiple myeloma, mammary tumors, testicular tumors).**
- **Familial (e.g., Chinese shar-pei, English foxhound, and beagle dogs, Abyssinian, Siamese, and Oriental shorthair cats).**
- **Others—cyclic hematopoiesis in gray collie, juvenile polyarteritis in beagles.**

### Diagnosis

**Differential Diagnosis**
- **Dogs—** GN; proteinuria tends to be more severe in dogs with glomerular amyloidosis than those with GN but there is great overlap. Can be associated with other causes of medullary renal disease (e.g., pyelonephritis, chronic interstitial disease).
- **CBC/Biochemistry/Urinalysis**
- **Nonneoplastic etiologies:** Findings in some dogs and cats with amyloid-induced renal failure.
- **Dogs—** may see hypercholesterolemia (85%), anemia (70%), hyperlipidemia (70%), hyperproteinemia (60%), hyperglycemia (50%), and metabolic acidosis.
- **Hypercholesterolemia—** common finding in cats with renal disorders (70% of cats with renal disease in one study) but does not reliably predict glomerular disease.
- **Hypoproteinemia—** more common than hyperproteinemia in cats with amyloidosis, hyperglobulinemia common in cats. Proteinuria—vasculitis may be evident in animals with medullary amyloidosis without glomerular involvement (most mixed-breed cats, at least 25% of Abyssinian cats, and at least 33% of Chinese shar-pei dogs). In a retrospective study with 31 cases of renal disease.
Amyloidosis in dogs, hypobulbinemia was more common in non-Chinese shar-pei dogs (100%) versus shar-pei dogs (65%).

**Laboratory Tests**

- Proteinuria—serum creatinine ratio to estimate severity.

**Imaging**

- Abdominal Radiographic Findings
  - Kidneys usually small in affected cats.
  - Kidneys small, normal-sized, or large in affected dogs.

- Abdominal Ultrasonographic Findings
  - Kidneys usually hyperechoic and small in affected cats; may be small, normal-sized, or large in affected dogs.

**Diagnostic Procedures**

- Renal biopsy: needed to differentiate amyloidosis from GN. In dogs other than Chinese shar-pei, amyloidosis is primarily a glomerular disease; diagnose by renal cortical biopsy. In most domestic cats, some Abyssinian cats, and some Chinese shar-pei dogs, medullary amyloidosis can occur without glomerular involvement; diagnose by renal medullary biopsy.

**Pathologic Findings**

- Small kidneys in cats; small, normal, or large kidneys in dogs. • Amyloid deposits appear homogeneous and eosinophilic when stained by hematoxylin and eosin and viewed by conventional light microscopy. They demonstrate green birefringence after Congo red staining when viewed under polarized light. Evaluation of Congo red–stained sections before and after permanganate oxidation permits presumptive diagnosis of AA amyloidosis (vs. other types) because AA amyloidosis loses its Congo red affinity after permanganate oxidation. • The liver is very friable and usually contains extensive amyloid deposits in cats presented with acute hepatic hemorrhage.

**Treatment**

- **Appropriate Health Care**
  - Hospitalize patients with chronic renal failure and dehydration for initial medical management. • Can manage stable patients and those with asymptomatic proteinuria as outpatients.

- **Diet**
  - Patients with chronic renal failure—restrict phosphorus and moderately restrict protein. • Patients with hypercalcemia—restrict sodium.

- **Client Education**
  - Discuss progression of the disease. • Discuss familial predisposition in susceptible breeds.

**Medications**

**Drug(s) of Choice**

- Identify underlying inflammatory and neoplastic processes and treat as possible.

- Manage renal failure according to the principles of conservative medical treatment (see Renal Failure, Acute, and Renal Failure, Chronic).

- Normalized blood pressure in patients with hypertension (see Hypertension, Systemic).

- Patients with thrombotic thrombocytopenic syndrome and nephrotic syndrome caused by glomerular amyloidosis usually have a low plasma concentration of antithrombin; thus heparin is relatively ineffective. Aspirin (0.5 mg/kg PO q12h) has been suggested for dogs with glomerular disease; this low dosage is effective in preventing platelet aggregation as is 10 mg/kg PO q48h. 

- DMSO—may help patients by solubilizing amyloid fibrils, reducing serum concentration of SAA, and reducing intestinal inflammation and fibrosis in the affected kidneys; may cause lens opacification in dogs. Preventive inflammation and local thrombosis may occur if undiluted DMSO is administered intravenously. Subcutaneous administration of undiluted DMSO may be painful. The authors have used 90% DMSO diluted 1:4 with sterile water subcutaneously at a dosage of 90 mg/kg 3 times per week in dogs. Whether or not DMSO treatment benefits renal amyloidosis in dogs remains controversial.

- Methylsulfonylmethane is an active metabolite of DMSO that can be given orally as a metabolite of DMSO. It has been used empirically in dogs with amyloidosis, but there is no evidence that it benefits dogs with renal amyloidosis.

- Colchicine—prompts release of SAA from hepatocytes, prevents development of amyloidosis in humans with familial Mediterranean fever (a familial amyloidosis) and stabilizes renal function in patients with nephrotic syndrome but without overt renal failure; no evidence of benefit once the patient develops renal failure; may cause vomiting, diarrhea, and idiosyncratic neuropenia in dogs. Colchicine (0.01–0.04 mg/kg PO q12h) is used particularly in shar-pei dogs with episodic fever or polyarthria before development of renal failure.

**Precautions**

- Dosing of drugs excreted by the kidneys may need adjustment in patients with renal failure. • Use nonsteroidal anti-inflammatory drugs cautiously in patients with medullary amyloidosis; they can decrease renal blood flow in dehydrated patients.

**Follow-Up**

**Patient Monitoring**

- Appetite and activity level daily by the owner; body weight weekly. • Serum albumin, creatinine, and BUN concentrations every 2–6 months in stable patients. • Can assess degree of proteinuria serially by urine protein-creatinine ratios.

**Prevention/Avoidance**

- Do not breed affected animals.

**Possible Complications**

- Renal failure • Nephrotic syndrome • Systemic hypertension • Hepatic rupture causing intraportal hemorrhage • Thrombotic thrombocytopenic syndrome

**Expected Course and Prognosis**

- Disease is progressive and usually advanced at the time of diagnosis. Prognosis improves if an underlying immune, inflammatory, or neoplastic disease is detected and successfully treated. Survival for dogs with glomerular amyloidosis varied from 3 to 20 months in 1 study; some dogs may occasionally live longer. Cats with renal failure because of amyloidosis usually survive ≤1 year. Mildly affected cats may not develop renal failure and have an almost normal life expectancy.

**Miscellaneous**

**Associated Conditions**

- Urinary tract infection • Polyarteritis nodosa • Polyarteritis nodosa

**See Also**

- Glomerulonephritis • Nephrotic Syndrome • Proteinuria • Renal Failure, Acute • Renal Failure, Chronic

**Abbreviations**

- AA = amyloid A protein • DMSO = dimethylsulfoxide • GN = glomerular nephritis • SAA = serum amyloid A protein

**Suggested Reading**


- Authors: Helio S. Auroa de Morais and Stephen F. Dillahunt

Consulting Editor: Carl A. Osborne

Client Education Handout available online
**Anaerobic Infections**

**OVERVIEW**

- Anaerobic bacteria (i.e., bacteria requiring low oxygen tension) comprise a large portion of the normal flora, especially on mucosal surfaces. May be Gram-positive or Gram-negative cocci or rods.
- Most common genera—Bacteroides, Fusobacterium, Actinomyces, Propionibacterium, Porphyromonas, and Clostridium. Most anaerobic infections are polymicrobial and contain at least two different anaerobe species admitted with facultative anaerobes or aerobic bacteria (especially E. coli). Individual organisms vary in potential to withstand oxygen exposure. Injured tissues and enzymes may be elaborated by the organisms, leading to extension of the infection into adjacent, healthy tissue. All body systems are at potential risk for anaerobic infection.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

- Wounds that fail to respond to appropriate medical therapy—if aerobic cultures are negative, suspect anaerobic organisms. Cats

**IMAGING**

As required for the circumstances of the individual patient (e.g., suspected bone infection, sepsis, etc.).

**DIAGNOSTIC PROCEDURES**

- Cytologic inspection reveals abundant degenerate neutrophils with morphologically diverse forms of intracellular and extracellular organisms. Presence of large filamentous bacteria is suggestive. If not performed in-house, Gram staining should be requested when the sample is submitted.

**MEDICATIONS**

- Thoracic drainage—important with proptosis (see specific chapter). Hyperbaric oxygen—some potential use; limited in availability.

**SURGERY**

- Should not be delayed when anaerobes are suspected. Combined with systemic antimicrobial therapy—the best chance of a positive outcome. Usually indicated when anaerobic organisms complicate pyometra, osteomyelitis, and peritonitis. Cleanse the wound of debris and devitalized tissue. Enhance drainage of pus. Improve local blood flow. Increase oxygen tension.

**DRUG(S)**

- Antimicrobial therapy alone—unlikely to be successful; poor drug penetration into exudates.
- Antibiotic selection—largely empirical, owing to the difficulty of isolating anaerobes and the delay in return of culture results. Because most anaerobic infections are polymicrobial, therapy targeted against both anaerobes and any aerobic components offers the greatest chance of success. Aminocillin with clavulinate—in many cases, considered the antibiotic of choice; convenient and accessible; clavulinate improves activity against Bacteroides. Impenem—beta lactam with significant activity against serious, resistant infections. Carbenicillin—a cephalosporin with reliable activity against anaerobes. Clindamycin—may be especially useful for respiratory tract infections; concentrated within leukocytes. Chloramphenicol—good tissue penetration but bacteriostatic and associated with adverse effects, especially in cats; concern for human exposure also limits use. Metronidazole—useful against all clinically significant anaerobes (except Actinomyces). Aminoglycosides—uniformly ineffective. Trimethoprim-sulfamethoxazole—ineffective; poor penetration into exudates. Quinolones—routinely ineffective, although newer expanded-spectrum quinolones do have activity against anaerobes (e.g., pradofloxacin).

**FOLLOW-UP**

**PATIENT MONITORING**

Medical parameters will vary with the circumstances of each patient.

**POSSIBLE COMPLICATIONS**

Localized infection may progress to systemic infection if not appropriately identified and treated.

**EXPECTED COURSE AND PROGNOSIS**

Dependent upon identification and resolution of the underlying cause; long-term antibiotic therapy may be required.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**

See "Causes & Risk Factors".

**ABBREVIATIONS**

- ALP = alkaline phosphatase
- FELV = feline leukemia virus
- FIV = feline immunodeficiency virus

**Suggested Reading**


**Author** Sharon Foshee Grace

**Consulting Editor** Stephen C. Barr
**Anal Sac Disorders**

**OVERVIEW**

- Anal sacs are reservoirs for secretions normally evacuated by compression during defecation.
- Normal gland secretions vary in consistency and color.
- Disorders include impaction, infection (sacculitis), abscess, and neoplasia.
- Treatment options include manual expression, flushing, antibiotics, and surgical excision.

**CAUSES & RISK FACTORS**

- **Impaction/Infection**
  - Anal pruritus—often manifested by "scooting".
  - Perianal pruritus
  - Tenesmus
  - Tail chasing.
  - Foul-smelling, non-fecal anal discharge
  - Refusal to sit and/or lift tail
  - Infection—hypersensitivity and/or keratinization disorders

- **Other predisposing factors**
  - Obesity
  - Diabetes mellitus
  - Tapeworm infestation
  - Flea bite hypersensitivity

**DIAGNOSIS**

- **BASICS**
  - **OVERVIEW**
    - Anal sacs are reservoirs for secretions normally evacuated by compression during defecation.
    - Normal gland secretions vary in consistency and color.
    - Disorders include impaction, infection (sacculitis), abscess, and neoplasia.
    - Treatment options include manual expression, flushing, antibiotics, and surgical excision.

- **CAUSES & RISK FACTORS**
  - **Impaction/Infection**
    - Anal pruritus—often manifested by "scooting".
    - Perianal pruritus
    - Tenesmus
    - Tail chasing.
    - Foul-smelling, non-fecal anal discharge
    - Refusal to sit and/or lift tail
    - Infection—hypersensitivity and/or keratinization disorders

- **Other predisposing factors**
  - Obesity
  - Diabetes mellitus
  - Tapeworm infestation
  - Flea bite hypersensitivity

- **DIAGNOSIS**
  - **Adverse food reaction or food hypersensitivity**
  - **Flea bite hypersensitivity**

**DIFFERENTIAL DIAGNOSIS**

- Adverse food reaction or food hypersensitivity
- Flea bite hypersensitivity

**TREATMENT**

- Gentle manual expression of contents for impaction and sacculitis.
- Sedation may be necessary to flush severely impacted or painful anal sacs.
- Inclusion of antibiotic and/or corticosteroid medications directly into the anal sacs.
- Drainage of abscesses
- Use of appropriate oral antibiotics and/or antiyeast medication.
- Anal sac excision with chronic disease.
- Surgical excision and staging of anal sac neoplasia, combine with chemotherapy.

**MEDICATIONS**

**DRUG(S)**

- **Infection**—use of appropriate antibiotics: ampicillin (22 mg/kg q12h), amoxicillin tridate-clavulanate potassium (10–15 mg/kg q12h), clindamycin (11 mg/kg q12h), trimethoprim-sulfamethoxasole (15 mg/kg q12h); metronidazole (15–15 mg/kg q12h); enrofloxacin (dogs, 10–20 mg/kg q12h; cats, 5 mg/kg/day); and cefibutilin (5 mg/kg q24h).
- **Chronic disease associated with perianal furuncles**—topical tacrolimus.

**CONSULTING EDITOR**

Alexander H. Werner

**SUGGESTED READING**


**AUTHOR**

Alexander H. Werner

**CONSULTING EDITOR**

Alexander H. Werner
BASICS
DEFINITION
• Acute manifestation of a Type I hypersensitivity reaction mediated through the rapid introduction of an antigen into a host having antigen-specific antibodies of the IgE subclass.
• The binding of antigen to mast cells sensitized with IgE results in the release of preformed and newly synthesized chemical mediators.
• Anaphylactic reactions may be localized (atopy) or systemic (anaphylactic shock).
• Anaphylaxis not mediated by IgE is designated an anaphylactoid reaction and will not be discussed.

PATHOPHYSIOLOGY
• First exposure of the patient to a particular antigen (allergen) causes a humoral response and results in production of IgE, which binds to the surface of mast cells; the patient is then considered to be sensitized to that antigen.
• Second exposure to the antigen results in cross-linking of two or more IgE molecules on the cell surface, resulting in mast cell degranulation and activation; release of mast cell granules initiates an anaphylactic reaction.
• Major mast cell-derived mediators include histamine, eosinophilic chemotactic factor, arachidonic acid, metabolites (e.g., prostaglandins, leukotrienes, and thromboxanes), platelet-activating factor, and proteases, which cause an inflammatory response of increased vascular permeability, smooth muscle contraction, inflammatory cell influx, and tissue damage.
• Clinical manifestations depend on the route of antigen exposure, the dose of antigen, and the level of the IgE response.

SYSTEMS AFFECTED
• Gastrointestinal—salivation, vomiting, and diarrhea.
• Vasculature (dogs)—because of portal hypotension and vasocnstriction.
• Respiratory (cats)—dyspnea and cyanosis
• Skin/Exocrine—pruritus, urticaria, and edema

GENETICS
Familial basis reported for Type I hypersensitivity reaction in dogs.
INCIDENCE/PREVALENCE
• Localized Type I hypersensitivity reactions not uncommon.
• Systemic Type I hypersensitivity reactions rare.

GEORGRAPHIC DISTRIBUTION
None

SIGNALMENT
Species
Dog and cat

Mean Age and Range
• Dogs—age of clinical onset ranges from 3 months to several years of age; most affected animals 1–3 years old.
• Cats—age of clinical onset ranges from 6 months to 2 years.

Predominant Sex
• Dogs—not breeds documented as having a predilection for any.
• Cats—no breeds documented as having a predilection for any.

SIGNS
General Comments
• Initial clinical signs vary depending on the route of exposure to the inciting antigen.
• Shock—end result of a severe anaphylactic reaction.
• Shock organ—dogs, liver; cats, respiratory and gastrointestinal systems.
• May be localized to the site of exposure but may progress to a systemic reaction.

Historical Findings
• Onset of signs immediate (usually within minutes).
• Dogs—pruritus, urticaria, vomiting, defecation, and urination.
• Cats—intense pruritus about the head, dyspnea, salivation, and vomiting.

Physical Examination Findings
• Localized cutaneous edema at the site of exposure.
• Hypersensitivity in many dogs.
• Hypersensitivity possible in early stages.
• Depression and collapse terminally.

CAUSES
• Virtually any agent; those commonly reported include venoms, blood-based products, vaccines, foods, and drugs.

RISK FACTORS
Previous exposure (sensitization) increases the chance of the animal developing a reaction.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Other types of shock.
• Trauma.
• Depends on the major organ system involved or if reaction is localized; diagnosis can be made largely on the basis of history and clinical signs.

CBC/BIOCHEMISTRY/URINALYSIS
Because of the acute onset of disease, no tests available that reliably predict individual susceptibility.

OTHER LABORATORY TESTS
• Intradermal skin testing to identify allergens.
• Radioallergosorbent test to quantify the concentration of serum IgE specific for a particular antigen.

IMAGING
N/A

DIAGNOSTIC PROCEDURES
Limited because a severely allergic animal can develop an anaphylactic reaction when exposed to even small quantities of antigen.

PATHOLOGIC FINDINGS
• Lesions vary, depending on severity of reaction, from localized cutaneous edema to severe pulmonary edema (in cats) and visceral pooling of blood (in dogs).
• Other non-specific findings vary and are characteristic of shock.
• Non-specific characteristics of localized reactions include edema, vasculitis, and thromboembolism.

TREATMENT

APPROPRIATE HEALTH CARE
In an acutely affected animal, the reaction is considered a medical emergency requiring hospitalization.

NURSING CARE
Elimination of inciting antigen, if possible.

Systemic Anaphylaxis
• Goal—emergency life support through the maintenance of an open airway, preventing circulatory collapse, and reestablishing physiologic parameters.
• Administer fluids intravenously at shock dosages to counteract hypotension.

Localized Anaphylaxis
Goal—limit the reaction and prevent progression to a systemic reaction.

ACTIVITY
N/A

DIET
If a food-based allergen is suspected (uncommon), avoid foods associated with hypersensitivity reaction.

CLIENT EDUCATION
• Discuss the unpredictable nature of the disease.
• Discuss the need to recognize that the animal has an allergic condition that may require immediate medical care.

SURGICAL CONSIDERATIONS
None
**Anaphylaxis**

### Medications

**Drug(s) of Choice**

- **Systemic Anaphylaxis**
  - Epinephrine hydrochloride parenterally (1:1,000: 0.01 mL/kg) for shock.
  - Corticosteroids for shock—prednisolone sodium succinate (2 mg/kg IV q8h) or dexamethasone sodium phosphate (0.25 mg/kg IV q12h).
  - Atropine sulfate (0.04 mg/kg IM) to counteract bradycardia and hypotension.
  - Aminophylline (10 mg/kg IM or slowly IV) in severely dyspneic patients.

- **Localized Anaphylaxis**
  - Diphenhydramine hydrochloride (1–2 mg/kg IV or IM).
  - Prednisolone (2 mg/kg PO).
  - Epinephrine hydrochloride (0.15 mL SC at site of initiation).

### Contraindications

None

### Precautions

Localized reaction can develop into systemic reaction.

### Possible Interactions

N/A

### Alternative Drug(s)

N/A

### Follow-Up

**Patient Monitoring**

Closely monitor hospitalized patients for 24–48 hours.

**Prevention/Avoidance**

If inciting antigen (allergen) can be identified, eliminate or reduce exposure.

**Possible Complications**

None

**Expected Course and Prognosis**

- If localized reaction is treated early, prognosis is good.
- If the animal is in shock on examination, prognosis is guarded to poor.

### Miscellaneous

**Associated Conditions**

None

**Age-Related Factors**

None

**Zoonotic Potential**

None

**Pregnancy/Fertility/Breeding**

N/A

**See Also**

Shock, Cardiogenic

**Internet Resources**


**Suggested Reading**


**Author**

Paul W. Snyder

**Consulting Editor**

Alan H. Rebar

**Client Education Handout available online**
Anemia of Chronic Kidney Disease

**BASES**

**DEFINITION**
Progressive decreases in PCV, RBC count, and hemoglobin and hypoplasia of erythroid elements of the bone marrow are predictable features of progressive CKD. Anemia is normocytic, normochromic, nonregenerative, and proportional to the stage of CKD. The underlying cause of the anemia of CKD is multifactorial. Although factors such as gastrointestinal blood loss, reduced red blood cell survival, deficiencies in iron and/or folate, cytokines and inflammatory mediators may be involved, the primary contributing factor to anemia of CKD is an inadequate production of erythropoietin (EPO) by the kidneys. Erythropoietin is a glycoprotein hormone that regulates red blood cell generation at the level of the bone marrow. Erythropoietin is produced in the peritubular interstitial cells of the kidney in response to decrease in tissue oxygen.

**SIGNALMENT**
Middle-aged to old dogs and cats most affected; seen in young animals with heritable, congenital, or acquired CKD.

**SIGNS**
- Anemia contributes to development of anorexia, weight loss, fatigue, lethargy, depression, weakness, spotty, cold intolerance, and behavior and personality changes characteristic of CKD.
- Pallor of the mucous membranes.
- Tachypnea.
- Tachycardia.
- Symptomatic murrin.
- Syncope and seizures (rare).

**CAUSES & RISK FACTORS**
- All inherited, congenital, and acquired forms of CKD (e.g., Ig lambda disorders, glomerulonephritis, amyloidosis, polycystic kidney disease, and lymphoma).
- Exacerbated by iron deficiency, inflammatory or neoplastic disease, gastrointestinal blood loss, hemolysis, and myeloproliferative disorders.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Anemia of chronic infectious, inflammatory, or neoplastic disease; myeloproliferative disease; chronic blood loss; aplastic anemia; endocrine disease; drug reaction; and chronic immune-mediated, toxic, viral, rickettsial, or parasitic anemic hemolysis.
- Regenerative anemia excludes diagnosis of anemia of CKD.
- Generally masked until advanced CKD.

**CBC/BIOCHEMISTRY/URINALYSIS**
- Normocytic, normochromic, hypoproliferative anemia (progressive; anemia may be masked by dehydration).
- Reticulocytes—low corrected indices and absolute counts (≤ 10,000/μL).
- Moderate to advanced CKD—elevated BUN, creatinine, and phosphorus; variably high calcium; variably low bicarbonate and potassium.
- High BUN:creatinine ratio may predict concurrent gastrointestinal blood loss.
- Impaired urine-concentrating ability, possible proteinuria, and variably active sediment.

**OTHER LABORATORY TESTS**
- Serum iron—normal or variably low.
- Transferin saturation—normal or variably low (≤ 20%).
- FeLV and FIV and/or haemobartonella testing (cats) or tick-borne titers or PCR (dogs) to exclude agent-induced myelosuppression.
- Serum erythropoietin—normal (inappropriately) or low.

**IMAGING**
- Small, irregular kidneys with loss or disruption of renal architecture detected by radiography or ultrasonography.
- Enlarged, polycystic, hydro nephrotic, unilateral.

**DIAGNOSTIC PROCEDURES**
- Cyclogic examination of bone marrow—erythroid hypoplasia; myeloid:erythroid ratio normal or high; stainable iron normal or variably low.

**TREATMENT**
- Stabilize azotemia in patients in with uremic crisis.
- Ensure adequate and appropriate nutrition.
- Stabilize any metabolic derangement (e.g., acidosis) that could contribute to reduced RBC lifespan and or anemia.
- Minimize micronutrient deficiencies that could negatively impact the production.
- Identify and manage GI blood loss (gastric acid suppression with H2 blockers or proton pump inhibitors) (GI protectants such as sucralfate).
- Ensure that patient is iron replete (serum iron panel).
- Correct systemic hypertension.

**MEDICATIONS**

**DRUG(S) AND FLUIDS**
- Blood Transfusion
- Short-term, rapid correction if hypoxic stress (typically PCV ≤ 15%)—give compatible whole blood or packed RBCs.
- Epoetin alfa—50–100 U/kg SC thrice 1.5–2.5 weeks as needed to maintain target.
- Darbepoetin—divide weekly units by 400 to reach target, then decrease to 2.0 μg/kg SC once weekly until PCV reaches low end of target, then decrease to q2–4 weeks as needed to maintain target. Recommend PCV prior to EVERY injection to avoid overtreatment.
- Epoetin alfa—50–100 U/kg SC thrice weekly until low end of target, then decrease to once to twice weekly.
- If converting from epoetin alfa to darbepoetin—divide weekly units by 400 to establish q4 to give once weekly.
- Individualize to each patient; life-long treatment required.
- If PCV exceeds target, discontinue until upper target range is achieved, then increase dosage interval.
- Serum iron and transferrin saturation should be normalized before initiating and during treatment. Injektable iron (10 mg/kg IM) should be administered when indicated on iron panel. Injectible iron is preferable and better tolerated than oral preparations.
- Species-specific erythropoietins for dogs and cats are not currently commercially available.
- Alternative erythropoietin-stimulating treatments are under development.

**ANABOLIC STEROIDS**
- Little or no efficacy or indication for use.

**FOLLOW-UP**

**PATIENT MONITORING**
- PCV—weekly to semi-monthly for 3 months, then monthly to bimonthly.
- Blood pressure—semi-monthly to monthly.
- Iron and transferrin saturation—at 1, 3, and 6 months, then semiannually.
- Discontinue erythropoietin if patient develops evidence of erythrocytosis, local or systemic sensitivity, anti-e1-HuEPO antibody
Anemia of Chronic Kidney Disease

Possible Complications

Erythropoietin-Related

- Development of erythrocythemia, seizures, hypertension, iron depletion, injection pain, and mucocutaneous reactions.
- Development of a pure red cell aplasia during the course of epoetin alfa treatment suggests formation of anti-r-HuEPO and native erythropoietin, causing severe anemia in 20–30% of animals, often reversible with cessation of treatment.
- Development of anti-r-HuEPO antibodies occurs in less than 5% of patients with darbepoetin alfa therapy.
- Signs associated with production of anti-r-HuEPO antibodies include decreasing PCV, erythroid hyperplasia, absolute reticulocyte counts approaching zero, and myeloid:erythroid ratio ≥ 8.
- Erythropoietin replacements should be used cautiously or withheld if hypertension or iron deficiency develop; treatment can be reintroduced once hypertension and iron deficiency are corrected.

Expected Course and Prognosis

- Correction of anemia increases appetite, activity, grooming, affection and playfulness, weight gain, and cold tolerance, and decreases sleeping.
- Use of erythropoietin replacement agents in dogs and cats requires careful assessment of the risks and benefits for individual patients.
- Short-term prognosis depends on the severity of the renal failure.
- Long-term prognosis is guarded to poor because of the underlying chronic renal failure.

Transfusion-Related

- Incompatibility reaction
- Circulatory or iron overload
- Systemic hypertension
- Transmissible infection

Abbreviations

- CKD = chronic kidney disease
- FeLV = feline leukemia virus
- FIV = feline immunodeficiency virus
- PCR = polymerase chain reaction
- PCV = packed cell volume
- RBC = red blood cell
- r-HuEPO = recombinant human erythropoietin

Suggested Reading


Authors

Sheri Ross and Ilaria Lippi

Consulting Editor

Carl A. Osborne

Acknowledgment

The author and editors acknowledge the prior contribution of Larry D. Cowgill.
Recovery of hematopoiesis may take weeks. Feline immunodeficiency virus (FIV) can affect hematopoietic precursor cells, and bone marrow core biopsy may be necessary to rule out aplastic anemia. Griseofulvin is often used to treat this condition, and bone marrow aspiration may reveal a normal bone marrow with adipose tissue. There is decreased production of granulocytes, erythrocytes, and platelets, resulting in pancytopenia in the peripheral blood. The disease is sometimes referred to as aplastic pancytopenia.

In the acute form, neutropenia and thrombocytopenia predominate because of the shorter life spans of these cells; in the chronic form, nonregenerative anemia also occurs. In both forms, the bone marrow exhibits variable degrees of pancytopenia. There are many precipitating causes of deficient hematopoiesis, including infectious diseases, drug administration, starvation, and tissue exposure; immune-mediated mechanisms are often suspected. Hematopoietic/immune systems affected.

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS

Causes of pancytopenia with normal to increased bone marrow cellularity (e.g., myelodysplastic disorders, leukemia, myelitis).

CBC/BIOCHEMISTRY/URINALYSIS

Leukopenia characterized by neutropenia with or without lymphopenia. Normocytic, normochromic, nonregenerative anemia. Thrombocytopenia.

OTHER LABORATORY TESTS

Immunologic tests for infectious diseases (e.g., serologic titers, ELISA, IFA). PCR for infectious agents.

Serologic test for anticytotoxic antibodies (Coombs’ test).

IMAGING

N/A

DIAGNOSTIC PROCEDURES

Bone marrow aspiration—frequently an inadequate or fatty sample is obtained because of decreased hematopoietic tissue and replacement by adipocytes. Bone marrow core biopsy—permits an evaluation of architecture and reveals hypoplasia of cell lines and replacement by adipose tissue.

TREATMENT

Supportive treatment, antibiotics, blood component therapy, as dictated by clinical condition.

MEDICATIONS

DRUG(S) OF CHOICE

 Cytoxan (cyclophosphamide), asparaginase, granulocyte colony-stimulating factor (G-CSF), antifolate, and corticosteroids-commonly used. Recombinant human erythropoietin (rHuEPO) can also be used to treat anemia in patients with cancer.

CONTRAINDICATIONS/POSSIBLE INTERACTIONS

Thrombocytopenia, neutropenia, and anemia are common complications of chemotherapy. G-CSF can cause bone pain and fever. Epoetin alfa can cause fluid retention and hypertension. Antifolates can cause nausea, vomiting, and diarrhea. Corticosteroids can cause fluid retention, hypertension, and hyperglycemia.

OTHER DRUGS

Antibiotics to treat secondary infections if fever and neutropenia present. Whole blood or component blood transfusion if indicated.

FOLLOW-UP

PATIENT MONITORING

CBC every 3–5 days to weekly. Repeat bone marrow evaluation if necessary.

PREVENTION/AVOIDANCE

Castration of cryptorchid males. Vaccination for infectious diseases. Chemotherapeutic drugs, including azathioprine, cyclophosphamide, cytosine arabinoside, doxorubicin, vinblastine, and hydroxyurea.

SIGNS

Neutropenia and thrombocytopenia predominate because of the shorter life spans of these cells; in the chronic form, nonregenerative anemia also occurs. In both forms, the bone marrow exhibits variable degrees of pancytopenia. There are many precipitating causes of deficient hematopoiesis, including infectious diseases, drug administration, starvation, and tissue exposure; immune-mediated mechanisms are often suspected. Hematopoietic/immune systems affected.

ACTION

Hematopoietic/immune systems affected.
Anemia, Heinz Body

Overview
- Heinz bodies cause hemolytic anemia and indicate oxidative damage to RBCs. • Heinz bodies form when oxidants overwhelm protective reductive pathways in RBCs, irreversible denaturation of the globin chains in hemoglobin causes precipitation and attachment of altered hemoglobin to the cell membrane. • RBCs with Heinz bodies are targeted for removal by macrophages in the spleen, and occasionally undergo intraosseous lysis. • The pitting function of the spleen may remove Heinz bodies, resulting in spherocytes. • Heinz bodies are usually caused by exposure to chemical or dietary oxidants. • Cats are particularly susceptible to Heinz body formation because their hemoglobin contains more sulfhydryl groups than that of dogs. • Healthy cats may have Heinz bodies with no anemia, possibly because cats have a nonsinusoidal spleen with limited pitting function. • Heinz bodies are reported in hyperthermia (cats), lymphoma (cats, dogs), and diabetes mellitus (cats, dogs), possibly due to increased endogenous oxidants (e.g., β-hydroxybutyrate in ketonuria). Anemia may or may not be present. • Heinz bodies may be accompanied by methemoglobinemia (hemoglobin containing Fe³⁺) and/or eccentrocytes (oxidative damage to RBC membranes causing adhesion of opposing membranes and displacement of hemoglobin to one side of the cell).

Signs
- Dogs and cats • No sex, breed, or age disposition

Historical Findings
- Exposure to oxidant • Sudden onset of weakness, lethargy, or anorexia.
- Reddish-brown urine (hemoglobinuria) if there is marked poikilocytosis.
- RBC surface. They may be difficult to identify in RBCs of cats without anemia.

Physical Examination Findings
- Pale and occasionally icteric mucous membranes • Dark or chocolate-colored blood with methemoglobinemia • Tachypnea, tachycardia

Causes & Risk Factors
- Dietary: onions (raw, cooked, dehydrated, and powdered), garlic (dogs), propylene glycol (cats), Chineseorris (dogs) • Drugs: acetaminophen, phenacemid (cats), phenaquopryline (cats), methylene blue, vitamin K₁ or K₃ (dogs), DL-methionine (cats), benzocaine (topical), phenylhydrazine (dog), propofol (cats) • Miscellaneous: zinc (nails, bolts, pennies, dermatologic creams), naphthalene (moth ball ingestion in dogs), skunk mask exposure (dogs).

Diagnosis
- Differential Diagnosis
  - Other causes of regenerative, hemolytic anemia (e.g., immune-mediated hemolytic anemia). • Heinz bodies may be found in healthy or ill cats without anemia. Diagnosis of a Heinz body anemia requires documentation of a regenerative anemia, supporting evidence of a hemolytic process (e.g., hyperbilirubinemia), identification of Heinz bodies on a blood smear, and elimination of other causes of hemolysis or blood loss.
  - CBC/Biochemistry/Urinalysis
    - Regenerative anemia (decreased HCT, polychromasia, nucleated RBCs) is expected if there has been sufficient time for a bone marrow response; the severity of anemia depends on dose of oxidant and duration of exposure. • Hemoglobin concentration and MCHC may be falsely increased due to Heinz body interference with hemoglobin measurement. • Heinz bodies are visible on a routinely stained blood smear as small, pale red, round inclusions that may protrude from RBC surface. They may be difficult to identify if there is marked poikilocytosis. • Single, small (< 0.5 μm) Heinz bodies may be found in RBCs of cats without anemia. • Large and/or multiple Heinz bodies in an anemic cat suggest a Heinz body hemolytic anemia.
    - Other laboratory tests
      - New methylene blue stains Heinz bodies blue, making them easy to identify and quantify on a blood smear, even with marked poikilocytosis. • Measure methemoglobin if blood is dark or chocolate colored. • Serum zinc concentration if indicated.

Imaging
- Abdominal radiographs may reveal gastrointestinal metal objects in zinc toxicity.

Treatment
- Immediate identification and removal of oxidant may be sufficient, though it often takes several days after exposure for the severity of anemia to reach nadir. • Consider administration of emetics with recent ingestion of an oxidant. • Supportive care depends on the severity of the hemolytic crisis and includes IV fluids, RBC transfusions, oxygen, and restricted activity. • Endoscopy or surgery to remove metallic items in gastrointestinal tract.

Medications
- Drug(s) of Choice
  - Acetaminophen toxicity in cats—N-acetylcysteine (140 mg/kg PO or IV followed by seven additional treatments of 70 mg/kg q8h).

Prevention/Avoidance
- Counsel clients about preventing exposure to oxidants.

Possible Complications
- N/A

Expected Course and Prognosis
- Prognosis is good with removal of oxidant and disappearance of Heinz bodies.

Follow-Up
- Patient Monitoring
  - Serial CBCs and review of blood smears are recommended to assess RBC regeneration and disappearance of Heinz bodies.

Dosage
- N/A

Interactions
- None

Contraindications/Possible

Follow-Up
- Patient Monitoring
  - Serial CBCs and review of blood smears are recommended to assess RBC regeneration and disappearance of Heinz bodies.

Prevention/Avoidance
- Counsel clients about preventing exposure to oxidants.

Possible Complications
- N/A

Expected Course and Prognosis
- Prognosis is good with removal of oxidant and supportive care once the hemolytic crisis is over.

Miscellaneous

See Also
- Acetaminophen (APAP) Toxicosis
- Anemia, Regenerative
- Methemoglobinemia • Zinc Toxicosis

Abbreviations
- HCT = hematocrit • MCHC = mean corpuscular hemoglobin concentration • RBC = red blood cell

Suggested Reading

Author
- Jennifer S. Thomas

Consulting Editor
- Alan H. Rebar
**ANEMIA, IMMUNE-MEDIATED**

**BASICS**

**DEFINITION**
Accelerated destruction or removal of RBCs due to a Type II hypersensitivity reaction.

**PATHOPHYSIOLOGY**
- Antibodies form against endogenous unaltered RBC surface antigens (primary IMHA) or plased RBC inclusions (secondary IMHA).
- Infectious organisms, drugs, exposure to previously unexposed antigens, or adsorption of permeal antigen-antibody complexes to the RBC membrane can alter RBC membrane antigens.
- Immunoglobulin deposits on RBC membrane, causing either direct intravascular hemolysis or accelerated removal by the monocyte/macrophage system.
- Intravascular hemolysis occurs when adsorbed antibodies (usually IgG) activate complement.
- In vivo agglutination of RBCs occurs when IgM or high titters of IgG molecules cause bridging of RBCs.
- Extravascular removal of RBCs occurs primarily in spleen, liver, bone marrow.
- Nonregenerative IMHA is believed to be caused by immune-mediated destruction of RBC precursors in the bone marrow.
- Rarely cold-agglutinating antibodies cause autoimmune hemolysis and erythrocyte agglutination in peripheral vasculature.

**SYSTEMS AFFECTED**
- Cardiovascular—tachycardia, low-grade heart murmur.
- Hemic/Lymphatic—Immune—immune-mediated destruction of RBCs, elaboration of proinflammatory mediators, DIC.
- Hepatobiliary—hyperbilirubinemia and icterus plus bilirubinuria when hepatic function is overwhelmed; centrilobular necrosis.
- Respiratory—tachypnea. PTE may result from hypercoagulable state.
- Skin—rarely cold-type IMHA may cause necrosis of extremities and ear tips.

**GENETICS**
Cooker spaniels are at increased risk (absence of dog erythrocyte antigen 7).

**GEOGRAPHIC DISTRIBUTION**
Secondary IMHA may have higher prevalence where associated infectious diseases are endemic.

**SIGNALMENT**

**Species**
Dog and cat

**Breed Predilections**
- Cooker spaniel at highest risk. Also, English springer spaniel, Old English sheepdog, Doberman pinscher, bichon frise, miniature pinscher, and Finnish spitz.
- Domestic shorthair cats.

**Mean Age and Range**
- Dogs, mean age 3–6 years (range 1–13 years)
- Cats, mean age 2 years (range 0.5–5 years)

**Predominant Sex**
- Female dogs at higher risk. Male cats overpresented

**SIGNS**

**Historical Findings**
- Leukocytosis/weakness/lethargy/collapse
- Anorexia
- Exercise intolerance/dyspnea, tachypnea
- Vomiting and/or diarrhea
- Dark red urine
- Pica (cats)

**Physical Examination Findings**
- Pale mucous membranes, tachycardia, tachypnea, petechiae, ecchymoses, thrombocytopenia
- Fever/lymphadenomegaly
- Positive ANA titer and LE cell

**PATHOLOGIC FINDINGS**
Primary IMHA
- Poorly characterized immune dysregulation

Secondary IMHA
- Infectious causes: hemophagocytic M. pyrophilum spp., E. coli spp., Anaplasma phagocytophilum, Anaplasma platys, Babesia spp., Leishmania, Daplatella enoitei, FeLV, FIP, chronic bacterial infection.
- Neoplasia: lymphoma, lymphoid leukemia, hemangiosarcoma, hemolytic hyalinocytic sarcoma.
- Drugs: beta lactam antibiotics, prophylactic sulfa, methotrexate, sulfonamides.
- SLE: Neutrophilic leukocytosis
- Hemolytic due to C3 inactivated blood transfusion
- Exposure to infectious agents, vaccination, chemicals/drugs, surgery, hormonal change, or other stressful event is hypothesized as potential trigger for IMHA.

**IMAGING**
- Radiographic findings—hemophagocytic spleenomegaly. Other findings usually normal. May see evidence of PT, patchy alveolar pattern, interstitial pattern, pleural fluid.
- Ultrasonographic findings—splenomegaly, lymphadenopathy, hepatic or splenic lymphoma.

**DIAGNOSTIC PROCEDURES**
- Bone marrow aspirate usually reveals erythroid hyperplasia.
- With nonregenerative IMHA, maturation arrest or erythroid hypoplasia may be evident.
- In chronic IMHA, myeloblastosis may be present.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Dogs
  - Pyruvate kinase deficiency
  - Phosphofructokinase deficiency
  - Toxicity
  - Severe myelophenomena
  - Anemia due to hemolitis (immune-mediated thrombocytopenia, reticulocyte toxicosis)
- Cats
  - Toxicity (acetaminophen, zinc, onions, garlic)
  - Severe hyperparphosphatemia

**OTHER LABORATORY TESTS**
- CBC/biochemistry—neutrophilia, lymphopenia, high ALT. Uricemia—hemoglobin, bilirubinuria.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Important during acute hemolytic crisis. Supportive when PCV stabilized, ongoing hemolysis controlled, and clinical signs of anemia resolved.
- Inpatient if complications such as DIC, PTE, thrombocytopenia, gastrointestinal bleeding, or a need for
multiple transfusions. Chronic low-grade extracutaneous hemolysis can be treated on outpatient basis if the patient not exhibiting clinical signs secondary to anemia.

**NURSING CARE**
- Fluid therapy to maintain vascular volume and correct dehydration. • Packed RBCs typed or cross-matched for naive recipient. Blood should be cross-matched for recipients that have received prior transfusions. Whole blood acceptable if packed RBCs not available. • Transfusion volume = recipient weight (kg) × 95 (dog) or 50 (cat) × desired PCV-current PCV/donor PCV. • Transfusion rate 0.25 mL/kg/hr for first 30 minutes then 5–10 mL/kg/hr. • Monitoring for complications such as PTE, bleeding (especially GI), DIC, infection. • Cage rest.

**CLIENT EDUCATION**
- IMHA and complications (e.g., DIC, PTE) can be fatal. • Life-long treatment may be needed; disease may recur. • Side effects of treatment may be severe.

**SURGICAL CONSIDERATIONS**
- Splenectomy can be considered if medical management fails to control disease. • Consider blood product administration preoperatively.

**MEDICATIONS**

**DRUG(S) OF CHOICE**
- Corticosteroids—prednisone 1–2 mg/kg/day q12h for 2–4 weeks. Use prednisolone in cats due to higher bioavailability. • Once PCV above 50%, decrease dose to 1 mg/kg q12h. Then taper by a maximum rate of 25–30% per month over a 1–to-6 month period, depending upon PCV and severity of side effects. If after 3–6 months disease is in remission on a low q48h dose, try discontinuing the drug. • Add additional immunosuppressive drug such as azathioprine (dog) cyclosporine (cat) if poor response to prednisone after 5–7 days or if poor prognostic indicators (e.g., intravascular hemolysis, serum bilirubin > 8–10 mg/dL, persistent autogalutamin, Evans syndrome). • Azathioprine dose 2 mg/kg/day can decrease to 0.5–1.0 mg/kg q48h if bone marrow suppression. Monitor for immunosuppression, hepatotoxicosis, pancreatitis.
- For prevention of thrombocytopenia (dogs) consider unfractionated heparin 80U/kg SC q6–8h (dose adjusted based on APTT prolongation or measurement of anti-Xa activity) or ultra-low-dose aspirin 0.5–1.0 mg/kg/dog or enoxaparin (low-molecular-weight heparin) 0.8 mg/kg SC q6–8h or 1–3.5 mg/kg PO q24h, or doubledose 2–3.5 mg/kg PO q3–4h (loading dose 10 mg/kg/day). • Address underlying cause (e.g., infection and drug) if secondary IMHA.

**CONTRAINDICATIONS**
- No heparin, enoxaparin, or aspirin in dogs (up to 80% of all cases at necropsy). • Pulmonary/multiorgan thromboembolism can be fatal.

**PRECAUTIONS**
- Monitor heart rate, respiratory rate, temperature frequently. • Monitor for adverse reactions to treatment (e.g., transfusion reactions/overhydration). • If PTE suspected, monitor thoracic radiographs and arterial blood gases frequently. • During first days of treatment, check PCV daily until stable, then every 1–2 weeks for months; if stable, check PCV monthly for 6 months, then 2–4 times per year; rechecks need to be more frequent if patient is on long-term medication especially cytotoxic drugs. • CBC and reticulocyte count should be rechecked at least monthly during treatment; if the neutrophil count falls < 5,000 cells/μL, discontinue cytotoxic drugs until count recovers, reinstitute at lower dosage. • Coombs’ tests and reticulocyte counts to assist in drug tapering.

**PREVENTION/AVOIDANCE**
- Consider need for vaccination on case-by-case basis in dogs that developed IMHA after vaccination.

**POSSIBLE COMPLICATIONS**
- Pulmonary/multiorgan thromboembolism (up to 80% of all cases at necropsy). • DIC.

**EXPECTED COURSE AND PROGNOSIS**
- AWARE—acute anemia: may have more gradual onset than typical IMHA and may be slower to respond to treatment. • IMHA may recur despite previous/current therapy.

**MISSING INFORMATION**

**SYNONYMS**
- Autoimmune hemolytic anemia • Immune-mediated anemia

**SEE ALSO**
- Anemia, Regenerative • Chapters on causes of secondary IMHA • Cold Agglutinin Disease • Disseminated Intravascular Coagulation

**ABBREVIATIONS**
- AAT = alpha antitrypsin • ANA = antinuclear antibody • ATPT = activated partial thromboplastin time • DEA = dog erythroid aplasia • DIC = disseminated intravascular coagulation • FeLV = feline leukemia virus • FIV = feline immunodeficiency virus • IMHA = immune-mediated hemolytic anemia • LEV = lupus erythematosus • MCV = mean cell volume • PCR = polymerase chain reaction • PCV = packed cell volume • PTE = pulmonary thromboembolism • PT = prothrombin time • RBC = red blood cell • SLE = systemic lupus erythematosus

**REFERENCES**
BASICS
OVERVIEW
• Adults—caused by chronic external hemorrhage.
• RBC produced by iron-limited erythropoiesis.
• Importance—prompts clinician to look for chronic external blood loss.

SIGNALMENT
• Fairly common in adult dogs.
• Rare in adult cats.
• Transient neonatal iron-deficiency anemia may occur at 5–10 weeks of age in kittens.

SIGNS
• Signs of anemia (e.g., lethargy, weakness, and enuclepexy) and underlying disease.
• Intermittent melena with gastrointestinal blood loss.
• Possible heavy bloodsucking parasite load.

CAUSES & RISK FACTORS
• Chronic external blood loss.
• Common cause—GI lymphoma, hookworms, GI neoplasia.
• Less common—skin (e.g., severe flea infestation) and urinary tract.
• Blood donor overuse.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Any cause of anemia, especially hemorrhage.
• Microcytic anemia in portosystemic shunt disease may or may not be due to iron deficiency.
• Anemia of inflammatory disease iron-limited erythropoiesis.

CBC/BIOCHEMISTRY/URINALYSIS
• PCV usually but not always decreased, generally 10–40% in dogs.
• Anemia either regenerative or non-regenerative.
• Microcytosis—indicated by low normal or low MCV, accompanied by increased heterogeneity, detected by erythrocyte histogram widening or increased RDW.
• RBC changes include microcytosis, hypochromia due to thin cell geometry, and keratoxy and schistocyte formation.
• Newer erythrocyte indices MCH and CHr, are sensitive for detecting iron-limited erythropoiesis; available on one hematology system.
• Lab tests indicate iron-limited erythropoiesis, but may not differentiate true from functional iron deficiency. Clinical findings of inflammatory disease versus blood loss are required to differentiate cause of iron limited erythropoiesis. It is also possible that making oral therapy of little value until partial iron repletion has occurred.

DIAGNOSTIC PROCEDURES
• Identify / correct cause of blood loss.
• Administer iron until hematologic features of iron deficiency resolve.
• If severe (i.e., PCV < 15%), transfusion may be required; whole blood (10–20 mL/kg IV) or packed RBC.

TREATMENT
• Administer iron until hematologic features of iron deficiency resolve.
• If severe (i.e., PCV < 15%), transfusion may be required; whole blood (10–20 mL/kg IV) or packed RBC.

DRUG(S)
Iron Supplementations
• Initiate iron therapy with injectable iron.
• Iron dextran—a slowly released form of injectable iron; one injection (10–20 mg/kg IM) followed by oral supplementation.

Oral Iron Supplementation
• Animals with severe iron deficiency may have impaired intestinal iron absorption, making oral therapy of little value until partial iron repletion has occurred.
• Follow injected iron with oral iron supplement for 1–2 months, or until resolved.
• Kittens undergo spontaneous iron repletion beginning at 5–6 weeks of age.

MISCELLANEOUS
ABBREVIATIONS
• MCH = mean cell hemoglobin concentration
• MCV = mean cell volume
• PCV = packed cell volume
• RBC = red blood cell
• RDW = red cell distribution width

Suggested Reading
Siebert JD, Olver CS. Hematologic and biochemical abnormalities indicating iron deficiency are associated with decreased reticulocyte hemoglobin content (CHr) and reticulocyte volume (MCVr) in dogs. Vet Clin Pathol 2005, 34:23–27.
Author Glade Weiser
Consulting Editor Alan H. Rebar

CONTRAINDICATIONS/POSSIBLE INTERACTIONS
• Oral iron is associated with unexplained death in kittens and should be avoided.

FOLLOW-UP
• Monitor CBC every 1–4 weeks; if the anemia is severe, more frequently as needed.
• Effective treatment associated with an increase in MCV and reticulocyte volume.
• Erythrocyte histogram—effective treatment associated with microcytic subpopulation reduction over time; it may take a few months to normalize the histogram.

ORAL IRON SUPPLEMENTS
• Ferrous sulfate powder—place in food or drinking water (100–300 mg PO q24h).
• Ferrous gluconate—one (325 mg) tablet PO q24h.

CONTRAINDICATIONS/POSSIBLE INTERACTIONS
• Oral iron is associated with unexplained death in kittens and should be avoided.
Anemia, Metabolic (Anemias with Spiculated Red Cells)

Basics

Overview
- Sometimes occurs concomitantly with diffuse diseases of the liver, kidney, and, rarely, spleen.
- In most animals with liver disease, spiculated cells have 2–10 elongated, blunt, finger-like projections from their surfaces and are classified as acanthocytes.
- Acanthocytic anemias can be associated with renal disease; anemias of renal disease most often have oval red cells with irregular or ruffled membranes (burr cells).
- Rarely, acanthocytic anemias can be seen in association with splenic disease alone.
- Pathogenesis not entirely clear; abnormal lipid metabolism with free cholesterol loading of RBC membranes is most frequently implicated as cause.
- Dogs with disseminated abdominal hemangiosarcoma with liver involvement often have acanthocytes.

Signalment
- Dogs and cats (infrequently)

Signs
- None in most animals (usually mild to moderate condition).
- Detection of spiculated RBCs on peripheral blood films can be first marker for liver, kidney, or splenic disease.
- In large-breed dogs with vague signs or large spleen, suggests possibility of splenic or hepatic hemangiosarcoma.

Causes & Risk Factors
- Any disease of the liver, kidneys, or possibly spleen
- The likelihood of RBC morphologic abnormalities parallels the severity of organ involvement.
- Hemangiosarcoma involving the liver is a frequent cause.
- Observed in cats with fatty liver syndrome.

Diagnosis

Differential Diagnosis
Determination of renal or hepatic causes based on results of biochemistry profile and urinalysis.

CBC/Biochemistry/Urinalysis
- Mild to moderately low PCV, RBC count, and hemoglobin.
- Normal mean corpuscular volume and mean corpuscular hemoglobin concentration in most animals.
- Normocytic, normochromic, and nonregenerative.
- Polychromasia on blood films only with accompanying blood loss (as with hepatic hemangiosarcoma).
- WBC changes variable, based on underlying cause of hepatic or renal pathology.
- Inflammatory conditions likely to be accompanied by inflammatory leukogram.
- Variable findings in liver and kidney function tests (serum biochemistry and urinalysis).

Hepatic Diseases
- High ALT, ALP, and γ-glutamyl transferase.
- High bile acids, serum ammonia.
- Possibly low albumin and serum urea nitrogen.
- Bilirubinuria, bilirubin crystals in urine.

Renal Diseases
- High serum urea nitrogen, creatinine, and phosphorus.
- Highly variable urinalysis findings, including isosthenuria (urine specific gravity 1.008–1.025 in dogs; 1.008–1.035 in cats).
- Tubular and/or protein casts.
- Proteinuria.
- Hematuria

Other Laboratory Tests
None

Imaging
Abdominal radiographs and ultrasound—evaluate hepatic, renal, and splenic structure.

Diagnostic Procedures
Liver or kidney biopsy if indicated.

Treatment
Focus treatment on diagnosis and treatment of underlying hepatic, renal, or splenic disease.

Medications
Drug(s)
Variable according to underlying cause.

Contraindications/possible Interactions
Variable according to underlying cause.

Follow-Up
Monitor CBC periodically while treating the underlying condition.

Miscellaneous

See Also
- Anemia of Chronic Kidney Disease
- Hemangiosarcoma. Spleen and Liver

Abbreviations
- ALT = alanine aminotransferase
- ALP = alkaline phosphatase
- ALP = α-glutamyl transferase.
- AST = aspartate aminotransferase
- CBC = complete blood count
- PCV = packed cell volume
- RBC = red blood cell
- WBC = white blood cell

Suggested Reading
Author Alan H. Rebar
Consulting Editor Alan H. Rebar
**BASICS**

**DEFINITION**
Low RBC mass without evidence of increased polychromasia or reticulocytosis in the peripheral blood.

**PATHOPHYSIOLOGY**
- Low erythropoietin production or release.
- Novel or selective altered synthesis and impaired mobilization of hepatic iron.
- Endocrine disease—thyroid hormones and cortisol stimulate erythropoiesis and facilitate the effect of erythropoietin.
- Immune-mediated destruction of precursors—Purpura red cell aplasia.
- Infectious destruction of precursors (although usually > one cell line is involved), e.g., FeLV and cheliosis.

**DEFINITION**
Nonregenerative Anemia without Other Cytopinas
- Anemia of inflammatory disease (AID)—most common cause of mild nonregenerative anemia, can be seen within 3–10 days of infection, inflammation, tissue injury, immune-mediated processes, and neoplasia.
- Increased liver production of hepcidin and release of cytokines from T-lymphocytes and macrophages lead to iron sequestration in macrophages, decreased iron absorption, low serum iron and transferrin, increased ferritin, decreased EPO production and function, and shortened RBC lifespan.
- Chronic renal failure—hemosiderin fail to produce adequate EPO; uremic toxins shorten RBC lifespan and impair response to EPO.
- Chronic liver disease—shortened RBC survival caused by changes in RBC membrane lipids, functional iron deficiency due to decreased transferrin synthesis and impaired mobilization of hepatic iron.
- Endocrine disease—thyroid hormones and cortisol stimulate erythropoiesis and facilitate the effect of erythropoietin.

**CAUSES**
Nonregenerative Anemia without Other Cytopinas

- Anemia of inflammatory disease (AID)—most common cause of mild nonregenerative anemia, can be seen within 3–10 days of infection, inflammation, tissue injury, immune-mediated processes, and neoplasia.
- Increased liver production of hepcidin and release of cytokines from T-lymphocytes and macrophages lead to iron sequestration in macrophages, decreased iron absorption, low serum iron and transferrin, increased ferritin, decreased EPO production and function, and shortened RBC lifespan.
- Chronic renal failure—hemosiderin fail to produce adequate EPO; uremic toxins shorten RBC lifespan and impair response to EPO.
- Chronic liver disease—shortened RBC survival caused by changes in RBC membrane lipids, functional iron deficiency due to decreased transferrin synthesis and impaired mobilization of hepatic iron.
- Endocrine disease—thyroid hormones and cortisol stimulate erythropoiesis and facilitate the effect of erythropoietin.

**RISK FACTORS**
- Renal failure—Inflammatory or chronic disease
- Liver failure—Sertoli cell tumor
- Cancer—Chronic blood loss
- Cats from multicat households (FeLV) Lead or arsenic exposure—chronic.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
Regenerative anemia initially nonregenerative; sudden onset of signs more consistent with regenerative than nonregenerative anemia; exacerbation of a chronic condition may produce the appearance of an acute onset.

**LABORATORY FINDINGS**
Disorders That May Alter Laboratory Results
- Lipemia can falsely elevate hemoglobin and MCHC values.
- Lead toxicity and impaired EPO production.

**Valid If Run in Human Laboratory**
- Dogs—yes.
- Cats—yes.

**CBC and Blood Smear**
- PCV, RBC count, and hemoglobin low.
- Anemia usually normocytic, normochromic, with normal MCV and MCHC.
- Macrocytosis (high MCV)—without polychromasia suggests nuclear maturation defect (cells skip a division); seen in cats with FeLV, rarely caused by vitamin B12 or folate deficiency.
- Microcytosis (low MCV)—suggested cytoplasmic maturation defect (cells undergo extra division); iron deficiency most common cause; in late stages, concurrent hypochromasia (low MCHC) common in dogs but not in cats; seen in approximately one-third of patients with hepatic insufficiency or vascular shunting.
- Specific RBC morphologies— oligocytes common with iron deficiency; poikilocytes or acanthocytes with liver disease; target cells with iron deficiency, liver disease, and hypothyroidism.

**Thrombocytosis**
Common in iron deficiency.

**High Number of NRBCs without polychromasia or disproportionate to the degree of anemia and polychromasia seen with lead toxicity, EMH, heat stroke, and injury to bone marrow stem by endotoxins or hemolysis.**
- RBC or WBC precursors in peripheral blood without orderly progression to more mature forms suggest myelodysplasia or myeloproliferative disease.
- Concurrent
cytopenia in other cell lines without evidence of marrow depression. A bone marrow biopsy will aid in confirming the diagnosis.

**Diagnostic Procedures**

- Cytologic examination of aspirates from multiple sites
- Bone marrow biopsy (useful in evaluation of bone marrow architecture and overall cellularity)
- Flow cytometry (after diagnosis of aplastic marrow or myelodysplasia)

**Medications**

- Erythropoietin (in patients with anemia of chronic kidney disease)
Anemia, Nuclear Maturation Defects (Anemia, Megaloblastic)

**Overview**
- Nonregenerative anemia characterized by arrested development of the nuclei of RBC precursors (as a result of interference with DNA synthesis) while the cytoplasm develops normally (nucleocytoplasmic asynchrony).
- Affected RBC precursors fail to divide normally and thus are larger than corresponding normal precursors with the same degree of cytoplasmic maturity (hemoglobinization); because their nuclei are deficient in chromatin (DNA), they have a distinctive open and stippled appearance; these giant precursors with atypical, immature nuclei are known as megaloblasts. Although these asynchronous changes are most prominent in RBC precursors, WBC and platelet precursors are similarly affected.

**Signalment**

**Signs**
- In dogs, generally mild, usually not clinically important. In cats with FeLV-associated nuclear maturation anemia, FeLV-related signs can be anticipated. Anemia may be mild to severe.

**Causes & Risk Factors**
- Infection—FeLV; retroviral infection the most common cause of megaloblastic anemia in cats. FIV has been reported as a cause much less frequently.
- Nutritional—folic acid and cobalamin deficiencies (Giant Schnauzers with inherited cobalamin malabsorption).
- Toxic—phenytoin, methotrexate (folate antagonist), alkylating agents (cyclophosphamide), plant alkaloids (vincristine), antimetabolites (azathioprine).
- Congenital—toy and miniature poodles.

**Diagnosis**

**Differential Diagnosis**
- In dogs, all other mild to moderate nonregenerative anemias, including anemia of inflammatory disease, renal disease, and lead poisoning.
- Differentiation based on the distinctive CBC and bone marrow findings listed.
- In cats, FeLV infection is the primary differential.

**CBC/Biochemistry/Urinealys**
- In dogs, mild to moderate anemia (PCV 30–40%).
- In cats, anemia can be mild to severe.
- Anemia classically macrocytic (high mean corpuscular volume) and normocromic (normal mean corpuscular with hemoglobin concentration). However, mean corpuscular volume and mean corpuscular hemoglobin concentration can be normal.
- Large, fully hemoglobinized RBCs; occasional to numerous megaloblasts, particularly at the feather edge; minimal to no polychromasia. In cats with FeLV, anemia may occur in association with a myelodysplastic syndrome or in conjunction with leukemia of a different cell line.

**Other Laboratory Tests**
- FeLV

**Imaging**
- N/A

**Other Diagnostic Procedures**
- Bone marrow biopsy
- Bone marrow aspirate

**Bone Marrow Biopsy**
- In dogs, usually hyperplastic, often in all cell lines. In cats, marrow findings are highly variable and may be hyper- to hypoplastic.

**Treatment**
- Treat by targeting the underlying cause if possible. Except for that occurring with FeLV in cats, megaloblastic anemia is a relatively mild condition. Treat most patients on an outpatient basis.

**Medications**

**Drug(s)**
- In animals with drug toxicity, discontinue the offending drug.
- In all animals, consider supplementation with folic acid (4–10 mg/kg/d) or vitamin B12 (dogs, 100–200 mg/day PO; cats, 50–100 mg/day PO).
- Giant schnauzers with inherited cobalamin malabsorption require parenteral treatment with vitamin B12 (0.5–1 IM weekly to every few months).

**Contraindications/possible Interactions**
- Drugs known to cause megaloblastic anemia (e.g., methotrexate and phenytoin) should be avoided in patients whose condition results from other causes.

**Follow-up**
- Monitor response to treatment by CBC (weekly) and occasional bone marrow smears. Frequently monitor FeLV-positive cats for evidence of onset of other signs of hematopoietic dyscrasia in the peripheral blood and bone marrow.
- Prognosis—depends on underlying cause; in FeLV-positive cats, prognosis guarded; in animals with drug-associated anemia, prognosis good when use of offending drug is interrupted.

**Miscellaneous**
- Anemia, Nonregenerative—Feline Leukemia Virus Infection (FeLV)

**Abbreviations**
- FeLV = feline leukemia virus
- PCV = packed cell volume
- RBC = red blood cell
- WBC = white blood cell
- FIV = feline immunodeficiency virus

**Suggested Reading**
- Author Alan H. Rebar
- Consulting Editor Alan H. Rebar
Musculoskeletal—progressive

Transfusion of a blood type B

Bloodsucking parasites

With

Anemia is usually

Lipemia can cause mild in vitro hemolysis,

Intravascular

Possible heart murmur,

Feline

In cats, some systemic diseases (e.g.,

Anorexia.

Some dog breeds have a genetic

PK deficiency—impaired ATP formation,

Feline congenital

Middle-aged female

Antibodies

Cats:

Rapid loss

Cardiovascular—murmurs with marked

Caused by blood loss or hemolysis.

Hemolysis may be either

Autoagglutination may

Dogs:

Caused by vasculitis, thromboembolic

PFK deficiency—

Hematomas

(dogs) can cause

Weakness, exercise intolerance.

Trauma

PK deficiency—basenji, beagle, cairn terrier,

Marked RBC osmotic

Possible

Bleeding neoplasms (e.g.,

Hepatic—anoxia causes centrilobular

Canine blood type DEA 1.1 can cause

r

Rare cause of

One of the most common causes of anemia is hemolytic anemia, which occurs when the body's red blood cells (RBCs) are destroyed before their normal lifespan is reached. This can be caused by various factors, including infections, immune reactions, genetic defects, or certain medications. The consequences of hemolytic anemia depend on the severity and cause of the condition. Conditions such as sickle cell anemia, thalassemia, and hemolytic uremic syndrome (HUS) can lead to severe anemia and organ failure if left untreated.

In addition to hemolytic anemia, there are other types of anemia, including iron deficiency anemia, which is caused by a lack of iron in the diet or due to blood loss, and aplastic anemia, which occurs when bone marrow fails to produce enough RBCs. The diagnosis of anemia often involves a thorough history, physical examination, and testing to determine the underlying cause.

Treatment for anemia depends on the specific cause and severity of the condition. Conventional treatments may include blood transfusions, iron supplements, or the use of medications to stimulate RBC production. In some cases, more aggressive interventions such as stem cell transplantation or gene therapy may be necessary.

It is important to note that anemia can be a symptom of other health issues, and therefore, it is crucial to identify the underlying cause to ensure appropriate management. If you suspect you or someone you know may have anemia, it is essential to consult a healthcare provider for accurate diagnosis and treatment.
Exercise and excitement can increase RBC count, PCV, and reticulocyte count through splenic contraction.

**Valid If Run in Human Laboratory?**

- Dogs—yes. Cats—yes, if hematology instrument uses species-specific parameters; instruments designed for analysis of human specimens may under-count small feline RBCs.

**CBC/BIOCHEMISTRY/URINALYSIS**

- PCV, RBC count, and hemoglobin level.
- Total protein often low with blood loss; normal PCV may be maintained through transient splenic contraction.
- Severity of acute blood loss may be underestimated until the plasma volume has been restored by fluid administration and/or internal fluid shifts. RBC indices vary depending on the cause of anemia and degree of regenerative response—MCV, normal to high; MCHC, normal to low in most patients; MCHC, artificially high with extravascular hemolysis and hemoglobinemia.

- With iron deficiency, dogs may have a low MCV, MCH, and MCHC; can have a low MCV but normal MCH and MCHC. Specific RBC morphologies may suggest cause of hemolysis: marked spherocytosis suggests autoimmune or inherited disease (not as easily detected in cats whose RBCs generally lack central pallor); Heinz bodies or schistocytes suggest oxidant injury; numerous schistocytes suggest microangiopathy. Agglutinated RBCs indicate anemia is immune mediated; distinguish autogglutination from rouleaux by generous sample dilution with saline.

- Hemolysis may cause inflammatory leukogram (neutrophilia with a left shift and monocytosis). Acute blood loss may be associated with stress leukogram (mild neutrophilia and lymphopenia). Blood loss may be accompanied by either thrombocytopenia or rebound thrombocytosis; iron deficiency is often accompanied by thrombocytosis.

- Hyperlipidemia and bilirubinemia accompany marked hemolysis; hemoglobinemia and hemoglobinuria seen with intravascular hemolysis.

**Other Laboratory Tests**

- In anemia automated absolute reticulocyte count (RBC count × reticulocyte %) > 60,000/µL (cats) or > 95,000/µL (dogs) suggests regenerative anemia. It takes 3–5 days for bone marrow to mount a peak regenerative response, so reticulocytosis may initially be absent with blood loss or hemolysis. Direct antiglobulin test (Coombs’ test) indicated when immune-mediated hemolytic anemia suspected; a positive test and evidence of phagocytosis (canine) in the peripheral blood is confirmatory; false negatives and false positives are possible. PCR test for PK deficiency—young Basenji, beagle, dachshund, Toy Foxterrier, West Highland white terrier, and cairn breeds with persistent anemia, massive reticulocytosis and a negative Coombs’ test. PCR test for PFK deficiency: Spanish and whippets with recurrent hemolytic crises.

**Diagnostic Procedures**

- Bone marrow aspirate—needed only when reticulocytosis is lacking; RBC hyperplasia confirms regenerative response. Bone marrow biopsy—useful in evaluation of bone marrow architecture and overall cellularity; important for confirmation of nonregenerative process.

**Treatment**

- Emergency if anemia is severe and develops rapidly. Massive hemolysis leads to hypovolemic shock and anuria; acute hemolysis leads to anuria. Cage rest and careful observation indicated, depending on severity of signs.

**Blood Loss Anemias**

- Traumatic blood loss leading to shock-cryocrystallized fluids can rapidly correct hypovolemia and restore circulation. RBC replacement (packed RBCs or whole blood) indicated if PCV < 15–20% and signs of severe hypoxia (i.e., extremely pale mucous membranes, weakness, tachycardia, pounding pulse, tachypnea). Initial dosage depends on product selected; 6–10 mL/kg for packed RBCs; 10–20 mL/kg for whole blood. Less blood may be needed in animals with chronic anemia. Determine blood type prior to transfusion, to ensure compatibility. Cross match against donor blood if blood typing reagents not available, or if patient requires second transfusion more than 4 days after first transfusion. Animals with chronic blood loss are normocytic with increased cardiac output, therefore transfusion volumes and rates should be conservative to avoid cardiac failure.

**Hemolytic Anemias**

- Blood transfusion may be indicated; in patients with immune-mediated process, RBCs probably survive similar to patient’s own RBCs, so transfusion should not be withheld if marked signs of anemia present.

**Follow-Up Patient Monitoring**

- Initially, monitor of RBC mass (e.g., PCV, RBC count, and hemoglobin) and morphologic features on a blood film (i.e., polychromasia) every 24 hours to evaluate effectiveness of treatment and bone marrow responsiveness. At regeneration becomes apparent (rising RBC values and polychromasia), recheck patients every 3–5 days; return to normal values occurs about 14 days after acute hemorrhage but may take longer with immune-mediated process. Following transfusion, monitor for complications (see Blood Transfusion Reactions).

**Miscellaneous**

- Anemia, Heinz Body
- Anemia, Immune-Mediated
- Anemia, Iron-Deficiency
- Babesiosis
- Bartonellosis
- Cats—yes, if hematology
- Cytophaga,acterized 
- Dogs—yes.
- Hyperbilirubinemia and bilirubinuria
- Hyperlipidemia
- Hemolytic anemias—varies with cause of hemolysis.
- It takes about 14 days after acute hemorrhage but may take longer with immune-mediated process.
- Systemic lupus erythematosus
- Zinc Toxicosis

**Suggested Reading**


**Author** Joyce S. Knoll

**Consulting Editor** Alan H. Rebar
BASICS

DEFINITION
Asymmetric pupils

PATHOPHYSIOLOGY
• Disruption of sympathetic (causing miosis) or parasympathetic (causing mydriasis) innervation to the eye.
• Ocular disease – numerous causes.

SYSTEMS AFFECTED
• Nervous
• Ophthalmic

GENETICS
None

INCIDENCE/PREVALENCE
Common

GEOGRAPHIC DISTRIBUTION
None

SIGNALMENT
• Dog and cat
• All ages affected
• No gender predisposition

Table 1

<table>
<thead>
<tr>
<th>Neurologic lesions causing anisocoria.</th>
<th>Lesion Localization</th>
<th>Differential List</th>
<th>Diagnostic Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mydriasis—Inability to constrict the pupil</td>
<td>Ipsilateral optic nerve/chiasm</td>
<td>Neuritis, neoplasia</td>
<td>MRI/CSF tap/ERG</td>
</tr>
<tr>
<td></td>
<td>Ipsilateral oculomotor nerve/nucleus</td>
<td>Encephalitis, neoplasia, trauma, retrolabial mass</td>
<td>MRI/CSF tap Ultrasound orbit</td>
</tr>
<tr>
<td>Miosis—Inability to dilate the pupil</td>
<td>Ipsilateral oculomotor nerve/nucleus</td>
<td>Trauma, myelitis, neoplasia, IVDD (rare)</td>
<td>MRI/myelogram/CT</td>
</tr>
<tr>
<td></td>
<td>C1-T2 myelopathy or C6-T2 brachial plexus</td>
<td>Trauma, myelitis, neoplasia, IVDD (rare)</td>
<td>MRI/myelogram/CT</td>
</tr>
<tr>
<td></td>
<td>Vagus/sympathetic trunk</td>
<td>Jugular venipuncture, trauma</td>
<td>MRI/ultrasound</td>
</tr>
<tr>
<td></td>
<td>Trigeminal nerve</td>
<td>Otitis media, neoplasia, trauma</td>
<td>MRI/CT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuritis, neoplasia</td>
<td>MRI</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Ocular diseases causing anisocoria.</th>
<th>Associated Signs</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior uveitis</td>
<td>Miosis, aqueous flare, corneal edema, conjunctival hyperemia</td>
<td>Infectious/inflammatory disease, trauma, neoplasia</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Mydriasis, Sluggish/absent PLR, increased intraocular pressure, corneal edema</td>
<td>Primary glaucoma, secondary glaucoma</td>
</tr>
<tr>
<td>Neoplasm</td>
<td>Miosis/mydriasis, iris color change</td>
<td>Lymphoma, melanoma</td>
</tr>
<tr>
<td>Posterior synechia</td>
<td>Variable pupil shape, sluggish/absent PLR, anterior uveitis</td>
<td>Secondary to anterior uveitis, Old age change</td>
</tr>
<tr>
<td>Iris atrophy</td>
<td>Variable pupil shape, iris thinning, sluggish PLR</td>
<td>Congenital Atrophi</td>
</tr>
<tr>
<td>Iris hypoplasia</td>
<td>Sluggish/absent PLR, irregular pupil margin, other ocular abnormalities</td>
<td>Congenital Atroph</td>
</tr>
<tr>
<td>Pharmacologic blockade</td>
<td>Mydriasis, Abnormal direct/consensual PLR</td>
<td>Congenital Atroph</td>
</tr>
<tr>
<td>Spastic pupil syndrome</td>
<td>Miosis, normal vision</td>
<td>FeLV</td>
</tr>
</tbody>
</table>
**Medication**
- **Drug(s) of Choice**: Dependent on underlying disease
- **Contraindications**: N/A
- **Precautions**: N/A
- **Possible Interactions**: N/A
- **Alternative Drug(s)**: N/A

**Follow-Up**
- **Patient Monitoring**: N/A
- **Prevention/Avoidance**: N/A
- **Possible Complications**: N/A
- **Expected Course and Prognosis**: Dependent on the underlying disease

**Miscellaneous**
- **Associated Conditions**: N/A
- **Age-Related Factors**: N/A
- **Zoonotic Potential**: N/A
- **Pregnancy/Fertility/Breeding**: N/A
- **Syonyms**: None
- **See Also**: [Anterior Uveitis—Cats](#), [Anterior Uveitis—Dogs](#), [Glaucoma](#), [Horner's Syndrome](#), [Iris Atrophy](#), [Optic Neuritis and Papillodema](#)

**Abbreviations**
- CNS = central nervous system
- CSF = cerebrospinal fluid
- CT = computed tomography
- ERG = electroretinogram
- FeLV = feline leukemia virus

**Internet Resources**
- None

**Suggested Reading**

**Acknowledgment**
- The author and editors acknowledge the prior contribution of David Lipsitz.

**Client Education Handout**
- Available online
Anorexia

**BASICS**

**DEFINITION**
The lack or loss of appetite for food; appetite is psychological and its existence in animals is assumed. Hunger is physiologically assessed by the body’s need for food. Anorexia may be partial (pseudonorexia) or complete. Anorexia results in decreased food intake, which then leads to weight loss. Pseudonorexia is associated with the inability to prehend or swallow food rather than actual loss of appetite.

**PATHOPHYSIOLOGY**
- The control of appetite is a complex interaction between the central nervous system and the periphery. The hypothalamus and brainstem contain peptidergic feeding-regulatory neurons that act as input stations for sensory and metabolic signals. These cell populations project to several brain regions and interconnect extensively. Sensory signals that affect appetite include the odor, taste, texture, and temperature of food as well as gastric and duodenal distention. Metabolic signals for hunger and satiety include a variety of peptides and hormones released during the fasting and fed states as well as plasma concentrations of glucose and fatty acids interacting with nutrient-specific receptors in the liver and gastrointestinal tract. Leptin is primarily produced by adipocytes and acts on specific hypothalamic receptors to decrease melanocortin and decrease appetite.
- Neuropeptide Y release from the gastrointestinal tract induces hunger and hyperphagia, and decreases energy expenditure after food restriction. Ghrelin produced by the stomach is a prokinetic and decreases leptin and increases neuropeptide Y production. Cholecystokinin and bombesin released from the gastrointestinal tract decrease appetite. Serotonin is an important and perhaps final mediator centrally via a serotonergic tract that passes near the ventromedial hypothalamus. Dopaminergic tracts in the hypothalamus help regulate food intake and are closely associated with the lateral hypothalamus (classical feeding center). Environmental factors including the location and timing of meals as well as learned behaviors and circadian rhythm modulate appetite and may override other signals for satiety and hunger. Appetite is stimulated by aldosterone and cortisol and suppressed by glucagon and somatostatin. Inflammatory and neoplastic disease can cause hyporexia by releasing proinflammatory cytokines such as interleukin-1, tumor necrosis factor, and interferon. The expected upregulation of dietary intake in response to elevated energy expenditure is frequently absent in cancer patients.

**SYSTEMS AFFECTED**
- All body systems

**SIGNALMENT**

- **Species**: Dog and cat
- **Breed Predictions**: N/A
- **Predominant Sex**: N/A
- **Historical Findings**
  - Refusal to eat is a common presenting complaint because pet owners strongly associate poor appetite with illness. Patients with disorders causing dysfunction or pain of the face, neck, oropharynx, and esophagus may display an interest in food but cannot eat. These patients are referred to as being pseudoanorectic. Animals lacking a sense of smell (anosmia) often show no snuffling behavior.
  - Weight loss may be noted.

**Physical Examination Findings**

- Clinical signs in animals with anorexia/hyporexia vary depending on the underlying cause but may include fever, pallor, icterus, abnormal lung sounds, adventitious lung sounds, abdominal distention, dyspnea, muffled heart sounds, abnormal heart sounds, cardiac murmurs, and masses. Weight loss and muscle wasting may be evident depending upon the extent and duration of decreased food intake.
- Pseudoanorectic patients commonly display weight loss, halitosis, excessive drooling, difficulty in prehending and masticating food, and odynophagia (painful swallowing).

**CAUSES**

**Anorexia/Hyporexia**
- Almost all systemic disease process can cause anorexia/hyporexia.
- Psychological—unpalatable diet, food aversion, stress, alterations in routine and environment.
- Pain. Toxicosis and drug side-effects.
- GI disease. Acute and chronic pancreatitis, gastrointestinal and liver disease, sepsis.
- Cardiac failure.
- Endocrine and metabolic disease.
- Neoplasia.
- Immune-mediated disease.
- Respiratory disease.
- Musculoskeletal disease.
- Miscellaneous (e.g., motion sickness, high environmental temperature).

**Pseudoanorexia**
- Any disease causing painful or dysfunctional prehension, mastication, and swallowing.
- Somatotropin, growth hormone, thyrotropin, and leptin.
- Inflammatory, bacterial or viral infections, foreign bodies, immune-mediated disease, neoplasia.
- Hypothyroidism, myasthenia gravis, botulism, and myositis.
- Retropharyngeal abscesses.
- Central nervous system lesions.
- Musculoskeletal lesions.
- Septic esophagus.
- Salivary gland neoplasia or inflammation.

**RISK FACTORS**

- N/A

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

- Perform a nutritional assessment. Gather information about the patient and diet (including all foods fed to the patient), food intake (current and normal) and obtain body and muscle condition scores.
- Elicit a thorough history regarding the patient’s environment, changes in routine, people, or other pets to help identify potential psychological etiologies.
- Question owners about the patient’s interest in food and ability to prehend, masticate, and swallow food.
- A complete physical examination is required to determine the presence of systemic disease.
- Perform a thorough ophthalmic, dental, oropharyngeal, facial, and cervical examination. Complete blood count, serum biochemistry panel, urinalysis, hepatic, and lymphatic imaging examination of tissue/cell samples are often required to make a definitive diagnosis.
- Only if the history, physical examination, and database strongly suggest psychological anorexia should further diagnostic work-up be forgone; in such cases, daily contact with the pet owner is essential until the anorexia has resolved.

**CBC/BIOCHEMISTRY/URINALYSIS**

- Abnormalities vary with different underlying diseases and causes of pseudoanorexia and anorexia. Can be
normal in patients with medical as well as psychologic causes of anorexia.

OTHER LABORATORY TESTS

Special diagnostic tests may be necessary to rule out specific diseases suggested by history, physical examination, and preliminary tests.

IMAGING

• Thoracic and abdominal imaging (radiographic and ultrasonographic studies) are often included in the minimum database to detect anatomic or functional abnormalities.
• Videofluoroscopy may be indicated to specifically evaluate pharyngeal and esophageal function.

DIAGNOSTIC PROCEDURES

• Vary with underlying condition suspected.
• Endoscopy may be useful for visualization of the pharyngeal and esophageal structures.

TREATMENT

• The mainstay of treatment is aimed at identifying and correcting the underlying disease. • Symptomatic therapy includes attention to fluid and electrolyte derangements, control of pain and/or nausea, reduction in environmental stressors, and modification of the diet to improve palatability. • Palatability can be improved by adding flavored toppings such as chicken and beef broth, seasoning with condiments such as garlic powder, increasing the moisture, fat or protein content of the food, and warming the food to body temperature. • When learned food aversion is suspected, food should be offered cautiously and removed immediately at the first signs of aversion. A patient showing signs of aversion to its normal diet may accept novel foods.
• Medications the patient is receiving should be reviewed for possible side-effects leading to reduced food intake.

POTENTIAL COMPLICATIONS

• Dehydration, malnutrition, and cachexia are most likely; these exacerbate the underlying disease.
• A loss of more than 25–30% of body protein compromises the immune system and muscle strength, and death results from infection and/or pulmonary failure.
• Feline hepatic lipidosis is a possible complication of anorexia in obese cats.
• Breakdown of the intestinal mucosal barrier is a concern in debilitated patients.

EXPECTED COURSE AND PROGNOSIS

Varies with underlying cause.

MISCELLANEOUS

ASSOCIATED CONDITIONS

N/A

AGE-RELATED FACTORS

N/A

PREGNANCY/FERTILITY/BREEDING

N/A

SYNONYMS

N/A

SEE ALSO

See “Causes”

ABBREVIATION

CCK = cholecystokinin

SUGGESTED READING


Author Katheryn E. Michel

Consulting Editor Stanley L. Marks

Acknowledgment The author and editors acknowledge the prior contribution of Elizabeth M. Streeter.

Client Education Handout available online
Antebrachial Growth Deformities

**Basics**

**Definition**
Abnormally shaped forelimbs and/or malalignments of the elbow or antebrachial carpal joints that result from maldevelopment of the radius or ulna in the growing animal.

**Pathophysiology**
- Premature radial physeal closure—implies deformities resulting from growth of one bone after premature closure or decreased growth rate of the paired bone. 
- Decreased rate of elongation in one bone behaves as a retarding strap; the growing paired bone must twist and curve around the short bone or overgrow at the elbow or carpus; causes joint malalignment. 
- Normal growth—bones elongate through the process of endochondral ossification, which occurs in the physeal closure occurs when the germinal cell layer stops producing new cartilage and the existing cartilage hypertrophies, ossifies, and is remodelled into bone. 
- Heredity—may be a component of common elbow joint malalignment in many chondrodysplastic breeds (e.g., basset hound and Lhasa apso). 
- Osteochondrosis or dietary over-supplementation—possibly associated with retardation of endochondral ossification of germinal cartilage cores in giant-breed dogs. 
- Hypertrophic osteodystrophy—juvenile growth syndrome with physeal and peristemal inflammation that may impede growth. 
- Trauma—most common cause; if germinal cell layer of the physe is damaged, new cartilage production and bone elongation are stopped. Commonly occurs with fractures involving the distal ulnar or radial growth plates. A crushing-type fracture (Salter-Harris type V) may not be detected on radiographs of the injured antebrachium, and angular deformity only becomes evident over time due to lack of growth of the affected bone.

**Systems Affected**
Musculoskeletal

**Genetics**
- Skye terrier—recessive inheritable trait. 
- Chondrodysplastic breeds (disturbed endochondral ossification results in asymmetrical growth of the paired bone system, resulting in altered growth and angular deformity. Affected dogs are predisposed to elbow malalignment.

**Incidence/Predominance**
- Most common cause; if germinal cell layer of the physe is damaged, new cartilage production and bone elongation are stopped. Commonly occurs with fractures involving the distal ulnar or radial growth plates. A crushing-type fracture (Salter-Harris type V) may not be detected on radiographs of the injured antebrachium, and angular deformity only becomes evident over time due to lack of growth of the affected bone.

**Geographic Distribution**
N/A

**Signalment**
- Species: Dog and cat
- Breed Predictions: 
  - Short-limbed breeds—various angular deformities generally more common. 
  - Shorter-limbed dogs—tend to develop more severe joint malalignments. 
  - Giant breeds (e.g., Great Dane, wolfhound)—may be induced by rapid growth owing to excessive or unbalanced nutrition, ossification, or hypertrophic osteodystrophy.

**Mean Age and Range**
- Trauma—time during the active growth phase. 
- Elbow malalignments—also may occur during growth; may not be recognized until secondary arthritic changes become severe, occasionally at several years of age.

**Predominant Sex**
N/A

**Signs**
- General Comments: 
  - Long-limbed dogs—angular deformities generally more common. 
  - Shorter-limbed dogs tend to develop more severe joint malalignments.
- Age at time of premature closure affects relative degree of deformity and joint malarticulation; dogs with more growth potential remaining tend to develop more severe deformity.

**Historical Findings**
- Trauma—progressive limb angulation or lameness 3–4 weeks after injury; owner may not be aware of causative event.
- Developmental elbow malalignments—insidious onset of lameness in one or both forelimbs; most apparent after exercise.

**Physical Examination Findings**
- Premature Distal Ulnar Closure
  - Results in three deformities of the distal radius—lateral deviation (valgus), cranial bowing (procervical), and external torsion resulting in supination of the manus.
  - Relative shortening of limb length compared to the contralateral normally growing limb.
  - Caudal subluxation of the distal ulnar carpal and malarticulation of the elbow joint—may occur, causes lameness and painful joint restriction.

- Premature Radial Physical Closure
  - Affected limb—significantly shorter than the normal contralateral. 
  - Severity of lameness—depends on degree of joint malarticulation. 
  - Complete symmetrical closure of distal radial—may note straight limb with a widened radiocarpal or radioulnar joint space; may note caudal bow (recurvatum) to radius and ulna.
  - Symmetrical closure of medial aspect of distal radial physe—valgus angular deformity; occasionally internal torsion and pronation.
  - Closure of lateral aspect of distal physe—external torsion.
- Premature closure of radial physe with continued ulnar growth—may result in orientation of the elbow joints; widened radioulnar joint space, and proximal subluxation of the humeroulnar joint (increased humerus to anconal process space).

**Causes**
- Trauma—Developmental basis
- Nutritional—may be induced by rapid growth owing to excessive or unbalanced nutrition, ossification, or hypertrophic osteodystrophy.

**Risk Factors**
- Forelimb trauma—Excessive dietary supplementation

**Diagnosis**

**Differential Diagnosis**
- Elbow dysplasia 
- Fragmented medial coronoid process 
- Ununited anconeal process 
- Panosteitis 
- Focal tendon contracture 
- Hypertrophic osteodystrophy

**CBC/Biochemistry/Urine Analysis**
N/A

**Other Laboratory Tests**
N/A

**Imaging**
- Damage to growth potential of the physe—commonly cannot be seen at the time of trauma; typically 2–4 weeks before radiographically apparent. 
- Standard cranio-caudal and mediolateral radiographic views—include entire elbow joint; from mid-humerus proximally extend to digits distally, take same series for comparison to normal contralateral limb. 
- Degree of angular deformities and relative shortening—determined by comparing relative lengths of radius and ulna within the deformed pair to the normal contralateral pair. 
- Degree of torsional deformity—determined by comparing position of the elbow and carpus on same view, i.e., lateral projection of elbow and 45° oblique of carpus on same view indicates torsional deformity. 
- Cross-sectional imaging and creation of models using stereolithography is useful for full appreciation of the deformity. 
- Elbow and carpal joints—evaluate for malalignment and degenerative changes. 
- Presence of degenerative change is associated with less optimal outcome following surgical treatment. 
- Elbow joint—evaluate for associated ununited anconal process and fragmented medial coronoid process.
ANTEBRACHIAL GROWTH DEFORMITIES

DIAGNOSTIC PROCEDURES

N/A

PATHOLOGIC FINDINGS

Cartilage of abnormal growth plate often replaced with bone. Angule deformity can occur due to retained cartilage core (osteochondrosis) of the ulna.

TREATMENT

APPROPRIATE HEALTH CARE

• Genetic predisposition—do not breed.
• Traumaticphysicaleffects—not seen at time of injury; revealed 2–4 weeks later. In young (<6 months) animals, surgical treatment is generally recommended as soon as possible following diagnosis. Treatment may require multiple surgical procedures.

NURSING CARE

N/A

ACTIVITY

Exercise restriction—reduces joint malalignment damage; slows arthritis progression.

DIET

• Decreasing nutritional supplementation in giant-breed dogs—slows rapid growth; may reduce incidence. • Avoid excess weight—helps control arthritic pain resulting from joint malalignment and overuse.

CLIENT EDUCATION

• Discuss heritability in chondrodystrophic breeds. • Explain that damage to physical growth potential is not apparent at time of forelimb trauma and that the diagnosis is often made 2–4 weeks following an injury.
• Discuss the importance of joint malalignment and resultant osteoarthritis as primary causes of lameness. • Emphasize that early surgical treatment leads to a better prognosis. • Depending on the patient's age, treatment may involve multiple procedures.

SURGICAL CONSIDERATIONS

• Premature distal ulnar physeal closure in a patient <5–6 months of age (significant amount of radial growth potential remaining)—treated with partial ulnar osteotomy, wedge deformities ≤ 25° may improve and may not require additional surgery; young patients and those with more severe deformities: often require a second definitive correction after maturity. • Radial or ulnar physical closure in a mature patient (limited or no growth potential) requires definitive deformity correction, joint realignment, or both. • Deformity correction—may be accomplished with a variety of osteotomy techniques; may be stabilized with several different internal or external fixation devices; must correct both torsional and angular deformities; performed at the point of greatest curvature. • Joint malalignment (particularly elbow)—must correct to minimize arthritis development (primary cause of lameness); obtain optimal joint alignment via dynamic proximal ulnar osteotomy (use triceps brachii muscle traction and joint pressure) or shortening longer bone (radial or ulnar osteotomy as indicated).
• Significant limb length discrepancies—distraction osteogenesis, osteotomy of the shortened bone is progressively distracted at the rate of 1 mm/day with an external fixator system to create new bone length.

MEDICATIONS

DRUG(S) OF CHOICE

Anti-inflammatory drugs—symptomatic treatment of osteoarthritis

CONTRAINDICATIONS

Corticosteroids—do not use owing to potential systemic side effects and cartilage damage seen with long-term use.

PRECAUTIONS

Warn client of possible gastrointestinal upset associated with chronic anti-inflammatory therapy.

POSSIBLE INTERACTIONS

N/A

ALTERNATIVE DRUG(S)

Neutraceuticals (e.g., chondroitin sulfate and glucosamine)—may help minimize cartilage damage and osteoarthritis development, but not proven.

FOLLOW-UP

PATIENT MONITORING

• Periodic checkups—evaluate arthritic status and anti-inflammatory therapy.

PREVENTION/AVOIDANCE

• Selective breeding of susceptible breeds.
• Avoid dietary oversupplementation in rapidly growing giant-breed dogs.

POSSIBLE COMPLICATIONS

Routinely seen with various osteotomy fixation techniques (e.g., infection, non-union of osteotomy, fixator pin tract infection, undercorrection)

EXPECTED COURSE AND PROGNOSIS

• Generally, best results seen with early diagnosis and surgical treatment—minimizes osteoarthritis. • Premature ulnar closure—tends to be easier to manage than premature closure of the radial growth plate. Progression is dependent on severity of the deformity, joint congruity, and presence of degenerative joint disease. The prognosis worsens with increasing severity. • Limb lengthening by distraction osteogenesis—requires extensive postoperative management by the veterinarian and owner; high rate of complications.

MISCELLANEOUS

ASSOCIATED CONDITIONS

• Osteochondromas • Hypertrophic osteodystrophy • Un-united anconal process

AGE-RELATED FACTORS

The younger the patient at the time of traumatically induced physical closure, the more severe the deformity and malarticulation.

ZOONOTIC POTENTIAL

N/A

PREGNANCY/FERTILITY/BREEDING

N/A

SYNONYMS

Radius curvus

ABBREVIATIONS

HOD = Hypertrophic Osteodystrophy
OC = osteochondrodysplasia
UAU = un-united anconal process

Suggested Reading


Author: A. Johnson
Consulting Editor: Walter C. Renberg
Acknowledgment: The author and editors acknowledge the prior contribution of Peter K. Shires.

Client Education Handout available online online
inflammatory cells adherent to corneal endothelial lattice, most notable ventrally.
• Aquous flare and cells—cloudiness of aqueous humor due to increased protein content and suspended cellular debris; best visualized with a bright, narrow beam of light shined through anterior chamber.
• Ciliary flush— injection of deep perilimbal anterior ciliary vessels. • Deep corneal vascularization—circumferential distribution (brush border). • Miosis and/or resistance to pharmacologic dilation. • Iridal swelling— may be generalized or nodular. • Reduced IOP is consistent with anterior uveitis but is not a uniform finding. • Posterior synchysis—adhesions between posterior iris and anterior lens surface. • Fibrin in anterior chamber.
• Hypopyon or hyphema—accumulations of white blood cells or red blood cells, respectively, in the anterior chamber, usually settles horizontally in ventral aspect of chamber but may be diffuse. • Chronic changes may include ruberosis iridis, iridal hypopigmentation, secondary cataract, lens luxation, pupillary scission, iris bomblet, secondary glaucoma, and phthisis bulbi.
CAUSES
• Infectious—mycotic (Blastomyces spp., Cryptococcus neoformans, Coccidioides immitis; Histoplasma capsulatum); protozoan (Toxoplasma gondii; Leishmania infantum); bacteria (Bartonella spp., Mycobacterium spp. or any bacterial septicaemia); viral (FIV, FeLV, feline coronavirus, FHV-1); parasitic (ophthalmoniomysis; ocular larval migrans).
• Idiopathic—lymphocytic-plasmacytic uveitis. • Immune-mediated—reaction to lens proteins (due to cataract or lens trauma). • Neoplastic—primary ocular tumors (esp. diffuse iris melanoma, ocular sarcoma); metastasis to uveal tract (esp. lymphoma).
• Metabolic—hyperplasia; hyperlipemia; hyperviscosity; systemic hypertension. • Miscellaneous—trauma (blunt or penetrating); ulcerative keratitis; corneal stromal abscess; toxemia of any cause.
RISK FACTORS
None specific; immune suppression and geographic location may increase incidence of certain infectious causes of uveitis.
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Conjunctivitis—redness limited to conjunctival hyperemia (i.e., no ciliary flush); ocular discharge usually thicker and more copious than in uveitis; discomfort may be alleviated by topical anesthetic. • Glaucouma—elevated IOP is most consistent distinguishing feature of this disease; others may include dilated pupil, Haab’s ring, and buphthalmos.
• Ulcerative keratitis—corneal fluorescein staining will detect ulcers; corneal edema associated with ulcers is either localized to, or most severe, at site of ulcers; ocular discharge often thicker and more copious than with uveitis; discomfort may be alleviated by topical anesthetic. • Horner’s syndrome—miosis, miosis, and nictitans protrusion are similar in both conditions, but Horner’s is non-painful with no ocular discharge; paresis with Horner’s is distinguished from blepharoedema, the latter is an active process minor conjunctival hyperemia may be noted with Horner’s, but cornea and anterior chamber lack diffuse, clinical signs of Horner’s syndrome resolve following topical application of ophthalmic 1–10% phenylephrine.
CBC/BIOCHEMISTRY/URINALYSIS
• CBC—often normal; changes may be present related to underlying disease.
• Biochemistry—often normal; most common abnormality in cats with uveitis is elevated serum proteins (usually due to polyclonal gammopathy). • Urinalysis—often normal; changes may be present related to underlying disease.
OTHER LABORATORY TESTS
• FELV serum titers. • FIV serum titers. • Coronavirus serologies—serum titers not specific for FIP but may influence the index of suspicion for this disease. • Toxoplasma gondii IgM and IgG titers performed on serum and/or aqueous humor. • Bartonella spp. serology, PCR (serum or aqueous humor) and/or blood culture.
IMAGING
• Thoracic radiography—may show evidence of caustic disease process (e.g., infiltrates related to infectious disease); evidence of metastatic neoplastic disease. • Ocular ultrasound—may reveal if opacity of ocular media precludes direct examination; may reveal intraocular neoplasm or retinal detachment.
DIAGNOSTIC PROCEDURES
• Tonometry—low IOP consistent with uveitis; elevated IOP indicates glaucoma (primary disease or secondary to uveitis).
• Ocular cerclage—if retinal detachment is present, surgery of subtotal retinopexy may reveal causative agents; anterior chamber cerclage may be performed for Toxoplasma gondii or Bartonella IgM and IgG titers on aqueous humor.
PATHOLOGIC FINDINGS
• Gross—see physical examination findings.
• Histopathologic—corneal edema; peripheral corneal deep stromal vascularization; keratic precipitates; periostal fibrovascular membrane; peripheral anterior synchysis; posterior synchysis; epiretinal membrane; anterior cataract; secondary cataract; with posterior segment involvement.
in inflammatory process, sydromic membrane; virebral traction bands and renal detachment may be present. • Lymphoplasmacytic infiltrate of iris and ciliary body (either diffuse or nodular) is most common histopathologic finding.

## TREATMENT
### APPROPRIATE HEALTH CARE
• Outpatient medical management generally sufficient

### ACTIVITY
No changes indicated in most cases.

### DIET
No changes indicated.

### CLIENT EDUCATION
• Inform of potential systemic diseases causing ophthalmic signs and emphasize importance of appropriate diagnostic testing.
• In addition to symptomatic uveitis treatment, treatment of underlying disease (when possible) is paramount to a positive outcome. • Inform of potential complications and emphasize compliance with treatment and follow-up recommendations that will reduce the likelihood of complications.

### SURGICAL CONSIDERATIONS
• None in most cases. • Specific instances requiring surgical intervention include removal of ruptured lenses and surgical management of secondary glaucoma.
• Chronic uveitis leading to secondary glaucoma commonly necessitates excision of affected globes. • Enucleation is recommended in cats with uveitis related to diffuse iris melanoma or other primary intraocular tumors.

### MEDICATIONS
#### DRUG(S)
**Corticosteroids**

- **Topical**
  - Prednisolone acetate 1%—apply 2–8 times daily, depending on severity of disease; taper medication as condition resolves.
  - Dexamethasone 0.1%—apply 2–8 times daily, depending on severity of disease; taper medication as condition resolves.

- **Subconjunctival**
  - Triamcinolone acetonide 4 mg by subconjunctival injection.
  - Methylprednisolone 4 mg by subconjunctival injection. • Often not required. • Indicated only in severe cases as one-time injection, followed by topical and/or systemic anti-inflammatories.

- **Systemic**
  - Prednisolone 1–3 mg/kg/day initially; taper dose after 7–10 days. • Use only if systemic infectious causes of uveitis have been ruled out.

- **Nonsteroidal Anti-inflammatory Drugs**
  - Topical
    - Flurbiprofen—apply 2–4 times daily, depending on severity of disease.
    - Diclofenac—apply 2–4 times daily, depending on severity of disease.

  - **Systemic**
    - Meloxicam 0.2 mg/kg IV, SC, PO once, then 0.05 mg/kg IV, SC, PO q24h for 2 days, then 0.25 mg/kg q24–48h. Due to potential renal effects, limit duration of use to 4 days.
    - Robenacoxib 1 mg/kg PO once daily; limit duration of use to 3 days. • Ketoprofen 1 mg/kg PO q24h; limit duration of use to 5 days.

- **Topical Mydriatic/Cycloplegic**
  - Atropine sulfate 1%—apply 1–2 times daily, depending on severity of disease. Use lowest frequency adequate to maintain dilated pupil and ocular comfort; taper medication as condition resolves. Ointment is preferred over solution in cats as it causes less salivation.

- **Contraindications**
  - Avoid the use of miotic medications (e.g., pilocarpine), including topical prostaglandins (e.g., latanoprost), in the presence of uveitis.
  - Topical and subconjunctival corticosteroids are absolutely contraindicated in the presence of ulcerative keratitis. • Corticosteroids (topically systemic) should be avoided in cats with systemic hypertension. Avoid systemic NSAIDs in cats with renal disease.

- **Precautions**
  - Owing to concern for secondary glaucoma, topical atropine should be used judiciously and IOP should be monitored periodically.

- **Possible Interactions**
  - Systemic corticosteroids and nonsteroidal anti-inflammatory drugs should not be used concurrently.

### FOLLOW-UP
#### PATIENT MONITORING
Frequency of subsequent rechecks dictated by severity of disease and response to treatment.

- **Systemic Complications**
  - Occur as a result of the systemic etiology of the uveitis.

- **Ophthalmic Complications**
  - Secondary glaucoma—common complication of chronic uveitis in cats.

### EXPECTED COURSE AND PROGNOSIS
- Guarded prognosis for affected eyes.
- Depends on underlying disease and response to treatment.
- Cats with treatable underlying disease (e.g., toxoplasmosis) are more likely to have a favorable ophthalmic outcome than those with idiopathic lymphocytic-plasmacytic uveitis or untreatable underlying condition (e.g., FIP, FIV).

### MISCELLANEOUS
#### AGE-RELATED FACTORS
- Younger cats more likely to be diagnosed with infectious etiology. • Older cats at higher risk of idiopathic lymphocytic-plasmacytic uveitis and intraocular neoplastic causes.

#### ZOONOTIC POTENTIAL
- None in most cases. • Some forms of systemic infection causing uveitis may pose a slight risk to immunocompromised owners.

#### PREGNANCY/FERTILITY/BREEDING
- Avoid systemic corticosteroids. Because of systemic absorption, topical corticosteroids may also pose a risk, especially with frequent application.

#### SYNONYM
- Iritis

#### SEE ALSO
- Horner’s Syndrome • Red Eye

#### ABBREVIATIONS
- FIV = feline immunodeficiency virus • FHV-1 = feline herpesvirus type 1 • FIP = feline infectious peritonitis • FIV = feline immunodeficiency virus • IOP = intraocular pressure

#### Suggested Reading
**BASES**

**DEFINITION**
- Inflammation of the anterior uveal tissues, including iris (iritis), ciliary body (cyclitis), or both (iridocyclitis).
- May be associated with concurrent posterior uveal and retinal inflammation (choroidal chorioretinitis).

**PATHOPHYSIOLOGY**
- Increased permeability of the blood-aqueous barrier due to infectious, immune-mediated, traumatic, or other causes allows entrance of plasma proteins and blood cellular components into aqueous humor.
- Disruption of blood-aqueous barrier is initiated and maintained by numerous chemical mediators, including histamine, prostaglandins, leukotrienes, serotonin, kinins, and complement.

**SYSTEMS AFFECTED**
- Ophthalmic. Other systems may also be affected by underlying disease process.

**INCIDENCE/PREVALENCE**
- Relatively common condition. True incidence/prevalence unknown.

**GEOGRAPHIC DISTRIBUTION**
- Geographic location may affect incidence of certain infectious causes of uveitis; breed predilections.

**RISK FACTORS**
- Breed (Breed predilections). Certain infectious causes of uveitis; breed affects geographic location and breed predilections.

**CAUSES**
- Infections—mycotic (Blastomyces dermatitidis, Cryptococcus neoformans), rickettsial (Rickettsia typhi, Coxiella burnetii, Francisella tularensis), parasitic (Toxoplasma gondii, Neospora caninum, Leishmania donovani), viral (Vesicular stomatitis virus, Varicella zoster virus, Herpes virus), bacterial (Streptococcus pneumoniae, Escherichia coli, Enterococcus faecalis, Pasteurella multocida, Clostridium perfringens), protozoal (Ehrlichia canis, Bartonella henselae, Piroplasmidae spp.), fungal (Candida albicans, Cryptococcus neoformans), bivalve (Blastomycetes), protozoal (Toxoplasma gondii), neoplastic (lymphoma, leukemia, mastocytoma, adenocarcinoma), metastatic neoplastic disease (lymphosarcoma, hemangiosarcoma, mast cell tumor).

**SIGNALMENT**

**Species**
- Dog.

**Breeds Predispositions**
- None for most cases. Uveitis associated with indolysusory cysts in golden retriever (e.g., golden retriever uveitis, pigmentary uveitis). Increased incidence of uveal dermatologic syndrome in Siberian husky, Alaskan malamute, and Shetland sheepdog.

**Mean Age and Range**
- Any age may be affected. Mean age in uveodermatologic syndrome—2.8 years. Mean age in golden retriever uveitis—8.6 years.

**SIGNS**

**Historical Findings**
- Red eye—due to conjunctival hyperemia and ciliary flush. Cloudy eye—due to corneal edema, aqueous flare, hypopyon, etc.
- Painful eye—manifest by blepharospasm, photophobia, or rubbing eye. Vision loss—variable.

**Physical Examination Findings**
- The importance of a thorough physical examination in dogs presenting with uveitis cannot be overstated.

**Ophthalmic Findings**
- Ocular discomfort manifested by blepharospasm, photophobia, and rubbing eye. • Ocular discharge—usually serous, sometimes mucoid to mucopurulent.
- Conjunctival hyperemia—bulbar and palpebral conjunctiva both usually affected.
- Corneal edema—diffuse, mild to severe.
- Keratic precipitates—multifocal aggregates of inflammatory cells adherent to corneal endothelium; most notably ventrally.
- Aqueous flare and cells—cloudiness of aqueous humor due to increased protein content and suspended cellular debris, best visualized with a bright, narrow beam of light shined through anterior chamber.
- Ciliary flush—injection of deep perilimbal anterior ciliary vessels.
- Deep corneal vascularization—circumcorneal distribution (brush border).
- Miosis and/or resistance to pharmacologic dilatation.
- Iris swelling.
- Reduced IOP is consistent with uveitis but is not a uniform finding.
- Posterior synechiae—adhesions between posterior iris and anterior lens surface.
- Hypopyon or phlebita—accumulations of white blood cells or red blood cells, respectively, in the anterior chamber.
- Sudden vision loss—dorsal retinal detachment.
- Cilioretinal vascularization—circumcorneal distribution.
- Lymph node aspirates—if enlarged nodes may be aspirated.
- Thoracic radiography may show evidence of causative disease process (e.g., systemic mycoses, neoplastic process).
- Abdominal ultrasonography may be warranted if suspicion for metastatic neoplastic disease is high.

**IMAGING**
- Thoracic radiography may show evidence of causative disease process (e.g., systemic mycoses, metastatic neoplasia).
- Ocular ultrasonography is indicated if opacity of ocular media precludes direct examination; may reveal intraocular neoplasm or retinal detachment.

**RISK FACTORS**
- Ocular discomfort may increase incidence of certain infectious causes of uveitic breed predispositions should be considered.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Conjunctivitis—redness limited to conjunctival hyperemia (i.e., no ciliary flush); ocular discharge usually thicker and more copious than in uveitis; discomfort may be alleviated with application of topical anesthetic.
- Glaucoma—elevated IOP is most consistent feature of this disease; others may include dilated pupil, Hauth's lies, and buphthalmo.
- Leukocoria—corneal edema may be localized to site of lens contact with endothelium or may be diffuse as a result of associated uveitis and/or glaucoma; lens location is highly breed associated.
- Ulcerative keratitis—corneal fluorescein staining will direct corneal edema associated with uveitis; anterior uveitis may be either localized to, or most severe at, site of ulcer; ocular discharge often thicker and more copious than with uveitis; discomfort may be partially alleviated by topical anesthetic.
- Corneal endothelial dystrophy or degeneration—diffuse corneal edema is present, but IOP is normal; conjunctival hyperemia and signs of ocular discomfort are generally absent.
- Horner's syndrome—miosis, epiphora, and ptosis are present.
- Neoplasia—idiopathic, lymphosarcoma, hemangiosarcoma, mast cell tumor.
- Metabolic—Aqueous flare and cells—cloudiness of aqueous humor due to increased protein content and suspended cellular debris, best visualized with a bright, narrow beam of light shined through anterior chamber.
- Glaucoma—elevated IOP is most consistent feature of this disease; others may include dilated pupil, Hauth's lies, and buphthalmo.
- Reduced IOP is consistent with uveitis but is not a uniform finding.
- Posterior synechiae—adhesions between posterior iris and anterior lens surface.
- Hypopyon or phlebita—accumulations of white blood cells or red blood cells, respectively, in the anterior chamber.
- Sudden vision loss—dorsal retinal detachment.
- Cilioretinal vascularization—circumcorneal distribution.
- Lymph node aspirates—if enlarged nodes may be aspirated.
- Thoracic radiography may show evidence of causative disease process (e.g., systemic mycoses, metastatic neoplasia).
- Abdominal ultrasonography may be warranted if suspicion for metastatic neoplastic disease is high.
- Ocular ultrasonography is indicated if opacity of ocular media precludes direct examination; may reveal intraocular neoplasm or retinal detachment.

**DIAGNOSTIC PROCEDURES**
- Tonometry—low IOP consistent with uveitis; elevated IOP indicates glaucoma (primary disease or secondary to uveitis).
- Lymph node aspirate—if enlarged nodes are present.
are palpable, aspiration for cytology is indicated. • Ocular center—of retinal detachment is present, cytology of subretinal aspirate may reveal causative agents; anterior chamber centers is generally unrewarding.

**PATHOLOGIC FINDINGS**
- Gross—see "Physical Examination Findings." • Histopathology—corneal edema, peripheral corneal deep stromal vascularization; keratic precipitates; preclinical fibrous vascular membrane; peripheral anterior synchiae; posterior synchiae; entropion or ephartion sore; leukocyte accumulation in iris, dilated body, sclera, choroid (lymphocytic, plasmaemic, supplicative, or granulomatous infiltrates, depending on etiology); cataract; with posterior segment involvement in inflammatory process, ciliary membrane; retinal traction bands and retinal detachment may be present.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
Outpatient medical management is generally sufficient.

**NURSING CARE**
None

**ACTIVITY**
• No changes indicated in most cases.
• Reduced exposure to bright light may alleviate discomfort.

**DIET**
No changes indicated.

**CLIENT EDUCATION**
• Inform of potential systemic diseases causing ophthalmic signs and emphasize importance of appropriate diagnostic testing.
• In addition to symptomatic uveitis treatment, treatment of underlying disease (when possible) is paramount to a positive outcome.

**PRECAUTIONS**
Avoid systemic corticosteroids. Because of possibility of systemic absorption, topical corticosteroids may also pose risk, especially with frequent application in small dogs.

**SURGICAL CONSIDERATIONS**
None in most cases. Specific instances requiring surgical intervention include removal of ruptured lenses, removal of cataracts causing uveitis (if prognosis for successful surgery is otherwise favorable), and surgical management of secondary glaucoma.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

**Corticosteroids**
Topical
- Prednisolone acetate 1%—apply 2–8 times daily, depending on severity of disease; taper medication as condition resolves.

**CONTRAINDICATIONS**
- Avoid the use of systemic medications (e.g., pilocarpine, demecarium bromide), including topical prostaglandin (e.g., latanoprost), in the presence of uveitis. • Topical and subconjunctival corticosteroids are contraindicated in ulcerative keratitis. • Avoid systemic corticosteroids in dogs with systemic hypertension or systemic infections.

**PRECAUTIONS**
Out of concern for secondary glaucoma, topical atropine should be used judiciously and IOP should be monitored periodically.

**POSSIBLE INTERACTIONS**
Systemic corticosteroids and NSAIDS should not be used concurrently.

**ALTERNATIVE DRUG(S)**
N/A
Antidepressant Toxicosis—SSRIs and SNRIs

Basics

Definition
- Toxicity secondary to the overdose of a selective serotonin reuptake inhibitor (SSRI), serotonin and noradrenaline reuptake inhibitor (SNRI) or co-ingestion of two types of serotonergic drugs.
- SSRIs include citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), viloxazine (Visudyne), vortisertine (Brontil). SNRIs include desvenlafaxine (Pristiq), duloxetine (Cymbalta), levomilnacipran (Fentana), milnacipran (Sri, Savella), tafinaxin (Elmidol, Tolcine), and venlafaxine (Effexor).

Pathophysiology
- SSRIs and SNRIs are antidepressants that inhibit reuptake of serotonin, a neurotransmitter involved in aggression, anxiety, appetite, depression, migraine, pain, and sleep. The SNRIs also inhibit the reuptake of norepinephrine.
- Excessive stimulation of serotonin receptors can occur by enhanced serotonin synthesis, increased presynaptic serotonin release, inhibition of serotonin uptake into the presynaptic neuron, inhibition of serotonin metabolism, or serotonin agonism. Serotonin syndrome is characterized in humans as a combination of symptoms that include at least three of the following: myoclonus, mental alteration, agitation, hypertension, tremors, diastase, ataxia, or hyperthermia.
- Toxic dosage varies widely among commonly available SSRIs and SNRIs and are not well defined in veterinary medicine.

Systems Affected
- Cardiovascular—decreased vascular tone (hypotension), increased heart rate and stroke volume (tachycardia).
- Gastrointestinal—increased smooth muscle contractility (vomiting, diarrhea).
- Nervous—stimulation (agitation, restlessness, seizures) and altered mental status (vocalization, disorientation).
- Neuromuscular—autonomic dysfunction (hyporeflexia) and neuromuscular hyperactivity (peripheral hyperreflexia, myoclonus, tremors).
- Ophthalmic—increased autonomic function (mydriasis).
- Respiratory—increased bronchial smooth muscle contraction (dyspnea).

Incidence/Prevalence
Second most common human prescription medication toxicity (after cardiac medications).

Signalment
Species
Dogs and cats

Mean Age and Range
Any age can be affected.

Signs

Historical Findings
- Agitation or lethargy
- Anorexia
- Vomiting
- Tremors
- Hypersalivation
- Hyperactivity (hyperreflexia, myoclonus, restlessness, seizures) and altered mental status (dysphoria).

Physical Examination Findings
- Agitation
- Anorexia
- Mydriasis
- Tremors
- Vomiting
- Disorientation
- Hyperthermia
- Hypersalivation
- Seizures
- Nyctagmus

CAUSE
- SSRIS/SNRI overdose—accidental exposure, inappropriate administration, or therapeutic use.
- Ingestion of an SSRI/SNRI along with another class of medications that increases serotonin (TCA, MAOIs, novel antidepressants, tramadol, fentanyl, propofol, amphetamines, cocaine, desmethylmorphin, 5-HT2B/1A, bupropion, triptans, LSD).

Risk Factors
- Animals on a serotonergic drug.
- Underlying liver or kidney disease.
- Cats are attracted to venlafaxine and will eat multiple capsules.

Diagnosis

Diff erential Diagnosis
- Toxicologic: TCAs, MAOIs, methadone, lead, ethylene glycol, hops, anticholinergics, antihistamines.
- Non-toxicologic: meningitis (e.g., rabies, canine distemper), neoplasia, heat stroke, malignant hyperthermia.

CBC/Biochemistry/Urinealysis
- CBC/biochemistry: no changes are expected.
- Urinalysis: myoglobinuria secondary to rhabdomyolysis may be seen.

Other Laboratory Tests
- Blood gas: metabolic acidosis may be seen.

Treatment

Appropriate Health Care
- Emesis (if asymptomatic and recent ingestion) or gastric lavage (if large number of pills ingested).
- Activated charcoal with cathartic (if severe signs are expected, may need to repeat due to long half-life).

Nursing Care
- IV fluids to help maintain blood pressure and body temperature, and to protect kidneys from myoglobinuria.

Client Education
- If animal appears blinded, sight should return.

Client Education

Drug(s) of Choice
- Antidepressants (e.g., paroxetine [Paxil], sertraline [Zoloft], escitalopram [Lexapro], venlafaxine [Effexor], citalopram [Celexa], fluoxetine [Prozac], duloxetine [Cymbalta], milnacipran [Fentana], levomilnacipran [Fetzima], viloxazine [Visudyne], tofacitin [Tofacetin], and vortioxetine [Brintellix]).

Precautions
- Benodiazepines (e.g., diazepam) are reported by some sources to exacerbate serotonin syndrome and their use for SSRIS/SNRI toxicity is not universally recommended.

Possible Interactions
- Increased levels of medications (decreased metabolism): theophylline, coumadin, digoxin.
FOLLOW-UP

PATIENT MONITORING
Blood pressure, heart rate, urine color: monitor hourly, then less frequently as the animal remains stable.

PREVENTION/AVOIDANCE
• Keep medications out of the reach of animals.
• Follow label directions when giving serotonergic drugs to animals.

POSSIBLE COMPLICATIONS
Renal failure secondary to myoglobinuria from rhabdomyolysis. DIC secondary to hyperthermia.

EXPECTED COURSE AND PROGNOSIS
• Prognosis is good in most cases, with recovery in 12-24 hours.
• Patients that present in status epilepticus or with severe hyperthermia have a guarded prognosis.

MISCELLANEOUS

AGE-RELATED FACTORS
Young and elderly animals are more at risk for developing serious toxicosis.

PREGNANCY/FERTILITY/BREEDING
SSRIs and SNRIs can cause increased litter mortality and possible birth defects.

ABBREVIATIONS
• 5-HTP = 5-hydroxytryptophan
• MAOI = monoamine oxidase inhibitor
• PCP = phencyclidine (angel dust)
• SNRI = serotonin and norepinephrine reuptake inhibitor
• SSRI = selective serotonin reuptake inhibitor
• TCA = tricyclic antidepressant

Suggested Reading


Author Tina Wismer
Consulting Editor Lynn R. Hovda
**Basics**

**Definition**
- Toxicity secondary to the acute or chronic ingestion of a tricyclic antidepressant (TCA).
- TCAs block the reuptake of norepinephrine, dopamine, and serotonin at the neuronal membrane. They also have anticholinergic activity and are thought to have membrane stabilizing effects on the myocardium (particularly inhibiting fast sodium channels in the ventricular myocardium). They can also have slight alpha-adrenergic blocking activity and antiarrhythmic effects.
- TCAs are rapidly and well absorbed across the digestive tract. They can decrease GI motility and delay gastric emptying, resulting in delayed drug absorption.
- Lipophilic, protein bound, and well distributed across all tissues.
- They are metabolized by the liver and undergo enterohepatic recirculation. The inactive metabolites are eliminated in the urine.

**Systems Affected**
- Nervous—increased dopamine, serotonin, and norepinephrine levels in the CNS contribute to CNS signs.
- Cardiovascular—anticholinergic effects and inhibition of norepinephrine reuptake contribute to tachycardia, alpha adrenergic blockade, cardiac membrane stabilization, and decreased cardiac contractility contribute to hypotension and arrhythmias.
- Gastrointestinal—anticholinergic effects may cause ileus and delayed gastric emptying.
- Ophthalmic—anticholinergic effects can cause pupillary dilation.
- Renal/Urinary—anticholinergic effects may cause urinary retention.

**Genetics**
- Species and individual differences in absorption, metabolism, and elimination can be significant.

**Incidence/Prevalence**
- Incidence is unknown.

**Signalment**
- Species:
  - Dogs and cats
- Breed Predilections:
  - None
- Mean Age and Range:
  - None

**Predominant Sex**
- None

**Signs**

- General Comments:
  - Signs can occur at therapeutic doses.
  - Signs of toxicity can occur within 30–60 minutes or be delayed by several hours.

- Historical Findings:
  - Evidence of accidental consumption of the owner’s or another pet’s medication
  - CNS depression (lethargy, ataxia)
  - Vocalization
  - Vomiting or hypersalivation
  - Hyperthermia
  - Tachycardia
  - Paresthesia
  - Taste disturbances
  - Tachyarrhythmias

- Physical Examination Findings:
  - CNS depression or stimulation
  - Tachycardia
  - Mydriasis
  - Mydriasis
  - Hypertension
  - Tachypnea or dyspnea
  - Tinnitus
  - Seizures
  - Urinary retention
  - Urinary retention
  - Constipation

**Cause**
- Accidental exposure, inappropriate medication administration, or therapeutic use.

**Risk Factors**
- Concurrent use of other antipsychotic medication
- Pre-existing cardiac disease

**Diagnosis**

**Differential Diagnosis**
- Toxicity caused by other antipsychotic medication, stimulant substances (e.g., amphetamines, cocaine, methylxanthines, or pseudophedrine) or substances capable of causing cardiac arrhythmias (e.g., quinidine, propranolol, atropine, digoxin).
- Non-toxicologic differentials include hyperkalemia, cardiac ischaemia, cardiomyopathy, and other diseases of cardiac conduction.

**CBC/Biochemistry/Urinalysis**
- Expected to be normal.

**Other Laboratory Tests**
- Blood gases—metabolic acidosis may be noted.
- OTC urine drug screen for TCAs—can be used to determine if exposure has occurred; not useful in determining degree of toxicity.
- Serum TCA levels—can be used to determine if exposure has occurred.

**Imaging**
- N/A

**Diagnostic Procedures**
- ECG to monitor for arrhythmias
- Blood pressure monitoring

**Pathologic Findings**
- No specific lesions expected

**Treatment**

**Appropriate Health Care**
- Outpatient—not recommended for symptomatic patients, patients with cardiac disease, or patients ingesting greater than a therapeutic dose of TCAs.
- Inpatient—antipsychotic:
  - Decontamination with emesis (less than 15 minutes of exposure time), gastric lavage in large exposures, and activated charcoal.
  - Monitor at a clinic for a minimum of 6 hours after exposure.
  - Impairment—symptomatic: stabilize the CV and CNS systems and provide supportive care.

**Nursing Care**
- Fluid therapy—reinstate hydration due to vomiting, regulate blood pressure when hypotension is noted.
- Thermoregulation as needed.
- Enema with warm water if not defecating within 6–12 hours.

**Diet**
- NPO if vomiting

**Client Education**
- With a prescribed TCA, instruct client to:
  - Monitor for adverse or idiosyncratic effects, and to stop the medication and contact the clinic if they occur.
  - Prevent exposure to non-prescribed medication.

**Surgical Considerations**
- N/A

**Medications**

**Drug(s) of Choice**

**Decontamination**
- Emesis within 15 minutes of ingestion only if asymptomatic; induce emesis with either hydrogen peroxide (dog, 1–2 mL/kg PO) or apomorphine (dog/cat, 0.03–0.05 mg/kg IV, IM, or 0.1 mg/kg SC, or 0.25 mg mixed in conjunctiva of eye).
- Gastric lavage under anesthesia may be considered with large exposures.
Antidepressant Toxicosis—Tricyclic

POSSIBLE INTERACTIONS
- TCAs increase risk of hyperthermia, seizures, and death with use of MAOIs.
- Sym pathetic oth and anti cholinergic medications increase the risk for arrhythmias or cardiac effects from TCAs.
- Lev ydroxine increases the risk for arrhythmias when used with TCAs.

ALTERNATIVE DRUG(S)
N/A

FOLLOW-UP

PATIENT MONITORING
- Acid-base status—monitor for acidosis and if implementing sodium bicarbonate therapy.
- Blood pressure—monitor until asymptomatic.
- ECG—monitor until asymptomatic.

PREVENTION/AVOIDANCE
Keep medications out of reach of pets.

EXPECTED COURSE AND PROGNOSIS
- Due to the variable half-lives of the different TCAs, signs can last 24 hours or longer.
- The prognosis is generally good in patients exhibiting mild to moderate signs.
- The prognosis is guarded in patients exhibiting severe signs such as seizures, arrhythmias, or hypotension that are poorly responsive to therapy.

MISCELLANEOUS

ASSOCIATED CONDITIONS
Serotonin syndrome may occur as a result of TCA ingestion.

AGE-RELATED FACTORS
None.

PREGNANCY/FERTILITY/BREEDING
TCAs cross the placenta and be found in breast milk; the significance of this is not known at this time.

SEE ALSO
- Antidepressant Toxicosis—SSRIs and SNRIs
- Poisoning (Intoxication) Therapy

ABBREVIATIONS
- CNS = central nervous system
- CV = cardiovascular
- ECG = electrocardiogram
- GI = gastrointestinal
- MAOI = monoamine oxidase inhibitor
- OTC = over-the-counter
- TCA = tricyclic antidepressant

INTERNET RESOURCES
- http://www.aspcapro.org/poison
- http://www.petpoisonhelpline.com/

Suggested Reading

Author
Cristine L. Hayes

Consulting Editor
Lynn R. Hovda
**Aortic Stenosis**

**BASICS**

**DEFINITION**
A narrowing of the left ventricular outflow tract (LVOT) that restricts blood flow leaving the ventricle. It is most commonly congenital but often acquired. The lesion is most commonly subvalvular in dogs, but may be valvular or supravalvular (more often in cats).

Subvalvular aortic stenosis (SAS) in dogs is caused by fibrous tissue massed as nodules, a ridge, ring or tunnel-like lesion. SAS may be associated with other defects including mitral valve dysplasia.

**PATHOPHYSIOLOGY**
Restoration to outflow generates pressure overload of the LV. Degree of obstruction is related to severity of secondary changes. Left ventricular pressure overload causes thickening of LV walls, resulting in diminished blood supply relative to muscle demand and myocardial ischemia. This may result in arrhythmogenesis and if severe or infarcted, mechanical dysfunction. The restriction to blood flow causes high velocity, turbulent flow across the valve, which may cause endocardial damage, lead to aortic insufficiency (AI) and predisposing to endocarditis. SAS may lead to chamber enlargement, distortion of the mitral valve annulus and mitral regurgitation with a possible sequel of left-sided congestive heart failure. Sudden death is common with severe SAS and may be secondary to arrhythmias or infarction.

**SYSTEMS AFFECTED**
- Cardiovascular—LV pressure overload leading to arrhythmias, syncope, sudden death, heart failure.
- Respiratory—possible pulmonary edema with CHF
- Multi-systemic—possible due to low cardiac output or endocarditis

**GENETICS**
SAS is inherited in the Newfoundland, golden retriever, rottweiler and Dogue de Bordeaux. A mutation in the phosphatidylinositol-binding clathrin assembly protein gene (PECLAM) is reported in Newfoundlands; a screening test is available. Dominant inheritance patterns are proposed with incomplete penetrance responsible for the disease appearing to skip generations. More than one gene or modifying genes may be involved.

**INCIDENCE/PREVALENCE**
SAS is one of the most common congenital heart defects of dogs. It is reported as second most common, but difficulty in diagnosing mild disease may underestimate true prevalence. Aortic stenosis has been reported as a small contributor of feline congenital heart disease, about 0.9%.

**SIGNS**

**Historical Findings**
- Many dogs with SAS show no clinical signs and have no relevant historical findings. SAS and may be secondary to arrhythmias or infarction.
- SAS is often diagnosed in athletic dogs, or with anaemia, fever, stress or excitement. Palpation of the carotid artery may elicit a thrill. The systolic murmur is a to-and-fro murmur.
- An unstable or systolic ejection murmur is noted with disease severity. As the disease worsens during early life, some may have absence of or a quiet murmur that develops to a more characteristic finding by 1 year.
- Diastolic murmurs may be present with significant AI. The combination of this diastolic murmur with the systolic ejection murmur is a to-and-fro murmur.
- Aortic valve insufficiency may be auscultated. Pulse deficits may be appreciated, often associated with ventricular arrhythmias.
- Weak pulses may be appreciated and reduced pulse quality, such as aortic root or narrowed mediastinum.

**Thoracic Radiography**
- Prominent aortic root and/or reduced echogenicity. Lung fields typically normal unless CHF with pulmonary venous distension and interstitial alveolar infiltrates.

**Echocardiography**
- Mitral valve thickening and increased echogenicity with valvar stenosis.
- Mitral regurgitation and

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
The systolic murmur must be differentiated from other causes of similar murmurs. Innocent or physiologic murmurs are commonly associated with athletic dogs, or with anaemia, fever, stress or excitement. Palpation of the carotid artery may elicit a thrill. The systolic murmur is a to-and-fro murmur.

**Physical Examination Findings**
- Systolic left basilar ejection murmur may radiate to the apex, path of the thorax, include the carotid arteries and if very loud or the cranium. A presystolic thrill may be palpable. Murmur intensity is loosely correlated to severity of stenosis. As the disease worsens during early life, some may have absence of or a quiet murmur that develops to a more characteristic finding by 1 year.
- Diastolic murmurs may be present with significant AI. The combination of this diastolic murmur with the systolic ejection murmur is a to-and-fro murmur.
- Aortic valve insufficiency may be auscultated. Pulse deficits may be appreciated, often associated with ventricular arrhythmias.
- Weak pulses may be appreciated and reduced pulse quality, such as aortic root or narrowed mediastinum.

**Thoracic Radiography**
- Prominent aortic root and/or reduced echogenicity. Lung fields typically normal unless CHF with pulmonary venous distension and interstitial alveolar infiltrates.

**Echocardiography**
- Mitral valve thickening and increased echogenicity with valvar stenosis.
- Mitral regurgitation and
thickening of valve leaflet possible.

- Post-stenotic dilatation of the aorta and associated valvular endothelial damage may be evident. Post-stenotic dilatation of the aorta and associated valvular endothelial damage may be evident. Post-stenotic dilatation of the aorta and associated valvular endothelial damage may be evident.

- Effective valve surgery, if successful, is reduced.

DIAGNOSTIC PROCEDURES

- ECG may show changes consistent with LV hypertrophy (fall R waves, widened QRS complex, left axis deviation); signs of myocardial ischemia (ST segment deviation or slurring). Ventricular arrhythmias may occur and contribute to syncope or sudden death.

- Holter monitoring may be used to quantify arrhythmia severity and therapeutic response.

PATHOLOGIC FINDINGS

Findings vary with severity but typically include LV concentric or mixed (if significant AI with secondary LV chamber enlargement and volume overload if significant). Left atrial enlargement may be seen with significant valve regurgitation. LVOT flow velocity estimated by the LVOT flow velocity (4 × flow velocity squared). Estimated gradients of 25–49 mmHg are considered mild; 50–79 mmHg moderate; and ≥ 80 mmHg severe. With myocardial failure the estimated pressure gradient may be falsely low.

Effective valve surgery, if successful, is reduced.

- Therapies for CHF may worsen a fixed obstruction and are used cautiously in this condition.

- Beta-blockers are contraindicated and continued use in patients with bronchoconstriction such as asthmatic cats may worsen bronchoconstriction.

- Beta-blockers should be used cautiously in animals with bronchoconstriction such as asthmatic cats. Beta-blockers may worsen bronchoconstriction and are used cautiously in this condition.

- Annular degenerative disease (heart failure) is frequent in dogs with severe SAS. SAS is not immediately apparent at birth but appears over few weeks to months of life.

- Survival times in dogs with severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.

- Severe SAS on atenolol was about 4.5 years.

- Severely affected dogs have limited lifespans and quality of life and may worsen on atenolol.

- Severely affected dogs may have a normal lifespan if treated with beta-blockers. Currently, data does not support surgery or intervention.
Aortic Thromboembolism

DEFINITION
Aortic thromboembolism results from a thrombus or blood clot that is dislodged within the aorta, causing severe ischemia to the tissues served by that segment of aorta.

PATHOPHYSIOLOGY
• ATE is commonly associated with myocardial disease in cats, most commonly hypertrophic cardiomyopathy. It is theorized that abnormal blood flow (stasis) and a hypercoagulable state contribute to the formation of a thrombus within the left atrium. The blood clot is then embolized distally to the aorta. The most common site of embolization is the caudal aortic trifurcation (hind legs). Other less common sites include the front leg, kidneys, gastrointestinal tract, or cerebrum.
• ATE in dogs typically is associated with neoplasia, sepsis, infectious endocarditis, Cardiomyopathy, protein-losing nephropathy, or other hypercoagulable states. However, in one recent retrospective study, no concurrent condition was identified in 58% of dogs.

SYSTEMS AFFECTED
• Cardiovascular—the majority of affected cats have advanced heart disease and left heart failure.
• Neurological/Musculoskeletal—severe ischemia to the muscles and nerves served by the segment of occluded aorta causes variable pain and paresis. Gait abnormalities or paralysis results in the leg or legs involved.

GENETICS
Hypertrophic cardiomyopathy, a common associated disease, is likely heritable. Additionally, a family of domestic shorthair cats with remodeled hypertrophic cardiomyopathy who all died of ATE has been reported.

INCIDENCE/PREVALENCE
• Prevalence is not known in the general population of cats. In two large studies of cats with hypertrophic cardiomyopathy, 12–16% presented with signs of ATE. In two retrospective studies of cats with ATE, 11–25% of cats had previous evidence of heart disease.
• Rare in dogs.

GEOGRAPHIC DISTRIBUTION
N/A

SIGNALMENT
Species
Cat, rarely dog

Breed Predictions
Mixed-breed cats are most commonly affected. Abyssinian, Birman, and ragdoll purebred cats were overrepresented in one study. In dogs, no breed predilection has been identified in the USA. A European study suggested that Cavalier King Charles Spaniels may be overrepresented.

Mean Age and Range
Age distribution is 1–20 years. The median age is approximately 8–9 years in cats. In dogs, the median age is 8–10 years.

Predominant Sex
Males > females (2:1) in cats. In dogs, no sex predilection in dogs in the USA. A European study suggested a male predilection.

SIGNS
The presence of the 5 “P”s is helpful to remember the classic clinical signs associated with ATE: Pain, Paralysis or Paresis, Pulselessness, Pallor, and Poikilothermic (cold).

Historical Findings
• Acute onset paralysis and pain are the most common complaints in cats. Vocalization and anxiety are also common.
• Lameness or a gait abnormality, typically of several week duration, is more common in dogs.
• Tachypnea or respiratory distress is common in cats.
• About 15% of cats may vomit prior to ATE.

Physical Examination Findings
• Usually paraparesis or paralysis of the rear legs with signs of lower motor neuron injury. Less commonly, monoparesis of a front leg. In dogs, the majority are parietic and ambulatory.
• Absent or diminished femoral pulses.
• Pain upon palpation of the legs.
• Gastrointestinal muscle often becomes firm several hours after embolization.
• Cyanotic or pale nail beds and foot pads.
• Tachypnea and hyperthermia are common in cats.
• Since commonly associated with heart disease in cats, a cardiac murmur, arrhythmias, or gag reflex may be present.

CAUSES
• Cardiomyopathy (all types)
• Hyperthyroidism
• Neoplasia
• Sepsis (dogs)
• Hyperadrenocorticism (dogs)
• Protein-losing nephropathy (dogs)

RISK FACTORS
In the cat, cardiomyopathy is a risk factor. Cardiomyopathic cats with a markedly enlarged left atrium, spontaneous echocardiographic contrast (smoke), or an intracardiac thrombus observed on an echocardiogram are at a higher risk for development of ATE.

In the dog, hypercoagulable conditions, such as neoplasia, sepsis, endocarditis, protein-losing nephropathy, or hyperadrenocorticism are risk factors.

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
Hind limb paralysis secondary to other causes such as spinal neoplasia, trauma, myelitis, fibrocartilaginous infarction, or intervertebral disc protrusion. These conditions resulting in spinal cord injury present with signs of upper motor neuron disease, whereas ATE patients present with signs of lower motor neuron disease.

CBC/BIOCHEMISTRY/URINALYSIS
• High creatinine kinase as a result of muscle injury.
• High separate aminotransferase and alanine aminotransferase as a result of muscle and liver injury.
• Hyperglycemia secondary to stress.
• Mild increases in blood urea nitrogen and creatinine due to low cardiac output and possible renal emboli.
• Electrolyte derangements, due to low output and muscle damage, such as hypocalcemia, hypoxanemia, hyperphosphatemia and hyperkalemia are not uncommon.
• CBC and urinalysis changes are non-specific.

OTHER LABORATORY TESTS
 Routinely available coagulation profiles typically do not reveal significant abnormalities because the hypercoagulability results from hyperaggregable platelets. In the dog, thrombolactography may suggest a hypercoagulable state with a clot strength (increased maximum amplitude) or shortened clotting time (decreased R).

IMAGING
Radiographic Findings
• Cardiomyopathy is common in cats.
• Pulmonary edema and/or pleural effusion in approximately 50% of cats.
• Rarely, a mass is seen in the lungs, suggestive of neoplasia.

Echocardiographic Findings
• Cardiomyopathy is common in cats with hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is most common, followed by restrictive or unclassified cardiomyopathy and then dilated cardiomyopathy.
• Most cases (> 50%) have severe left atrial enlargement (i.e., left atrial to aortic ratio of ≥ 2).
• A left atrial thrombus or spontaneous echocardiographic contrast (smoke) may be seen.

Abdominal Ultrasoundographic Findings
• May be able to identify the thrombus in the caudal aorta.
• Typically not necessary to reach a diagnosis in the cat but often needed to reach a diagnosis in the dog.
**Sinus rhythm and sinus tachycardia**

Nonselective or CT angiography should identify a negative filling defect in the caudal aorta representing the thrombus.

**DIAGNOSTIC PROCEDURES**

- Electrocardiography
- Sinus rhythm and sinus tachycardia most common. Less common rhythms include atrial fibrillation, ventricular arrhythmias, supraventricular arrhythmias, and sinus bradycardia.
- Left ventricular enlargement patterns and left ventricular contraction disturbances (left anterior fascicular block) are common.

**PATHOLOGIC FINDINGS**

- Thrombus typically is identified at the caudal aortic trifurcation.
- Occasionally, a left atrial thrombus is seen.
- Emboli of the kidneys, gastrointestinal tract, cerebrum, and other organs also may be seen.

**TREATMENT**

**APPROPRIATE HEALTH CARE**

Initially, cats with ATE should be treated as inpatients because many have concurrent congestive heart failure and require injectable drugs, in addition to being in considerable pain and distress.

**NURSING CARE**

- Fluid therapy is cautiously used as most cats have advanced myocardial disease. If in congestive heart failure, IV fluid therapy may not be necessary.
- Initially, minimally handle the affected legs. However, as reperfusion occurs, physical therapy (active extension and flexion of the legs) may speed full recovery.
- Do not perform venipuncture on the affected legs.
- These animals may have difficulty posturing to urinate and may need to have their bladders expressed to prevent overdistention or urinate scald.

**ACTIVITY**

- Restrict activity and stress

**DIET**

Initially, most cats are anorexic. Tempt these cats with any type of diet to keep them eating and avoid hepatic lipoidosis.

**CLIENT EDUCATION**

- Short- and long-term prognosis is poor in both dogs and cats.
- Most cats will re-embolize. Most cats that survive an initial episode will be on some type of anticoagulant therapy that may require frequent re-evaluations and an indoor lifestyle.
- Most cats that survive an initial episode will recover complete function to the legs; however, if ischemia was severe and prolonged, sloughing of parts of the distal extremities or persistent neurologic deficits may result. In one study, approximately 15% of cats had permanent neuromuscular abnormalities after surviving the embolic event.
- Based on 3 small retrospective studies in dogs, the prognosis is generally poor but may be better in dogs presenting with chronic (vs. acute) lameness and dogs treated appropriately with warfarin.

**SURGICAL CONSIDERATIONS**

- Surgical embolectomy typically is not recommended because these patients are high risk for surgery because of severe heart disease.
- Rheolytic thrombectomy has been used with limited success in a small number of cats with ATE.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

- Thrombolytic therapy (e.g., tissue plasminogen activator (TPA)) is used extensively in humans and infrequently in cats and dogs. These drugs are expensive and carry a significant risk for bleeding complications; to date, they have not demonstrated improved treatment efficacy and thus are rarely used in general practice. TPA is theorized to be more beneficial if given early, ideally, within the first 6 hours of the event.
- Clopidogrel is an antiplatelet aggregation drug. One may choose to give a loading dose of clopidogrel for treatment of an acute embolic event. The loading dose in the cat is 75 mg/cat PO once and then maintenance dose starting 24h later is 18.75 mg/cat (one-fourth of 75 mg tablet) PO q48h. The loading dose in the dog is approximately 10 mg/kg once and then a maintenance dose of 1 mg/kg q24h. When compared to aspirin, clopidogrel was superior in preventing re-embolization, resulting improved survival times in cats that had survived an ATE.
- Unfractionated heparin is the preferred anticoagulant drug in general practice for initial management of feline ATE. Heparin has no effect on the established clot; however, it prevents further activation of the coagulation cascade. In either a cat or dog, give an initial dose of 100–200 units/kg IV and then 200–300 units/kg SC q8h. Alternatively, heparin can be administered as a CRI, if there is concern about adequate bioavailability via the SC route, at a dose of 25–35 units/kg/h. Titrate the dose to prolong the activated partial thromboplastin time approximately two-fold.
- Aspirin is theoretically beneficial during and after an episode of thromboembolism because of its antiplatelet effects. The dose in cats is an 81 mg tablet PO q48–72h. Vomiting and diarrhea are not uncommon. Some specialists advocate a mini dose of 5 mg/cat q24h.
- Antithrombotic dose recommendations for dogs range from 0.5 to 2 mg/kg q24h. Always give aspirin with food.
- Buprenorphine in the cat is useful and has no effect on the established clot; however, it prevents further activation of the coagulation cascade. In either a cat or dog, give an initial dose of 100–200 units/kg IV and then 200–300 units/kg SC q8h. For stronger analgesia, use fentanyl or hydromorphone.
- Acyclovir may be cautiously used for its antiviral and vasodilatory properties at a dose of 0.1–0.2 mg SC q8–12h.
- Warfarin, a vitamin K antagonist, is the anticoagulant most widely used in humans and has been proposed for prevention of re-embolization in cats surviving an initial episode. The initial dose is 0.25–0.5 mg/cat PO q24h or 0.05–0.2 mg/kg PO q 24h in the dog. Overlap with heparin therapy for 3 days. The dose is then adjusted to prolong the prothrombin time approximately two times its baseline value or to attain an international normalized ratio of 2 to 3. Long-term management with warfarin can be challenging because of frequent monitoring and dose adjustments in addition to bleeding complications. In one study, dogs treated appropriately with warfarin had a better clinical outcome.
- Low molecular weight heparin has recently been proposed for the long-term prevention of feline ATE. LMWH has a more predictable relationship between dose and response than warfarin and does not need monitoring or dose adjustments. It also has a lower risk of bleeding complication. The main disadvantage of LMWH is high drug cost and the injectable route of administration. The two LMWHs that have been used in feline ATE are dalteparin (100–150 units/kg SC q8–24h) and enoxaparin (1 mg/kg SC q12–24h). Best dose unknown. LMWH usually starts q24h due to cost. Some studies suggest q8h dosing necessary for stable blood levels, but may increase bleeding risk.

**CONTRAINDICATIONS**

N/A

**PRECAUTIONS**

- Anticoagulant therapy with heparin, warfarin, or the thrombolytic drugs may cause bleeding complications.
- Avoid a nonselective beta-blocker such as propranolol as it may enhance peripheral vasodilatation.
Aortic Thromboembolism (Continued)

POSSIBLE INTERACTIONS
Warfarin may interact with other drugs, which may enhance its anticoagulant effects.

ALTERNATIVE DRUG(S)
N/A

FOLLOW-UP

PATIENT MONITORING
• ECG monitoring while the cat is in hospital is helpful to detect reperfusion injury and hyperkalemia related ECG changes.
• Monitoring electrolytes and renal parameters periodically may be helpful to optimize management of the cardiac disease.
• Examine the legs frequently to assess clinical signs and if treated with warfarin.
• If warfarin is used, PT or INR is measured two to three times yearly or when drug regimen is altered.

PREVENTION/AVOIDANCE
Because of the high rate of re-embolization, prevention with either clopidogrel, aspirin, warfarin, or LMWH is strongly recommended.

POSSIBLE COMPLICATIONS
• Bleeding with the anticoagulant therapy.
• Permanent neurologic deficits or muscular abnormalities in the hind limbs may arise with prolonged ischemia.
• Recurrent congestive heart failure or sudden death.
• Reperfusion injury and death usually associated with hyperkalemic arrhythmias.

EXPECTED COURSE AND PROGNOSIS
• In two large studies, ~ 60% of cats were euthanized or died during the initial thromboembolic episode. Long-term prognosis varies between 2 months to several years; however, the average is a few months with treatment. Prediction of poorer prognosis include hyperkalemia (< 99 F) and congestive heart failure. One study demonstrated a median survival time of 77 days in cats with congestive heart failure and 223 days in cats without congestive heart failure. Predictors of better prognosis include normothermia, single leg affected, and presence of motor function on initial exam.
• In dogs, the disease is rare and prognosis in general is also poor. One study suggested a better prognosis if the dog had chronic clinical signs and if treated with warfarin.
• Recurrence of ATE is common.

MISCELLANEOUS

ASSOCIATED CONDITIONS
See “Causes” and “Risk Factors”

AGE-RELATED FACTORS
N/A

ZOONOTIC POTENTIAL
None

PREGNANCY/FERTILITY/BREEDING
N/A

SYNONYMS
• Saddle thromboembolism
• Systemic thromboembolism

SEE ALSO
• Cardiomyopathy, Dilated—Cats
• Cardiomyopathy, Hypertrophic—Cats
• Cardiomyopathy, Restrictive—Cats

ABBREVIATIONS
• APTT = activated partial thromboplastin time
• ATE = aortic thromboembolism
• CRI = continuous rate infusion
• ECG = electrocardiogram
• INR = international normalized ratio
• LMWH = low molecular weight heparin
• PT = prothrombin time

Suggested Reading

Author: Teresa C. DeFrancesco
Consulting Editors: Larry P. Tilley and Francis W.K. Smith, Jr.
**BASICS**

**OVERVIEW**
- Tumors of endocrine cells that are capable of amine precursor uptake and decarboxylation and secretion of peptide hormones; the tumors are named after the hormone they secrete.
- APUD cells are generally found in the gastrointestinal tract and CNS.
- Gastrin- and pancreatic polypeptide-secreting tumors are discussed here; insulinoma and glucagonoma are discussed separately.
- Hypergastrinemia from gastrin-secreting tumors causes gastritis and duodenal hyperacidity, which can cause gastric ulceration, esophageal dysfunction from chronic reflux, and intestinal villous atrophy.
- High concentration of pancreatic polypeptide also causes gastric hyperacidity and its consequences.

**SIGNALMENT**
- Gastrinoma—rare in dogs and cats; age range 3–12 years, mean 7.5 years (dogs).
- Pancreatic polypeptide—extremely rare in dogs.

**SIGNS**
- Vomiting
- Weight loss
- Anorexia
- Diarrhea
- Leukos, depression
- Polydipsia
- Melaena
- Abdominal pain
- Hematemesis
- Hematochezia
- Fever

**CAUSES & RISK FACTORS**
Unknown

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Other conditions associated with hypergastrinemia, gastric hyperacidity, and gastrointestinal ulceration
- Uremia
- Hepatic failure
- Drug-induced ulceration (e.g., NSAIDs or steroids)
- Inflammatory gastritis
- Stress-induced ulceration
- Mass cell disease

**CBC/BIOCHEMISTRY/URINALYSIS**
- Normal or reflect the chronic effects of general disease
- Iron-deficiency anemia secondary to gastrointestinal bleeding

**OTHER LABORATORY TESTS**
- Serum gastrin concentration normal or high-normal in patients with gastrinoma.
- Treatment with H2 antagonists or proton pump inhibitors increases serum concentrations of gastrin and could lead to false-positive diagnosis of gastrinoma, but withdrawal of these drugs results in return of gastrin concentrations to baseline in dogs without gastrinoma.
- Provocative test of gastrin secretion—increased gastrin concentration after intravenous calcium gluconate or secretin administration suggest gastrinoma; see Appendix II for protocol and interpretation.

**DIAGNOSTIC PROCEDURES**
- Endoscopy with gastric and duodenal biopsy
- Aspirate any detectable masses because of suspicion of mast cell disease.
- If no detectable masses exist, examine a Buffy coat smear for mast cells.

**PATHOLOGIC FINDINGS**
- Endoscopic biopsy reveals gastrinomas.
- Histopathologic examination of pancreatic tumors reveals findings consistent with islet cell tumor but not specific for hormone type.
- Immunocytochemical staining can aid in the specific diagnosis.
- Histopathologic examination also can reveal metastasis to liver and regional lymph nodes.

**TREATMENT**
- Tell owner that most APUDomas are malignant and have metastasized by the time of diagnosis and that long-term control is often difficult.
- Aggressive medical management can sometimes palliate signs for months to years.
- Surgical exploration and excisional biopsy of a pancreatic mass are important both diagnostically and therapeutically.
- Medical management is useful for gastric hyperacidity.

**MEDICATIONS**
- Histamine H2-receptor antagonists—cimetidine, ranitidine, and famotidine decrease acid secretion by gastric parietal cells.
- Omeprazole—a proton pump inhibitor, the most potent inhibitor of gastric acid secretion available, highly effective and expensive.
- Sucralfate—adheres to ulcerated gastric mucosa and protects it from acid; promotes healing by binding pepsin and bile acids and stimulating local prostaglandins.

**EXPECTED COURSE AND PROGNOSIS**
- Difficult to predict.
- Patients with gastrinoma have been controlled on medical management for months to years.
- No cure available.

**MISCELLANEOUS**

**SEE ALSO**
Gastroduodenal Ulceration/Erosion

**ABBREVIATIONS**
- APUD = amine precursor uptake and decarboxylation
- CNS = central nervous system
- NSAID = nonsteroidal anti-inflammatory drug

**Suggested Reading**

**Author** Thomas K. Graves

**Consulting Editor** Deborah S. Greco
Arteriovenous Fistula and Arteriovenous Malformation

Overview

Abnormal, low-resistance connections between an artery and vein which bypass a capillary bed; arteriovenous malformations (AVM) are typically congenital and involve a vascular nidus, or complex of communicating vessels, while arteriovenous fistulas (AVF) are often acquired direct connections. Large AVMs and AVFs allow a significant fraction of the total cardiac output to bypass the capillary bed. The resulting increase in cardiac output may lead to circulatory volume overload and congestive heart failure (CHF). The anatomic location of AVMs is variable, most often reported in the liver of dogs. The location of AVFs is also variable, occurring frequently in the limbs or at the site of previous surgery/trauma.

Signalement

- Dog and cat (rare in both).
- No specific age, breed, or sex predilections known, though AVMs are typically seen in younger animals.

Signs

- Historical Findings
  - Animals with AVF often have a history of trauma to the affected area.
  - Owner may notice a warm, non-painful swelling at the site.
  - Other findings depend on the lesion location (e.g., ascites with hepatic AVM).
  - The shunt may cause local organ dysfunction.

- Physical Examination Findings
  - Vary and depend on location of the AVM/AVF.
  - Signs of CHF (e.g., coughing, dyspnea, tachypnea, exercise intolerance) may develop in animals with long-standing disease and high blood flow.
  - Bounding pulses may be present because of high ejection volume and rapid runoff through the AVM/AVF.
  - Continuous murmur (bruit) at the site caused by turbulent blood flow through the lesion.
  - Cautious compression of the artery proximal to the lesion abolishes the bruit.
  - When blood flow is high, this compression may also elicit an immediate reflex decrease in heart rate (Branham’s sign).
  - Edema, ischemia, and congestion of organs and tissues caused by high venous pressure in the proximity of the lesion.
  - If the lesion is on a limb, pitting edema, lameness, ulceration, scabbing, and gangrene may result.
  - Lesions near vital organs may cause signs associated with organ failure such as ascites (liver), seizures (brain), paralysis (spinal cord), and dyspnea (lung).

CAUSES & RISK FACTORS

- AVMs are rare; frequently a congenital lesion. Acquired AVFs typically result from local damage to vasculature secondary to trauma, surgery, neoplasia, or perivascular injection, or tumor.

Diagnosis

Differential Diagnosis

- The lesion may look like a mass if peripherally located (limb, ear). Other differentials include an aneurysm or false aneurysm.
- Arterial findings, depending on location, may suggest other disease processes; AVF or AVM may be a late diagnostic consideration.

CBC/Biochemistry/Urinalysis

May reflect damage to systems in the vicinity of the lesion, i.e., biochemical abnormalities suggesting hepatic, renal, or other organ dysfunction are possible.

Other Laboratory Tests

N/A

Imaging

Thoracic Radiographic Findings

Cardiac enlargement and pulmonary overcirculation in some animals with hemodynamically significant lesions.

Ultrasonographic Findings

- AVM and AVF appear as cavernous, vascular structures. Duplex ultrasound may demonstrate high-velocity, turbulent flow within the lesion.

Cross-sectional Imaging

Computed tomography or magnetic resonance angiography can aid in the diagnosis, particularly when imaged with contrast injection to highlight the vascular anatomy.

Angiography

Selective angiography defines the lesion and may be necessary for definitive diagnosis. This is performed at the time of intervention, if transcatheter therapy is pursued. Placement of the catheter close to the lesion and rapid injection is necessary; high-volume blood flow dilutes the contrast medium quickly.

Diagnostic Procedures

N/A

Treatment

- Surgery can be difficult and labor-intensive and may require blood transfusion, though is the traditional treatment for clinically-significant lesions.
- Transcatheter therapies with coils, devices, or glue represent newer treatment options. Coils or devices are often sufficient for treatment of AVF, AVMs typically require glue embolization, as closure of the nidus is required for complete cure. Potential advantages include less invasive treatment and intravascular access to remote lesions. AVMs and AVFs may recur. In some animals, surgical removal of the affected limb or organ (e.g., amputation, liver lobectomy) may be necessary.

Medications

Drug(s)

- Concurrent medical treatment depends on the site of the lesion and secondary clinical features.
- Medical treatment for CHF or other organ dysfunction may be required before surgery.

Contraindications/Possible Interactions

Avoid excessive fluid administration; animals with these lesions are often volume overloaded.

Follow-up

Postoperative reevaluation is needed to determine whether the AVM or AVF has recurred and if organ dysfunction has normalized.

Miscellaneous

See Also

- Congestive Heart Failure, Left-Sided

Abbreviations

- AVF = arteriovenous fistula
- AVM = arteriovenous malformation
- CHF = congestive heart failure

Suggested Reading


Author Brian A. Scansen

Consulting Editors Larry P. Tilley and Francis W.K. Smith, Jr.

Acknowledgment The author and editors acknowledge the prior contribution of Donald J. Brown.
**OVERVIEW**
- Intrahepatic arteriovenous (AV) malformations (also referred to as AV fistulae) are communications between proper hepatic arteries and intrahepatic portal veins; this anatomic union results in hepatofugal flow (away from the liver) splanchic circulation.
- Blood flows directly from a hepatic artery into portal vasculature retrograde into the vena cava through multiple acquired portosystemic shunts (APSS).
- Associated with ascites.
- Rarely, bruit auscultated over AV

**Differential Diagnosis**
- CNS signs—infected disorders (e.g., distemper); toxicity (e.g., lead); hydrocephalus; idiopathic epilepsy; metabolic disorders (e.g., hyperglycemia, hypokalemia or hyperkalemia); HE (e.g., acquired liver disease or PSVA).
- Abdominal effusion—true transudate; protein-losing nephropathy, liver disease; modified transudate (congenital cardiac malformation; right-sided heart failure; pericardial tamponade, supraventricular, vena caval obstruction, neoplasia, portal vein thrombosis); hematemesis.
- Portal hypertension—chronic hepatic disease, dural plate malformations/congenital hepatic fibrosis, non-cirrhotic or idiopathic portal hypertension, cirrhosis, portal-thrombosis.

**SIGNS**

**General Comments**
- Vague signs include: lethargy, anorexia, Portal hypertension—chronic hepatic disease, dural plate malformations/congenital hepatic fibrosis, non-cirrhotic or idiopathic portal hypertension, cirrhosis, portal-thrombosis.

**Diagnosis**

**DIFFERENTIAL DIAGNOSIS**
- CNS signs—infectious disorders (e.g., distemper); toxicity (e.g., lead); hydrocephalus; idiopathic epilepsy; metabolic disorders (e.g., hyperglycemia, hypokalemia or hyperkalemia); HE (e.g., acquired liver disease or PSVA).
- Abdominal effusion—true transudate; protein-losing nephropathy, liver disease; modified transudate (congenital cardiac malformation; right-sided heart failure; pericardial tamponade, supraventricular, vena caval obstruction, neoplasia, portal vein thrombosis); hematemesis.
- Portal hypertension—chronic hepatic disease, dural plate malformations/congenital hepatic fibrosis, non-cirrhotic or idiopathic portal hypertension, cirrhosis, portal-thrombosis.

**CAUSES & RISK FACTORS**
- Usually congenital vascular malformations (single or multiple vessels) reflecting failed differentiation of common embryologic anlage.
- Rare, history auscultated over AV malformation.

**IMAGING**
- Radiography
  - Microphthia or normal sized liver due to enlarged liver with AV malformation
  - Renomegaly
  - Normal thorax

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Inpatient—Treat HE and ascites prior to surgical approach or percutaneous selective superior mesenteric artery embolization.

**NURSING CARE**
- Diet—restrict nitrogen intake to ameliorate HE and hyperammonemia; restrict sodium to attenuate ascites formation.
- HE—evaluate endoprophyletic, electrolyte and hydration disturbances; treat infections, initiate treatments to alter enteric uptake and formation of HE toxins (see Hepatic Encephalopathy).
- Ascites—mobilize by restricting activity and sodium intake and instituting dual diuretic therapy (furosemide and spironolactone); reserve therapeutic abdominoscopy for tense ascites impairing ventilation, nutrition, sleep, or recumbent posture; (see Portal Hypertension, Portosystemic Shunting, Acquired, and below).

**SURGICAL CONSIDERATIONS**
- Resection of liver lobe containing AV malformation is complicated by coexistence of additional hepatic vascular malformations; clinical care possible but unlikely.
Arteriovenous Malformation of the Liver (Continued)

• Percutaneous selective acrylamide vascular embolization; complicated by risk of thromboembolism of additional vasculature; temporary improvement; but treatment may be curative.

• Multiple microscopic vascular malformations continue portal hypertension and APSS.

• Do not ligate APSS nor band the vena cava.

MEDICATIONS

DRUG(S)

Hepatic Encephalopathy

See Hepatic Encephalopathy

Ascites

• Restrict sodium intake.

• Furosemide (0.5–2 mg/kg PO IM or IV q12–24h)—combine with spironolactone.

• Spironolactone (0.5–2 mg/kg PO q24h)—double initial dose as loading dose once.

• Chronic diuretic therapy—individualized to response, 4– to 7-day assessment intervals used to titrate dose to response, avoiding hypotension, electrolyte, and HE complications.

• Diuretic-resistant ascites—may require therapeutic abdominocentesis, to initiate diuresis.

• Vasopressin V1 receptor antagonists newly available may control ascites accumulation. (See Portosystemic Shunting, Acquired.)

Gastrointestinal Hemorrhage

• Histamine type-2 receptor antagonists (famotidine 0.5–2 mg/kg PO, IV, or SC q12–24h); or H2 pump inhibition (omeprazole 1.0 mg/kg/24h PO or pantoprazole 1 mg/kg/24h IV [omeprazole may induce p450 cytochrome-associated drug interactions and may have a 24–48h delay onset of action]; some clinicians recommend chronic treatment to minimize gastrointestinal bleeding and ulceration that may be chronic problems).

• Gastroprotection—sucralfate: 0.25–1.0 g/10 kg PO q8–12h; titrate to effect, beware of drug interactions as sucralfate may bind other medications, reducing bioavailability.

CONTRAINDICATIONS

Avoid drugs dependent on hepatic biotransformation or first pass hepatic extraction (reduced by APSS) or that react with GABA-benzodiazepine receptors because of propensity for HE.

FOLLOW-UP

PATIENT MONITORING

Biochemistry—initially monthly until stabilized after surgery or AV malformation embolization, thereafter quarterly; monitor for hypoalbuminemia, infection, optimization of HE management and control of ammonium biurate crystalluria.

EXPECTED COURSE AND PROGNOSIS

• Prognosis fair if patient survives surgical resection of AV malformation or embolization.

• Most patients require indefinite nutritional and medical management (HE, ascites) because of continuing microscopic vascular malformations across the liver; APSS persists requiring continued management of HE.

MISCELLANEOUS

SEE ALSO

• Ascites

• Hepatic Encephalopathy

• Hypertension, Portal

• Portosystemic Shunting, Acquired

• Portosystemic Vascular Anomaly, Congenital

ABBREVIATIONS

• APSS = acquired portosystemic shunt

• GABA = γ-aminobutyric acid

• HE = hepatic encephalopathy

• PSVA = portosystemic vascular anomalies

Author Sharon A. Center
Consulting Editor Sharon A. Center
Arthrocentesis and synovial fluid analysis—Pain of DJD

Dog—very common; 20% of dogs older
Clinical Subchondral bone becomes
Biopsy of synovial
Bone nuclear scintigraphy can assist
Secondary DJD due to congenital disorders
Bacterial culture of
Immune-mediated
Primary DJD is rare.
Working, athletic, and obese dogs place
Periarticular fibrosis occurs to reduce
Rickettsia
Cat—90% of cats over 12 years of age had
Osteophytes and enthesiophytes develop
Synovial
Primary—no known cause.
Neurologic conditions causing
Fibrillation or erosion of articular cartilage.
Decreased range of motion.
Neoplastic (synovial sarcoma; rarely,
These changes
SYSTEMS AFFECTED
Musculoskeletal—diarthrodial joints
GENETICS
• Primary DJD is rare. • Dogs—causes of secondary DJD are varied, including hip and elbow dysplasia, osteochondrosis dissecans, patellar luxations, congenital shoulder luxation, Legg-Perthes, and cranial cruciate ligament rupture. • Cats—causes of secondary DJD are patellar luxation, hip dysplasia, and arthroplasty.
INCIDENCE/PREVALENCE
• Dog—very common; 20% of dogs older than 1 year have some degree of DJD.
• Cat—90% of cats over 12 years of age had evidence of DJD on radiographs. • Clinical problems are more prevalent in larger, overweight, and very active animals.
• Primary DJD is rare.

SIGNALMENT
Species Dog and cat
Mean Age and Range
• Secondary DJD due to congenital disorders (OCD, hip dysplasia) seen in immature animals, some present with DJD signs when older (hip and elbow dysplasia). • Secondary to trauma—stiff legs.

SIGNS
Historical Findings
• Dogs—decreased activity level, unwilling to perform certain tasks; intermittent lameness or stiff gait that slowly progresses; possible history of joint trauma, OCD, or developmental disorders; may be exacerbated by exercise, long periods of recumbency, and cold weather. • Cats—stiff lameness may not be seen. May have difficulty grooming, jumping onto furniture, or accessing the litter box; increased irritability.

Physical Examination Findings
• Stiff-legged or altered gait (e.g., bunny hopping in hip dysplasia) or non-use of leg.
• Decreased range of motion. • Crepitus.
• Joint swelling (effusion and/or thickening of the joint capsule). • Joint pain. • Joint instability.

CAUSES
• Primary—no known cause. • Secondary—results from an initiating cause: abnormal wear on normal cartilage (e.g., joint instability, joint incongruity, trauma to cartilage or supporting soft tissues) or normal wear on abnormal cartilage (e.g., osteochondral defects).
RISK FACTORS
• Working, athletic, and obese dogs place more stress on their joints. • Dogs with disorders that affect collagen or cartilage (Cushing’s disease, diabetes mellitus, hyperthyroidism, hyperplasia, elongid, or ecosid).

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Neoplastic (synovial sarcoma; rarely, chondrosarcoma, osteosarcoma). • Septic arthritis (caused by bacteria; spirochetes; L. forms in cats; Mycoplasma, Rickettsia, Ehrlichia, viruses, such as feline calicivirus, fungi, and protozoa). • Immune-mediated arthritis (response vs. non-response). • Other musculoskeletal conditions that cause lameness. • Neurologic conditions causing lameness or decreased activity/weakness.

OTHER LABORATORY TESTS
• Cosin’s test, ANA, and rheumatoid factor may help to rule out immune-mediated arthritis. • Serum titers for Borrelia, Ehrlichia, and Rickettsia to evaluate for infectious arthritis.

IMAGING
• Radiographic changes—include joint effusion and synovial thickening, subchondral sclerosis and rarefaction, and intra-articular calcified bodies (joint mice). • Radiographic severity often does not correlate with clinical severity. • Stress radiography may identify underlying instability and accentuate joint incongruity (e.g., distraction index, passive hip laxity of the coxofemoral joint is predictive of hip DJD). • Bone nuclear scintigraphy can assist in localizing subtle DJD.

DIAGNOSTIC PROCEDURES
• Arthrocentesis and synovial fluid analysis—cell counts are normal or slightly increased (<2,000–5,000 cells/mL) predominantly mononuclear (macrophages) and occasional synovial lining cells. • Bacterial culture of synovial fluid—negative. • Biopsy of synovial tissue to rule out neoplasia or immune-mediated arthritis (lymphocytic plasmacytic synovitis, SLER).

PATHOLOGIC FINDINGS
• Fibrocartilage or articular cartilage.
• Erosion and sclerosis of subchondral bone. • Thickening and fibrosis of the joint capsule. • Synovial fluid can be grossly turbid, yellowish, greenish, or straw-colored.

TREATMENT
APPROPRIATE HEALTH CARE
• Medical—usually tried initially. Surgical options—to improve joint geometry or remove bone-on-bone contact areas.

NURSING CARE
• Physical therapy—very beneficial. • Maintaining or increasing joint motion—passive range of motion exercises, massage, swimming. • Pain management—cold and heat therapy. • Muscle tone/strengthening—swimming, (terrestrial exercise with minimal weight bearing); controlled leash walks up hills or on soft surfaces, such as sand or dry or underwater treadmill.
ACTIVITY
Limited to a level that minimizes aggravation of clinical signs.

DIET
• Weight reduction for obese patients—decreases stress placed on arthritic joints.
• Omega-6 and -3 fatty acids decrease the production of certain prostaglandins and modulate inflammation.

CLIENT EDUCATION
• Medical therapy is palliative and the condition is likely to progress. Discuss treatment options, activity level, and diet.

SURGICAL CONSIDERATIONS
• Arthroscopy—used to remove aggravating causes (e.g., fragmented coronoid process, un-united anconeal process, osteochondral flaps). Arthroscopy—used to diagnose and remove aggravating causes; flushing the joint may be beneficial.
• Reconstructive procedures—used to eliminate joint instability and correct anatomic problems (patella luxation, angular deformity).
• Joint removal—femoral head and neck osteotomy, tarsometatarsal joint arthrotomy.
• Joint replacement—total hip replacement is widely used, total elbow replacement still experimental. Joint fusion (arthrodesis)—in selected chronic cases and for joint instability, complete or partial; carpus, hock generally selected chronic cases and for joint instability, complete or partial; carpus, hock generally excellent outcome; shoulder, elbow, stifles—less predictable outcome.

MEDICATIONS

DRUG(S) OF CHOICE
NSAIDs
• Inhibit prostaglandin synthesis through cyclooxygenase enzymes.
• Diclofenac (3–4 mg/kg PO q48h, chewable).
• Carprofen (2.2 mg/kg PO q12h or q24h).
• Meloxicam (load 0.2 mg/kg PO, then 0.1 mg/kg PO q24h; liquid).
• Tepoxalin (load 20 mg/kg, then 10 mg/kg PO q48h).
• Carprofen (0.1 mg/kg PO q44h; liquid) or robenacoxib (1 mg/kg PO q24h for 3 days).

Chondroprotective/Regenerative Supplements
• Supply PSGAG molecules to repair and regenerate cartilage.
• Host of products, many with little production oversight so effects vary widely.
• Glucosamine and chondroitin sulfate—injectable Adequan, oral Cosequin, oral MSM, mixtures (e.g., Glycoflex II, Synflex).
• Adequan—clinical study in dogs with hip dysplasia; 4.4 mg/kg IM every 5–3 days for 8 injections had a positive, temporary effect.
• Cosequin—trials showed positive effects.

CONTRAINDICATIONS
• NSAIDs must not be given with steroids.
• Acromegalin must not be given to cats.

PRECAUTIONS
• NSAID may cause gastric ulceration.
• COX-2 selective drugs may interfere with liver function. When switching NSAIDs—wait 3 days for washout before starting new drug.

POSSIBLE INTERACTIONS
Steroids and NSAIDS

ALTERNATIVE DRUG(S)

• Free-radical scavengers. Glucocorticoids—inhibit inflammatory mediators and cytokines; however, chronic use delays healing and initiates damage to articular cartilage; potential systemic side effects documented; goal is low-dose (dogs, 0.5–2 mg/kg; cats, 2–4 mg/kg) q48h. Prednisone—initial dose 1–2 mg/kg PO q24h for dogs and 4 mg/kg PO q48h for cats.
• Tramadol hexanoate—intra-articular injection of 5 mg in dogs showed a protective and therapeutic effect in one model.

FOLLOW-UP

PATIENT MONITORING
Clinical deterioration—indicates need to change drug selection or dosage; may indicate need for surgical intervention.

PREVENTION/AVOIDANCE
Early identification of predisposing causes and prompt treatment to help reduce progression of secondary conditions, e.g., surgical removal of osteochondral lesions.

EXPECTED COURSE AND PROGNOSIS
• Slow progression of disease likely.

MISCELLANEOUS

SYNONYMS
• Degenerative arthritis • Degenerative joint disease • Osteoarthritis • Osteoarthrosis

ABBREVIATIONS
• ANA = antinuclear antibody • COX-2 = cyclooxygenase-2 • DJD = degenerative joint disease • NSAID = nonsteroidal anti-inflammatory drug • OCD = osteochondrodysplasia • PSGAGs = polysulfated glycosaminoglycans • SLE = systemic lupus erythematosus

Suggested Reading
Acknowledgment The author and editors acknowledge the prior contribution of Peter K. Shires.

Anti-inflamatory drug • OCD = osteochondrodysplasia • PSGAGs = polysulfated glycosaminoglycans • SLE = systemic lupus erythematosus

Available online

Client Education Handout available online

Blackwell’s Five-Minute Veterinary Consult

Arthritis (Osteoarthritis)

A
**BASICS**

**DEFINITION**
Pathogenic microorganisms within the closed space of one or more synovial joints

**PATHOPHYSIOLOGY**
- Usually caused by contamination associated with traumatic injury (e.g., a direct penetrating injury such as a bite, gunshot wound, foreign object), a sequela to surgery, or an invasive procedure of the joint
- Penetrating injury, prior surgery, or other invasive procedures of the joint
- Bacteria or fungus (e.g., Chlamydia, Pasteurella, Mycoplasma)
- Fungal and atypical mycobacterial agent (e.g., Coccidioides, Histoplasma)
- Reactive arthritis

**CAUSES**
- Aerobic bacterial organisms—most common: *Staphylococcus*, *Streptococcus*, *Eikenella*, and *Porphyromonas*
- Anaerobic organisms—most common: *Propionibacterium*, *Prevotella*, and *Peptostreptococcus*
- Spirochetes—*Borrelia burgdorferi*
- Mycoplasma
- Viral agents—*Mycoplasma*
- Fungal agents—*Candida*

**RISK FACTORS**
- Predisposing factors for hematogenous infection—urogenital, integumentary, cardiac, and gastrointestinal systems
- Systemic immunosuppression
- Hematogenous spread of microorganisms from a distant septic focus, or less commonly the extension of primary osteomyelitis
- Primary sources of hematogenous infection—urogenital, integumentary (including ears and and sacs), respiratory, cardiac, and gastrointestinal systems

**SYSTEMS AFFECTED**
- Musculoskeletal—usually affects one joint

**GENETICS**
- N/A

**INCIDENT/PREVALENCE**
- Relatively uncommon cause of monoarticular arthritis in dogs and cats

**GEOGRAPHIC DISTRIBUTION**
- May be an increased incidence in Lyme disease-endemic areas

**SIGNALMENT**

**Species**
- Most common in dogs
- Rare in cats

**Breed Predilections**
- Any. Medium to large breeds—most commonly German shepherds, Dobermans, and Labrador retrievers

**Age and Range**
- Any age, usually between 4 and 7 years
- Hematogenous: more common in immature animals

**Predominant Sex**
- Male

**SIGNS**

**General Comments**
- Always consider the diagnosis in patients with acute, monoarticular lameness associated with soft tissue swelling, heat, and pain
- Lethargy
- Anorexia
- May report previous trauma—dog bite, penetrating injury, prior surgery or other invasive procedure of the joint

**Physical Examination Findings**
- Monoarticular lameness, rarely polyarticular
- Joint pain and swelling—commonly carpus, stifl, hock, shoulder, or cubital joint
- Localized joint heat
- Decreased range of motion
- Local lymphadenopathy
- Fever

**DIFFERENTIAL DIAGNOSIS**
- Osteoarthritis
- Trauma
- Immune-mediated arthropathy
- Postvaccinal or postoperative trauma
- Synovial hyperplasia
- Gout
- Septic arthritis

**OTHER LABORATORY TESTS**
- Hemogram—inflammatory left shift in some cases
- Other results normal

**IMAGING**
- Radiography
- Early disease—may reveal thickened and dense periarticular tissue; may see evidence of synovial effusion
- Later disease—bone destruction, osteolytic, irregular joint space, discrete erosions, and periarticular osteosclerosis

**DIAGNOSTIC PROCEDURES**
- Synovial fluid analysis
  - Elevated WBC count (→ 80% neutrophils with > 40,000/mm³ (normal joint fluid) < 10% neutrophils and < 3,000/mm³)
  - Neutrophils may show degenerative changes (chromatolysis, vacuolation, nuclear swelling, loss of segmentation)
- Neutrophils with phagocytosed bacteria—definitive diagnosis or bacteria in the synovial fluid

**SYNOVIAL FLUID CULTURE**
- Positive culture is definitive but not necessary for diagnosis
- Must be collected aseptically; requires heavy sedation or general anesthesia
- Place fluid sample in aerobic and anaerobic culture media
- Use 1/9 dilution of synovial fluid to blood culture media
- Cultures samples—cultured immediately upon arrival to the laboratory
- Blood culture medium—culturing after 24 hours of incubation increases accuracy by 50% and is the preferred method
- Mycoplasma, bacterial L-forms and protozoa require specific culture procedures—contact laboratory prior to sample collection

**TREATMENT**
- SIMPLIFIED APPROACH TO HEALTH CARE
- Inpatient—initial stabilization; initiate systemic antibiotic therapy as soon as fluid is obtained for bacterial culture; consider joint drainage/lavage as soon as possible to minimize intra-articular injury
- Identify and treat source if hematogenous spread is suspected
- Outcome—long-term management

**NURSING CARE**
- Alternating heat and cold packing—beneficial in promoting increased blood flow and decreased swelling

**ACTIVITY**
- Restricted until resolution of symptoms

**DIET**
- N/A

---

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Osteoarthritis
- Trauma
- Immune-mediated arthropathy
- Postvaccinal or postoperative trauma
- Synovial hyperplasia
- Gout
- Septic arthritis

**OTHER LABORATORY TESTS**
- Hemogram—inflammatory left shift in some cases
- Other results normal

**IMAGING**
- Radiography
- Early disease—may reveal thickened and dense periarticular tissue; may see evidence of synovial effusion
- Later disease—bone destruction, osteolytic, irregular joint space, discrete erosions, and periarticular osteosclerosis

**DIAGNOSTIC PROCEDURES**
- Synovial fluid analysis
  - Elevated WBC count (→ 80% neutrophils with > 40,000/mm³ (normal joint fluid) < 10% neutrophils and < 3,000/mm³)
  - Neutrophils may show degenerative changes (chromatolysis, vacuolation, nuclear swelling, loss of segmentation)
- Neutrophils with phagocytosed bacteria—definitive diagnosis or bacteria in the synovial fluid

**SYNOVIAL FLUID CULTURE**
- Positive culture is definitive but not necessary for diagnosis
- Must be collected aseptically; requires heavy sedation or general anesthesia
- Place fluid sample in aerobic and anaerobic culture media
- Use 1/9 dilution of synovial fluid to blood culture media
- Cultures samples—cultured immediately upon arrival to the laboratory
- Blood culture medium—culturing after 24 hours of incubation increases accuracy by 50% and is the preferred method
- Mycoplasma, bacterial L-forms and protozoa require specific culture procedures—contact laboratory prior to sample collection
- Other
  - Synovial biopsy—to rule out immune-mediated joint disease; no more effective than incubated blood culture medium for growing bacterial organisms
  - Blood and urine cultures if hematogenous source is suspected

**PATHOLOGIC FINDINGS**
- Synovium—thickened, discolored; often very proliferative
- Histology—evidence of hyperplastic synoviocytes
- Increased numbers of neutrophils, macrophages, and fibrinous debris
- Carilage—loss of proteoglycans, destruction of articular surface, pannus formation

**TREATMENT**
- SIMPLIFIED APPROACH TO HEALTH CARE
- Inpatient—initial stabilization; initiate systemic antibiotic therapy as soon as fluid is obtained for bacterial culture; consider joint drainage/lavage as soon as possible to minimize intra-articular injury
- Identify and treat source if hematogenous spread is suspected
- Outcome—long-term management

**NURSING CARE**
- Alternating heat and cold packing—beneficial in promoting increased blood flow and decreased swelling

**ACTIVITY**
- Restricted until resolution of symptoms

**DIET**
- N/A
CLIENT EDUCATION
- Discuss probable cause.
- Warn client about the need for long-term antibiotics and the likelihood of residual degenerative joint disease.

SURGICAL CONSIDERATIONS
- Acute disease with minimal radiographic changes—joint drainage and lavage via needle arthrocentesis, arthroscopic lavage or arthrotomy. An irrigation catheter (ingress/egress) can be placed in larger joints.
- Chronic disease—may require open arthrocentesis with debridement of the synovium and copious lavage; if appropriate, an irrigation catheter (ingress/egress) may be placed to lavage the joint postoperatively.
- Lavage—use warmed physiologic saline or lactated Ringer’s solution (2–4 mL/kg q24h) until effluent is clear. Do not add povidone/iodine or chlorhexidine to lavage fluid.
- Effluent fluid—cytologically monitored daily for existence and character of bacteria and neutrophils.
- Removal of catheters—when effluent fluid has no bacteria and the neutrophils are cytologically healthy.
- Arthroscopy allows for visual assessment of articular cartilage, lavage and biopsy, and is a less invasive method of thorough joint lavage than arthrocentesis.
- Recent reports suggest there may be no difference between combined medical and surgical management and medical management alone.

MEDICATIONS
DRUG(S) OF CHOICE
- Pending culture susceptibility data—bacterial antibiotics, such as first-generation cephalosporin or amoxicillin–clavulanic acid, preferred.
- Choice of antimicrobial drugs—primarily depends on in vitro determination of susceptibility of microorganisms, toxicity, frequency, route of administration and expense also considered; most penetrate the synovium well, need to be given for a minimum of 4–8 weeks.
- NSAIDs—may help decrease pain and inflammation.

CONTRAINDICATIONS
Avoid fluroquinolones in pediatric patients; they induce cartilage lesions experimentally.

PRECAUTIONS
Failure to respond to conventional antibiotic therapy—may indicate anaerobic disease or other unusual cause (fungus, spirochete).

POSSIBLE INTERACTIONS
N/A

FOLLOW-UP
PATIENT MONITORING
- If drainage and irrigation catheters have been placed—may be removed after 4–6 days or after reassessment of synovial fluid cytology.
- Duration of antibiotic therapy—2 weeks following resolution of clinical signs. Total treatment may be 4–8 weeks or longer depending on clinical signs and pathogenic organism.
- Persistent synovial inflammation without viable bacterial organisms (dogs)—may be caused by antigenic bacterial fragments or antigen antibody deposition.
- Systemic corticosteroid therapy (after joint drainage and irrigation catheters have been placed to lavage the joint postoperatively) may help decrease pain and inflammation.

PREVENTION/AVOIDANCE
If clinical signs recur, early (within 24–48 hours) treatment provides the greatest benefit.

POSSIBLE COMPLICATIONS
- Chronic disease—severe degenerative joint disease.
- Recurrence of infection.
- Limited joint range of motion.
- Generalized sepsis.
- Osteomyelitis.

EXPECTED COURSE AND PROGNOSIS
- Acute disease (within 24–48 hours) responds well to antibiotic therapy.
- Delays in diagnosis or resistant or highly virulent organisms—guarded to poor prognosis.

MISCELLANEOUS
ASSOCIATED CONDITIONS
N/A

AGE-RELATED FACTORS
N/A

ZONOTOIC POTENTIAL
N/A

PREGNANCY/FERTILITY/BREEDING
N/A

SYNONYMS
- Infectious arthritis.
- Joint ill.

SEE ALSO
- Osteoarthritis.
- Polyarthritis, Immune-mediated.

ABBREVIATION
NSAIDs = nonsteroidal anti-inflammatory drugs.
To detect hypoproteinemia—protein.

Specific gravity

Obesity.

Depletion of plasma proteins associated with renal or gastrointestinal disease—protein-lowering nephropathy or enteropathy, respectively.

Obstruction of the vena cava or portal vein, or lymphatic drainage due to neoplastic occlusion.

Obstructive peritonitis, abdominal neoplasia, and hemorrhage.

Differentiating Diseases

Transudate—nephrotic syndrome, cirrhosis of liver, right-sided CHF, hypoproteinemia, and ruptured bladder.

Exudate—peritonitis, abdominal neoplasia, and hemorrhage.

Cirrhosis of liver

High in patients with biliary obstruction.

Hemorrhage

Peritonitis—infective or inflammatory.

Ascites can be caused by the following:

+ CHF and associated interference in venous return.

+ Depletion of plasma proteins associated with inappropriate loss of protein from renal or gastrointestinal disease—protein-lowering nephropathy or enteropathy, respectively.

+ Obstruction of the vena cava or portal vein, or lymphatic drainage due to neoplastic occlusion.

+ Obstructive peritonitis, abdominal neoplasia, and hemorrhage.

Liver cirrhosis.

SYSTEMS AFFECTED

+ Cardiovascular

+ Gastrointestinal

+ Hematopoietic/Immune

+ Renal/Urologic

RISK FACTORS

N/A

IMAGING

Thoracic and abdominal radiography is sometimes helpful.

Ultrasoundography of the liver, spleen, pancreas, kidney, bladder, and abdomen can often determine cause.

Stages of ascites:

+ Stage I: minimal ascites. Detected by ultrasound only.

+ Stage II: moderate ascites. Abdominal distension visible and/or noted on ballottement.

+ Stage III: significant ascites. Marked abdominal distension. Patient uncomfortable, possibly with labored breathing.

DIAGNOSTIC PROCEDURES

Ascitic Fluid Evaluation

Exfoliative cytologic examination and bacterial culture and antibiotic sensitivity—remove approximately 3–5 mL of abdominal fluid via aseptic technique.

Transude

+ Red or pink.

+ Protein < 2.5 g/dL.

+ Specific gravity < 1.018.

+ Cells < 5,000/mm³—neutrophils and mesothelial cells.

Modified Transude

+ Red or pink, may be slightly cloudy.

+ Protein 2.5–5 g/dL.

+ Specific gravity < 1.018.

+ Cells < 5,000/mm³—neutrophils, mesothelial cells, erythrocytes, and lymphocytes.

Exudate (Non-septic)

+ Pink or white, cloudy.

+ Protein 2.5–5 g/dL.

+ Specific gravity 1.018.

+ Cells 5,000–50,000/mm³—neutrophils, mesothelial cells, macrophages, erythrocytes, and lymphocytes.

Exudate (Septic)

+ Red, white, or yellow; cloudy.

+ Protein > 4 g/dL.

+ Specific gravity > 1.018.

+ Cells 5,000–100,000/mm³—neutrophils, mesothelial cells, macrophages, erythrocytes, lymphocytes, and bacteria.

Hemorrhage

+ Red; spun supernatant clear and sediment red.

+ Protein > 5.5 g/dL.

+ Specific gravity 1.007–1.027.

+ Cells consistent with peripheral blood.

+ Does not clot.

BASICS

DEFINITION

The escape of fluid, either transudate or exudate, into the abdominal cavity between the parietal and visceral peritoneum.

PATHOPHYSIOLOGY

+ Ascites can be caused by the following:

+ CHF and associated interference in venous return.

+ Depletion of plasma proteins associated with inappropriate loss of protein from renal or gastrointestinal disease—protein-lowering nephropathy or enteropathy, respectively.

+ Obstruction of the vena cava or portal vein, or lymphatic drainage due to neoplastic occlusion.

+ Obstructive peritonitis, abdominal neoplasia, and hemorrhage.

Liver cirrhosis.

SYSTEMS AFFECTED

+ Cardiovascular

+ Gastrointestinal

+ Hematopoietic/Immune

+ Renal/Urologic

RISK FACTORS

N/A

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS

Differentiating Abdominal Distension without Effusion

+ Organomegaly—hepatomegaly, splenomegaly, renalomegaly, and hydrometra.

+ Abdominal neoplasia.

+ Pregnancy.

+ Bladder distension.

+ Obesity.

+ Gastric dilatation.

Differentiating Diseases

Transudate—nephrotic syndrome, cirrhosis of liver, right-sided CHF, hypoproteinemia, and ruptured bladder.

Exudate—peritonitis, abdominal neoplasia, and hemorrhage.

C CBC/BIOCHEMISTRY/URINALYSIS

+ Neutrophilic leukocytosis occurs in patients with systemic infection.

+ Albumin is low in patients with impaired liver synthesis, gastrointestinal loss, or renal loss.

+ Cholesterol is low in patients with impaired liver synthesis.

Liver Enzymes

+ Low to normal in patients with impaired liver synthesis.

+ High in patients with liver inflammation, hyperadrenocorticism, gallbladder obstruction, and chronic passive congestion.

Total and Direct Bilirubin

+ High in patients with liver inflammation.

+ BUN and Creatinine

+ Low in patients with impaired liver synthesis.

+ High in patients with biliary obstruction caused by tumor, gallbladder distension, or obstruction.

BUN and Creatinine

+ High in patients with renal failure.

+ BUN low in patients with impaired liver synthesis or hyperadrenocorticism.

Glucose

+ Low in patients with impaired liver synthesis.

OTHER LABORATORY TESTS

+ To detect hyperproteinemia—protein electrophoresis and immune profile.

+ To detect proteinuria—urinary protein:creatinine ratio (normal < 0.5:1).

+ To detect ascites—analysis of serum ascites albumin gradient.

EXAMINATION

+ Groaning when lying down.

+ Abdominal discomfort when palpated.

+ Ballottement.

+ Rales when breathing.

+ Uncomfortable, possibly with labored breathing.

+ Anorexia.

+ Vomiting.

+ Weight gain.

+ Scrotal or penile edema.

+ Grueling when lying down.

CAUSES

+ Nephrotic syndrome.

+ Cirrhosis of liver.

+ Right-sided CHF.

+ Hypoproteinemia.

+ Ruptured bladder.

+ Peritonitis.

+ Abdominal neoplasia.

+ Abdominal hemorrhage.
ASCITES

Chyle
- Pink, straw or white.
- Protein 2.5–7 g/dL.
- Specific gravity 1.007–1.040.
- Cells < 10,000/mm³—neutrophils, mononuclear cells, and large population of small lymphocytes.
- Other—fluid in tube separates into cream-like layer when refrigerated; fat droplets stain with Sudan III.

Pseudochyle
- White.
- Protein > 2.5 g/dL.
- Specific gravity 1.007–1.040.
- Cells < 10,000/mm³—neutrophils, mononuclear cells, and small lymphocytes.
- Other—fluid in tube does not separate into cream-like layer when refrigerated; does not stain with Sudan III.

Urine
- Clear to pale yellow.
- Protein > 2.5 g/dL.
- Specific gravity 1.007–1.040.
- Cells 5,000–50,000/mm³—neutrophils, erythrocytes, lymphocytes, and macrophages.
- Other—if the urinary bladder ruptured < 12 hours before, urinary glucose and protein could be negative; if bladder ruptured > 12 hours before, urine becomes a dialysis medium with ultrafiltrate of plasma, and urine contains glucose and protein.

Blind
- Slightly cloudy and yellow.
- Protein > 2.5 g/dL.
- Specific gravity > 1.018.
- Cells 5,000–750,000/mm³—neutrophils, erythrocytes, macrophages, and lymphocytes.
- Other—bilirubin confirmed by urine dipstick; non-icteric patient may have gallbladder rupture, biliary tract leakage, or rupture in the proximal bowel.

Treating
- Can design treatment on an outpatient basis, with follow-up or supportive care, depending on physical condition and underlying cause.
- If patients are markedly uncomfortable when lying down or become more dyspneic with stress, consider removing enough ascites to reverse these signs.
- Dietary salt restriction may help control transudate fluid accumulation due to CHF, cirrhosis, or hypoproteinemia.
- For exudate ascites control, address the underlying cause; corrective surgery is often indicated, followed by specific therapeutic management (e.g., patient with splenic tumor: tumor removed, abdominal bleeding controlled, blood transfusion administered).

Large-volumen Paracentesis
- Stage III treatment.
- Pretreat patient with hetastarch (6%) at 1–2 mL/kg for 2 hours.
- Abdominal tap (paracentesis), until drainage slows.
- Post-treat patient with hetastarch (6%) at 1–2 mL/kg for 4 hours.

Medication

Drug(s) of Choice
- Patients with liver insufficiency or CHF—restrict sodium and give a diuretic combination of hydrochlorothiazide (2–4 mg/kg q12h PO) and spironolactone (1–2 mg/kg q12h PO); if control is inadequate, furosemide (1–2 mg/kg q8h PO) can be substituted for the thiazide with spironolactone continued; must monitor serum potassium concentration to prevent potassium imbalances.
- Patients with hypoproteinemia, nephrotic syndrome, and associated ascitic fluid accumulation—can treat as above with the addition of hetastarch (6% hetastarch in 0.9% NaCl); administer an IV bolus (dogs, 20 mL/kg; cats, 10–15 mL/kg) slowly over ~1 hour; hetastarch increases plasma oncotic pressure and pulls fluid into the intravascular space for up to 24–48 hours.
- Systemic antibiotic therapy is dictated by bacterial identification and sensitivity testing in patients with septic exudate ascites.

Follow-up

Patient Monitoring
- Varies with the underlying cause.
- Check sodium, potassium, BUN, creatinine, and weight fluctuations periodically if the patient is maintained on a diuretic.

Possible Complications
- Aggressive diuretic administration may cause hypokalemia, which could predispose to metabolic alkalosis and exacerbation of hepatic encephalopathy in patients with underlying liver disease; alkalosis causes a shift from NH₃ to NH₄.

Miscellaneous

AGE-RELATED FACTORS
- N/A

PREGNANCY/FERTILITY/BREEDING
- N/A

SYNONYMS
- N/A

ABBREVIATIONS
- CHF = congestive heart failure

Suggested Reading

Author
- Jerry A. Thornhill

Consulting Editors
- Larry P. Tilley and Francis W.K. Smith, Jr.
Aspergillosis, Nasal

**BASICS**

**DEFINITION**
- Nasal disease caused by *Aspergillus* spp., primarily *A. fumigatus*. Saprophytic fungus that is ubiquitous in the environment.
- Opportunistic pathogen.

**PATHOPHYSIOLOGY**
- Inhalation of fungus leads to disease in the nasal cavity and frontal sinus with destruction of turbinates, formation of plaques, and overproduction of mucus causing clinical signs of nasal disease.
- Rarely may be associated with underlying foreign body or previous trauma.
- Causes a locally aggressive and invasive disease but does not result in systemic mycosis. Confined to nasal cavity and frontal sinus—sino-orbital disease in cats.

**SYSTEMS AFFECTED**
- Respiratory—nasal cavity, sinus, orbit (cats, rare in dogs)

**GENETICS**
- Unknown

**INCIDENCE/PREVALENCE**
- Unknown, but a common diagnosis in dogs with nasal discharge in many locations.

**GEOGRAPHIC DISTRIBUTION**
- Worldwide

**SIGNALMENT**

**Species**
- Dog and cat (less common)

**Breed Predilections**
- Dogs—dolichocephalic and mesocephalic breeds.
- Cats—brachycephalic breeds may be overrepresented.

**Mean Age and Range**
- Dogs—predominantly young to middle-aged.
- Cats—no predilection.

**Predominant Sex**
- None identified

**SIGNS**

**Historical Findings**
- Undulating or bilateral nasal discharge—typically mucoid, mucopurulent, or serosanguinous but may be primarily purulent.
- Sneezing.
- Typically chronic signs—several months.
- Many patients will have been treated with antibiotics for a possible bacterial infection before presentation with variable response.

**Physical Examination Findings**
- Undulant or bilateral nasal discharge.
- Increased nasal airflow on the affected side.
- Depigmentation with ulceration of the nasal planum—40% of dogs.
- Facial pain.
- Ipsilateral mandibular lymphadenopathy.
- Serous, exophthalmos, hard palate ulceration, facial asymmetry, loss of nasal airflow—sino-orbital disease in cats.

**CAUSES**
- No underlying cause identified, although preexisting foreign body or trauma is occasionally implicated.
- Likely due to inhalation of a large bolus of fungus that is ubiquitous in the environment.
- Species—most commonly *A. fumigatus* in dogs, *A. falcis* in cats others—*A. niger*, *A. flavus*.

**RISK FACTORS**
- Unknown

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Foreign body—Otornal fluid.
- Lymphoplasmacytic rhinitis
- Neoplasia
- Nasopharyngeal polyp
- Nasal tumor
- Opportunistic pathogen.
- Allows direct rhinoscopic visualization of affected area under cup treatment of the area using a red rubber
- Nasal polyp
- Nasal tumor
- Oronasal fistula
- Foreign body
- Biopsies obtained of affected area under endoscopic debridement.

**IMAGING**

**Computed Tomography**
- Imaging method of choice.
- Cavitated turbinate lysis.
- Thickening of the mucosa along the nasal turbinates.
- Frontal sinus proliferative mass effect.
- Soft tissue mass in the choana or nasopharynx—cats.

**Skull Radiography**
- Intranasal dorsoventral radiographs of the nasal cavity shows turbinate lysis.
- Rostralcaudal or skylined frontal sinus view may show increased soft tissue density in the frontal sinus.
- Cannot evaluate cribriform plate.

**DIAGNOSTIC PROCEDURES**

**Rhinoscopy**
- Flexible rhinoscope in dogs allows examination of the nasopharynx and possibly the frontal sinus if the opening of the nasofrontal duct is destroyed by fungal infection.
- Rigid rhinoscopy—examination of the nasal cavity alone; good visualization is possible due to large airways caused by turbinate lysis; excessive mucus and bleeding can make full examination difficult.
- Visualization of fungal plaques (white, yellow, black, or light-green) on the mucosa of the nasal cavity and/or frontal sinus confirms fungal infection.
- Sinuscopy—may be required to confirm the diagnosis in dogs that lack nasal plaques.

**PATHOLOGIC FINDINGS**
- Biopsies obtained of affected area under direct rhinoscopic visualization using cup biopsy instruments.
- Samples immersion-fixed in buffered 10% formalin, routinely processed.
- Evidence supportive of a diagnosis of aspergillosis—identification of separate, branching hyphae and conidia on histopathology. Surrounding inflammation is commonly neutrophilic or lymphohistiocytic, rarely eosinophilic.
- Blind biopsies in an unaffected area of the nasal cavity can result in a false diagnosis of inflammation.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Overnight hospitalization advised after topical treatment or surgery.

**NURSING CARE**
- Maintain fresh air free of nasal discharge.

**ACTIVITY**
- Restriction of activity is not required if no bleeding is documented.

**DIET**
- N/A

**CLIENT EDUCATION**
- Dogs—inform client that multiple topical treatments are usually necessary to cure the disease; follow-up with rhinoscopy is highly recommended to ensure resolution.
- No established protocols for treatment in cats.

**SURGICAL CONSIDERATIONS**

**Endoscopic Debridement**
- Extensive curarization and removal of fungal material from the nose and frontal sinus is essential to allow efficacy of topical medication.

**Trephination of the Frontal Sinus**
- Can be required for dogs with frontal sinus involvement.
- Performed using a Jacob’s chuck and intramedullary pin.
- Allows direct visualization of the frontal sinus with a rigid rhinoscope and local debridement of fungal plaques.
- Allows for lavage and topical treatment of the area using a red rubber catheter.

**CLIENT EDUCATION**
- N/A

**DIFFERENTIAL DIAGNOSIS**
- Foreign body—Otornal fluid.
- Lymphoplasmacytic rhinitis
- Neoplasia
- Nasopharyngeal polyp
- Nasal tumor
- Opportunistic pathogen.
- Allows direct rhinoscopic visualization of affected area under cup treatment of the area using a red rubber
- Nasal polyp
- Nasal tumor
- Oronasal fistula
- Foreign body
- Biopsies obtained of affected area under endoscopic debridement.

**IMAGING**

**Computed Tomography**
- Imaging method of choice.
- Cavitated turbinate lysis.
- Thickening of the mucosa along the nasal turbinates.
- Frontal sinus proliferative mass effect.
- Soft tissue mass in the choana or nasopharynx—cats.

**Skull Radiography**
- Intranasal dorsoventral radiographs of the nasal cavity shows turbinate lysis.
- Rostralcaudal or skylined frontal sinus view may show increased soft tissue density in the frontal sinus.
- Cannot evaluate cribriform plate.

**DIAGNOSTIC PROCEDURES**

**Rhinoscopy**
- Flexible rhinoscope in dogs allows examination of the nasopharynx and possibly the frontal sinus if the opening of the nasofrontal duct is destroyed by fungal infection.
- Rigid rhinoscopy—examination of the nasal cavity alone; good visualization is possible due to large airways caused by turbinate lysis; excessive mucus and bleeding can make full examination difficult.
- Visualization of fungal plaques (white, yellow, black, or light-green) on the mucosa of the nasal cavity and/or frontal sinus confirms fungal infection.
- Sinuscopy—may be required to confirm the diagnosis in dogs that lack nasal plaques.

**PATHOLOGIC FINDINGS**
- Biopsies obtained of affected area under direct rhinoscopic visualization using cup biopsy instruments.
- Samples immersion-fixed in buffered 10% formalin, routinely processed.
- Evidence supportive of a diagnosis of aspergillosis—identification of separate, branching hyphae and conidia on histopathology. Surrounding inflammation is commonly neutrophilic or lymphohistiocytic, rarely eosinophilic.
- Blind biopsies in an unaffected area of the nasal cavity can result in a false diagnosis of inflammation.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Overnight hospitalization advised after topical treatment or surgery.

**NURSING CARE**
- Maintain fresh air free of nasal discharge.

**ACTIVITY**
- Restriction of activity is not required if no bleeding is documented.

**DIET**
- N/A

**CLIENT EDUCATION**
- Dogs—inform client that multiple topical treatments are usually necessary to cure the disease; follow-up with rhinoscopy is highly recommended to ensure resolution.
- No established protocols for treatment in cats.

**SURGICAL CONSIDERATIONS**

**Endoscopic Debridement**
- Extensive curarization and removal of fungal material from the nose and frontal sinus is essential to allow efficacy of topical medication.

**Trephination of the Frontal Sinus**
- Can be required for dogs with frontal sinus involvement.
- Performed using a Jacob’s chuck and intramedullary pin.
- Allows direct visualization of the frontal sinus with a rigid rhinoscope and local debridement of fungal plaques.
- Allows for lavage and topical treatment of the area using a red rubber catheter.
Surgical Debridement and Exenteration
• Used in some cats with sino-orbital disease.

MECHANISMS

DRUG(S) OF CHOICE
Topical Clotrimazole or Enilconazole Therapy
• 1-hour infusion into nasal cavity under anesthesia.
• Treatment is usually performed during the same anesthesia as diagnostics.
• Treatment of choice in dogs; reported efficacy 85–89% with multiple treatments.
• Foley catheters are used to occlude the nares and nasal passages.
• Dose—Clotrimazole: 1 gram in 100 mL of polyethylene glycol 200 (5% solution) evenly divided between two 50 mL syringes slowly infused over 1 hour into each side for large dogs; if respiration is used, divide the amount between the nasal cavity and sinus on the same side; less volume in smaller dogs.
• Enilconazole: 100 mL of 1%, 2%, or 5% solution.
• Dog is placed in dorsal recumbency with head turned to each side every 15 minutes during the infusion.
• Dog is placed in sternal recumbency with head down at the end of the procedure to drain all medication from the nasal cavity.
• Has been used in cats without orbital involvement in combination with oral antifungal therapy with varying success.

Systemic Therapy
• Antifungal triazole drugs should be considered if the cribriform plate is not intact; less volume in smaller dogs.
• Can also be used in combination with topical clotrimazole.
• May be cost-prohibitive.
• Itraconazole 5 mg/kg PO q12h in dogs with a reported efficacy of 60–70%; 10 mg/kg PO q24h in cats.
• Voriconazole 5 mg/kg PO q12h, efficacy as sole therapy has not been established.
• Neurotoxicity in cats.
• Posaconazole: dogs, 5–10 mg/kg PO q12–24h; cats, 5 mg/kg PO q24h or divided q12h; efficacy as sole therapy has not been established.
• Fluconazole is not recommended due to resistance.

CONTRAINDICATIONS
• Breach in the cribriform plate can allow contact of antifungal medication with brain resulting in neurologic signs and possible death. • Sino-orbital-disease necessitates the use of systemic therapy. Amphotericin B should be considered.

PRECAUTIONS
• Topical clotrimazole and enilconazole are caustic to all mucosal surfaces—protective gear (gloves, goggles) should be worn by all staff that are in close contact. • Enilconazole can be associated with tissue swelling and upper airway obstruction.

ALTERNATIVE DRUG(S)
Enilconazole
• Also active in the vapor phase.

Combined Clotrimazole Irrigation and Depot Therapy
• Clotrimazole (1%) is flushed through a trephine hole in the frontal sinus over 5 minutes; 50 mL in each side in dogs > 10 kg; 25 mL in each side in dogs < 10 kg.
• Clotrimazole cream (1%) is then inserted into the front sinuses; 20 g in each side in dogs > 10 kg, 10 g in each side in dogs < 10 kg. • Reported efficacy similar to topical clotrimazole or enilconazole alone (86%).

FOLLOW-UP

PATIENT MONITORING
Dogs
• Monitor clinical signs, although reduction of clinical signs does not establish resolution of disease. • Follow-up rhinoscopy is recommended in all cases to establish response to treatment, regardless of clinical signs—histopathology and culture can help establish response. • Serial serology (AGID) appears not to correlate with clinical status.
• Repeat CT scan should be considered for reassessment of the cribriform plate before repeat topical treatment if a worsening clinical signs are seen. • Monitor liver enzymes in animals on triazole therapy. • Monitor renal parameters in animals on Amphotericin B.

Cats
• Monitor clinical signs for improvement or resolution. • Monitor liver enzymes in animals on triazole therapy. • Monitor renal parameters in animals on Amphotericin B.

PREVENTION/AVOIDANCE
None

POSSIBLE COMPLICATIONS
• Topical therapy—monitor after treatment for any complications such as swelling of upper airway, neurologic signs, infection/ swelling of trephine site. • Triazoles can cause anorexia and can be hepatotoxic. • Amphotericin B can be nephrotoxic.

EXPECTED COURSE AND PROGNOSIS
• Studies have shown an 87% response rate to topical therapy in dogs after one to three treatments. • A newer study showed that recurrence or reinfection is more common than previously thought and can occur years after supposedly successful therapy. • The prognosis for cats with sinonasal aspergillosis is better than with the sino-orbital form.
**OVERVIEW**

- Opportunistic fungal infection caused by *Aspergillus spp.* Common molds that are ubiquitous in the environment, forming numerous spores in dust, straw, grass clippings, and hay.
- Disseminated disease does not appear to be related to the nasal form of the disease, although one report of a dog developing fungal osteomyelitis 6 months after treatment for nasal aspergillosis raises the possibility.
- Disseminated disease—usually *A. terreus* or *A. deflectus.*
- Portal of entry not definitively established (bronchopulmonary) only, or rarely, cornea or ear canal only.

**CAUSES & RISK FACTORS**

- Caused by *Aspergillus* species, most commonly *A. terreus* or *A. deflectus,* *A. fumigatus,* *A. niger,* *A. flavipes,* and *A. alabamensis* also associated. *A. fumigatus* recently reported to cause fungal rhinosinusitis in cats, disseminated disease in dogs, and pulmonary aspergillosis in humans.
- German shepherds and immunosuppressed animals at higher risk.
- Geographic/environmental conditions—may be a factor, as some regions have a higher incidence (e.g., California, Louisiana, Michigan, Georgia, Florida, and Virginia in the United States; Western Australia; Barcelona; and Milan).
- Cats—associated with FIP, FeLV, FeLV, FIV, diabetes mellitus, and immunosuppressant use.

**SIGNALLMENT**

- More common in dogs than in cats.
- German shepherds, and less so Rhodesian ridgebacks, overrepresented but reported sporadically in many breeds; average age 3 years (range 2–8 years); females three times more likely to develop disease as males.
- Persians—marginally increased incidence.
- Disseminated cases mostly affect the lungs and/or gastrointestinal tract.

**SIGNS**

- Dogs:
  - May develop acutely or slowly over a period of several months, usually terminally ill when first presenting.
  - Lumen—fungal osteomyelitis causing pronounced swelling and discharging, fistulous tracts.
  - Neurologic—fungal discospondylitis causing paraparesis, paraplegia, spinal pain.
  - Central signs—vestibular signs, seizures, caused by osteomyelitis of the head, etiologically related to the nasal form of the disease, may have a factor, as some regions have a higher incidence (e.g., California, Louisiana, Michigan, Georgia, Florida, and Virginia in the United States; Western Australia; Barcelona; and Milan).

- Cats:
  - Usually nonspecific signs (e.g., lethargy, depression, vomiting, and diarrhea).
  - Ocular—exophthalmos.
  - Uveitis—Dogs).

**CBC/BIOCHEMISTRY/URINALYSIS**

- Nonregenerative anemia and leukopenia. Cats—may have nonregenerative anemia. "White blood cell spikes" are more likely to develop disease as males.

**DIFFERENTIAL DIAGNOSIS**

- Bacterial osteomyelitis/discospondylitis; skeletal neoplasia; bacterial pneumonia; other causes of vertebral signs/trauma; other causes of urethritis (see Anterior Uveitis—Cats, Anterior Uveitis—Dogs)

**Ultrasonographic Findings**

- Ultrasonography useful for further defining brain lesions in animals with CNS changes; signs similar to other infectious and non-infectious inflammatory brain diseases. May help to identify subtle vertebral lesions in dogs with dissection osteomyelitis.

**DIAGNOSTIC PROCEDURES**

- Arteriovenous malformations are more likely to develop disease as males.

**BASICS**

- Opportunistic fungal infection caused by *Aspergillus spp.* Common molds that are ubiquitous in the environment, forming numerous spores in dust, straw, grass clippings, and hay.
- Disseminated disease does not appear to be related to the nasal form of the disease, although one report of a dog developing fungal osteomyelitis 6 months after treatment for nasal aspergillosis raises the possibility.
- Disseminated disease—usually *A. terreus* or *A. deflectus.*
- Portal of entry not definitively established (bronchopulmonary) only, or rarely, cornea or ear canal only.

**CAUSES & RISK FACTORS**

- Caused by *Aspergillus* species, most commonly *A. terreus* or *A. deflectus,* *A. fumigatus,* *A. niger,* *A. flavipes,* and *A. alabamensis* also associated. *A. fumigatus* recently reported to cause fungal rhinosinusitis in cats, disseminated disease in dogs, and pulmonary aspergillosis in humans.
- German shepherds and immunosuppressed animals at higher risk.
- Geographic/environmental conditions—may be a factor, as some regions have a higher incidence (e.g., California, Louisiana, Michigan, Georgia, Florida, and Virginia in the United States; Western Australia; Barcelona; and Milan).
- Cats—associated with FIP, FeLV, FeLV, FIV, diabetes mellitus, and immunosuppressant use.

**SIGNALLMENT**

- More common in dogs than in cats.
- German shepherds, and less so Rhodesian ridgebacks, overrepresented but reported sporadically in many breeds; average age 3 years (range 2–8 years); females three times more likely to develop disease as males.
- Persians—marginally increased incidence.
- Disseminated cases mostly affect the lungs and/or gastrointestinal tract.

**SIGNS**

- Dogs:
  - May develop acutely or slowly over a period of several months, usually terminally ill when first presenting.
  - Lumen—fungal osteomyelitis causing pronounced swelling and discharging, fistulous tracts.
  - Neurologic—fungal discospondylitis causing paraparesis, paraplegia, spinal pain.
  - Central signs—vestibular signs, seizures, caused by osteomyelitis of the head, etiologically related to the nasal form of the disease, may have a factor, as some regions have a higher incidence (e.g., California, Louisiana, Michigan, Georgia, Florida, and Virginia in the United States; Western Australia; Barcelona; and Milan).

- Cats:
  - Usually nonspecific signs (e.g., lethargy, depression, vomiting, and diarrhea).
  - Ocular—exophthalmos.
  - Uveitis—Dogs).

**CBC/BIOCHEMISTRY/URINALYSIS**

- Nonregenerative anemia and leukopenia. Cats—may have nonregenerative anemia. "White blood cell spikes" are more likely to develop disease as males.

**DIFFERENTIAL DIAGNOSIS**

- Bacterial osteomyelitis/discospondylitis; skeletal neoplasia; bacterial pneumonia; other causes of vertebral signs/trauma; other causes of urethritis (see Anterior Uveitis—Cats, Anterior Uveitis—Dogs)

**Ultrasonographic Findings**

- Ultrasonography useful for further defining brain lesions in animals with CNS changes; signs similar to other infectious and non-infectious inflammatory brain diseases. May help to identify subtle vertebral lesions in dogs with dissection osteomyelitis.

**DIAGNOSTIC PROCEDURES**

- Arteriovenous malformations are more likely to develop disease as males.
**PATHOLOGIC FINDINGS**
- Hyphae usually visualized, special stains assist organism detection.
- Focal osteomyelitis with multiple pale granulomas in kidneys, spleen, lymph node, myocardium, pancreas, and liver.
- Microscopic granulomas can be found in lungs, eye, thyroid, uterus, brain, and prostate and contain numbers of separate, branching hyphae that may have characteristic lateral branching aleuriospores.
- Best visualized with periodic acid-Schiff, Gomori's methenamine silver, or Cuscut's stain.

**TREATMENT**

**DOGS**
- Treatment rarely curative; severely ill dogs are recognized to have poor prognosis. May halt progression of clinical signs.
- Fluid therapy—indicated by the degree of renal compromise and azotemia.
- Pulmonary lobectomy followed by systemic antifungals has been successful in dogs with cavitary lesions without evidence of dissemination.

**CATS**
- Disseminated—likely difficult to treat; limited data.

**MEDICATIONS**

**DRUG(S)**
- Combination itraconazole 5–10 mg/kg PO q24h (can be divided) and amphotericin B (dogs, 2–5 mg/kg PO q6h) and amphotericin B may prove successful, but no published reports.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**
- Amphotericin B—contraindicated in dogs with pre-existing renal compromise or failure; amphotericin B lipid complex significantly reduced nephrotoxicity.
- Oral azoles—nausea, intermittent anorexia, liver enzyme elevation.
- Combination of fluconazole and amphotericin B can cause cutaneous drug eruptions in dogs.
- Avoid midazolam and cisapride with azoles—fatal drug reactions noted in humans.
- Hepatotoxicity and ulcerative dermatitis more likely to occur at doses of 10 mg/kg/day or higher. Discontinue itraconazole if adverse effects occur. May be able to reinstitute at lower dose once side effects have resolved.

**FOLLOW-UP**
- Disseminated—monitor serial radiographs every 1–2 months, renal function, and urine cultures; prognosis poor, especially in German shepherds.

**MISCELLANEOUS**

**ZOONOTIC POTENTIAL**
- None

**ABBREVIATIONS**
- ALP = alkaline phosphatase
- ALT = alanine transaminase
- BUN = blood urea nitrogen
- CSF = cerebrospinal fluid
- ELISA = enzyme-linked immunosorbent assay
- FeLV = feline leukemia virus
- FePLV = feline panleukopenia virus
- FIP = feline infectious peritonitis
- FIV = feline immunodeficiency virus
- MRI = magnetic resonance imaging

**Suggested Reading**

**Acknowledgment**
The author and editors acknowledge the prior contributions of Tania N. Davey.

**Client Education Handout** available online
Aspirin Toxicosis

**BASICS**

**OVERVIEW**
- Given for its antipyretic, analgesic, anti-inflammatory, and antiplatelet effects.
- Aspirin inhibits cyclooxygenase, reducing the synthesis of prostaglandins and thromboxanes.
- Gastric irritation and hemorrhage can occur; dogs are especially sensitive.
- Repeated doses can produce gastrointestinal ulceration and perforation.
- Tonic hepatic, metabolic acidosis, and anemia can occur, especially in cats.

**SIGNALMENT**
- Cats and less commonly dogs

**SIGNS**
- Depression
- Anorexia
- Vomiting—vomitus may be blood-tinged
- Tachypnea
- Hyperthermia
- Muscular weakness and ataxia
- Ataxia, coma, seizures, and death in 1 or more days

**CAUSES & RISK FACTORS**
- Owners employing human dosage guidelines to medicate cats and dogs.
- Cats have a decreased ability to conjugate salicylate with glycine and glucuronic acid due to a deficiency in glucuronyl transferase.
- Half-life increases with dosage—cats, 22–27 hours for 5–12 mg/kg and approximately 44 hours for 25 mg/kg; dogs, 7.5 hours; responsible for higher risk in cats.
- Elimination is slower in neonatal and geriatric patients.
- Patients with hypoprothrombinemia may be at higher risk of toxicity because aspirin is highly protein bound to plasma albumin.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Ethylene glycol or alcohol
- Anticoagulant rodenticides
- Other causes of liver failure, including acetaminophen, iron, metaldehyde, and blue-green algae

**CBC/BIOCHEMISTRY/URINALYSIS**
- Cats—prone to Heinz body formation
- Hyponatremia and hypokalemia
- Anemia, hypoproteinemia, elevated liver enzymes, elevated white blood cell count

**OTHER LABORATORY TESTS**
- Initial respiratory alkalosis followed by metabolic acidosis
- High ketones and pyruvic, lactic, and amino acid levels
- Decreased sulfuric and phosphoric acid renal clearance

**DIAGNOSTIC PROCEDURES**
- Salicylic acid concentrations in serum or urine

**TREATMENT**
- Inpatient—following general principles of poisoning management
- Induced gastric emptying—gastric lavage or induced emesis
- Correction of acid-base balance—continuous intravenous fluids; assisted ventilation and supplemental oxygen for severely-affected animals
- Whole blood transfusions for severe cases of hemorrhage and hypotension
- Peritoneal dialysis, hemodialysis, or charcoal hemoperfusion—advanced procedures

**MEDICATIONS**

**DRUG(S)**
- No specific antidote available.
- Activated charcoal—1–2 g/kg PO.
- Sodium bicarbonate 1 mEq/kg IV alkalizes urine, must closely monitor acid-base status.
- Gastrointestinal protectants—sucralfate and a H2 blocker or proton pump inhibitor; misoprostol for patients at higher risk for gastrointestinal hemorrhage.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**

**FOLLOW-UP**
- Maintaining renal function and acid-base balance is vital.
- Severe acid-base disturbances, severe dehydration, toxic hepatitis, bone marrow depression, and coma are poor prognostic indicators.

**MISCELLANEOUS**
- Be sure that history of “aspirin” medication does not refer to other available pain medications.
- Question owner about any pre-existing painful condition that may have prompted the aspirin administration.

**Suggested Reading**

**Acknowledgment**
- The author and editors acknowledge the prior contribution of Frederick W. Oehme.

**Author**
- Lisa A. Murphy

**Consulting Editor**
- Lynn R. Hovda
Asthma, Bronchitis—Cats

**Basics**

**Definition**
- Chronic bronchitis—inflammation in the airways (bronchi and bronchioles) lacking a specific etiology; chronic daily cough of greater than 2 months in duration.
- Asthma—acute or chronic airway inflammation associated with increased airway reactivity to various stimuli; airway narrowing due to smooth muscle hyperreactivity or constriction, reversibility of airway obstruction, and presence of eosinophil, lymphocytes, and mast cells within the airways. Bronchitis is thought to result in airflow obstruction due to airway remodeling while asthma is associated with airway constriction; however, clinically the two disease processes can appear similar. No physical examination findings or biomarkers can distinguish between the two syndromes, although reversal of airflow obstruction following administration of a beta-agonist is suggestive of the asthmatic form of disease.

**Pathophysiology**
- Lower airway inflammation likely results from inhalation of irritant substances.
- Bronchial smooth muscle contraction—reversible spontaneously or with treatment.
- Increase in mucus goblet cells, mucus production, and edema of bronchial wall associated with inflammation. Excessive mucus can cause bronchial obstruction, atelectasis, or bronchiectasis. Smooth muscle hyperreactivity implies chronicity—usually not reversible. Chronic inflammation leads to airway remodeling and irreversible airflow obstruction.

**Systems Affected**
- Respiratory—Cardiac—pulmonary hypertension rarely

**Geographic Distribution**
Worldwide.

**Signalement**
Species: Cat

**Breed Predictions**
Siamese overrepresented

**Mean Age and Range**
Any age; more common between 2 and 8 years

**Predominant Sex**
One study showed females overrepresented

**Signs**

**Historical Findings**
- Coughing, tachypnea, labored breathing or wheezing.
- Signs are typically episodic and can be acute or chronic.

**Pathological Findings**
- Diffuse bronchial wall thickening; interstitial or patchy alveolar patterns also possible.
- Severity of radiographic changes does not necessarily correlate with clinical severity or duration, and normal radiographs can be found.
- Hypertension of lung fields—flattened and caudally displaced diaphragm, increased distance between the heart and diaphragm, extension of lungs to the first lumbar vertebra thought to reflect bronchoconstriction. Collapse of right middle lung lobe due to mucous plugging and atelectasis reported in 11% of cases.

**Diagnosis**

**Differential Diagnosis**
- Rule out infectious pneumonia (Mycoplasma, Toxoplasma, bacterial or fungal pneumonia).
- Giardia, Cryptosporidium in primary lung parasites (Deltamoeba aberti, Capillaria aerophilia, Paragonimus kellicotti). More common in southern and midwest US, and in outdoor and hunting cats in some geographic regions.
- Primary or metastatic neoplasia can have similar clinical and radiographic appearance. Clinical presentation of idiopathic pulmonary fibrosis may appear similar to feline bronchitis.

**CBC/Biochemistry/Urinalysis**
Frequently normal, ~40% of cats with bronchial disease have peripheral eosinophilia.

**Other Laboratory Tests**
- Fecal exams—rotation for Capillaria, sedimentation for Paragonium, Baermann for Aelurostrongylus. False-negative tests common.
- Heartworm antigen and antibody testing, particularly if coughing occurs in conjunction with vomiting. Radiologic or serologic testing or intradermal skin testing—no correlation between skin allergies and respiratory disease currently documented.

**Imaging**
- Classically, diffuse bronchial wall thickening; interstitial or patchy alveolar patterns also possible.
- Hypertension of lung fields—flattened and caudally displaced diaphragm, increased distance between the heart and diaphragm, extension of lungs to the first lumbar vertebra thought to reflect bronchoconstriction. Collapse of right middle lung lobe due to mucous plugging and atelectasis reported in 11% of cases.

**Treatment**

**Appropriate Health Care**
- Remove patient from environment that exacerbates disease. Hospitalize for acute respiratory distress.

**Nursing Care**
Oxygen therapy, bronchodilators, and sedatives in an acute crisis. Minimize manipulation in order to lessen stress and oxygen needs of the animal.

**Activity**
Usually surgery-limited by patient.

**Diets**
Calorie restriction for obese cats.

**Client Education**
- Most causes are chronic and progressive.
- Do not discontinue medical therapy when clinical signs have resolved—relapsed inflammation is common and can lead to progression of disease. Lifelong medication and environmental changes usually necessary.
- Some clients can be taught to give.
terbutaline subcutaneously and corticosteroid injections at home for a crisis situation.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

**Emergency Treatment**
- Oxygen and a parenteral bronchodilator
- Injectable terbutaline (0.01 mg/kg IV or SC); repeat if no clinical improvement (decrease in respiratory rate or effort) in 20–30 minutes.
- A sedative can aid in decreasing anxiety (butorphanol tartrate at 0.2–0.4 mg/kg IV or IM, imipramine at 0.01 mg/kg IV or IM, or azipropiramine at 0.01–0.05 mg/kg SC).

**Inhaled Bronchodilators**
- Albuterol—preferred inhalant bronchodilator, effect lasts less than 4 hours.
- Long-term use of traditional racemic form of inhaled albuterol (R and S-enantiomers) has been associated with worsened airway inflammation. Enantiomer specific: R-albuterol should be used if the drug is needed in moderately to severely affected cats (12-24h) or during respiratory distress.

**Contraindications**
- Equine bronchitis, asthmatic bronchitis, lower airway disease.
- Cor pulmonale can be a sequela to chronic lower airway disease.

**ALTERNATIVE DRUG(S)**
- Leukotriene receptor blockers and inhibitors of generation: no evidence to support use.
- Anti-serotonin and antihistamine drugs: no evidence to support use.
- Leukotriene antagonists.
- Beta-2 antagonists (e.g., propranolol) are used with caution.

**FOLLOW-UP**

**PATIENT MONITORING**
- Owners should report any increase in coughing, sneezing, wheezing, or respiratory distress. Medications should be increased appropriately or additional therapy initiated if clinical signs worsen.
- Follow-up radiographs may be helpful to detect onset of new disease.
- Owners should watch for signs of PU/PD that could indicate diabetes mellitus or renal disease. Monitor blood glucose and urine cultures.

**PREVENTION/AVOIDANCE**
- Eliminate any environmental factors that could indicate diabetes mellitus or renal disease.
- Consult with veterinarian to develop a treatment plan.

**POSSIBLE COMPLICATIONS**
- Acute episodes can be life-threatening.
- Right-sided heart disease rarely develops as a result of long-term bronchitis.

**EXPECTED COURSE AND PROGNOSIS**
- Long-term therapy should be expected.
- Most cats do well if recurrence of clinical signs is carefully monitored and medical therapy appropriately adjusted.
- A few cats will be refractory to treatment; these carry a much worse prognosis.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
- Cor pulmonale can be a sequela to chronic lower airway disease.

**PREGNANCY/FERTILITY/BREEDING**
- Glucocorticoids are contraindicated in the pregnant animal. Bronchodilators should be used with caution.

**SYNONYMS**
- Allergic bronchitis, asthmatic bronchitis, feline lower airway disease, extrinsic asthma, eosinophilic bronchitis.

**SEE ALSO**
- Heartworm Disease—Cats
- Respiratory Parasites

**ABBREVIATIONS**
- BAL = bronchoalveolar lavage
- MDI = metered-dose inhaler
- PU/PD = polyuria/polydipsia

**INTERNET RESOURCES**
- www.fritzthebrave.com: source for clients to order facemasks
- www.Aerokat.com: for ordering facemasks

**Suggested Reading**

**Authors**
- Garcia J, Miller and Lynelle R. Johnson

**Consulting Editor**
- Lynelle R. Johnson

**Client Education Handout available online**
Astrocytoma

OVERVIEW

• Glioma cell neoplasm, most commonly affecting the brain and rarely the spinal cord.
• Neoplastic cells of astrocytic origin. • It is the most common intra-axial (situated inside of the brain parenchyma) intracranial neoplasms of dogs but is rarely diagnosed in cats. • Tumors are often located in the pyramidal area of the temporal lobe, the cerebral hemispheres, the thalamus, hypothalamus, or midbrain. • Biologic behavior of this tumor is dictated by the histopathologic grade (I–IV, from best to worst prognosis) and anatomic involvement. • Tumors typically do not penetrate the ventricular system or metastatize outside of the cranial vault.

SIGNAMENT

• Dog—often brachyccephalic breeds >5 years of age; no sex predilection reported. • Cat—usually >9 years; no sex or breed predilection reported.

SIGNS

• Location and growth kinetic dependent • Seizures • Behavioral changes • Apathy towards normal activities including eating, playing, and societal interactions • Disorientation • Loss of consciousness • Proptosis • Cranial nerve abnormalities • Head muscle atrophy • Upper motor neuron tetraparesis

DIAGNOSIS

DIFFERENTIAL DIAGNOSIS

• Other primary tumors arising from tissues of the central nervous system • Metastatic neoplasia with brain tropism such as hemangiosarcoma • Granulomatous meningoencephalitis • Trauma
• Cerebrovascular infarction • Meningitis

CBC/BIOCHEMISTRY/URINALYSIS

Usually unremarkable

OTHER LABORATORY TESTS

CSF analysis may show albumin-cytologic dissociation (high protein with low number of nucleated cells). The CSF analysis is indicated to exclude infectious etiology, not to diagnose astrocytoma.

IMAGING

• MRI of brain is ideal for mass lesion confirmation, as it is superior to CT scanning for detecting lesions in the middle and caudal fossae. Additionally, MRI is more sensitive than CT for detecting inflammation, bleeding, and edema. • Brain MRI may be useful in establishing a tentative differential diagnosis of a glial tumor, based on tumor characteristics highlighted in specific sequences.

DIAGNOSTIC PROCEDURES

• Neurologic exam. • Ophthalmic exam. • MRI. • CSF analysis. • Tumor biopsy for definitive diagnosis, when specific antineoplastic treatment is sought (surgery, curative-intent radiation therapy, experimental therapies).

TREATMENT

• Surgery • Radiation therapy can be very effective in improving neurologic signs. • Chemotherapy with lomustine, procarbazine, or temozolomide might exert cytoreductive activities. • Anti-inflammatory dosing with corticosteroids to reduce perinatal edema. • Consultation with a neurosurgeon and a radiation oncologist is essential for the appropriate patient management.

MEDICATIONS

DRUG(S)

Seizure Control

• Status epilepticus—diazepam (0.5–1 mg/kg IV, up to three times to achieve effect); if no response to diazepam, use pentobarbital (5–15 mg/kg IV slowly to effect). • Long-term management—phenobarbital (1–4 mg/kg PO q12h) or adjuvant potassium bromide (20 mg/kg PO q24h).

Tumor Control

• Timely consultation with a neurosurgeon is of paramount importance for the appropriate management of the patient. • Radiation therapy may be effective, and consultation with a radiation oncologist is recommended. • Stereotactic radiosurgery or intensity modulated radiation therapy may be considered as first-line treatment options. • Chemotherapy may be effective for treating dogs. Potential drugs that may exert measurable anticancer effects include CCNU (60–70 mg/m 2 PO every 3 weeks) or temozolomide (100–120 mg/m 2 PO q24h for 5 days every 3 weeks). • Prednisone (1 mg/kg q24h) is effective in reducing perinatal edema and improving the neurologic signs. Patients may need to be on steroids long term, even after the definitive treatment of the tumor.

CONTRAINDICATIONS/POSSIBLE INTERACTIONS

• Prednisone and phenobarbital may cause polyphagia, polydipsia, and polyuria. • Phenobarbital may cause sedation for up to 2 weeks after initiation of treatment, and increase in hepatic enzymes on serum biochemical panel. • CBC and platelet count is recommended 7–10 days after chemotherapy and immediately before each dose of chemotherapy to monitor myelosuppression. • Chemotherapy has the potential to be synergistic with radiation therapy. Timely specialty to a referral center with neurosurgery, radiation therapy, and medical oncology capabilities is important for patients seeking more than palliative care.

FOLLOW-UP

PATIENT MONITORING

• Blood phenobarbital concentration should be assessed after 7–10 days of treatment, with modifications to dosages for achieving target plasma concentrations. • Serial MRIs should be considered for documenting response if multimodality therapy is used. • Serial CBC and platelet counts should be performed to monitor myelosuppression associated with chemotherapy.

EXPECTED COURSE AND PROGNOSIS

• Long-term prognosis—guarded. • Median survival after chemotherapy plus medical management may be up to 7 months. • Median survival after radiation therapy has been reported to be as high as 12 months.

ABBRÉVIATIONS

ABBREVIATIONS

• CSF = cerebrospinal fluid • CT = computed tomography • MRI = magnetic resonance imaging

SUGGESTED READING


AUTHOR Nick DeRiviere

CONSULTING EDITOR Timothy M. Fan

ACKNOWLEDGMENTS The author and editors acknowledge the prior contribution of Wallace B. Morrison.
Astrovirus Infection

**BASICS**

**Overview**
An uncommon intestinal viral infection characterized by enteritis and diarrhea.

**Signalment**
- Cats
  - No known breed, sex, or age predilection

**Signs**
- Small bowel diarrhea often green and watery.
  - Kittens show more severe signs.
  - May be severe and acute enough to cause dehydration and anorexia.

**Causes & Risk Factors**
- A small, non-enveloped, RNA virus of the genus *Astrovirus*.
- Details of the incidence, prevalence, and predisposing factors unknown.

**Diagnosis**

**Differential Diagnosis**
- Many causes of gastrointestinal disease
  - Food allergy
  - Toxic ingestion
  - Inflammatory bowel disease
  - Neoplasia
  - Intestinal parasites
  - Viral infections—panleukopenia, rotavirus, emetic coronavirus, emetic calicivirus
  - Bacterial infections—salmonelliosis, colibacillosis
  - Protozoal infections—Giardia, cryptosporidiosis

**CBC/Biochemistry/Urinalysis**
N/A

**Other Laboratory Tests**
- Electron microscopy of feces—identify astrovirus particles.
  - Difficult to isolate in the laboratory.

**Imaging**
N/A

**Diagnostic Procedures**
None

**Pathologic Findings**
None described; similar to mild enteritis, rotavirus, or coronavirus enteritis.

**Treatment**
- Control diarrhea.
- Reestablish fluid and electrolyte balance.

**Medications**
- No specific antiviral drugs.

**Contraindications/possible Interactions**
None

**Follow-up**
- Monitor fluid and electrolytes.

**Prevention/Avoidance**
- Isolate infected cats during acute disease.

**Possible Complications**
Secondary intestinal viral and bacterial infections.

**Expected Course and Prognosis**
- Illness usually <1 week.
- Mortality—appears low.
- Prognosis—good.
- If diarrhea persists, investigate other causes.

**Miscellaneous**

**Zoonotic Potential**
Sequence analysis of human and animal astroviruses suggests human-to-animal transmission does not occur.

**Suggested Reading**

**Author**
Fred W. Scott

**Consulting Editor**
Stephen C. Barr
Ataxia

Basics

Definition

- A sign of sensory dysfunction that produces incoordination of the limbs, head, and/or trunk.
- Three clinical types—sensory ( proprioceptive), vestibular, and cerebellar, all produce changes in limb coordination, but vestibular and cerebellar ataxia also produce changes in head-trunk movement.

Pathophysiology

Sensory (Proprioceptive)

- Proprioceptive pathways in the spinal cord (i.e., fasciculus gracilis, fasciculus cuneatus, and spinocerebellar tracts) relay limb and trunk position to the brain. When the spinal cord is slowly compressed, proprioceptive deficits are usually the first signs observed, because these pathways are located more superficially in the white matter and their larger sized axons are more susceptible to compression than are other tracts.
- Generally accompanied by weakness owing to early concomitant upper motor neuron involvement; weakness not always obvious early in the course of the disease.
- Ataxia can occur with spinal cord, brainstem, and cerebral lesions; mild to absent with unilateral brainstem lesions, and subtle to absent with unilateral cerebral lesion.

Vestibular

- Changes in head and neck position are relayed through the vestibulo-cochlear nerve to the brainstem.
- Vestibular receptors or the nerve in the inner ear are considered part of the peripheral nervous system, whereas nuclei in the brainstem are part of the central nervous system.
- Localize the vestibular signs to peripheral or central vestibular system.

Signalement

Any age, breed, or sex

Signs

- Important to define the type of ataxia to localize the problem.
- Only one limb involved—consider a lameness problem.
- Only hind limbs affected—likely a spinal cord disorder affecting the spinocerebellar tracts.
- All or both bilateral limbs affected—cervical spinal cord, or cerebellar localization.
- Head tilt and/or nystagmus—vestibular localization.

Causes

Neurologic

Cerebellar

- Degenerative—atrophy (Kerry blue terrier, Gordon setter, rough-coated collie, Australian kelpie, Airedale, Bernese mountain dog, Finnish hound, Brittany spaniel, border collie, beagle, Samoyed, white fox terrier, Labrador retriever, Great Dane, collie, Rhodesian ridgeback, domestic shorthair cats); storage diseases often have cerebellomedullary involvement.
- Anomalous—hypoplasia secondary to compression of the nearby ascending proprioceptive pathways to the cerebellum.
- Peripheral vestibular signs do not include changes in mental status, vertical nystagmus, proprioceptive deficits, quadriaparesis or hemiparesis.

Vestibular

- Bilateral vestibular involvement, peripheral or central in origin, has characteristic exaggerated head motion with often poor to absent physiologic nystagmus.
- Central—The cerebellum regulates, coordinates, and modulates motor activity.
- Proprioception normal because the ascending proprioceptive pathways to the cerebellum tract are intact; weakness does not occur because the upper motor neurons are intact.
- Inadequacy in the performance of motor activity; strength preservation; no proprioceptive deficits.
- Affected animal shows uncoordinated motor activity of limbs, head, and neck, hypermetria, dysmetric; head tremors; intention tremors; and truncal sway. Menace responses may be absent without visual dysfunction.

Systems Affected

Nervous—spinal cord (and brainstem and cortex), cerebellum, vestibular system.

Risks Factors

- Genetic—congenital anomalous; focal atrophy secondary to meningitis, abscess.
- Neurologic—compressive, e.g., mass effect from tumor, vasculitis, axonal degeneration.
- Traumatic.
- Anomalous—hypoplasia secondary to compression of the nearby ascending proprioceptive pathways to the cerebellum.

Vestibular—Central Nervous System

- Infectious—FIP; canine distemper virus; toxoplasma gondii.
- Inflammatory—idiopathic, immune-mediated—granulomatous meningoencephalomyelitis, meningitis, and encephalitis.
- Nutritional—thiamine deficiency.

Vestibular—Peripheral Nervous System

- Infectious—otoitalis interna; Cryptococcus neoformans (cats).
- Inflammatory—nasopharyngeal (middle ear) polyps (cats).
- Idiopathic—genetic vestibular disease (dogs); idiopathic vestibular syndrome (cats).
- Metabolic—hypothyroidism.

Traumatic

- Degenerative—congenital myelopathy (old German shepherd, Welsh corgi).
- Vascular—fibrinolytic embolic myelopathy.
- Anomalous—hemivertebrae; dysgenesis of the vertebral body; meningioma.

Spinal Cord

- Degenerative—degenerative myelopathy (old German shepherd, Welsh corgi).
- Vascular—fibrinolytic embolic myelopathy.

Neurologic

Cerebellar

- Degenerative—atrophy (Kerry blue terrier, Gordon setter, rough-coated collie, Australian kelpie, Airedale, Bernese mountain dog, Finnish hound, Brittany spaniel, border collie, beagle, Samoyed, white fox terrier, Labrador retriever, Great Dane, collie, Rhodesian ridgeback, domestic shorthair cats); storage diseases often have cerebellomedullary involvement.
- Anomalous—hypoplasia secondary to compression of the nearby ascending proprioceptive pathways to the cerebellum.
- Peripheral vestibular signs do not include changes in mental status, vertical nystagmus, proprioceptive deficits, quadriaparesis or hemiparesis.

Vestibular

- Bilateral vestibular involvement, peripheral or central in origin, has characteristic exaggerated head motion with often poor to absent physiologic nystagmus.
- Central—The cerebellum regulates, coordinates, and modulates motor activity.
- Proprioception normal because the ascending proprioceptive pathways to the cerebellum tract are intact; weakness does not occur because the upper motor neurons are intact.
- Inadequacy in the performance of motor activity; strength preservation; no proprioceptive deficits.
- Affected animal shows uncoordinated motor activity of limbs, head, and neck, hypermetria, dysmetric; head tremors; intention tremors; and truncal sway. Menace responses may be absent without visual dysfunction.

Systems Affected

Nervous—spinal cord (and brainstem and cortex), cerebellum, vestibular system.

Risks Factors

- Genetic—congenital anomalous; focal atrophy secondary to compression of the nearby ascending proprioceptive pathways to the cerebellum.
- Neurologic—compressive, e.g., mass effect from tumor, vasculitis, axonal degeneration.
- Traumatic.

Vestibular—Central Nervous System

- Infectious—FIP; canine distemper virus; toxoplasma gondii.
- Inflammatory—idiopathic, immune-mediated—granulomatous meningoencephalomyelitis, meningitis, and encephalitis.
- Nutritional—thiamine deficiency.

Vestibular—Peripheral Nervous System

- Infectious—otoitalis interna; Cryptococcus neoformans (cats).
- Inflammatory—nasopharyngeal (middle ear) polyps (cats).
- Idiopathic—genetic vestibular disease (dogs); idiopathic vestibular syndrome (cats).
- Metabolic—hypothyroidism.

Traumatic

- Degenerative—degenerative myelopathy (old German shepherd, Welsh corgi).
- Vascular—fibrinolytic embolic myelopathy.

Spinal Cord

- Degenerative—degenerative myelopathy (old German shepherd, Welsh corgi).
- Vascular—fibrinolytic embolic myelopathy.

Neurologic

Cerebellar

- Degenerative—atrophy (Kerry blue terrier, Gordon setter, rough-coated collie, Australian kelpie, Airedale, Bernese mountain dog, Finnish hound, Brittany spaniel, border collie, beagle, Samoyed, white fox terrier, Labrador retriever, Great Dane, collie, Rhodesian ridgeback, domestic shorthair cats); storage diseases often have cerebellomedullary involvement.
- Anomalous—hypoplasia secondary to compression of the nearby ascending proprioceptive pathways to the cerebellum.
- Peripheral vestibular signs do not include changes in mental status, vertical nystagmus, proprioceptive deficits, quadriaparesis or hemiparesis.

Vestibular
**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Differentiate the types of ataxia.
- Differentiate from other disease processes that can affect gait—musculoskeletal, metabolic, cardiovascular, respiratory.
- Musculoskeletal disorders—typically produce lameness, pain, and a reluctance to move; degenerative joint disease signs often improve with increased movements.
- Systemic illness and endocrine, cardiovascular, and metabolic disorders—can cause intermittent ataxia, especially of the pelvic limbs; with fever, weight loss, murmurs, arrhythmias, hair loss, or collapse with exercise, suspect a non-neurologic cause; obtain minimum data from hemogram, biochemistry, and urinalysis.
- Head tilt or nystagmus—likely vestibular localization.
- Intention tremors of the head or hypermetria—likely cerebellar localization.
- All four limbs affected—lesion is in the cervical spinal cord, cerebellum or is multifocal to diffuse.
- Only pelvic limbs affected—lesion is anywhere below the second thoracic vertebra.

**CBC/BIOCHEMISTRY/URINALYSIS**
- Normal unless metabolic cause (e.g., hypoglycemia, electrolyte imbalance, anemia, polycythemia).

**OTHER LABORATORY TESTS**
- Hypoglycemia—determine serum insulin concentration on sample that has low glucose value; low glucose and higher than expected insulin value suggest insulin-secreting tumor.
- Anemia—differentiate as nonregenerative or regenerative on the basis of the reticulocyte count.
- Electrolyte imbalance—correct the problem; see if ataxia resolves.

**IMAGING**
- Spinal radiography, myelography, CT or MRI—if spinal cord dysfunction suspected.
- Bular radiography—if peripheral vestibular disease suspected; CT or MRI superior; for inner ear disease, MRI superior to CT.
- Thoracic radiography—for older patients and patients suspected to have neoplasia or systemic fungal infection.

**DIAGNOSTIC PROCEDURES**
- Cerebrospinal fluid—helps confirm nervous system etiology.

**TREATMENT**
- Usually outpatient, depending on severity and acuteness of clinical signs.
- Exercise—decrease or restrict if ataxia originates from spinal cord disease.
- Client should monitor gait for increasing dysfunction or weakness; if paresis worsens or paralysis develops, other testing is warranted.
- Avoid drugs that could contribute to the problem; may not be possible in patients on antiepileptic drugs for seizures.

**MEDICATIONS**
- Not recommended until the source or cause of the problem is identified.

**FOLLOW-UP**
- Periodic neurologic examinations to assess condition.

**POSSIBLE Complications**
- Spinal cord—progression to weakness and possibly paralysis.
- Hypoglycemia—seizures
- Cerebellar disease—head tremors and bobbing
- Brainstem disease—stupor, coma, death

**MISCELLANEOUS**

**AGE-RELATED FACTORS**
- N/A
Atherosclerosis

**BASICS**

**OVERVIEW**
Thickening of the inner arterial wall in association with lipid deposits. Chronic arterial change characterized by loss of elasticity, luminal narrowing, and proliferating and degenerative lesions of the intima and media.

**SIGNALMENT**
- Rare in dogs.
- Not described in cats.
- Higher prevalence in miniature schnauzer, Doberman pinscher, poodle, and Labrador retriever.
- Geriatric patients (> 9 years).

**SIGNS**

**Historical Findings**
- None in some animals
- Lethargy
- Anorexia
- Weakness
- Dyspnea
- Collapse
- Vomiting
- Diarrhea

**Physical Examination Findings**
- Dryness
- Irregular rhythm
- Heart failure
- Dilation
- Blindness
- Cerebral
- Goma
- Episodic lameness

**CAUSES & RISK FACTORS**
- Severe hypothyroidism
- Increasing age
- Hyperlipidemia in miniature schnauzers
- Male gender (male dogs may have predisposition)
- High total cholesterol
- Diabetes
- Glomerulonephritis

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
Arteriosclerosis

**CBC/BIOCHEMISTRY/URINALYSIS**
- Hypercholesterolemia
- Hyperlipidemia
- High BUN and creatinine
- High liver enzymes

**OTHER LABORATORY TESTS**
- Low T3 and T4
- High values for alpha-2 and beta fractions on protein electrophoresis.

**IMAGING**
Thoracic and abdominal radiographs may reveal cardiomegaly and hepatoencephalopathy.

**DIAGNOSTIC PROCEDURES**

**Electrocardiography**
- Conduction abnormalities and notched QRS complexes.
- Arrhythmia.
- ST segment elevation or depression with myocardial infarction.

**TREATMENT**
- Treat the underlying disorder and clinical signs (e.g., dyspnea if congestive heart failure develops).
- Diet—low-fat diet, weight loss program, and high soluble fiber intake to control hyperlipidemia.
- Treat conduction disturbances and arrhythmias if clinically indicated.
- Thyroid replacement if hypothyroidism is confirmed.
- Antihypertensive therapy if hypertension is documented.
- Blood cholesterol-reducing medications if hyperlipidemic.
- Treat diabetes.

**FOLLOW-UP**
- Monitor T4 concentration 4–6 hours post-administration after the first 6 weeks of treatment and adjust dosage accordingly.
- Monitor blood triglyceride and cholesterol levels.
- Monitor ECG for conduction disturbances and ST segment changes.

**MEDICATIONS**

**DRUG(S)**
- Treat conduction disturbances and arrhythmias if clinically indicated.
- Thyroid replacement if hypothyroidism is confirmed.
- Antihypertensive therapy if hypertension is documented.
- Blood cholesterol-reducing medications if hyperlipidemic.
- Treat diabetes.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**
N/A

**ASSOCIATED CONDITIONS**
- Hypothyroidism
- Diabetes
- Mitral valve disease (myxomatous)
- Glomerulonephritis

**AGE-RELATED FACTORS**
Geriatric patients (> 9 years)

**SEE ALSO**
Myocardial Infarction

**INTERNET RESOURCES**
www.vetgo.com/cardio

**Suggested Reading**

**Author** Larry P. Tilley

**Consulting Editors** Larry P. Tilley and Francis W.K. Smith, Jr.
**ATLANTOAXIAL INSTABILITY**

### OVERVIEW

- Results from malformation or disruption of the articulation between the first and second cervical vertebrae (atlas and axis, respectively), causing spinal cord compression.
- AA instability can result in spinal cord trauma or compression at the junction between the atlas and axis—may cause neck pain and/or varying degrees of general proprioceptive (GP) ataxia (upper motor neuron [UMN] tetraparesis, tetraplegia with or without nociception), and death from respiratory arrest.

### ETIOLOGY

- Congenital: anomaly of the dens (aplasia, hypoplasia, or malformation [dorsal angulation] of the dens) and its ligamentous attachments.
- Acquired: may be a consequence of traumatic injury.

### SIGNALMENT

- Congenital—toy-breed dogs (Yorkshire terrier, miniature or toy poodle, Chihuahua, Pekingese, and Pomeranian).
- Age at onset—usually before 12 months of age.
- Uncommon in larger-breed dogs, dogs over 1 year old, and cats.
- No sex predilection.

### SIGNS

- Intermittent or progressive ambulatory tetraparesis, usually with neck pain—most common.
- Neurologic signs vary from mild to moderate GPT/UMN ambulatory tetraparesis to non-ambulatory GPT/UMN tetraparesis, or tetraplegia depending on degree of spinal cord compression and secondary pathology (i.e., edema, hemorrhage, or gloss). Animals may have only neck pain without concurrent neurologic deficits.
- Episodes of collapse secondary to weakness.
- Abnormal postural reactions with spinal reflexes that are normal to exaggerated with normal to increased muscle tone in all four limbs.
- Acute death may occur when accompanied by trauma and respiratory arrest (uncommon).

### CAUSES & RISK FACTORS

- Usually caused by abnormal development of the dens and/or ligamentous support structures, resulting in subluxation of the atlantoaxial joint.
- Fracture of the axis.
- Clinical signs often occur as a result of mild or insignificant trauma (e.g., jumping or playing).
- Clinical signs may be exacerbated by activity such as flexion of the neck.

### DIAGNOSIS

#### DIFFERENTIAL DIAGNOSIS

- Differential diagnoses are consistent with various causes of cervical myelopathies, including:
  - Other congenital malformation.
  - Trauma.
  - Meningitis or meningo(myelitis (i.e., infectious or non-infectious [granulomatous meningoencephalomyelitis]).
  - Fibrocartilaginous embycoid myelopathy.
  - Disk herniation.
  - Neoplasia.

#### CBC/BIOCHEMISTRY/URINALYSIS

- Normal

#### IMAGING

- Plain radiography of the cervical vertebral column:
  - Lateral view—caudal and dorsal displacement of the axis in relation to the atlas, resulting in an increased distance between vertebral bodies.
  - Ventral dorsal or oblique view—may reveal absence, hypoplasia, or malformation (dorsal angulation) of the dens.
  - Cross-sectional imaging:
    - MRI
    - Diagnosis based on observation of caudal and dorsal displacement of the axis in relationship to the atlas as evidenced by the following features of the atlantoaxial articulation: (1) Dorsal: displacement of the spinous process of the axis at the occipito-atlas-axis joint cavity.
      - Allows identification of spinal cord compression.
      - Allows recognition of secondary spinal cord pathology such as edema, hemorrhage, or gloss, which may impact prognosis.
      - Computed tomography:
        - May provide visualization of bony structures, which allows for the creation of three-dimensional reconstructed image to help surgical planning.
      - Precautions:
        - Proper positioning will require sedation or general anesthesia.
        - Sedation or general anesthesia carries significant risk for iatrogenic trauma.
        - Care needs to be exercised when positioning animals.
        - AVOID EXCESSIVE FLEXION OF THE NECK!
        - Flexion may exacerbate compression, which may worsen clinical signs or cause death due to spinal cord trauma.
        - To protect against neck flexion during recovery, affected animals should be closely monitored until they are capable of maintaining normal head and neck carriage.

- Unusual posture due to spinal cord compression or secondary pathology (i.e., edema, hemorrhage, or gloss).

#### TREATMENT

- Prior to treatment, consultation with a board-certified neurologist or surgeon should be pursued.
- Improper treatment can lead to irreversible deterioration of neurologic function.

#### MEDICAL

- Neck brace (splat) to stabilize the cervical vertebral column in extension.
- Fiberglass cast material is positioned ventrally from the natal aspect of mandible to the xiphoid and incorporated into bandage material, which immobilizes the head and neck.
- Strict exercise restriction (cage confinement) for a minimum of 8 weeks.
- Frequent bandage/splint changes are needed.
- Adjunctive medication (see below).

#### OVERALL PROGNOSIS

- Successful outcome observed in 62.5% of dogs.
- Improved prognosis was associated with an acute onset and short duration of clinical signs (<30 days).
- Surgery is recommended to treat animals that fail to improve or experience recurrence of signs following medical treatment.

#### SURGERY

- Treatment of choice in the majority of cases.
- Surgical approach: ventral method is preferred.
- Ventral approach—variety of methods:
  - Transarticular pinning or lag screw technique; ventral tips of the pins incorporated in polymethylmethacrylate to provide fixation.
  - Fiber glass cast is positioned longitudinally and wired to the screws; screw heads and K-wires are incorporated in polymethylmethacrylate to provide fixation.
  - Dorsal approach—use wire or synthetic suture material to fix the spinous process of the axis to the dorsal arch of the atlas, provide less rigid fixation and may be associated with greater implant failure.
- Strict exercise restriction is required for the first month postoperatively, followed by a gradual return to activity over an additional month.
- Adjunctive medication (see below).
- Overall prognosis ranges from 63% to 91% success; improved prognosis was associated with young (<24 months) dogs, duration of clinical signs <10 months, and mild neurologic deficits.
ATLANTOAXIAL INSTABILITY

- Complications:
  - Failure to improve/worsening of neurologic deficits.
  - Implant failure/infection.
  - Respiratory—respiratory arrest, dyspnea, cough, and aspiration pneumonia.
  - Death.

**MEDICATIONS**

**DRUG(S)**

- **Anti-inflammatory medication**:
  - Corticosteroids: prednisone 0.5–1.0 mg/kg PO divided twice daily for 2 weeks, followed by a tapering regime. Suggested protocol following initial dose: 0.5 mg/kg PO daily for 5 days, followed by 0.5 mg/kg PO every other day for 5 days. NSAID: 1- to 4-week course.

**Analgesia**:

- Tramadol 2.0–4.0 mg/kg PO q6–8h.
- Gabapentin 10–20 mg/kg PO q6–8h.
- Pregabalin 3–4 mg/kg (begin with 2 mg/kg) PO q8–12h.

**CONTRAINDICATIONS/POSSIBLE INTERACTIONS**

- Corticosteroids—use caution when given in conjunction with medical treatment; may reduce pain, resulting in increased activity and spinal cord trauma.
- Avoid NSAIDs in combination with corticosteroids in all patients—increases risk of life-threatening gastrointestinal hemorrhage.

**FOLLOW-UP**

- Dogs treated medically require frequent (weekly) bandage changes for associated soft tissue trauma.
- All dogs should be reevaluated at 1 and 3 months (postoperatively or after neck brace removal) and monthly until neurologic deficits resolve or remain static over 2–3 months.
- More frequent rechecks may be needed for dogs experiencing complications or recurrence of signs.
- Unretrieved animals may experience deterioration in neurologic function, catastrophic acute spinal cord trauma, respiratory arrest, and death.

**MISCELLANEOUS**

- Rehabilitation may play a significant role in the ultimate neurologic functional level of the patient.
- Rehabilitation should only be considered in dogs >30 days postoperatively or after neck brace (splint) removal.

**ABBREVIATIONS**

- GP = general proprioceptive
- MRI = magnetic resonance imaging
- NSAID = nonsteroidal anti-inflammatory drug
- UMN = upper motor neuron

**INTERNET RESOURCES**


**Suggested Reading**


**Authors**

- Mathieu M. Glassman and Marc Kent

**Consulting Editor**

Walter C. Renberg
A genetically predisposed hypersensitivity reaction to normally innocuous substances. • Manifests as an inflammatory, chronically relapsing, non-contiguous and pruritic skin condition.

PATHOPHYSIOLOGY
• Atopic dermatitis (AD) has a multifactorial etiology involving genetic, structural, and immunologic factors. • Clinical theory describes the pathway through which susceptible animals become sensitized to environmental allergens producing allergen-specific IgE, followed by mast cell degranulation upon re-exposure to allergens via epicutaneous absorption (extrinsic AD). • A subset of AD patients does not have increased allergen-specific IgE (intrinsic AD). • Current focus on the pathogenesis of AD includes abnormalities in barrier function and T-cell dysregulation or imbalance. • Barrier function impairment, shown as increased transepidermal water loss and decreased filagrin expression, in affected dogs has been demonstrated. • Acute lesions of AD are characterized by increased TH2 lymphocyte activity while TH1 cytokines predominate in chronic lesions. Thus a TH2:TH1 imbalance in AD has been proposed. • Recently, aberrant regulatory T-cell function has been reported. • Following repeat epicutaneous absorption of allergens, mast cell degranulation results in the release of histamine, proteolytic enzymes, cytokines, chemokines, and other chemical mediators. • Bacterial superantigens, auto-antigens released via keratinocyte damage, and Malassezia may play a role in perpetuating the inflammation.

SYSTEMS AFFECTED
• Ophthalmic • Respiratory • Skin/Ecstine

BASICS
DEFINITION
• A genetically predisposed hypersensitivity reaction to normally innocuous substances. • Manifests as an inflammatory, chronically relapsing, non-contiguous and pruritic skin condition.

DEFINITION
Atopic dermatitis (AD) is a multifactorial etiology involving genetic, structural, and immunologic factors. Clinical theory describes the pathway through which susceptible animals become sensitized to environmental allergens producing allergen-specific IgE, followed by mast cell degranulation upon re-exposure to allergens via epicutaneous absorption (extrinsic AD). A subset of AD patients does not have increased allergen-specific IgE (intrinsic AD). Current focus on the pathogenesis of AD includes abnormalities in barrier function and T-cell dysregulation or imbalance. Barrier function impairment, shown as increased transepidermal water loss and decreased filagrin expression, in affected dogs has been demonstrated. Acute lesions of AD are characterized by increased TH2 lymphocyte activity while TH1 cytokines predominate in chronic lesions. Thus a TH2:TH1 imbalance in AD has been proposed. Recently, aberrant regulatory T-cell function has been reported. Following repeat epicutaneous absorption of allergens, mast cell degranulation results in the release of histamine, proteolytic enzymes, cytokines, chemokines, and other chemical mediators. Bacterial superantigens, auto-antigens released via keratinocyte damage, and Malassezia may play a role in perpetuating the inflammation.

SYSTEMS AFFECTED
Ophthalmic • Respiratory • Skin/Ecstine

GEOMETRIC DISTRIBUTION
Canine—recognized worldwide; local environmental factors (temperature, humidity, and flora) influence the seasonality, severity, and duration of signs.

SIGNALLMENT
Species
Dogs and cats

Breed Predilections
• Canine—any breed, including mongrels, recognized more frequently in certain breeds or families (can vary geographically). • United States—Boston terrier, honter, cairn terrier, Chinese Shar-Pei, cocker spaniel, Dalmatian, English bulldog, English and Irish setter, French bulldog, American pit bull terrier, Lhasa apso, miniature schnauzer, pug, Scottish terrier, Scottish white terrier, West Highland white terrier, wirehaired fox terrier, Labrador retriever, and golden retriever.

Mean Age and Range
• Canine—mean age at onset 1–3 years; range 3 months–6 years; signs may be mild the first year but usually progress and become clinically apparent before 3 years of age.
• Feline—months to 2 years.

Predominant Sex
None reported

SIGNS
General Comments
• Pruritus—itching, scratching, rubbing, licking. • Most cutaneous changes caused by self-induced trauma; primary lesions usually unrecognized.

Historical Findings
• Facial, pedal, or auricular pruritus • Early age of onset • History in related individuals • May be initially seasonal • Recurring skin or ear infection • Temporary response to glucocorticosteroids • Symptoms progressively worsen with time • Feline—face and neck pruritis

Physical Examination Findings
• Areas most commonly affected—intradermal spaces, carpal and tarsal areas, muzzle, perineal region, zitular, groin, and pinnae.
• Lesions—vary from none to broken hairs or salivary discoloration to erythema, papules, and/or crusting; hyperpigmentation; lichenification. The skin may become excessively oily or dry secondary, and hyperhidrosis (apocrine sweating). • Secondary bacterial and yeast skin infections (common). • Chronic relapsing cutis externa. • Conjunctivitis, blepharitis, and rhinitis may occur.

CAUSES
• Pollens (grasses, weeds, and trees) • Mold spores (indoor and outdoor) • Malassezia • House dust and storage mites • Animal dander • Insects

RISK FACTORS
• Temperate environments with long allergy seasons and high pollen and mold spore levels. • Concurrent pruritic dermatoses, such as flea bite hypersensitivity and adverse food reaction (summation effect).

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Atopy (may cause identical symptoms) • Malassezia • Allergic contact dermatitis • Demodicosis • Flea allergy dermatitis • Folliculitis • Pyoderma • Sensitization to insect venom • Dermatomyositis • Sweet’s syndrome • Lymphoma • Leukemia

ADVERSE FOOD REACTIONS
• Food ingredients: milk, soy, wheat, fish, egg, lamb, beef, chicken, and seafood. • Environmental allergens: insect, pollen, and mold.

GENETICS
• Polygenic inheritance. • Two susceptibility loci have been identified: Atopy 1 (ATP1) on chromosome 15 and Atopy 2 (ATP2) on chromosome 18.

RISK FACTORS
• Temperate environments with long allergy seasons and high pollen and mold spore levels. • Concurrent pruritic dermatoses, such as flea bite hypersensitivity and adverse food reaction (summation effect).

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
Atopic dermatitis may cause identical symptoms, may occur concurrently with articular disease, and may be secondary to other causes. A subset of AD patients does not have increased allergen-specific IgE (intrinsic AD). Recent studies have demonstrated that aberrant regulatory T-cell function has been reported. Following repeat epicutaneous absorption of allergens, mast cell degranulation results in the release of histamine, proteolytic enzymes, cytokines, chemokines, and other chemical mediators. Bacterial superantigens, auto-antigens released via keratinocyte damage, and Malassezia may play a role in perpetuating the inflammation.
positive and false negative reactions may occur.

**PATHOLOGIC FINDINGS**

Skin biopsy—rule out other differential diagnostic results not pathognomonic; acanthosis, mixed mononuclear superficial perivascular dermatitis, sebaceous gland hyperplasia, with secondary superficial bacterial folliculitis.

**TREATMENT**

**APPROPRIATE HEALTH CARE**

_outpatient

**ACTIVITY**

Avoid offering allergens when possible

**DIET**

Diet rich in essential fatty acids may be beneficial

**CLIENT EDUCATION**

- Explain the inheritable and progressive nature of the condition.
- Rarely goes into remission and cannot be cured.
- Ongoing therapy may be necessary to maintain quality of life.

**MEDICATIONS**

**DRUG(S) OF CHOICE**

**Immunotherapy (Hyposensitization)**

- Subcutaneous or sublingual administration of gradually increasing doses of the causative allergens to reduce sensitivity. *Allergen selection—based on allergy test results, patient history, and/or knowledge of local exposure.*
- Immunotherapy formulation procedures and administration protocols are not standardized and vary widely between clinicians. *Preferred treatment in most cases, especially indicated when it is desirable to avoid or reduce the amount of corticosteroids required to control signs, when signs last longer than 4–6 months per year, or when non-steroid forms of therapy are ineffective."
- Successfully reduces pruritus in 60–80% of dogs and cats.
- Response is slow, requiring at least 3 months and up to 1 year for full effect.

**Cyclosporine**

- Cyclosporine, modified (name brand preferred—Aquinza 5 mg/kg/day) effective in controlling pruritus associated with chronic atopic dermatitis. *Response is similar to that of glucocorticosteroids.*
- Slow onset of activity (1–4 weeks). *Many patients can be adequately controlled with less frequent dosing (every 2–4 days).*
- Patient monitoring is recommended. *Drug-blood level monitoring recommended in cats.

**Corticosteroids**

- May be given for short-term relief and to break the itch-scratch cycle. *Should be tapered to the lowest dosage that adequately controls pruritus.*
- Prednisolone (0.25–0.5 mg/kg PO q48h).
- Cortisone or very infrequent methylprednisolone acetate by injection (2–4 mg/kg).

**Antihistamines**

- Less effective than corticosteroids.
- Dogs—hydroxyzine (1–2 mg/kg PO q12h), diphenhydramine (2.2 mg/kg PO q12h), fexofenadine (2–5 mg/kg PO q12–24h), and demestin (0.04–0.10 mg/kg PO q24h).
- Cats—chlorpheniramine (0.1 mg/kg PO q12h); efficacy estimated at 10–50%.

**Oclacitinib**

Oclacitinib Apoquel (0.4–0.6 mg/kg PO q24h for 14 days then q24h). *Dogs—effective in controlling pruritus associated with chronic atopic dermatitis. Onset time and response similar to glucocorticoids. Long-term safety and efficacy undetermined."

**PRECAUTIONS**

- Cyclosporine—may affect glucose homeostasis; may increase incidence of urinary tract infection. *Corticosteroids—use judiciously in dogs to avoid iatrogenic hyperglaucocorticosteroid and associated problems, aggravation of pyoderma, and induction of demodicosis.*
- Antihistamines—can produce drowsiness, and rarely anorexia, vomiting, diarrhea, increased pruritus; use with caution in patients with cardiac arrhythmias.
- Oclacitinib—not for use in dogs under 1 year of age. *Insufficient long-term experience."

**POSSIBLE INTERACTIONS**

Concurrent use of cyclosporine and keracmaeol permits a 50% dose reduction of each drug.

**ALTERNATIVE DRUG(S)**

- Frequent bathing (once to twice weekly) in cool water with antipruritic shampoo is very beneficial and should be strongly encouraged.
- Fatty acids ω-3 (eicosapentaenoic acid 66 mg/kg/day) may be more effective than ω-6 (linoleic acid 130 mg/kg/day) fatty acids.
- Triyclic antidepressants: dog—(doxepin 1–2 mg/kg PO q12h, or amipryline 1–2 mg/kg PO q12h); overall effectiveness is unclear, not extensively studied in the cat.
- Gabapentin (dogs, 10–30 mg/kg q6–12h; cats, 3–8 mg/kg q6–8h).
- Pentoxyfilline 10 mg/kg q8–12h.
- Topical triamcinolone spray 0.015% can be used over large body surfaces to control pruritus with minimal side effects.

**FOLLOW-UP**

**PATIENT MONITORING**

- Examine patient every 2–8 weeks when a new course of therapy is started. *Monitor pruritus, self-trauma, development of bacterial folliculitis, and possible adverse drug reactions.*
- Once an acceptable level of control is achieved, examine patient every 3–12 months. *CBC, serum chemistry profile, and urinalysis with culture—recommended every 3–12 months for patients on chronic corticosteroid, cyclosporine or Oclacitinib therapy.*

**PREVENTION/AVOIDANCE**

- If offending allergens have been identified through allergy testing, avoidance may help to reduce the level of pruritus; this is seldom possible. *Minimizing other sources of pruritus (e.g., flea infestation, adverse food reaction, and secondary skin infection) permits better response to therapy."

**POSSIBLE COMPLICATIONS**

- Secondary bacterial folliculitis or Malassezia dermatitis.
- Concurrent flea bite hypersensitivity and/or adverse food reaction.

**EXPECTED COURSE AND PROGNOSIS**

- Not life-threatening unless intractable pruritus results in euthanasia. *Degree of pruritus usually worsens and the duration of signs last longer each year without intervention. *Some cases spontaneously resolve."

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**

- Secondary bacterial folliculitis or Malassezia dermatitis.
- Otitis externa

**AGE-RELATED FACTORS**

- Seventy women with age

**PREGNANCY/FERTILITY/BREEDING**

- Corticosteroids—contraindicated during pregnancy
- Affected animals should not be used for breeding

**SYNONYMS**

- Atopy
- Canine atopic dermatitis

**SEE ALSO**

- Flea Bite Hypersensitivity and Flea Control
- Food Reactions, Dermatologic
- Otitis Externa and Media
- Pyoderma

**ABBREVIATION**

IDT = intradermal test

**Suggested Reading**


**Author** Alexander H. Werner

**Consulting Editor** Alexander H. Werner

**Client Education Handout** available online
Atrial Fibrillation and Atrial Flutter

Atrial Fibrillation and Atrial Flutter

BASICS

DEFINITION
• Atrial fibrillation—rapid, irregularly irregular supraventricular rhythm. Two forms recognized: primary atrial fibrillation, an uncommon disease that occurs mostly in large dogs with no underlying cardiac disease; and secondary atrial fibrillation, which occurs in dogs and cats secondary to underlying cardiac disease. • Atrial flutter is similar to atrial fibrillation, but the atrial rate is generally slower and is characterized by saw-toothed flutter waves in the baseline of the ECG. The ventricular response is generally rapid but may be regular or irregular.

ECG FEATURES
Atrial Flutter
• Atrial rhythm usually regular; rate approximately 300–400 bpm. • P waves usually discerned as either discrete P waves or a "saw-toothed" baseline. • Ventricular rhythm and rate generally depend on the atrial rate and AV nodal conduction, but are generally regular or regularly irregular and rapid. • Conduction pattern to the ventricles is variable—in some cases every other atrial depolarization produces a ventricular depolarization (2:1 conduction ratio), giving a regular ventricular rhythm; other times the conduction pattern appears random, giving an irregular ventricular rhythm that can mimic atrial fibrillation.

Secondary Atrial Fibrillation
• No P waves present—baselinel may be flat or may have small irregular undulations ("F" waves); some undulations may look like P waves. • Ventricular rate high—usually 180–240 bpm in dogs and > 220 bpm in cats. • Interval between QRS complexes is irregularly irregular. • QRS complexes usually appear normal.

Primary Atrial Fibrillation
Similar to secondary atrial fibrillation except ventricular rate usually in the normal range.

PATHOPHYSIOLOGY
• Atrial fibrillation—caused by numerous small reentrant pathways creating a rapid (>500 depolarizations/minute) and disorganized depolarization pattern in the atria that results in cessation of atrial contraction. Depolarizations continuously bombard the AV nodal tissue, which acts as a filter and does not allow all depolarizations to conduct to the ventricles. Many atrial depolarizations are seen as only a part of the atrial depolarization as they do not reach the AV node. The atrial impulses penetrate into the AV junctional tissue but are not robust enough to penetrate the entire length. Blocked impulses affect the conduction properties of the AV junctional tissue and alter conduction of subsequent electrical impulses; electrical impulses are conducted through the AV junction irregularly, producing an irregular ventricular rhythm. • Atrial flutter—probably originates from one site of reentry that moves continuously throughout the atrial myocardium and frequently and regularly stimulates the AV node. When the atrial rate becomes sufficiently fast, the refractory period of the AV node exceeds the cycle length (P to P interval) of the SVT, and some atrial depolarizations are blocked from traversing the AV node (functional second-degree AV block).

SYSTEMS AFFECTED
Cardiovascular
Loss of atrial contraction may result in decreased stroke volume and cardiac output depending on heart rate; high heart rate may result in deterioration in myocardial function (tachycardia-induced myocardial failure).

GENETICS
No herding studies available.

SIGNALMENT
Species
Dog and cat

Breed Predilections
Large- and giant-breed dogs are more prone to primary atrial fibrillation.

Mean Age and Range
N/A

Predominant Sex
N/A

SIGNS
General Comments
• Generally related to the underlying disease process and/or CHF rather than the arrhythmia itself, but previously stable animals may decompensate. • Patients with primary atrial fibrillation are generally asymptomatic but may demonstrate mild exercise intolerance.

Historical Findings
• Coughing/dyspnea/tachypnea • Exercise intolerance • Rarely syncope • Dogs with primary atrial fibrillation are typically asymptomatic.

Physical Examination Findings
• On auscultation, patients with atrial fibrillation have an erratic heart rhythm that sounds like "tennis shoes in a dryer." • First heart sound intensity in atrial fibrillation is variable; second heart sound only heard on beats with effective ejection, not on every beat. • Third heart sound (gallop sounds) may be present. • Patients with atrial fibrillation have pulse deficits and variable pulse quality. • Signs of CHF often present (e.g., cough, dyspnea, cyanosis).

CAUSES
• Cardiac valvular disease • Congenital heart disease • Cardiomyopathy • Medications • Hypo/hyperthyroidism • Digitalis toxicity • Idiopathic • Ventricular preexcitation (atrial flutter)

DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
• Premature atrial (supraventricular) premature depolarizations • Supraventricular tachycardia with AV block • Multifocal atrial tachycardia (irregular)

CBC/BIOCHEMISTRY/URINALYSIS
N/A

OTHER LABORATORY TESTS
N/A

IMAGING
• Echocardiography and radiography may characterize type and severity of the underlying cardiac disease; moderate to severe left atrial enlargement common. • Typically normal in patients with primary atrial fibrillation, although mild left atrial enlargement may accompany the hemodynamic alterations imposed by the arrhythmia.

DIAGNOSTIC PROCEDURES
A baseline 24-hour Holter is recommended to determine if the arrhythmia is chronic or paroxysmal. If it is chronic, drug therapy is indicated.

TREATMENT
APPROPRIATE HEALTH CARE
• Patients with atrial fibrillation are treated medically to slow the ventricular rate. Converting the atrial fibrillation to sinus rhythm would be ideal, but such attempts in patients with severe underlying heart disease or left atrial enlargement are generally futile because of a low success rate and high rate of recurrence. Consider electrical cardioversion to sinus rhythm for a dog with primary atrial fibrillation and only mild structural heart disease. • Patients with primary atrial fibrillation may be converted back to normal sinus rhythm. The success rate depends on chronicity. Patients that have been in atrial fibrillation for >4 months generally have a lower success rate and a higher rate of recurrence. In these patients, rate control, if necessary, is the recommended treatment.
• Electrical cardioversion—application of a transthoracic electrical shock at a specific time in the cardiac cycle requires special equipment, trained personnel, and general anesthesia. Using a monophasic defibrillator. Start with 4 J/kg; if no conversion occurs,
Atrial flutter with 2:1 conduction at ventricular rate of 330/minute in a dog with an atrial septal defect. This supraventricular tachycardia was associated with a Wolff-Parkinson-White pattern. (From: Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Baltimore: Williams & Wilkins, 1992, with permission.)

**MEDICATIONS**

**DRUG(S) OF CHOICE**

- **Dogs**
  - **Digoxin**—maintenance oral dose 0.005–0.01 mg/kg PO q12h; to achieve a therapeutic serum concentration more rapidly, the maintenance dose can be doubled for the first day. If digoxin is administered alone and the heart rate remains high, check the digoxin level and adjust the dose to bring the level into the therapeutic range. If the heart rate remains high, consider adding a calcium channel blocker or a β-adrenergic blocker.
  - **Diltiazem**—initially administered at a dose of 0.5 mg/kg PO q8h, then titrated up to a maximum of 1.5 mg/kg PO q8h or until an adequate response is obtained.

**Cats**

- **Diltiazem** (1–2.5 mg/kg PO q8h) or atenolol (6.25–12.5 mg/cat PO q12–24h) are the drugs of choice in most cats.

If the heart rate is not sufficiently slowed with these drugs or if myocardial failure is present, digoxin (5 μg/kg PO q24–48h) can be added.
CONTRAINDICATIONS
- Digoxin, diltiazem, propranolol, and atenolol should not be used in patients with preexisting AV block.
- Use of calcium channel blockers in combination with beta blockers should be avoided because clinically significant bradyarrhythmias and/or AV block can develop.

PRECAUTIONS
- Calcium channel blockers and β-adrenergic blockers, both negative inotropes, should be used cautiously in animals with myocardial failure. Using high-dose oral quinidine for conversion into sinus rhythm carries a risk of quinidine toxicity (e.g., hypotension, weakness, ataxia, and seizures)—administration of diazepam intravenously controls seizures; other signs abate within several hours of discontinuing quinidine administration.

POSSIBLE INTERACTIONS
Quinidine raises the digoxin level, generally necessitating a digoxin dose reduction.

FOLLOW-UP
PATIENT MONITORING
- Monitor heart rate and ECG closely. As heart rates in the hospital and those measured on the surface ECG may be inaccurate (due to patient anxiety and other environmental factors), Holter monitoring provides a more accurate means for assessing the need for heart rate control and/or the efficacy of medical therapy for heart rate control.

POSSIBLE COMPLICATIONS
- Worsening of cardiac function with onset of arrhythmia.

EXPECTED COURSE AND PROGNOSIS
- Secondary atrial fibrillation—associated with severe heart disease, so a guarded-to-poor prognosis. Primary atrial fibrillation with normal ultrasound findings—generally a good prognosis.

MISCELLANEOUS
ABBREVIATIONS
- AV = atrioventricular
- CHF = congestive heart failure
- ECG = electrocardiogram
- SVT = supraventricular tachycardia

Suggested Reading


Acknowledgment
The author and editors acknowledge the prior contribution of Richard D. Kienle.
Atrial Premature Complexes

**Basics**

**Definition**
Premature atrial beats that originate outside the sinus node and disrupt the normal sinus rhythm for 1 or more beats.

**ECG Features**
- Heart rate usually normal; rhythm irregular due to the premature P wave (called a P′ wave) that disrupts the normal P wave rhythm (Figure 1).
- Ectopic P wave—premature; configuration differs from that of the sinus P waves and may be negative, positive, biphasic, or superimposed on the previous T wave.
- QRS complex—premature; configuration usually normal (same as that of the sinus complexes). If the P′ wave occurs during the refractory period of the AV node, ventricular conduction does not occur (non-conducted APCs), so no QRS complex follows the P′ wave. If there is partial recovery in the AV node or intraventricular conduction systems, the P′ wave is conducted with a long P′–R interval or with an abnormal QRS configuration (aberrant conduction). The more premature the complex, the more marked the aberration.
- In the P–QRS relationship, the P′–R interval is usually as long as, or longer than, the sinus P′–R interval.

**Pathophysiology**
- Mechanisms—an increase in automaticity of atrial myocardial fibers or a single reentrant circuit.
- May be normal finding in aged dogs; commonly seen in dogs with atrial enlargement secondary to chronic valvular insufficiency; may also be observed in cats or cats with any atrial disease.
- May not cause hemodynamic problems; the clinical significance relates to their frequency, timing relative to other complexes, and the underlying clinical problems.
- Can preclude more serious rhythm disturbances (e.g., atrial fibrillation, atrial flutter, or atrial tachycardia).

**Systems Affected**
Cardiovascular

**Genetics**
N/A

**Incidence/Prevalence**
Not documented

**Signalment**

**Species**
Dog and cat

**Breed Predilections**
Small-breed dogs

**Mean Age and Range**
Geriatric animals, except those with congenital heart disease

**Signs**

**Historical Findings**
- No signs
- CHF
- Coughing and dyspnea
- Exercise intolerance
- Syncope

**Physical Examination Findings**
- Irregular heart rhythm
- Cardiac murmur
- Gallop rhythm
- Signs of CHF

**Causes & Risk Factors**
- Chronic valvular disease
- Congenital heart disease
- Cardiomyopathy
- Atrial myxomatosis
- Electrolyte disorders
- Neoplasia
- Hyperthyroidism

**Diagnosis**

**Differential Diagnosis**
- Marked sinus arrhythmia.
- Ventricular premature complexes when aberrant ventricular conduction follows an APC.

**CBC/Biochemistry/Urinalysis**
N/A

**Other Laboratory Tests**
N/A

**Imaging**
Echocardiography and Doppler ultrasound may reveal the type and severity of the underlying heart disease.

**Pathologic Findings**
Atrial enlargement; other features vary depending on underlying cause.

**Treatment**

**Appropriate Health Care**
- Treat animal as inpatient or outpatient.
- Treat the underlying CHF, cardiac disease, or other causes.

**Nursing Care**
Usually not necessary; varies with underlying cause.

**Activity**
Restrict if symptomatic.

---

**Atrial Premature Complexes**

APCs in a dog. P′ represents the premature complex. The premature QRS resembles the basic QRS. The upright P′ wave is superimposed on the T wave of the preceding complex. (From: Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Blackwell Publishing, 1992, with permission.)
Atrial Premature Complexes

Figure 2.

APCs in bigeminy in a cat under general anesthesia. The second complex of each pair is an APC, where the first is a sinus complex. The abnormality in rhythm disappeared after the anesthetic was stopped. (From: Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Blackwell Publishing, 1992, with permission.)

DIET
No modifications unless required for management of underlying condition (i.e., low-salt diet).

CLIENT EDUCATION
APCs may not cause hemodynamic abnormalities; may be precursors of serious arrhythmias.

SURGICAL CONSIDERATIONS
N/A

MEDICATIONS

DRUG(S) OF CHOICE
Treat CHF and correct any electrolyte or acid/base imbalances.

- Dogs
  - Digoxin (0.005–0.01 mg/kg PO q12h, maintenance dosage); diltiazem (0.5–1.5 mg/kg PO q8h), or atenolol (0.25–1 mg/kg PO q12h) are used to treat clinically significant arrhythmias.
  - Digoxin—treatment of choice; also indicated to treat the cardiac decompensation that is usually present.
  - CHF is treated with appropriate dosage of diuretic, angiotensin converting enzyme inhibitor, and pimobendan; appropriate management of CHF may reduce APC frequency.

- Cats
  - Cats with hypertrophic cardiomyopathy—diltiazem (1–2.5 mg/kg PO q8h) or atenolol (6.25–12.5 mg PO q12–24h).
  - Cats with dilated cardiomyopathy—digoxin (one-fourth of a 0.125 mg digoxin tablet q24h or q48h).

CONTRAINDICATIONS
Negative inotropic agents (e.g., propranolol) should be avoided in animals with CHF.

PRECAUTIONS
Use digoxin, diltiazem, atenolol, or propranolol cautiously in animals with underlying anteroventricular block or hypotension.

POSSIBLE INTERACTIONS
N/A

ALTERNATIVE DRUG(S)
N/A

FOLLOW-UP

PATIENT MONITORING
Monitor heart rate and rhythm with serial ECG.

PREVENTION/AVOIDANCE
N/A

POSSIBLE COMPLICATIONS
Frequent APCs may further diminish cardiac output in patients with underlying heart disease and worsen clinical symptoms.

EXPECTED COURSE AND PROGNOSIS
Even with optimal antirhythmic drug therapy some animals have an increased frequency of APCs or deteriorate to more severe arrhythmia as the underlying disease progresses.

MISCELLANEOUS

ASSOCIATED CONDITIONS
None

AGE-RELATED FACTORS
Typically occurs in geriatric dogs.

PREGNANCY/FERTILITY/BREEDING
N/A

SYNONYMS
Atrial extrasystoles, atrial premature contractions, atrial premature impulses

SEE ALSO
Supraventricular Tachycardia

ABBREVIATIONS
- APC = atrial premature complex
- AV = anterioventricular
- CHF = congestive heart failure

INTERNET RESOURCES
www.vetgo.com/cardio.

Suggested Reading

Author
Larry P. Tilley

Consulting Editors
Larry P. Tilley and Francis WK, Smith, Jr.

Acknowledgment
The author and editors acknowledge the prior contribution of Naomi L. Burnick.
Atrial Septal Defect

Overview

Congenital defect in which the interatrial septum fails to develop normally, resulting in communication between the atria. Unknown cause; genetic basis suspected. Acquired ASD secondary to atrial rupture reported in dogs with degenerative mitral valve disease.

- Comprises 0.7–3.7% of congenital heart defects in dogs and ≤10% of congenital heart defects in cats. Significantly higher incidence (87.7%) noted in a more recent study.
- 3 major types of ASD classified based on the location of the defect within the interatrial septum: ostium primum ASD (most apical portion of septum, adjacent to the atrioventricular valves), ostium secundum ASD (central portion of the septum, region of fossa ovalis), and sinus venosus ASD (upper portion of septum, junction of cranial vena cava).
- Secundum ASD with left-to-right shunting is most common (98.7% in one study of dogs and cats).
- Ostium primum ASDs typically large; may be component of atrioventricular (AV) canal defect.
- Sinus venosus ASDs typically located at the junction of the cranial vena cava (less commonly the caudal vena cava) and right atrium. Right pulmonary veins may be directed at the right atrium through the defect. May be associated with anomalies of pulmonary venous connections of some or all pulmonary veins.
- Isolated ASDs typically shunt left-to-right. Magnitude of flow dependent on size (ostium) of defect, relative systemic and pulmonary resistance, and relative compliance of the ventricles. Small defects allowing atria to maintain normal differential pressure are termed restrictive. Large defects more likely to cause significant left-to-right shunting and volume overload to the right heart and pulmonary vessels. Development of secondary pulmonary hypertension can lead to reverse (right-to-left) shunting, termed Eisenmenger's physiology. ASDs may occur with concurrent defects; conditions increasing right atrial pressure (i.e., pulmonic stenosis, tricuspid valve dysplasia, tricuspid valve stenosis) can also cause balanced or reverse shunting.

Signs

- Dog and cat
- Various breeds affected; higher prevalence in boxer and standard poodle
- No sex predisposition

General Comments

- Most commonly asymptomatic (73.7% in one study).
- Severe cases may present with signs of CHF.
- Signs related to generalized cyanosis may occur with right-to-left shunting.

Historical Findings

Clinical signs related to concurrent heart disease or cyanotic, exercise intolerance, syncope, cough, and dyspnea.

Physical Examination Findings

- Soft systolic murmur over the pulmonic valve due to relative pulmonic stenosis (increased blood flow across a normal pulmonic valve).
- Rarely a diastolic murmur over the tricuspid valve due to relative tricuspid stenosis.
- Split S2 (fixed) due to delayed closure of the pulmonic valve.
- Cyanosis with right-to-left shunting.
- Ascites and jugular venous distension with right heart failure.

Echocardiographic Findings

- None with small defects.
- Right-sided heart enlargement and pulmonary overcirculation with significant shunting.
- Cyanosis with right-to-left shunting.
- Ascites and jugular venous distension with right heart failure.

Diagnosis

CBC/Biochemistry/Urinalysis

- Typically normal.
- Polycythemia in some patients with right-to-left shunting.

Imaging

- Radiographic Findings
  - None with small defects.
  - Right-sided heart enlargement and pulmonary overcirculation with significant shunting.

ECHOCARDIOGRAPHIC FINDINGS

- Right atrial and/or ventricular dilation
- Septal dropout (not arterial septal dropout in the region of the fossa ovalis)
- Shunting across ASD by color-flow or spectral Doppler
- Increased pulmonic flow velocity
- Dilatation of the pulmonary trunk

Treatment

- Standard treatment of CHF (furosemide, pimobendan, ACE inhibitor).
- Treatment of polycythemia (right-to-left shunting) if clinically indicated.
- Pulmonary artery banding as palliative measure to limit left-to-right shunting.
- Open heart surgery under cardiopulmonary bypass - direct surgical closure using patch graft.
- Amplatzer® atrial septal occluder (ASO) device delivered percutaneously through the jugular vein for secundum-type defects; requires adequate atrial diameter, ostium diameter, ASD rim tissue, and vessel size for venous access.
- Hybrid procedure involving surgical access to right atrium, transatrial delivery of ASO device, and active device fixation under inflow occlusion reported.

Follow-up

- Recheck when decompensation or other clinical signs develop.
- Expected course and prognosis
  - Dependent on defect size and co-existing abnormalities.
  - Small, isolated defects unlikely to cause clinical signs.
  - Defects > 12 mm more likely to cause heart failure.

Miscellaneous

- ASD = atrial septal defect
- CHF = congestive heart failure

Suggested Reading


Author Sandra P. Tou

Consulting Editors Larry P. Tilley and Francis W.K. Smith, Jr.
Atrial Standstill

PATHOPHYSIOLOGY

Persistent Atrial Standstill
Caused by an atrial muscular dystrophy; skeletal muscle involvement common.

Hyperkalemic Atrial Standstill
Generally occurs with serum potassium levels > 8.5 mEq/L; value influenced by serum sodium and calcium levels and acid-base status. Hyperkalemic patients with atrial standstill have sinus node function, but impulses do not activate atrial myocytes; thus, the associated rhythm is termed a sinoventricular rhythm. Since the sinus node is functional, an irregular rhythm may be due to sinus arrhythmia.

SYSTEMS AFFECTED
Cardiovascular

GENETICS
None

INCIDENCE/PREVALENCE
Rare rhythm disturbance

GEOGRAPHIC DISTRIBUTION
None

SIGNALMENT
Species
Dog and cat

Breed Predictions
Persistent atrial standstill—most common in English springer spaniels; other breeds occasionally affected.

Diagnosis

DIFFERENTIAL DIAGNOSIS
- Slow atrial fibrillation
- Sinus bradycardia with small P waves lost in the baseline

CBC/BIOCHEMISTRY/URINALYSIS
Persistent Atrial Standstill

Normal

Hyperkalemic Atrial Standstill

- Hyperkalemia
- Hyperuricemia and sodium-potassium ratio < 27 if atrial standstill secondary to hyperkalemiccitrism.
- Anemia and hyperphosphatemia with hyperkalemiccitrism, renal failure, and rupture or obstruction of the urinary tract.

OTHER LABORATORY TESTS

ACTH stimulation test if hyperkalemia suspected

IMAGING

Echocardiogram and electromyography if persistent atrial standstill suspected—cardiomegaly and depressed contractility may be seen.

Pathologic Findings

Persistent Atrial Standstill
- Gearedly enlarged and paper-thin atria; usually baritral involvement, although one case of only left atrial involvement was reported.
- Severe scapular and brachial muscle wasting in some dogs.
- Marked fibrosis, fibroelastosis, chronic mononuclear cell inflammation, and necrosis throughout the atria and interatrial septum.

Treatment

APPROPRIATE HEALTH CARE
Persistent Atrial Standstill
Not life-threatening condition; animal can be treated as an outpatient.

Hyperkalemic Atrial Standstill
Potentially life-threatening; often requires aggressive treatment.

NURSING CARE
Aggressive fluid therapy with 0.9% saline often required to correct hypokalemia and lower serum potassium levels (see Hyperkalemia) in patients with hyperkalemic atrial standstill.

Activity
Restrict activity in patients with persistent atrial standstill and signs of CHF or syncope.

Diet
N/A

CLIENT EDUCATION
Persistent Atrial Standstill
Clinical signs generally improve after pacemaker implantation; signs of CHF may develop, and weakness and lethargy may persist even after heart rate and rhythm are corrected with the pacemaker.

SURGICAL CONSIDERATIONS
Persistent Atrial Standstill
Implant permanent ventricular pacemaker to regulate rate and rhythm.

Hyperkalemic Atrial Standstill
Hyperkalemia secondary to urinary tract obstruction or rupture may require surgery.

Medications

Drug(s) of Choice
Persistent Atrial Standstill
- Treat with diuretics and ACE inhibitor (e.g., enalapril or benazepril) if CHF develops.

Hyperkalemic Atrial Standstill
- Aggressive fluid therapy with 0.9% saline and possibly sodium bicarbonate or insulin
Atrial Standstill (Continued)

Figure 1. Atrial standstill in a dog with a potassium of 9 mEq/L. Note the absence of P waves and wide QRS complexes.

POSSIBLE COMPLICATIONS
CHF in patients with persistent atrial standstill

EXPECTED COURSE AND PROGNOSIS
Persistant Atrial Standstill
Clinical signs generally improve after pacemaker implantation. Signs of CHF may develop, and weakness and lethargy persist even after heart rate and rhythm are corrected with the pacemaker. There may be persistence of signs related to muscular dystrophy.

Hyperkalemic Atrial Standstill
Long-term prognosis is excellent if underlying cause can be corrected and hyperkalemia reversed.

MISCELLANEOUS

ASSOCIATED CONDITIONS
Diseases causing hyperkalemia (e.g., hypoadrenocorticism, urethral obstruction or urinary tract tear, acidosis, and drugs).

AGE-RELATED FACTORS
Persistent atrial standstill—usually diagnosed in young animals; hypoadrenocorticism—usually diagnosed in young to middle-aged animals.

ZOONOTIC POTENTIAL
None

PREGNANCY/FERTILITY/BREEDING
N/A

SYNONYMS
Silent atrial

SEE ALSO
Digoxin Toxicity
Hyperkalemia
Hypoadrenocorticism (Addison’s Disease)
Urinary Tract Obstruction

ABBREVIATIONS
ACE = angiotensin converting enzyme
ACTH = adrenocorticotropic hormone
CHF = congestive heart failure
ECG = electrocardiogram

Suggested Reading


Author Francis W.K. Smith, Jr.
Consulting Editors Larry P. Tilley and Francis W.K. Smith, Jr.

Client Education Handout available online
Atrial Wall Tear

**DEFINITION**
- Endocardial splitting is a linear defect limited to the endocardial layer of the atrium (typically the left atrium) resulting from dissection of the atrial wall beyond its elastic limits. Atrial tear may result if the split extends through the mycardium and epicardium, resulting in a full thickness defect into the pericardial space.

**PATHOPHYSIOLOGY**
- Endocardial splitting typically results from increased left atrial volume and pressure secondary to severe mitral regurgitation and mechanical trauma from the regurgitant jet; primary endocardial degeneration may also play a role. If the tear is incomplete, fibrin may seal the defect temporarily; this either leads as a linear depression in the endocardial surface or subsequently extends through the myocardium resulting in a complete left atrial tear. A left atrial tear results in pericardial bleeding into the pericardial sac and severe, life-threatening hemodynamic compromise secondary to acute cardiac tamponade. If a tear occurs in the interatrial septum, an acquired atrial septal defect may form.
- Tearing of either atrium may also rarely occur secondary to blunt trauma, or iatrogenically during pericardiocentesis.

**SYSTEMS AFFECTED**
- Cardiovascular • Respiratory

**INCIDENCE/PREVALENCE**

**SIGNS**
- Middle-aged to older dogs are predisposed.

**BASICS**
- Chordae tendineae rupture may be seen; thickened mitral valve leaflets with rolled edges; chordae tendineae rupture may be seen; thickened mitral valve leaflets with rolled edges.
- Hemorrhagic pericardial effusion in the dog encompassing approximately 2% of pericardial effusion cases.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Other causes of acute cardiovascular collapse or syncope • Pericardial effusion from other causes (e.g., neoplastic and idiopathic) • Heart failure • Severe cardiac arrhythmias

**CBC/BIOCHEMISTRY/URINALYSIS**
- Anemia is uncommon unless pericardioceles is performed since volume of blood loss is relatively small.
- Hypoproteinemia is common.
- Elevations in serum lactate, metabolic acidosis.
- Increased ALT, AST in some patients.
- Pericardial effusion is evidenced by a hypoechoic space between the heart and pericardial sac; the volume of pericardial effusion identified may be relatively small as the pericardium remains inelastic due to the acute nature of the bleed; a characteristic linear, hyperdense blood clot may be seen within the pericardial sac. The atrial tear is often not identified though an associated thrombus is occasionally visualized within the left atrium.
- Cardiac tamponade is evidenced by diastolic collapse of the left atrium and/or ventricle. Signs of advanced mitral endocardiosis, including mitral valve thickening and prolapse, moderate to severe left atrial enlargement and often one or more ruptured chordae tendineae.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- If a left atrial tear is strongly suspected, perform pericardiocentesis only if the effusion is causing symptomatic, life-threatening cardiac tamponade, since further hemorrhage into the pericardial sac or exsanguination may occur once pericardial fluid is removed. If pericardiocentesis is performed, remove only enough fluid to improve clinical signs.
- Pericardiocentesis will likely be difficult given the small volume of effusion typically identified, severe cardiac enlargement, and the small size of most dogs with left atrial rupture; ultrasound guidance and continuous ECG monitoring are highly recommended. Best practices for management of left atrial tears have not been clearly established; however, aggressive medical management to lower left atrial pressure using afterload and preload reducing agents is recommended based on the author’s clinical experience.
Atrial Wall Tear

(Continued)

forms over the defect, the patient may stabilize and recover.

Nursing care
- Administer oxygen to dogs with dyspnea or signs of hemorrhagic instability.
- Administer IV fluids or blood products only if evidence of hypovolemia is present; most dogs remain in a volume overloaded state and further intravascular volume expansion will increase left atrial pressure and potentially worsen tamponade.

Activity
- Strict cage rest in the acute period should be followed by chronic exercise restriction.

Client education
- Left atrial tear typically accompanies advanced cardiac disease and chronic medical therapy will be necessary; though the prognosis is guarded for surviving the acute event some dogs with left atrial tear have lived more than a year after the incident.

Surgical considerations
- Exploratory thoracotomy may be considered if hemorrhage persists or recurs but should be undertaken cautiously given the advanced state of cardiac disease typically present. • Transseptal puncture and bulb tonometry of the four atria may also be considered to decompress the left atrium; however, right heart failure or hypotension due to right-to-left shunting may result.

Medications

Drug(s) of choice
- Atrial tears occur secondary to elevated left atrial pressure; thus medical therapy should be focused on lowering of left atrial pressures in order to reduce continued hemorrhage into the pericardial space and permit fibrin clot formation at the site of the tear; this may be accomplished with preload (e.g., diuretics, nitroglycerin paste) and/or afterload reducers (arterial vasodilators).
- Preload and afterload reduction must be undertaken cautiously to avoid worsening of hemodynamic compromise.
- Afterload reduction may be achieved by conservative doses of sodium nitroprusside; a low starting CRI dose of 0.5–1 mcg/kg/min is recommended to achieve a decrease in LA pressure without precipitating significant hypotension; blood pressure monitoring is recommended and the dose may be uptitrated every 15–30 minutes up to a maximum of 10 mcg/kg/min to achieve an improvement in clinical signs and/or a reduction in blood pressure of 10–15 mmHg.
- Alternatively, amiodarone may be started at 0.1–0.2 mg/kg PO q24h; chronic amiodarone therapy may be implemented in normotensive or hypertensive animals to reduce regurgitant fraction and lower left atrial pressure.
- Diuretics should be used cautiously if needed to treat dyspnea associated with concomitant congestive heart failure (e.g., 1–2 mg/kg of furosemide IV as needed); signs of left-sided congestive heart failure may worsen as cardiac tamponade resolves due to augmentation of preload; more aggressive diuretic therapy may then be required.
- Pimobendan (0.2–0.3 mg/kg PO q12h) may result in a further reduction in left atrial pressure though studies have not specifically examined its use in the setting of left atrial rupture and the author typically delays starting inestopes for several days so as not to disrupt stability of the fibrin clot.
- Once the patient is stable, ACE inhibitors (e.g., enalapril 0.5 mg/kg q12–24h) should be implemented for chronic management of accompanying heart failure.

Precautions
- Aggressive fluid therapy is not warranted in these patients; further volume expansion may increase left atrial pressure, worsen cardiac tamponade, and contribute to hemodynamic compromise. • Best practices for management of left atrial tear have not been clearly established; the choice of whether to perform pericardiocentesis, and whether to administer preload and/or afterload reducers should be made based on assessment of the volume status, blood pressure and clinical stability of the patient.

Possible interactions
- Sodium nitroprusside should never be administered concurrently with phosphodiesterase-V inhibitors (e.g., sildenafil or tadalafil) due to the potential for life-threatening systemic hypotension.

Follow-up

Patient monitoring
- Recommended close monitoring of respiratory rate and effort, mucous membrane color and CRT, pulse quality, and heart rate; blood pressure monitoring is recommended if arterial vasodilators are implemented.
- Follow-up examination with echocardiography helps determine resolution of pericardial effusion and resection of an atrial or pericardial clot. • Close follow-up every 2–3 months thereafter is recommended for repeat pericardial fluid checks and medication adjustments as deemed appropriate.

Prevention/avoidance
- Recommend avoidance of strenuous physical activity and excitement.

Possible complications
- Even if the tear seals, the patient is prone to further tears because of underlying cardiac disease. • Most dogs have or will develop concurrent CHF.

Expected course and prognosis
- Prognosis for survival is guarded to poor; however, some animals can do well for several months or longer with close monitoring, exercise restriction and optimal medical management of cardiac disease.

MISCELLANEOUS

Associated conditions
- Chronic valvular disease • CHF • Malnourishment • Bronchial compression

Synonyms
- Atrial rupture • Atrial splitting

See also
- Atrial septal defect • Atrioventricular valve (myxomatous) disease • Congestive heart failure • Pericardial effusion • Syncope

Abbreviations
- ACE = angiotensin-converting enzyme • ALT = alanine aminotransferase • AST = aspartate aminotransferase • CHF = congestive heart failure

Internet resources
- Suggested reading
- Author: Suzanne M. Cunningham
- Consulting editors: Larry P. Tilley and Francis W.K. Smith, Jr.
Atrioventricular Block, Complete (Third Degree)

**BASICS**

**DEFINITION**
- All atrial impulses are blocked at the AV junction; atria and ventricles beat independently. A secondary “escape” pacemaker site (junctional or ventricular) stimulates the ventricles.
- Atrial rate normal.
- Idioventricular escape rhythm slow.

**ECG Features**
- Ventricular rate slower than the atrial rate (more P waves than QRS complexes)—ventricular escape rhythm (idioventricular) usually ≤ 40 bpm; junctional escape rhythm (idiojunctional) 40-60 bpm in dogs and 60-100 bpm in cats.
- P waves—usually normal configuration (Figure 1).
- QRS complex—wide and bizarre when pacemaker located in the ventricle, or in the lower AV junction in a patient with bundle branch block; normal when escape pacemaker in the lower AV junction (above the bifurcation of the bundle of His) in a patient without bundle branch block.
- No conduction between the atria and the ventricles; P waves have no constant relationship with QRS complexes; P-P and R-R intervals relatively constant (except for a sinus arrhythmia).

**PATHOPHYSIOLOGY**
Slow ventricular escape rhythms (< 40 bpm) result in low cardiac output and eventual heart failure, often when animal is excited or exercised, since demand for greater cardiac output is not satisfied. As the heart fails, signs increase with mild activity.

**SYSTEMS AFFECTED**
Cardiovascular

**GENETICS**
- Can be an isolated congenital defect
- Other congenital heart defects
- Lyme disease
- Chagas disease

**INCIDENCE/ PREVALENCE**
- Not documented

**GEOGRAPHIC DISTRIBUTION**
- N/A

**SIGNALMENT**
- Dog and cat

**Breed Predilections**
- Cocker spaniel—can have idiopathic fibrosis.
- Pug and Doberman pinscher—can have associated sudden death, AV conduction defects, and bundle of His lesions.

**Mean Age and Range**
- Geriatric animals, except congenital heart disease patients. Median age for cats—14 years.

**Predominant Sex**
- Intact female dogs

**SIGNS**

**Historical Findings**
- Exercise intolerance
- Weakness or syncope
- Occasionally, CHF

**Physical Examination Findings**
- Bradycardia
- Variable third and fourth heart sounds
- Variation in intensity of the first heart sounds
- Signs of CHF
- Intermittent “cannon” A waves in jugular venous pulses

**CAUSES & RISK FACTORS**
- Isolated congenital defect
- Idiopathic fibrosis
- Infiltrative cardiomyopathy (amyloidosis or neoplasia)
- Hypertrophic cardiomyopathy in cats
- Digitalis toxicity
- Hypothyroidism in cats
- Myocarditis
- Endocarditis
- Electrolyte disorder
- Myocardial infarction

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Advanced second-degree AV block
- Atrial standstill
- Accelerated idioventricular rhythm

**CBC/BIOCHEMISTRY/URINALYSIS**
- Abnormal serum electrolytes (e.g., hyperkalemia, hypokalemia) possible.
- High WBC with left shift in animals with bacterial endocarditis.

**OTHER LABORATORY TESTS**
- High serum digoxin concentration if AV block is due to digoxin toxicity.
- Lyme titer and accompanying clinical signs if AV block due to Lyme disease.

**IMAGING**
- Echocardiography and Doppler ultrasound to assess cardiac structure and function.

**DIAGNOSTIC PROCEDURES**
- Electrocardiography
- His bundle electrogram to determine the site of the AV block.
- Long-term (Holter) ambulatory recording if AV block is intermittent

**PATHOLOGIC FINDINGS**
- Degeneration or fibrosis of the AV node and its bundle branches, associated with endocardial and myocardial fibrosis and organized endomyocarditis.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Temporary or permanent cardiac pacemaker—only effective treatment in symptomatic patients.

---

Figure 1.
Complete heart block. The P waves occur at a rate of 120, independent of the ventricular rate of 50. The QRS configuration is a right bundle branch block pattern. The regular rate and slow QRS indicate that the reexcitation focus is probably near the AV junction. (From: Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Blackwell Publishing, 1992, with permission.)
Atrioventricular Block, Complete (Third Degree) (Continued)

Figure 2.

Complete heart block in a cat. The P waves rate is 240/minute, independent of the ventricular rate of 48/minute. QRS configuration is a left bundle branch block pattern. (From: Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Blackwell Publishing, 1992, with permission.)

- Carefully monitor asymptomatic patients without a pacemaker for development of clinical signs.

NURSING CARE
- Cage rest prior to pacemaker implantation; when the pulse generator is put into a subcutaneous pocket, a non-constricting bandage is required around the ventral neck or abdomen for 3–5 days to prevent seroma formation or pacemaker movement.

ACTIVITY
- Restrict if symptomatic

DIET
- No modifications unless required to manage underlying condition (e.g., low-salt diet).

CLIENT EDUCATION
- Temporary or permanent cardiac pacemaker—only effective treatment in symptomatic patients.
- Asymptomatic patients without a pacemaker—must be carefully monitored for development of clinical signs.

SURGICAL CONSIDERATIONS
- Most patients—at high anesthetic cardiopulmonary risk; usually paced preoperatively with a temporary external pacemaker system.
- The small size of cats makes pacemaker implantation more difficult than in dogs.

MEDICATIONS
- Treatment with drugs—usually of no value.
  - Traditionally used to treat complete AV block atropine, isoproterenol, and dobutamine.
  - Intravenous isoproterenol infusion may help increase the rate of the ventricular escape rhythm to stabilize hemodynamics.
  - If CHF—diuretic and vasodilator therapy may be needed before pacemaker implantation.

CONTRAINDICATIONS
- Avoid digoxin, xylazine, acepromazine, beta blockers (e.g., propranolol and atenolol), and calcium channel blockers (e.g., verapamil and diltiazem); ventricular antiarrhythmic agents are dangerous because they suppress lower escape foci.

PRECAUTIONS
- Vasodilators—may cause hypotension in animals with complete AV block; monitor closely if used, especially prior to pacemaker implantation.

FOLLOW-UP
- PATIENT MONITORING
  - Monitor—pacemaker function with serial ECGs.
  - Radiographs—following pacemaker implantation, to confirm the position of the lead and generator.

PREVENTION/AVOIDANCE
- N/A

POSSIBLE COMPLICATIONS
- Pulse generators—broad range of clinical life; pacemaker replacement necessary when battery is depleted, pulse generator malfunction occurs, or exit block develops; pacemaker leads can become dislodged and infected.

EXPECTED COURSE AND PROGNOSIS
- Poor long-term prognosis if no cardiac pacemaker implanted, especially when the animal has clinical signs. Cats can sometimes survive >1 year.

MISCELLANEOUS

ASSOCIATED CONDITIONS
- None

ABBREVIATIONS
- AV = atrioventricular
- CHF = congestive heart failure
- ECG = electrocardiogram
- WBC = white blood cell

INTERNET RESOURCES
- www.vetgo.com/cardio

Suggested Reading

Author Larry P. Tilley
Consulting Editors Larry P. Tilley and Francis W.K. Smith
Acknowledgment The author and editors acknowledge the prior contribution of Naomi L. Burnick.

Client Education Handout available online
Atrioventricular Block, First Degree

**BASICS**

**DEFINITION**
Refers to a delay in conduction that occurs between atrial and ventricular activation.

**ECG Features**
- Rate and rhythm—usually normal.
- Usually there are regularly occurring normal P waves and QRS complexes (Figures 1 and 2).
- Prolonged, consistent PR intervals—dogs, > 0.13 sec; cats, > 0.09 sec (Figures 1 and 2).

**PATHOPHYSIOLOGY**
- Virtually never causes clinical signs.
- May become a more severe AV conduction disturbance in some animals.
- Normally the PR interval tends to shorten with rapid heart rates.
- May be the result of intra-atrial conduction delay (prolongation of the PA interval on surface ECG and simultaneous His bundle electrogram) or delay of conduction within the AV node itself (prolongation of the AH interval on His bundle electrogram).

**SYSTEMS AFFECTED**
Cardiovascular

**GENETICS**
N/A

**INCIDENCE/PREVALENCE**
Common

**GEOGRAPHIC DISTRIBUTION**
None

**SIGNALMENT**
Species
Dog and cat

**Breed Predilections**
American cocker spaniel, dachshund, brachycephalic dogs, Persian cats

**Mean Age and Range**
- May occur in young, otherwise healthy dogs as a manifestation of high vagal tone.
- Intra-atrial conduction delay involving the right atrium may be seen with congenital heart disease, especially atrioventricular septal defects.
- May be noted in aged patients with degenerative conduction system disease, particularly cocker spaniels and dachshunds.
- Persian cats of any age with high vagal tone and in cats of any age with hypertrophic cardiomyopathy.

**RISK FACTORS**
Any condition or intervention that raises vagal tone

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
P waves superimposed upon preceding T waves because of first-degree AV block should be differentiated from bifid T waves.

**CBC/BIOCHEMISTRY/URINALYSIS**
- Serum electrolytes—hypokalemia and hyperkalemia may predispose to AV conduction disturbances.
- Leukocytosis—may be noted with bacterial endocarditis or myocarditis.

**OTHER LABORATORY TESTS**
- Serum digoxin concentration—may be high.
- T. cruzi, B. burgdorferi, R. rickettsii titers—may be high.
- T4—may be high in cats if associated with thyrotoxic myocardial disease.

**IMAGING**
Echocardiographic examination—may reveal hypertrophic or infiltrative myocardial disorder.

**DIAGNOSTIC PROCEDURES**
May be needed to identify causes of high vagal tone—upper airway disease, cervical and thoracic masses, gastrointestinal disorders, and high intraocular pressure.

**PATHOLOGIC FINDINGS**
Variable—depend on underlying cause
Atrioventricular Block, First Degree (Continued)

Figure 2.

Lead II ECG rhythm strip recorded from a dog showing sinus tachycardia (175 bpm) and first-degree atrioventricular conduction block. Because the heart rate is rapid, P waves are superimposed on the downslopes of the preceding T waves. The PR interval exceeds 0.16 second (paper speed = 50 mm/s).

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Remove or treat underlying cause(s).
- Hospitalization may be necessary to manage the underlying cause (e.g., cardiomyopathy, gastrointestinal disease, anxiety disease).

**NURSING CARE**
N/A

**ACTIVITY**
Unrestricted; unless restriction required for an underlying condition.

**DIET**
No modifications or restrictions unless required to manage an underlying condition.

**CLIENT EDUCATION**
Generally unnecessary.

**SURGICAL CONSIDERATIONS**
None unless required to manage an underlying condition.

**MEDICATIONS**

**DRUG(S) OF CHOICE**
Medications used only if needed to manage an underlying condition.

**CONTRAINDICATIONS**
- Avoid hypokalemia—increases sensitivity to vagal tone, may potentiate first-degree block.
- Avoid drugs likely to impair impulse conduction further (calcium channel blocking agents, β-adrenergic antagonists, α₂-adrenergic agonists, amiodarone, propafenone).

**PRECAUTIONS**
Drs. with vagomimetic action (e.g., digoxin, bethanechol, physostigmine, pilocarpine) may potentiate first-degree block.

**POSSIBLE INTERACTIONS**
N/A

**ALTERNATIVE DRUG(S)**
N/A

**FOLLOW-UP**

**PATIENT MONITORING**
Except in healthy young animals, monitor ECG to detect any progression in conduction disturbance.

**PREVENTION/AVOIDANCE**
N/A

**POSSIBLE COMPLICATIONS**
N/A

**EXPECTED COURSE AND PROGNOSIS**
- Depends on underlying cause.
- Prognosis usually excellent if no significant underlying disease is present.

**MISCELLANEOUS**

**ASSOCIATED CONDITIONS**
None

**AGE-RELATED FACTORS**
PR interval—tends to lengthen with advancing age.

**ZONOTIC POTENTIAL**
None

**PREGNANCY/FERTILITY/BREEDING**
N/A

**SEE ALSO**
- Atrioventricular Block, Complete (Third Degree)
- Atrioventricular Block, Second Degree—Mobitz I
- Atrioventricular Block, Second Degree—Mobitz II

**ABBREVIATIONS**
- AV = atrioventricular
- ECG = electrocardiogram
- T₄ = thyroxine

**Suggested Reading**

**Authors**
Francis W.K. Smith, Jr and Larry P. Tilley

**Consulting Editors**
Larry P. Tilley and Francis W.K. Smith, Jr.

**Client Education Handout**
available online
Atrioventricular Block, Second Degree—Mobitz I

**BASICS**

**DEFINITION**
Second-degree AV block refers to failure of one or more P waves but not all P waves to be conducted. Mobitz Type I second-degree AV block occurs when AV transmission is progressively delayed prior to a blocked P wave.

**ECG Features**
- PR interval—becomes progressively longer prior to the appearance of a P wave that is not followed by a QRS complex (Figure 1).
- Heart rate and QRS morphology—usually normal.
- Often cyclical.

**PATHOPHYSIOLOGY**
- Frequently associated with high resting vagal tone and sinus arrhythmia in dogs.
- Generally not pathologic or hemodynamically significant.
- This type of AV block usually results from conduction delay within the AV node itself (rather than delay in other segments of the AV conducting system) and is characterized by a progressive increase in AH interval with eventual block between the A and H deflections on a His bundle recording.

**SYSTEMS AFFECTED**
Cardiovascular

**GENETICS**
N/A

**INCIDENCE/PREVALENCE**
Radiotelemetry studies have shown that this arrhythmia occurs in 64% of healthy adult dogs and 100% of healthy puppies 8–12 weeks of age.

**GEOGRAPHIC DISTRIBUTION**
N/A

**SIGNALMENT**
Species
- Dog; uncommon in cat

Breed Predilections
N/A

**Mean Age and Range**
- Usually occur in young, otherwise healthy dogs as a manifestation of high vagal tone.
- Occasionally occur in older dogs with abnormally strong vagal tone.
- Rarely noted in old dogs with degenerative conduction system disease.

**SIGNS**

**Historical Findings**
- Most animals are asymptomatic.
- If drug-induced, owner may report signs of drug toxicity—anorexia, vomiting, and diarrhea with digoxin; weakness with calcium channel blockers or β-adrenergic antagonists.
- If heart rate is abnormally slow, syncope or weakness may occur.

**Physical Examination Findings**
- May be normal unless signs of more-generalized myocardial disease or non-cardiac disease are present.
- Intermittent pauses in the cardiac rhythm.
- First heart sound may become progressively softer, followed by a pause.
- An audible S4 may be heard unaccompanied by S1 and S2 when block occurs.

**CAUSES**
- Occasionally noted in normal animals.
- Enhanced vagal stimulation resulting from non-cardiac diseases—usually accompanied by sinus arrhythmia, sinus arrest.
- Pharmacologic agents—digoxin, β-adrenergic antagonists, calcium channel blocking agents, propafenone, amiodarone, α2-adrenergic agonists, opioids.

**RISK FACTORS**
- Any condition or intervention that enhances vagal tone.
- Type II second-degree AV block (no variation in PR intervals).

**CBC/BIOCHEMISTRY/URINALYSIS**
- Hypokalemia may predispose to AV conduction disturbances.

**OTHER LABORATORY TESTS**
- Serum digoxin concentration—may be high

**IMAGING**
N/A

**DIAGNOSTIC PROCEDURES**
- May be necessary to identify specific causes of enhanced vagal tone (e.g., upper airway disease, cervical and thoracic masses, gastrointestinal disorders, and high intraocular pressure).
- Atropine response test—administer 0.04 mg/kg atropine IM and repeat ECG in 20–30 minutes; may be used to determine whether AV block is due to vagal tone; resolution of AV block with atropine supports vagal cause.
- Electrophysiologic studies are generally unnecessary but will confirm this type of second-degree AV block if surface ECG is equivocal.

**PATHOLOGIC FINDINGS**
Generally, no gross or histopathologic findings

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Treatment usually unnecessary
- Treat or remove underlying cause(s)

**NURSING CARE**
- Generally unnecessary

**ACTIVITY**
Unrestricted

**DIET**
Modifications or restrictions only to manage an underlying condition.

**CLIENT EDUCATION**
- Explain that any treatment is directed toward reversing or eliminating an underlying cause.
### Atrioventricular Block, Second Degree—Mobitz I (Continued)

#### Surgical Considerations
N/A except to manage an underlying condition

#### Medications
**Drug(s)**
Only as needed to manage an underlying condition

#### Precautions
Drug with vagomimetic action (e.g., digoxin, bethanechol, physostigmine, pilocarpine) may potentiate block.

#### Precautions
Hypokalemia increases the sensitivity to vagal tone and may potentiate AV conduction delay.

#### Possible Interactions
N/A

#### Follow-Up
Patient Monitoring
Typically not necessary

#### Prevention/Avoidance
N/A

---

#### Possible Complications
N/A

#### Miscellaneous

### Associated Conditions
N/A

#### Age-Related Factors
N/A

#### Pregnancy/Fertility/Breeding
N/A

#### Synonyms
- Wenckebach periodicity
- Wenckebach phenomenon

#### See Also
- Atrioventricular Block, Complete (Third Degree)
- Atrioventricular Block, First Degree
- Atrioventricular Block, Second Degree—Mobitz II

#### Abbreviations
- AV = atrioventricular
- ECG = electrocardiogram

**Suggested Reading**
- Authors Francis W.K. Smith, Jr. and Larry P. Tilley
- Consulting Editors Larry P. Tilley and Francis W.K. Smith, Jr.
- Acknowledgment The authors and editors acknowledge the prior contribution of Janice McDonald Bright.

**Client Education Handout available online**
Atrioventricular Block, Second Degree—Mobitz II

**Basics**

**Definition**
Second-degree AV block refers to failure of one or more P waves but not all P waves to be conducted. Mobitz Type II second-degree AV block occurs when one or more P waves are blocked without a preceding progressive delay in AV transmission.

**ECG Features**
- One or more P waves not followed by a QRS complex; PR interval is constant but may be either normal or consistently prolonged (Figure 1).
- Ventricular rate—usually slow.
- Fixed ratio of P waves to QRS complexes may occur (e.g., 2:1, 3:1, 4:1 AV block).
- High-grade (advanced) second-degree AV block is characterized by two or more consecutive blocked P waves.
- In second-degree AV block with a 2:1 conduction ratio or higher, it is impossible to observe prolongation of the PR interval before the block, so a designation of Mobitz is not appropriate.
- QRS complexes may appear normal but may also be wide or have an abnormal morphology due to aberrant intraventricular conduction or to ventricular enlargement.
- Abnormally wide QRS complexes may indicate serious, extensive cardiac disease.

**Pathophysiologic**
- Rate in healthy animals.
- May be hemodynamically important when ventricular rate is abnormally slow.
- Frequently progresses to complete AV block, particularly when accompanied by wide QRS complexes.
- Typically this type of AV block results from conduction delay within the AV node itself (rather than delay in another segment of the AV conducting system) that is characterized by normal or prolonged AH intervals with intermittent block between A and H deflections on a His bundle electrogram.

**Systems Affected**
- Cardiovascular.
- Central nervous or musculoskeletal systems if inadequate cardiac output.

**Genetics**
May be heritable in pugs.

**Incidence/Prevalence**
Unknown.

** Geographic Distribution**
N/A.

**Signalment**
Species
- Dog and cat

**Bread Predilections**
American cocker spaniel, pug, dachshund, Airedale terrier, Doberman pinscher.

**Mean Age and Range**
Generally occurs in older animals

**Predominant Sex**
N/A.

**Signs**
**Historical Findings**
- Presenting complaint may be syncope, collapse, weakness, or lethargy.
- Some animals are asymptomatic.
- Animals may show signs of the underlying disease process.

**Physical Examination Findings**
- Bradycardia common.
- May be intermittent pauses in the cardiac rhythm.
- An S4 may be audible in lieu of the normally expected heart sounds (i.e., S1, S2) when the block occurs.
- If associated with digoxin intoxication, there may be vomiting, anorexia, and diarrhea.
- May be other abnormalities reflecting the underlying etiology.

**Causes**
- Heritable in pugs.
- Enhanced vagal stimulation from non-cardiac diseases.
- Degenerative change within the cardiac conduction system—replacement of AV nodal cells and/or Purkinje fibers by fibrotic and adipose tissue in old cats and dogs.
- Pharmacologic agents (e.g., digoxin, β-adrenergic antagonists, calcium channel blocking agents, propafenone, a- adrenergic agonists, muscarinic cholinergic agonists, or severe procainamide or quinidine toxicity).
- Infiltrative myocardial disorders (neoplasia, amyloidosis).
- Endocarditis (particularly involving the aortic valve).
- Myocarditis (viral, bacterial, parasitic, idiopathic).
- Cardiomyopathy (especially in cats).
- Trauma.
- Atropine administered intravenously may cause a brief period of first- or second-degree heart block before increasing the heart rate.

**Risk Factors**
Any condition or intervention that enhances vagal tone.

**Diagnosis**

**Differential Diagnosis**
- High-grade (advanced) form must be distinguished from complete AV block.
- Non-conducted P waves arising from refractoriness of the conduction system during supraventricular tachycardias must be differentiated from pathologic conduction block.

**Biochemistry/Urinalysis**
- Serum electrolytes—hypokalemia and hyperkalemia may predispose to AV.
- Complete blood count and chemistry panel and urinalysis.
- Cardiac enzymes.
- Leukocytosis—may be noted with bacterial endocarditis or myocarditis.
- Electrolyte abnormalities (e.g., severe hypokalemia, hyperkalemia, or hypercalcemia) may predispose to AV block.

- Image 1
  - Lead II ECG rhythm strip recorded from a dog with both first- and second-degree atrioventricular block. The second-degree AV block is high grade with both 2:1 and 3:1 block resulting in variation in the RR intervals. The PR interval for the conducted beats is prolonged (0.28 second) (paper speed = 25 mm/s).

- Figure 1
**Atrioventricular Block, Second Degree—Mobitz II (continued)**

### Other Laboratory Tests
- Serum digoxin concentration—may be high.
- High T₁ in cats—if associated with hyperthyroidism.
- High arterial blood pressure—if associated with hypertensive heart disease.
- Positive Roseola, Rickettsia, or Treponema spp. titer—if associated with one of these infectious agents.
- Blood cultures may be positive in patients with vegetative endocarditis.

### Imaging
Echocardiographic examination may reveal structural heart disease (e.g., endocarditis, neoplasia, or cardiomyopathy).

### Diagnostic Procedures
- Atropine response test—administer 0.04 mg/kg atropine IM and repeat ECG in 20–30 minutes. This may be used to determine whether AV block is due to high vagal tone.
- Electrophysiologic testing is generally unnecessary but can be done to confirm this type of AV block if surface ECG findings are equivocal.

### Pathologic Findings
- Variable—depends on underlying cause.
- Old animals with degenerative change of the conduction system may have focal mineralization of the interventricular septal crest visible grossly; chondroid metaplasia of the central fibrous body and increased fibrous connective tissue in the AV bundle is noted histopathologically.

### Treatment

#### Appropriate Health Care
- Treatments—may be unnecessary if heart rate maintains adequate cardiac output.
- Positive dobutamine or dopamine are indicated for symptomatic patients.
- Treat or remove underlying cause(s).

#### Nursing Care
Generally unnecessary.

#### Activity
- Cage rest advised for symptomatic patients.

#### Diet
- Modifications or restrictions only to manage an underlying condition.

#### Client Education
- Need to seek and specifically treat underlying cause.
- Pharmacologic agents may not be effective long term.

#### Surgical Considerations
- Permanent pacemaker may be required for long-term management of symptomatic patients.

### Medications

#### Drug(s) of Choice
- Atropine (0.02–0.04 mg/kg IV, IM) or glycopyrrolate (5–10 μg/kg IV, IM) may be used short term if positive atropine response.
- Chronic anticoagulant therapy (prothrombin time 0.5–2 μg/kg PO q6–12h or heparin sodium 3–6 μg/kg q8h)—indicated for symptomatic patients if improved AV conduction with atropine response test.
- Isoproterenol (0.04–0.09 μg/kg/minute IV to effect) or dopamine (2–5 μg/kg/minute IV to effect) may be administered in acute, life-threatening situations to enhance AV conduction and/or accelerate an escape focus.
- Phenytoin (10–15 mg/kg or less IV or IM) may be useful to effect or therapeutic serum digoxin concentration—may be used short term if positive atropine response.
- Lidocaine, calcium channel blocking agents, β-adrenergic blocking agents, and pilocarpine (propantheline 0.5–2 mg/kg PO q8–12h or glycopyrrolate 5–10 μg/kg/minute IV) may potentiate block.
- Pilocarpine (0.04–0.09 μg/kg/minute IV to effect) or dopamine (2–5 μg/kg/minute IV to effect) may be administered in acute, life-threatening situations to enhance AV conduction and/or accelerate an escape focus.

#### Contraindications
- Drugs with vagomimetic action (e.g., digoxin, berenilol, physostigmine, pilocarpine) may potentiate block.
- Avoid drugs likely to impair impulse conduction further or depress ventricular escape focus (e.g., procainamide, quinidine, lidocaine, calcium channel blocking agents, β-adrenergic blocking agents).

#### Precautions
- Hypokalemia—increases sensitivity to vagal tone and may potentiate AV conduction delay.
- Positive atropine response test.
- Prolonged bradycardia may cause secondary myocardial disease.

#### Possible Interactions
- N/A

#### Alternative Drug(s)
N/A

### Follow-Up

#### Patient Monitoring
- Frequent ECG because often progresses to complete (third-degree) AV block.

#### Prevention/Avoidance
N/A

#### Possible Complications
- Prolonged bradycardia may cause secondary congestive heart failure or inadequate renal perfusion.

#### Expected Course and Diagnosis
- Variable—depends on cause: If degenerative disease of the cardiac conduction system, often progresses to complete (third-degree) AV block.

### Miscellaneous

#### Associated Conditions
- May be noted in cats with primary or secondary myocardial disease.

#### Age-Related Factors
N/A

#### Zoonotic Potential
N/A

#### Pregnancy/Fertility/Breeding
N/A

#### See Also
- Atrioventricular Block, Complete (Third Degree)
- Atrioventricular Block, Second Degree—Mobitz I

#### Abbreviations
- AV = atrioventricular
- ECG = electrocardiogram
- T₁ = thyroxine

**Suggested Reading**

**Authors**
- Larry P. Tilley and Francis W.K. Smith, Jr.

**Consulting Editors**
- Larry P. Tilley and Francis W.K. Smith, Jr.

Acknowledgments
- The editors acknowledge the prior contribution of Janice McIntosh Bright.

**Client Education Handout**
- Available online
**PATHOPHYSIOLOGY**

- **Tricuspid valve dysplasia** can result in valvular insufficiency, valvular stenosis, or dynamic outflow tract obstruction, depending on the anatomic abnormality. AVVD may occur alone or in association with abnormalities of the ipsilateral outflow tract (e.g., valvular or subvalvular aortic or pulmonary stenosis). It is not uncommon for mitral and tricuspid valve dysplasia to occur together in the same patient. Valvular insufficiency results in dilation of the ipsilateral atrium, eccentric hypertrophy of the associated ventricle, and, if sufficiently severe, signs of CHF. Cardiomyopathy of chronic volume overload and elevated atrial pressures are the end results culminating in pulmonary congestion if the mitral valve is affected and systemic congestion if the tricuspid valve is affected. Valvular stenosis results in atrial dilation and hypertrophy and, when severe, hypoplasia of the receiving ventricle. Tricuspid valve stenosis results in elevated right atrial pressure and systemic congestion if pressures exceed 15–20 mm Hg. Right-to-left shunting may occur if there is an atrial septal defect or patent foramen ovale. Mitral valve stenosis results in elevated pulmonary capillary pressure and pulmonary edema if pressures exceed 25–30 mm Hg. Pulmonary hypertension is a common complicating condition in animals with mitral valve stenosis. Outflow tract obstruction may develop from defects that translocate the anterior leaflet to a position closer to the interventricular septum. Concomitant left ventricular hypertrophy develops in proportion to the severity of the obstruction.

**SYSTEMS AFFECTED**

- Cardiovascular— Infero-obstruction due to valvular stenosis and chronic volume overload from valvular insufficiency results in elevated pulmonary (left AV valve) or systemic (right AV valve) venous pressures. Signs of left atrial and left ventricular enlargement develop secondary to dynamic outflow obstruction. Respiration— Pulmonary edema may develop secondary to mitral stenosis or mitral valve insufficiency. Pulmonary hypertension is a common complication in animals with mitral stenosis. Neurologic— Collapse and loss of consciousness, most often during physical exertion, may occur with severe disease due to low cardiac output and hypotension. Collapse in animals with dynamic outflow obstruction is most often due to ventricular arrhythmia.

**GENETICS**

Tricuspid valve dysplasia is inherited as an autosomal recessive trait in Labrador retrievers. Heritability and pattern of inheritance not established in other breeds.

**INCIDENCE/PREVALENCE**

These are common congenital cardiac anomalies in cats (17% of reported congenital cardiac defects in one study). Less frequently diagnosed in dogs.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**

- With the noted exception of the age of onset, congenital AV valvular insufficiency resembles acquired degenerative AV valve insufficiency with respect to historical findings, physical examination abnormalities, and clinical sequelae.
- The right-sided murmur of tricuspid insufficiency is sometimes confused with the right-sided murmur of a ventricular septal defect.
- Auscultation caused by silent tricuspid regurgitation or tricuspid valve stenosis is often attributed to pericardial effusion, hepatic disease, or obstruction of the caudal vena cava.
- Dogs and cats with ascites due to heart failure—ascites and, more rarely, peripheral edema with severe malformations.
and modestly increased transmirtal inflow velocities. Mitral stenosis results in left atrial dilation while the left ventricular dimensions are normal or small. The valve leaflets are often thickened, relatively immobile, and often fused. Doppler echocardiography demonstrates a high velocity transmirtal diastolic jet with a reduced EF slope. There may also be evidence of concurrent mitral insufficiency and/or secondary pulmonary hypertension. Exclude the possibility of cor triatriatum sinister. Dynamic left ventricular outflow obstruction is characterized by systolic motion of the anterior mitral valve leaflet toward the intervenclavicular septum, increased LV outflow tract velocities, and concentric left ventricular hypertrophy. 

**Tricuspid Valve Dysplasia**
- **Venal insufficiency** results in right atrial dilation and eccentric hyper trophy of the right ventricle. The papillary muscles and chordae tendineae may be fused, creating a curtain-like appearance of the tricuspid valve. Doppler echocardiography demonstrates a high velocity retrograde trans-tricuspid jet with a reduced EF slope. There may be evidence of concurrent tricuspid valve insufficiency and/or right-to-left shunting across a patent foramen ovale or associated atrial septal defect. Exclude the possibility of cor triatriatum dexter.

**Cardiac Catheterization**
- Indicated only in those cases in which the diagnosis cannot be confirmed by echocardiography or if surgical correction is anticipated. Mitral dysplasia—hemodynamic measurements should include left ventricular pressure, pulmonary capillary wedge pressure or direct measurement of LA pressure, pulmonary artery pressures, and, in cases of dynamic obstruction, simultaneous recording of aortic and left ventricular pressures with medical provocation. Contrast studies are best accomplished with a left ventricular injection in cases of valvular insufficiency, and direct left atrial injection via trans-septal catheterization in cases of valvular stenosis. Tricuspid dysplasia—hemodynamic measurements should include right ventricular and right atrial pressures. Contrast studies are best accomplished with a right ventricular injection in cases of valvular insufficiency, and right atrial injection in cases of valvular stenosis.

**DIAGNOSTIC PROCEDURES**

**Electrocardiographic Findings**
- Usually reflect pattern of chamber enlargement. Severe defects may be accompanied by a variety of arrhythmias, particularly atrial premature beats, supraventricular tachycardia, or atrial fibrillation.

**TREATMENT**

**APPROPRIATE HEALTH CARE**
- Inpatient treatment required for CHF.

**CLIENT EDUCATION**
- Owners should be informed of heritability and advised against breeding.

**DIET**
- Sodium-restricted if overt or pending CHF. Medication advisable.

**MEDICATIONS**

**DRUG(S) OF CHOICE**
- **Mitra** or tricuspid dysplasia with insufficiency—diuretics, angiotensin converting enzyme inhibitors, and pimobendan (0.5 mg/kg q12–24h) for patients with imminent or overt congestive heart failure. Furosemide (2–4 mg/kg q12–24h),enalapril (0.5 mg/kg q12h) are used to control congestion. Digoxin (2–4 mg/kg q12h) is used to control supraventricular tachyarrhythmias. 
- **Mitral** or tricuspid stenosis—diuretics to control edema. Furosemide (2–4 mg/kg q12–24h) dose adjusted to resolve congestion. Heart rate should be maintained near 150 bpm using digoxin (2–4 mg/kg q12h), a calcium channel blocker such as diltiazem (1–1.5 mg/kg q8h), or a beta-receptor blocking drug, such as atenolol (0.5–1.5 mg/kg q12–24h).
- **Dynamic outflow tract obstruction**—titrate a beta-receptor blocking drug, such as atenolol (0.5–1.5 mg/kg q12–24h), to abolish or diminish severity of outflow obstruction.

**PRECAUTIONS**
- Standard patient monitoring for cardiac medication side effects (e.g., digitalis toxicity, azotemia).

**FOLLOW-UP**

**PATIENT MONITORING**
- Recheck weekly if no signs of heart failure.
- Recheck at a minimum of every 3 months if signs of CHF (thoracic radiographs, ECG, and echocardiography advisable).

**PREVENTION/AVOIDANCE**
- Do not breed affected animals.

**POSSIBLE COMPLICATIONS**
- Congestive heart failure—left-sided with mitral valve dysplasia; right-sided with tricuspid valve dysplasia. 
- Collapsing or syncope with exercise. 

**ASSOCIATED CONDITIONS**
- Mitral valve dysplasia commonly accompanies valvular or subvalvular aortic stenosis as well as TVD. Tricuspid valve dysplasia commonly accompanies pulmonic stenosis as well as MVD.

**PREGNANCY/FERTILITY/BREEDING**
- Should be avoided—heritable defect and possibility of causing decompensated or worsening heart failure.

**SEE ALSO**
- Congestive Heart Failure, Left-Sided
- Congestive Heart Failure, Right-Sided

**ABBREVIATIONS**
- AV = atrioventricular 
- AVVD = atrioventricular valve dysplasia 
- CHF = congestive heart failure 
- ECG = electrocardiogram 
- MVD = mitral valve dysplasia 
- TVD = tricuspid valve dysplasia

**Suggested Reading**

**Author**
- David D. Sisson

**Consulting Editors**
- Larry P. Tilley and Francis W.K. Smith, Jr.
Incidence/Prevalence
The most common cardiac disease in dogs. The prevalence is strongly influenced by age. It is uncommon in young individuals but common in old dogs. The prevalence reaches > 90% in some affected dog breeds > 10 years.

Signalment
Species
Mainly dogs. Extremely rare in cats.

Breed Predilections
Typically small breeds (< 20 kg but may be encountered in larger dogs), such as Cavalier King Charles spaniels, Chihuahuas, Miniature schnauzers, Maltese, Pomeranians, Cocker spaniels, Pekingese, Poodles, and others.

Mean Age and Range
Murmur may be detected from 2 years of age with a peak incidence at 6–8 years in affected breeds, such as Cavalier King Charles spaniels. Onset of CHF from 8–12 years.

Predominant Sex
Male develop the disease at a younger age than females, which means a higher prevalence at a given age in males.

Signs
Signs depend on the stage of the disease. The descriptions here align with the grading system described in the ACVIM consensus statement on myxomatous mitral valve disease.

Clinically Healthy Patients but Belonging to a Risk Group (ACVIM Stage A)
No abnormal findings.

Patients Without Overt Clinical Signs (ACVIM Stage B)

- Systolic click (early stage).
- Systolic murmur best heard over the mitral valve (valve prolapse).
- With progression, the regurgitation develops on systole, leading to backward regurgitation of blood from the ventricle into the atrium.
- With progression, the leaflets become thickened and elongated, leading to stenotic atrial displacement of the valve leaflets (valve prolapse).
- With progression, the valve lesions cause insufficient coaptation of the leaflets during systole, leading to backward regurgitation of blood from the ventricle into the atrium.
- Severity and progression of AV valve regurgitation depend on severity and progression of valve lesions (leaflets and/or tendinous chords).
- Compensatory mechanisms include cardiac dilatation and eccentric hypertrophy, increased force of contraction, increased heart rate, increased pulmonary lymphatic drainage (left-sided AV valve regurgitation), fluid retention, and neurohormonal modulation of cardiovascular system.
- With progression, the valvular regurgitation can no longer be compensated, leading to reduced cardiac output and increased venous pressures (leading to pulmonary edema if left-sided congestive heart failure [CHF] and to ascites if right-sided). With atrial tear, acute cardiac tamponade may result.

Systems Affected

- Cardiovascular—both AV valves are commonly affected, but semilunar valves less commonly affected.
- Hepatic—passive congestion.
- Renal—uremia—renal azotemia.
- Respiratory—edema and/or pulmonary hypertension develops.

Genetics
Etiology currently unknown, but the current leading scientific hypothesis is that a genetically determined dystrophic process initiates the valve degeneration. The age at which the disease develops is inherited as a polygenic threshold trait (i.e., multiple genes influence the trait and a certain threshold has to be reached before the disease develops).

Incidence/Prevalence
The most common cardiac disease in dogs. The prevalence is strongly influenced by age. It is uncommon in young individuals but common in old dogs. The prevalence reaches > 90% in some affected dog breeds > 10 years.

Signalment
Species
Mainly dogs. Extremely rare in cats.

Breed Predilections
Typically small breeds (< 20 kg but may be encountered in larger dogs), such as Cavalier King Charles spaniels, Chihuahuas, Miniature schnauzers, Maltese, Pomeranians, Cocker spaniels, Pekingese, Poodles, and others.

Mean Age and Range
Murmur may be detected from 2 years of age with a peak incidence at 6–8 years in affected breeds, such as Cavalier King Charles spaniels. Onset of CHF from 8–12 years.

Predominant Sex
Male develop the disease at a younger age than females, which means a higher prevalence at a given age in males.

Signs
Signs depend on the stage of the disease. The descriptions here align with the grading system described in the ACVIM consensus statement on myxomatous mitral valve disease.

Clinically Healthy Patients but Belonging to a Risk Group (ACVIM Stage A)
No abnormal findings.

Patients Without Overt Clinical Signs (ACVIM Stage B)

- Systolic click (early stage).
- Systolic murmur best heard over the mitral or tricuspid areas.
- Murmurs may range from being of soft, low intensity to loud holosystolic. With progression, the murmur typically gets louder and radiates more widely.
- Initially patients have no obvious radiographic or echocardiographic changes in cardiac chamber size (ACVIM stage B1). As the disease progresses, evidence of cardiomegaly will be seen (ACVIM stage B2), often before obvious clinical signs of heart failure are recognized.

Patients with Overt Clinical Signs or Stabilized by CHF Therapy (ACVIM stages C and D)

- Usually loud heart murmur.
- Tachycardia and loss of respiratory sinus arrhythmia.
- Arhythmias and pulse deficit may be present, most commonly supraventricular premature beats or atrial fibrillation.
- Weak femoral pulse, prolonged capillary refill time and pale mucous membranes in case of low output failure.

Other Laboratory Tests

- Natriuretic peptides—concentrations are usually unremarkable unless severe disease and ongoing CHF therapy.
- Precordial heave secondary to impaired left ventricular performance; upright urinary specific gravity is high unless complicated by underlying renal disease or previous diuretic administration.
- High liver enzyme activity in many patients with right-sided CHF.

Diagnostic Imaging

Indicators

- Dilated cardiomyopathy
- Congenital heart disease
- Bacterial endocarditis
- Chronic atrial or interstitial lung disease
- Pulmonary embolism
- Pulmonary neoplasia
- Heartworm disease

CBC/Biochemistry/Urinalysis

CBC/Biochemistry usually unremarkable unless severe disease and ongoing CHF therapy.

DIFFERENTIAL DIAGNOSIS

- Dilated cardiomyopathy
- Congenital heart disease
- Bacterial endocarditis
- Chronic atrial or interstitial lung disease
- Pulmonary embolism
- Pulmonary neoplasia
- Heartworm disease

CBC/Biochemistry/Urinalysis

CBC/Biochemistry usually unremarkable unless severe disease and ongoing CHF therapy.

RISK FACTORS

- Breed
- Sex (males have an earlier onset)

Diagnosis

Differential Diagnosis

- Dilated cardiomyopathy
- Congenital heart disease
- Bacterial endocarditis
- Chronic atrial or interstitial lung disease
- Pulmonary embolism
- Pulmonary neoplasia
- Heartworm disease

CBC/Biochemistry/Urinalysis

CBC/Biochemistry usually unremarkable unless severe disease and ongoing CHF therapy.

RISK FACTORS

- Breed
- Sex (males have an earlier onset)

Diagnosis

Differential Diagnosis

- Dilated cardiomyopathy
- Congenital heart disease
- Bacterial endocarditis
- Chronic atrial or interstitial lung disease
- Pulmonary embolism
- Pulmonary neoplasia
- Heartworm disease

CBC/Biochemistry/Urinalysis

CBC/Biochemistry usually unremarkable unless severe disease and ongoing CHF therapy.

Risk Factors

- Breed
- Sex (males have an earlier onset)
PATHOLOGIC FINDINGS

- Gross valvular changes range from only a few discrete nodules at the line of closure to gross distortion of the valve by gray-white nodules and plaques causing contraction of the cusps and rolling of the free edge; the chordae are irregularly thickened, with regions of tapering and rupture.

- Mild disease—normal cardiac size. More recent and healed LA splits or tears in some patients.

- Small thrombi in the LA are rarely seen.

- Electrocardiographic Findings

  - Sinus tachycardia is common in patients with CHF.
  - Slow rates at home, and at which rate new contact with the veterinarian.
  - Electrocardiographic findings may not be present.

- Abdominoscintigraphy—modified transudate is characteristic of CHF.

- Doppler evaluation for the presence of pulmonary hypertension should be routinely performed.

DIAGNOSTIC PROCEDURES

- Systemic blood pressure should be monitored in patients with severe disease or receiving diuretics to check for hypotension.

- Arterial/venous blood gases can be used to quantify hypoxemia and monitor treatment response.

- Abdominoscintigraphy

- Absolute exercise restriction for symptomatic patients.

- Stable patients receiving medical treatment—avoid strenuous exercise.

- Oxygen therapy as needed for hypoxemia.

DIET

- In patients with mild to moderate CHF, a normal diet is appropriate.

- Dogs with severe CHF may need a diet with a lower sodium content.

- Dogs with severe CHF and pulmonary hypertension should be considered only in hospitalized dogs when monitored by a specialist.

- Diuretics

  - Furosemide IV, SC, IM, or PO. Dose is dependent on severity of CHF.

  - Mild to moderate CHF: 2–4 mg/kg q6–24h.

  - Severe or fulminant CHF: 4–8 mg/kg q6–12h, preferably IV, IM, or SC.

- Antiarrhythmics—as needed.

- Oxygen supplementation and cage rest to reduce work load and increase cardiac output.

- Nitrate therapy may develop if appropriate 12-hour nitrate-free intervals are omitted from the dosing schedule.

- Beta-blockers are negative inotropes and may have an acute adverse effect on myocardial function and clinical status.

- Stable patients receiving medical therapy may become normo- or, less commonly, hypotensive.

- Diuretics should be used in Stage B2 patients with significant diastolic 40% increase in O2 saturation.

- Additional options in cases with severe CHF:

  - Dobutamine (dogs, 1–10 μg/kg/minute CRI).

  - Nitroglycerin: ointment (one-fourth inch 5–2 inches percutaneously).

  - Sildenafil at 0.5–2 mg/kg in case of severe pulmonary hypertension.

MEDICATIONS

- CEI: enalapril [0.5 mg/kg q24h], benazepril [2–5 mg/kg q12–24h], captopril [0.25–0.5 mg/kg q12h], fosinopril [2–5 mg/kg q24h].

- Hydralazine/nitroprusside:

  - Hydralazine at 0.5 mg/kg q12h titrated up to 2 mg/kg if necessary, or sodium nitroprusside at 1–10 μg/kg/minute. Both drugs require blood pressure monitoring and should be considered only in hospitalized dogs when monitored by a specialist.

- Diuretics

  - Furosemide IV, SC, IM, or PO. Dose is dependent on severity of CHF.

  - Mild to moderate CHF: 2–4 mg/kg q6–24h.

  - Severe or fulminant CHF: 4–8 mg/kg q6–12h, preferably IV, IM, or SC.

- Beta-blocker treatment in Stage B2 patients is of unknown value at this time.

- Bisoprolol (dogs, 1–10 μg/kg/minute; cats, 1–5 μg/kg/minute).

- Dopamine (1–10 μg/kg/minute).

- Antiarrhythmics—as needed.

- Severe asystole may require abdominal paracentesis.

- Chronic CHF (Typically Treated as Outpatient)

  - Exact composition of medical therapy depends on disease severity and clinical signs.

  - All dogs with CHF require life-long treatment with a diuretic, such as furosemide.

  - Mild to moderate CHF: 1 mg/kg q4–24h to 3–4 mg/kg q8h PO.

  - Moderate to severe CHF: 2–3 mg/kg q12h or higher.

  - Furosemide at 0.25 mg/kg q12h PO.

  - ACEI (i.e., enalapril, benazepril, ramipril).

  - Spironolactone at 2 mg/kg q12–24h PO and/or hydrochlorothiazide at 2–4 mg/kg q24h PO.

  - Digestion at 0.22 mg/m² q12h PO, or lower.

  - Adequate antiarrhythmic treatment if significant arrhythmia is present.

  - Sildenafil at 0.5–2 mg/kg in case of pulmonary hypertension.

PRECAUTIONS

- Use digoxin, diuretics, and ACE inhibitors with caution in patients with renal disease.

- Nitrate tolerance may develop if appropriate 12-hour nitrate-free intervals are omitted from the dosing schedule.

- Beta-blockers are negative inotropes and may have an acute adverse effect on myocardial function and clinical status.
POSSIBLE INTERACTIONS
- Furosemide potentiates the effects of an ACE-inhibitor, spironolactone, or a thiazide.
- Nonsteroidal anti-inflammatory drugs should be used with caution in patients receiving furosemide and ACEI.

ALTERNATIVE DRUG(S)
- Diuretics—add thiazide and/or potassium-sparing diuretic (e.g., spironolactone) in refractory animals.
- Torsemide and bumetanide are alternatives to furosemide.
- Vasodilators—isosorbide dinitrate can be used in place of nitroglycerin ointment in patients requiring long-term nitrate administration.

FOLLOW-UP
PATIENT MONITORING
- Frequency of reexaminations depends on severity of myxomatous valve disease and severity of CHF (if present).
- Dogs without signs of CHF:
  - Slight to moderate disease severity: Perform echocardiography when a murmur is first detected and every 6-12 months thereafter to document progressive cardiomegaly. A baseline radiograph may be useful.
  - Moderate to severe disease severity may require more frequent monitoring.
- Dogs with signs of CHF:
  - Once acute CHF has been successfully treated, dogs can be treated at home.
  - Reexamination after 1 to 2 weeks of therapy (check for signs of decompensated CHF, dehydration, electrolyte imbalance, renal dysfunction, and presence of a complication). Moderate to severe disease severity may require more frequent monitoring.

POSSIBLE COMPLICATIONS
- Asymptomatic patients may develop CHF
- Recurrent CHF in patients stabilized by medical therapy
- Pulmonary hypertension
- Biventricular CHF in patients with initial left-sided CHF
- Mild pleural and/or pericardial effusion
- Atrial wall tear leading to acquired atrial septal defect or cardiac tamponade
- Rupture of first-order tendinous chord(s), leading to a flail valve leaflet
- Formation of intracardiac thrombus and/or myocardial infarction.

EXPECTED COURSE AND PROGNOSIS
The lesions on the AV valves are progressive in nature and myocardial function may worsen, necessitating increasing drug dosages; long-term prognosis depends on response to treatment and stage of heart failure.

MISCELLANEOUS
SYNONYMS
- Chronic valvular disease (CVD)
- Chronic mitral valve disease
- Degenerative valvular disease
- Degenerative mitral valve disease (DMVD)
- Myxomatous mitral valve disease (MMVD)
- Endocardiosis

SEE ALSO
- Atrial Wall Tear
- Congestive Heart Failure, Left-Sided
- Congestive Heart Failure, Right-Sided

ABBREVIATIONS
- ACE = angiotensin converting enzyme
- AV = atrioventricular
- CHF = congestive heart failure
- LA = left atrium
- LV = left ventricle
- MMVD = myxomatous mitral valve disease

Suggested Reading
Authors Ingrid Ljungvall and Jens Hägström Consulting Editors Larry P. Tilley and Francis W.K. Smith, Jr.

Client Education Handout available online
Atrioventricular Valvular Stenosis

**BASICS**

**DEFINITION**
Atrioventricular valvular stenosis is a pathologic narrowing of the mitral or tricuspid valve orifice due to valvular dysplasia or an obstructive, supravalvar ring.

**PATHOPHYSIOLOGY**
- **Initial**
  - Increases stroke volume and cardiac output.
  - Mitral inflow velocity increases.
  - E-to-F ratio increases.
  - E-a ratio increases.
  - Systolic and diastolic pressures rise.
  - Pulmonary hypertension can develop.
  - Mitral annulus diameter increases.

**Incidence**
- **Ratios**
  - Atrioventricular valve stenosis is more common than isolated left atrial appendage enlargement.

**Signs**
- **Physical**
  - A soft diastolic murmur with point of maximal intensity over the left apex.
  - Crackles from pulmonary edema.

**Diagnosis**
- **Imaging**
  - Thoracic radiography: cardiomegaly, pleural effusion.
  - Echocardiography: systolic or diastolic tricuspid stenosis.

**DIFFERENTIAL DIAGNOSIS**
- **Congenital**
  - Tetralogy of Fallot.
  - Ventricular septal defect.
- **Acquired**
  - Rheumatic valvular disease.
  - Previous surgical repair.

**TREATMENT**
- **Medical**
  - Diuretics.
  - Dopaminergic agents.
  - Calcium channel blockers.

**PROGNOSIS**
- **Vascular**
  - Depends on underlying cause and severity of mitral stenosis.

**GENETICS**
- **Dominant trait with reduced penetrance.**
- **Rearrangements of chromosome 9 inherited as an autosomal recessive trait in dogs with tricuspid stenosis.**
- **Recessive**: a congenital dysplasia of the mitral or tricuspid valve that may be familial.

**RISK FACTORS**
- **Breed predispositions (see above); see “Risk Factors” for Endocarditis, Infective;** permanent tracheostomy.

**DIAGNOSIS**
- **Differential diagnosis**
  - Atrioventricular valve stenosis must be differentiated from the more common causes of mitral and tricuspid regurgitation in the absence of stenosis. These include both congenital and acquired lesions of the atrioventricular valves and support apparatus.
  - Acquired lesions that obstruct the inflow tracts (see “Causes”).

**IMAGING**
- **Thoracic radiography**
  - Cardiomegaly, pleural effusion.

**Echocardiography**
- **Diagnosis**
  - Test of choice.
  - Two-dimensional echocardiography reveals most myocardial dilatation.
  - Valve excision during diastole.
  - Echocardiographic findings:
    - E-to-F slope is decreased.
    - E-a ratio is increased.
    - Systolic and diastolic pressures rise.
    - Pulmonary hypertension can develop.
    - Mitral annulus diameter increases.

**GENETICS**
- **Dominant trait with reduced penetrance.**
- **Rearrangements of chromosome 9 inherited as an autosomal recessive trait in dogs with tricuspid stenosis.**
- **Recessive**: a congenital dysplasia of the mitral or tricuspid valve that may be familial.
Atrioventricular Valvular Stenosis

- Concurrent defects such as patent foramen ovale, ASD, or bridging septal leaflet.
- Angiography: Right atrium injection demonstrates a markedly dilated atrium in TS; with concurrent PFO or ASD, opacification of the left atrium is also observed following right atrial injection.
- Might visualize thickened, irregular valve leaflets or a stenotic valve funnel.
- Ventriculocoronary injection often reveal valvular regurgitation.
- There is delayed opacification of the ventricles and great vessels.

Cardiac Catheterization
- A diastolic pressure gradient is identified between the atrium and ventricle. A large "A" wave is common if atrial function is preserved.
- High left atrial, pulmonary capillary wedge, and pulmonary artery pressures occur in MS.
- High right atrial and central venous pressures are present in TS.
- Ventricular pressure may be normal in the absence of concurrent defects.

DIAGNOSTIC PROCEDURES

Electrocardiography
- Variable enlargement and ventricular conduction patterns are observed. Widened or tall P-waves are commonly observed.
- Splintered R-waves are present in some dogs with tricuspid dysplasia.
- Axis deviation due to hypertrophy or ventricular conduction disturbances is relatively common in cats with mitral valve malformations.
- Ectopic rhythms, especially of atrial origin, are often observed. Atrial fibrillation is the most important rhythm disturbance as atrial contribution to filling is lost and the R to R intervals vary with short cycles increasing the mean diastolic gradient.

PATHOLOGIC FINDINGS
- The atrioventricular valve is abnormal, with thickened leaflets and fused commissures.
- Other lesions may be identified such as a supra-mitral ring (see "Causes").
- Many cases also have abnormal chordae tendineae and papillary muscles.
- Atrial dilation and hypertrophy are common.
- Patent foramen ovale with TS or partial atrioventricular septal defect (primum ASD and bridging septal leaflet) with supravalvar mitral (ring) stenosis.

TREATMENT

APPROPRIATE HEALTH CARE

Patients in overt CHF should be treated with inpatient medical management. Surgical or catheter-based interventions can be considered once heart failure has been stabilized. Control of heart rhythm disturbances, especially AF, is also important.

These patients are typically complicated and consultation with a cardiacist is highly recommended. Echocardiography should be considered but advanced atrial disease can render the procedure less effective or limit the duration of sinus rhythm.

NURSING CARE

Sedation with butorphanol is appropriate for dyspnic patients. Oxygen therapy should be administered to the patient with dyspnea or hypoxemia from left-sided congestive heart failure. Fluid therapy is typically contraindicated in the patient with overt CHF except in cases of moderate to severe anemia, renal compromise, or severe dehydration. Therapeutic paracocaine may be considered in the patient with pleural effusions or tympanic auscultation.

ACTIVITY

Exercise restriction is important recommended for any animal with this condition because tachycardia increases the mean gradient across the stenotic valve predisposing to pulmonary edema or venous congestion. Cage rest for patients with CHF.

Diet
- Feed a sodium-restricted diet to patients in CHF.

CLIENT EDUCATION

The client must be advised of symptoms associated with CHF and the urgency of treatment, particularly with left-sided CHF. Atrial fibrillation can lead to rapid ventricular response, which predisposes to congestive heart failure. The client must be advised of symptoms associated with CHF and the urgency of treatment, particularly with left-sided CHF. Atrial fibrillation can lead to rapid ventricular response, which predisposes to congestive heart failure.

SURGICAL CONSIDERATIONS

- Surgical valve replacement or repair requires cardiopulmonary bypass or hypothermia. Cost, availability, and high complication and mortality rates are greatly limiting factors.
- Balloon valvuloplasty is an alternative referral treatment and has been used successfully for managing some cases of AV stenosis.

MEDICATIONS

DRUG(S) OF CHOICE

CHF
- Furosemide—dops, 2–6 mg/kg IV, IM, SC, PO q8–24h; cats, 1–4 mg/kg IV, IM, SC, PO q12–24h.
- ACE inhibitor—enalapril—dops, 0.25–0.5 mg/kg PO q12–24h; cats, 0.25–0.5 mg/kg PO q12–24h; see below under "Follow-Up" for patient monitoring.
- Nitroglycerin paste (one-fourth of a 0.125-mg tablet PO q4–8h); adjust dosage based on serum concentrations.

Atrial Tachyarrhythmias
- Digitalis—dogs, 0.5–3 mg/kg PO q12–24h; cats, one-fourth of a 0.125-mg tablet PO q4–8h; adjust dosage based on serum concentrations.
- Beta-blockers such as atenolol or the calcium channel blocker diltiazem for suppression of frequent atrial premature complexes and for heart rate control in atrial tachyarrhythmias such as atrial tachycardia/flutter/fibrillation. Beware of using these drugs in uncontrolled CHF.
- Typical diltiazem dosage: dogs, 0.25–3.0 mg/kg q12–24h; cats, 6.25–12.5 mg/cat q12–24h; start low and titrate to effect.
- Diltiazem dosages: dogs, 2–6 mg/kg/day in two (long-acting diltiazem) or three divided dosages; start low and titrate to effect; cats, 7.5 mg diltiazem HCl PO q12h. Higher dosages are sometimes needed.
- Sotalol for intractable/recurrent arrhythmias—dogs, 1–2 mg/kg PO q12h; cats, 10–20 mg/cat q12h.
- Dogs can be referred for electrocardioversion to convert AF to sinus rhythm (with follow-up therapy with sotalol or amiodarone), however, revision back to AF is common owing to marked atrial dilatation.

Pulmonary Hypertension
- Sildenafil—dogs, 0.5–3 mg/kg PO q8–12 hours.

PRECAUTIONS

- As a general rule pimobendan is relatively contraindicated in pure valvular stenosis; however, its benefit in cases with advanced CHF have been treated with this drug with suppressive success, especially when there is combined stenosis/regurgitation of the valve.
- Use ACE inhibitors or other vasodilators in patients with CHF; cardiac output is limited and vasodilatation may induce hypotension. Monitor arterial blood pressure and renal function.

POSSIBLE INTERACTIONS

- Furosemide and ACE inhibitors can affect kidney function, alter blood electrolytes, and reduce blood pressure; these parameters should be monitored.
- Sildenafil can also reduce systemic blood pressure and should not be used with nitroglycerin paste or other nitrates.

ALTERNATIVE DRUG(S)

Spironolactone (2 mg/kg PO q12–24h) should be considered as an ancillary diuretic and for its anithrombotic benefit (as an aldosterone antagonist).

FOLLOW-UP

PATIENT MONITORING
- Thoracic radiographs for pulmonary edema or pleural effusion.
Atrioventricular Valvular Stenosis

- Echocardiography with Doppler studies—to estimate pulmonary pressures and subjectively assess right heart function if on sildenafil.
- Digoxin level—check 7–10 days following institution of therapy; 8- to 12-hour trough should be 0.8–1.5 ng/mL.
- Renal function, electrolyte status, and arterial blood pressure when on diuretic and/or ACE inhibitor.
- Standard rhythm ECG or Holter (ambulatory ECG) if arrhythmias are present.

Possible Complications
- CHF
- Atrial fibrillation
- Syncope
- Atrial thromboembolism—cats with MS
- Pulmonary hemorrhage with MS

Expected Course and Prognosis
- Morbidity is high; except for mild cases, prognosis is generally poor once an animal becomes symptomatic. However, some animals will live for many years even with relatively severe stenosis of the mitral or tricuspid valve.
- Surgical intervention or balloon valvuloplasty might alter course of disease, but data are limited.

Miscellaneous Associated Conditions

Concurrent congenital defects are common (e.g., subaortic stenosis in MS, PFO in TS; primum ASD in cats with supravalvular mitral (ring) stenosis).

Pregnancy/Fertility/Breeding
- The possibility that this may be a heritable defect must be considered in assessing suitability of the animal for breeding, particularly in breeds with a predilection for this defect. The additional hemodynamic burden of gestation may be poorly tolerated by an already compromised heart. In general breeding is strongly discouraged.

Synonyms
- Atrioventricular valve dysplasia with stenosis
- Supravalvular mitral ring

See Also
- Atrioventricular Valve Dysplasia
- Endocarditis, Infective

Abbreviations
- ACE = angiotensin converting enzyme
- AF = atrial fibrillation
- AV = atrioventricular
- CHF = congestive heart failure
- ECG = electrocardiogram
- MS = mitral stenosis
- PFO = patent foramen ovale
- TS = tricuspid stenosis

Suggested Reading

Authors
- Lora S. Hitchcock and John D. Bonagura

Consulting Editors
- Larry P. Tilley and Francis W.K. Smith, Jr.
Azotemia and Uremia

**BASICS**

**DEFINITION**
- Azotemia is an excess of urea, creatinine, or other non-protein nitrogenous substances in blood, plasma, or serum.
- Uremia is the polyserotic toxic syndrome that results from marked loss in kidney functions. Uremia occurs simultaneously in animals with increased quantities of urine constituents in blood (azotemia), but azotemia may occur in the absence of uremia.

**PATHOPHYSIOLOGY**
- Azotemia can be caused by (1) increased production of non-protein nitrogenous substances, (2) decreased glomerular filtration rate, or (3) reabsorption of urine that has escaped from the urinary tract into the bloodstream. High production of non-protein nitrogenous waste substances may result from high intake of protein (diet or gastrointestinal bleeding) or accelerated catabolism of endogenous proteins. Glomerular filtration rate may decline because of reduced renal perfusion (prerenal azotemia), acute or chronic kidney disease (renal azotemia), or urinary obstruction (post-renal azotemia). Reabsorption of urine into the systemic circulation may also result from leakage of urine from the excretory pathways (also a form of post-renal azotemia).
- Pathophysiology of uremia—completely understood, may be related to (1) metabolic and toxic systemic effects of waste products retained because of enhanced catabolism of substances (e.g., erythropoietin and degradation of hormones and other substances, (2) decreased glomerular filtration rate, (3) impaired renal production and degradation of hormones and other substances (e.g., calcitriol and 1,25-dihydroxycholecalciferol).

**SYSTEMS AFFECTED**
- Uremia affects virtually every body system.
- Cardiovascular—arterial hypertension, left ventricular hypertrophy, heart murmur, cardiomyopathy, cardiac rhythm disturbances.
- Endocrine/Metabolic—renal secondary hyperparathyroidism, inadequate production of 1,25-dihydroxycholecalciferol (calcitriol) and erythropoietin, hypergastremia, weight loss.
- Gastrointestinal—anorexia, nausea, vomiting, diarrhea, uremic stomatitis, xerostomia, uremic breath, constipation.
- Hematopoietic/Lymph/Immune—anemia and immunodeficiency.
- Neuromuscular—dullness, drowsiness, lethargy, fatigue, irritability, tremors, gait imbalance, flaccid muscle weakness, myoclonus, behavioral changes, dementia, isolated cranial nerve deficits, seizures, stupor, coma, impaired thermoregulation (hypothermia).
- Ophthalmic—scleral and conjunctival injection, retinopathy, acute-onset blindness.
- Skin/Exocrine—pallor, bruising, increased bleeding, unkempt appearance, loss of normal sheen to coat.

**SIGNALMENT**

**DOG and cat**

**SIGNS**

**General Comments**
- Azotemia may not be associated with historical or physical abnormalities. Unless patient has uremia, clinical findings are limited to the disease responsible for azotemia. Findings described here are those of uremia.

**Historical Findings**
- Weight loss
- Declining appetite or anorexia
- Reduced activity
- Depression
- Fatigue
- Weakness
- Vomiting
- Diarrhea
- Hallitosis
- Constipation
- Polyuria
- Changes in urine volume (increase or decrease)
- Poor haircoat or unkempt appearance
- Petechiae and ecchymoses
- Dull and unkempt haircoat
- Scleral and conjunctival injection
- Relative hypothermia

**CAUSES**

**Prerenal Azotemia**
- Reduced renal perfusion due to low blood volume or low blood pressure.
- Acute or chronic kidney disease affecting glomeruli, renal tubules, renal interstitium, or renal vascularity that impair at least 75% of kidney function (glomerular filtration rate).

**Post-renal Azotemia**
- Urinary obstruction; rupture of the excretory pathway.

**RISK FACTORS**
- Hypovolemia
- Intestinal obstruction
- Myocardial infarction
- Shock
- Crush injury
- Trauma
- Neoplasia
- Infection
- Endotoxemia
- Obstructive nephropathy
- Bilateral ureteral obstruction

**SIGNS**

**DIFFERENTIAL DIAGNOSES**

**RISK FACTORS**
- Medical conditions—kidney disease, hypodermococcosis, low cardiac output, hypotension, fever, sepsis, polyuria, liver disease, pyometra, hypothyroidism, dehydration, acidosis, exposure to nephrotoxic chemicals, gastrointestinal hemorrhage, urolithiasis, urethral plugs in cats, urethral trauma, and neoplasia.
- Advanced age may be a risk factor.
- Drugs—potentially nephrotoxic drugs, nonsteroidal anti-inflammatory drugs, diuretics, antihyperperitoneal medications; failure to adjust dosage of drugs primarily eliminated by the kidneys to correspond with decline in renal function.

**DIAGNOSIS**

**DIFFERENTIAL DIAGNOSIS**
- Dehydration, poor peripheral perfusion, low cardiac output, history of recent fluid loss, high protein diet, or black, tarry stools—rule out prerenal azotemia.
- Recent onset of altered urine output (high or low), clinical signs consistent with uremia, exposure to possible nephrotoxicants or ischemic renal injury, or kidney size normal or enlarged—rule out acute renal failure.
- Progressive weight loss, polyuria, polydipsia, small kidneys, disparate kidney size (cats—big kidney and little kidney), polyuria, and signs of uremia that have developed over several weeks to months—rule out chronic renal failure.
- Abrupt decline in urine output and onset of signs of uremia, disparate kidney size (cats—big kidney and little kidney), occasionally dysuria, stranguria, and hematuria, large urinary bladder or fluid-filled abdomen—rule out post-renal azotemia.

**CANCER/BIOCHEMISTRY/URINALYSIS**

**CBC**
- Nonregenerative anemia (normocytic, normochromic)—often present with chronic renal failure.
- Hemococoncentration—often present with prerenal azotemia; can also be seen with acute renal failure and post-renal azotemia.

**Biochemistry**

- Serial determinations of serum urea nitrogen and creatinine concentrations may help differentiate the cause of azotemia. Appropriate therapy to restore renal perfusion typically yields a dramatic reduction in azotemia in patients with prerenal azotemia (typically within 24–48 hours). Correcting...
obstruction to urine flow or a rent in the excretory pathway typically is followed by a rapid reduction in the magnitude of azotemia.

- Concurrent hyperkalemia may be consistent with post-prerenal azotemia, primary renal azotemia due to oliguric renal failure, or post-renal azotemia associated with hypoadrenocorticism.
- Increased serum albumin and globulin concentration suggest prerenal azotemia or a prerenal component.

**Urinalysis**

- A urine specific gravity value ≥ 1.030 in dogs and ≥ 1.035 in cats supports a diagnosis of prerenal azotemia. Administration of fluid therapy before urine collection may interfere with interpretation of low specific gravity values.
- Azotemic patients that have not been treated with fluids and have urine specific gravity < 1.030 in dogs and < 1.035 in cats typically have primary renal azotemia. A notable exception to this rule is dogs and cats with glomerulonephritis. Glomerulopathy is sometimes characterized by glomerular renal imbalance in which adequate urine-concentrating ability may persist despite sufficient renal glomerular damage to cause primary renal azotemia; these patients are recognized by moderate to marked proteinuria in the absence of hematuria and pyuria.
- Urine specific gravity is not useful in identifying post-renal azotemia.

**OTHER LABORATORY TESTS**

Endogenous enzymes screening, including ALT, AST, or insulin clearance tests or other specific tests of glomerular filtration rate may be used to confirm that azotemia is caused by reduced glomerular filtration rate.

**IMAGING**

- Abdominal radiographs—used to determine kidney size (small kidneys consistent with chronic kidney disease) and to moderate to marked enlargement of kidneys may be consistent with acute renal failure or urinary obstruction and to rule out urinary obstruction (marked dilation of the urinary bladder or mineral densities within the excretory pathway).
- Ultrasonography—may detect changes in echogenicity of the renal parenchyma and size and shape of kidneys that support a diagnosis of primary renal azotemia; useful to rule out post-renal azotemia characterized by distension of the excretory pathway and urethral or ureteric obstruction or impedance on the excretory pathway and intrarenal fluid accumulation (with rupture of the excretory pathway).
- Excretory urography, pyelography, or cystourethrography—may help establish the diagnosis of post-renal azotemia due to urinary obstruction or rupture of the excretory pathway.

**DIAGNOSTIC PROCEDURES**

Renal biopsy can be used to confirm the diagnosis of primary kidney disease, to differentiate acute from chronic kidney disease, and to attempt to establish the underlying disease process responsible for primary kidney disease.

**TREATMENT**

- Peri-renal azotemia caused by impaired renal perfusion—correct the underlying cause of renal hypoperfusion; aggressiveness of treatment depends on the severity of the underlying condition and the probability that persistent renal hypoperfusion will lead to primary renal injury or failure.
- Primary renal azotemia and associated uremia—(1) specific therapy directed at halting or reversing the primary disease process affecting the kidneys, and (2) symptomatic, supportive, and palliative therapies that ameliorate clinical signs of uremia; minimize the clinical impact of deficits and excesses in fluid, electrolyte, acid-base balances; minimize the effects of inadequate renal biosynthesis of hormones and other substances, and maintain adequate nutrition.
- Post-renal azotemia—eliminate urinary obstruction or repair rents in the excretory pathway; supplemental fluid administration is often required to prevent dehydration that may develop during the solute diuresis that follows correction of post-renal azotemia.
- Fluid therapy—indicated for most azotemic patients; preferred fluids include 0.9% saline or lactated Ringer’s solution. Determine fluid volume to administer on the basis of severity of dehydration or volume depletion. If no clinical dehydration is evident, cautiously assume that the patient is less than 5% dehydrated and administer a corresponding volume of fluid. Generally provide 25% of calculated fluid deficit in the first hour. Thereafter, serially monitor perfusion (capillary refill time, pulse pressure, heart rate, and temperature of feet), blood pressure and urine output to assess adequacy of fluid therapy. If perfusion has not improved, additional fluid should be administered. Provide the remaining fluid deficit over the next 12–24 hours. Fluid therapy should be cautiously administered to patients with overt or suspected cardiac failure and patients that are oliguric or anuric.
- Treat patients in shock appropriately.
- Consider feeding diets formulated for kidney disease to reduce the magnitude of azotemia, hyperphosphatemia, and acidosis.

**DIAGNOSTIC PROCEDURES**

Renal biopsy can be used to confirm the diagnosis of primary kidney disease, to differentiate acute from chronic kidney disease, and to attempt to establish the underlying disease process responsible for primary kidney disease.

**TREATMENT**

- Peri-renal azotemia caused by impaired renal perfusion—correct the underlying cause of renal hypoperfusion; aggressiveness of treatment depends on the severity of the underlying condition and the probability that persistent renal hypoperfusion will lead to primary renal injury or failure.
- Primary renal azotemia and associated uremia—(1) specific therapy directed at halting or reversing the primary disease process affecting the kidneys, and (2) symptomatic, supportive, and palliative therapies that ameliorate clinical signs of uremia; minimize the clinical impact of deficits and excesses in fluid, electrolyte, acid-base balances; minimize the effects of inadequate renal biosynthesis of hormones and other substances, and maintain adequate nutrition.
- Post-renal azotemia—eliminate urinary obstruction or repair rents in the excretory pathway; supplemental fluid administration is often required to prevent dehydration that may develop during the solute diuresis that follows correction of post-renal azotemia.
- Fluid therapy—indicated for most azotemic patients; preferred fluids include 0.9% saline or lactated Ringer’s solution. Determine fluid volume to administer on the basis of severity of dehydration or volume depletion. If no clinical dehydration is evident, cautiously assume that the patient is less than 5% dehydrated and administer a corresponding volume of fluid. Generally provide 25% of calculated fluid deficit in the first hour. Thereafter, serially monitor perfusion (capillary refill time, pulse pressure, heart rate, and temperature of feet), blood pressure and urine output to assess adequacy of fluid therapy. If perfusion has not improved, additional fluid should be administered. Provide the remaining fluid deficit over the next 12–24 hours. Fluid therapy should be cautiously administered to patients with overt or suspected cardiac failure and patients that are oliguric or anuric.
- Treat patients in shock appropriately.
- Consider feeding diets formulated for kidney disease to reduce the magnitude of azotemia, hyperphosphatemia, and acidosis.

**DIAGNOSTIC PROCEDURES**

Renal biopsy can be used to confirm the diagnosis of primary kidney disease, to differentiate acute from chronic kidney disease, and to attempt to establish the underlying disease process responsible for primary kidney disease.

**TREATMENT**

- Peri-renal azotemia caused by impaired renal perfusion—correct the underlying cause of renal hypoperfusion; aggressiveness of treatment depends on the severity of the underlying condition and the probability that persistent renal hypoperfusion will lead to primary renal injury or failure.
- Primary renal azotemia and associated uremia—(1) specific therapy directed at halting or reversing the primary disease process affecting the kidneys, and (2) symptomatic, supportive, and palliative therapies that ameliorate clinical signs of uremia; minimize the clinical impact of deficits and excesses in fluid, electrolyte, acid-base balances; minimize the effects of inadequate renal biosynthesis of hormones and other substances, and maintain adequate nutrition.
- Post-renal azotemia—eliminate urinary obstruction or repair rents in the excretory pathway; supplemental fluid administration is often required to prevent dehydration that may develop during the solute diuresis that follows correction of post-renal azotemia.
- Fluid therapy—indicated for most azotemic patients; preferred fluids include 0.9% saline or lactated Ringer’s solution. Determine fluid volume to administer on the basis of severity of dehydration or volume depletion. If no clinical dehydration is evident, cautiously assume that the patient is less than 5% dehydrated and administer a corresponding volume of fluid. Generally provide 25% of calculated fluid deficit in the first hour. Thereafter, serially monitor perfusion (capillary refill time, pulse pressure, heart rate, and temperature of feet), blood pressure and urine output to assess adequacy of fluid therapy. If perfusion has not improved, additional fluid should be administered. Provide the remaining fluid deficit over the next 12–24 hours. Fluid therapy should be cautiously administered to patients with overt or suspected cardiac failure and patients that are oliguric or anuric.
- Treat patients in shock appropriately.
- Consider feeding diets formulated for kidney disease to reduce the magnitude of azotemia, hyperphosphatemia, and acidosis.

**DIAGNOSTIC PROCEDURES**

Renal biopsy can be used to confirm the diagnosis of primary kidney disease, to differentiate acute from chronic kidney disease, and to attempt to establish the underlying disease process responsible for primary kidney disease.

**TREATMENT**

- Peri-renal azotemia caused by impaired renal perfusion—correct the underlying cause of renal hypoperfusion; aggressiveness of treatment depends on the severity of the underlying condition and the probability that persistent renal hypoperfusion will lead to primary renal injury or failure.
- Primary renal azotemia and associated uremia—(1) specific therapy directed at halting or reversing the primary disease process affecting the kidneys, and (2) symptomatic, supportive, and palliative therapies that ameliorate clinical signs of uremia; minimize the clinical impact of deficits and excesses in fluid, electrolyte, acid-base balances; minimize the effects of inadequate renal biosynthesis of hormones and other substances, and maintain adequate nutrition.
- Post-renal azotemia—eliminate urinary obstruction or repair rents in the excretory pathway; supplemental fluid administration is often required to prevent dehydration that may develop during the solute diuresis that follows correction of post-renal azotemia.
- Fluid therapy—indicated for most azotemic patients; preferred fluids include 0.9% saline or lactated Ringer’s solution. Determine fluid volume to administer on the basis of severity of dehydration or volume depletion. If no clinical dehydration is evident, cautiously assume that the patient is less than 5% dehydrated and administer a corresponding volume of fluid. Generally provide 25% of calculated fluid deficit in the first hour. Thereafter, serially monitor perfusion (capillary refill time, pulse pressure, heart rate, and temperature of feet), blood pressure and urine output to assess adequacy of fluid therapy. If perfusion has not improved, additional fluid should be administered. Provide the remaining fluid deficit over the next 12–24 hours. Fluid therapy should be cautiously administered to patients with overt or suspected cardiac failure and patients that are oliguric or anuric.
- Treat patients in shock appropriately.
- Consider feeding diets formulated for kidney disease to reduce the magnitude of azotemia, hyperphosphatemia, and acidosis.
MISCELLANEOUS ASSOCIATED CONDITIONS

An association may exist between hypokalemia and azotemia in cats. Preliminary findings suggest that hypokalemia may be associated with functional or structural renal changes leading to azotemia.

AGE-RELATED FACTORS

Primary renal failure may occur in animals of any age, but geriatric dogs and cats appear to be at substantially higher risk for both acute and chronic kidney disease. However, do not assume that azotemia in geriatric dogs and cats indicates primary kidney disease; these patients are also at higher risk for prerenal and post-renal causes for azotemia.

ZOONOTIC POTENTIAL

Leptospirosis

PREGNANCY/FERTILITY/BREEDING

Data on azotemia and pregnancy in dogs and cats are very limited. Humans may tolerate minimal renal disease well during pregnancy; however, ability to sustain a viable pregnancy declines as renal function declines. Pregnant azotemic animals—pharmacologic agents excreted by non-renal pathways are preferred.

SEE ALSO

• Chapters on acute and chronic kidney disease
• Urinary Tract Obstruction

INTERNET RESOURCES


Suggested Reading


Author: David J. Polzin

Consulting Editor: Carl A. Osborne